Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. IDSA: Switch to Complera in Clinical Practice Usually Safe and Effective - Mark Mascolini - (10/24/14)
     
  2. IDSA: HIV Risk Behavior Increases Between HIV Tests in Half of Wisconsin Group - Mark Mascolini - (10/24/14)
     
  3. IDSA: Asking Patients About Sex Only Factor Tied in Syphilis Screening in HIV Group - Mark Mascolini - (10/24/14)
     
  4. IDSA: Pregnancy Outcomes and Postdelivery Mortality in Perinatally HIV-Infected Women - Mark Mascolini - (10/24/14)
     
  5. IDSA: Preterm Delivery Rate Doubled With HIV in Canada--Boosted PIs Key Factor - Mark Mascolini - (10/24/14)
     
  6. IDSA: Only One Third of MSM in Routine HIV Care Tested for Gonorrhea or Chlamydia - Mark Mascolini - (10/24/14)
     
  7. IDSA: In-Hospital Antiretroviral Errors Correctly Quickly With Two-Pronged Strategy - Mark Mascolini - (10/24/14)
     
  8. IDSA: Current PI, White Race, Lower BMI Linked to Higher Selenium in HIV Group - Mark Mascolini - (10/24/14)
     
  9. AGE: Testosterone Lower in AM But Not PM in MACS Men With vs Without HIV - (10/23/14)
     
  10. AGE: Diastolic Dysfunction Tied to Impaired Exercise Capacity in Older Men With HIV - (10/23/14)
     
  11. ACA/59% Use Specialty Meds Prescriptions: HIV/HCV Prominent-Express Scripts Report - (10/23/14)
     
  12. IDSA: Raltegravir Containing regimen, for Post Exposure Prophylaxis (PEP) well tolerated in Health Care Workers (HCW) - (10/23/14)
     
  13. IDSA: Tolerability, adherence and completion of new occupational post-exposure prophylaxis regimen (tenofovir + emtricitabine and raltegravir) - (10/23/14)
     
  14. IDSA: Efavirenz & Suicidality....New analysis among Medicaid & Commercial databases finds no association, reflects current EFV use patterns & safer/proper use of EFV....... - (10/23/14)
     
  15. IDSA: Longitudinal Trends in HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) at a Boston Community Health Center Between 1997 and 2013 - (10/23/14)
     
  16. IDSA: Attitudes and Interest Toward HIV Pre-Exposure Prophylaxis (PrEP) Among Participants Using HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) - (10/23/14)
     
  17. IDSA: Veterans Aging Cohort Study (VACS) Index, Functional Status, and Other Patient Reported Outcomes in Older HIV-positive (HIV+) Adults in SF.....Poor Outcomes in HIV+ Aging age 53-61 - (10/23/14)
     
  18. IDSA: HIV at ID Week 2014 David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/22/14)
     
  19. What is Frailty in HIV?: Geriatric Syndrome to Physiologic Process - (10/22/14)
     
  20. Food, Protein, Cancer, Diabetes, Mortality - (10/22/14)
     
  21. IWCADR: Hypertension Increased in HIV+ vs HIV-neg in Amsterdam AgehIV Cohort Study (45% vs 31%) & HIV is Independently Associated with Hypertension - (10/17/14)
     
  22. IWCADR: Effect of initiating antiretroviral therapy on markers of monocyte activation, endothelial dysfunction and platelet activation in HIV-1 infection - (10/17/14)
     
  23. IWCADR: Initiating Protease Inhibitor-only therapy is associated with increased subcutaneous adipose tissue PPARG expression, reduced mitochondrial stress together with altered expression of insulin signalling genes - (10/17/14)
     
  24. IWCADR: Persistence of HIV Associated Neurocognitive Disorders (HAND) in the Combination Antiretroviral Therapy Era (cART) - (10/17/14)
     
  25. IDSA: Three Quarters of NPEP Users Show Interest in Trying PrEP - Mark Mascolini - (10/16/14)
     
  26. IDSA: High Rate of NPEP Completion, Good Safety, With Raltegravir Plus TDF/FTC - Mark Mascolini - (10/16/14)
     
  27. IDSA: Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/16/14)
     
  28. IDSA: Commercial and Medicaid Claims Databases Show No Evidence of Higher Suicidality With Efavirenz - Mark Mascolini - (10/15/14)
     
  29. IDSA: Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)
     
  30. IDSA: Factors associated with the selection of initial antiretroviral therapy: Real-world channeling - (10/15/14)
     
  31. IDSA: A 28-Day High-Dose Safety and Pharmacokinetics Study of Raltegravir in Healthy Subjects - (10/15/14)
     
  32. IDSA: Using Real World Data to Assess the Risk of Suicidality among Patients Initiating an Efavirenz versus an Efavirenz-Free Antiretroviral Regimen - (10/15/14)
     
  33. IDSA: Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/14/14)
     
  34. IDSA: Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)
     
  35. IDSA: Erectile Dysfunction Drug Use Tied to Sexual Risk and STIs in HIV+ US Men - written by Mark Mascolini - (10/14/14)
     
  36. IDSA: Low Trabecular BMD, High TNF-Alpha in Women With HIV/HCV vs Only HIV or HCV - written by Mark Mascolini - (10/14/14)
     
  37. IDSA: Almost 80% of Visits to Bronx Center Rank as Missed Chances for HIV Diagnosis - written by Mark Mascolini - (10/14/14)
     
  38. IDSA: ROC Curves Pinpoint ART Failure Threshold at 95 Copies at Week 24 - written by Mark Mascolini - (10/14/14)
     
  39. IWCADR: Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men, preliminary interim report - (10/10/14)
     
  40. IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)
     
  41. IDSA: STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has similar efficacy and is well-tolerated compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve females at Week 96 - (10/10/14)
     
  42. IDSA: Simplification to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Ritonavir-Boosted Protease Inhibitor Plus Emtricitabine/Tenofovir DF Maintains HIV Suppression and Improves Fasting Triglycerides at Week 48 - (10/10/14)
     
  43. IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)
     
  44. IDSA: HIV Care Cascade Differs by Gender and Age in Large US Healthcare System - written by Mark Mascolini - (10/10/14)
     
  45. IDSA: More Positive HIV Tests Via Social Networks Than Standard Approach - written by Mark Mascolini - (10/10/14)
     
  46. IDSA: Risk Score and Race Predict Missed HIV Appointments in US Group - written by Mark Mascolini - (10/10/14)
     
  47. IDSA: Gender, Depression, Heart and Liver Disease Affect First-Line ART Choice in US - written by Mark Mascolini - (10/10/14)
     
  48. IDSA: Acute Retroviral Syndrome Tied to Higher HIV RNA and DNA in Blood, Colon, CSF - written by Mark Mascolini - (10/10/14)
     
  49. IDSA: Delayed HIV Rebound More Frequent After Early Treatment and With NNRTIs - written by Mark Mascolini - (10/10/14)
     
  50. IWCADR: Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men - (09/09/14)
     
  51. IWCADR: Effect on lipids and reverse cholesterol transport of switching to unboosted atazanavir vs. remaining on ritonavir-boosted atazanavir in regimens with a tenofovir backbone - (09/09/14)
     
  52. IWCADR: Heart Disease/Inflammation/Activation - T-cell Activation and E-Selectin Associated with Coronary Plaque in HIV-infected Youth - (09/09/14)
     
  53. IWCADR: Independent Effects of Visceral Fat, Age and HIV Infection on Brain Structure .....'VAT(belly fat) associated with brain atrophy' - (10/08/14)
     
  54. IWCADR: Self-reported Body Fat Change in HIV-infected Men is a Marker of Decline in Physical Health-related Quality of Life.... "...may be at an greater risk for decline in physical function with aging, compared to HIV-neg men" - (10/08/14)
     
  55. IWCADR: Impaired Cardiac Strain and Biomarkers of Immune Activation in HIV - (10/08/14)
     
  56. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (10/06/14)
     
  57. Progress toward curing HIV infections with hematopoietic stem cell transplantation/NIAID Workshop - (10/02/14)
     
  58. Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology - (10/02/14)
     
  59. HCV & HIV African-American/Latino Disparities of Care.... - (10/01/14)
     
  60. CDC Reports HIV/MSM Cascade of Care: African-Americans had lowest levels of linkage to care, retention in care, ART prescription & viral suppression - (10/01/14)
     
  61. Curing HIV Mystery, The Berlin Patient - (09/30/14)
     
  62. Adherence/how many Tenofovir PrEP pills worked in study - Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.....iPrEx open-label extension - (09/29/14)
     
  63. Patterns and Correlates of PrEP Drug Detection among MSM and Transgender Women in the Global iPrEx Study. - (09/29/14)
     
  64. HCV Screening in HIV is Poorly Implemented, MSM don't get screened adequately, only 55% get screened again after initial screen - (09/29/14)
     
  65. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation - (09/29/14)
     
  66. HIV & Aging - Mental Needs: Policy, Mental Health Services Program, Comorbidities, Services for Aging/Older HIV+ - (09/29/14)
     
  67. PreP Research MSM/IDUs - TDF/FTC, GSK744 Once A Month or Every 3 Months Perhaps, TDF/FTC Vaginal Ring......new: "Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York City" - (09/29/14)
     
  68. Elvitegravir / Vitekta FDA Approval - (09/26/14)
     
  69. Cobicistat/Tybost FDA Approves - (09/26/14)
     
  70. Persistence of Virus Reservoirs in ART-Treated SHIV-Infected Rhesus Macaques after Autologous Hematopoietic Stem Cell Transplant - (09/26/14)
     
  71. Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies - (09/24/14)
     
  72. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.....predicting degree of reservoir reduction needed for cure - (09/22/14)
     
  73. Dolutegravir & Rilpivirine CNS Penetration - (09/22/14)
     
  74. ICAAC: Serum levels of soluble cellular adhesion molecules are associated with survival and liver-related events in adults coinfected with HIV/HCV - (09/16/14)
     
  75. ICAAC: Pre-ART Profile Differs for Mortality and TB-IRIS in People Starting ART - (09/15/14)
     
  76. ICAAC: The Effects of Interferon/Ribavirin Therapy on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Subjects - (09/15/14)
     
  77. ICAAC: Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep - Mark Mascolini - (09/15/14)
     
  78. ICAAC: TDF/FTC Vaginal Ring Protects 6 of 6 Monkeys From Weekly SHIV Exposure - Mark Mascolini - (09/15/14)
     
  79. ICAAC: PK Data and Dose Selection for Experimental NNRTI, Doravirine - Mark Mascolini - (09/15/14)
     
  80. ICAAC: Similar 144-Week Results With Cobicistat or Ritonavir as Atazanavir Booster - Mark Mascolini - (09/15/14)
     
  81. ICAAC: First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks - Mark Mascolini - (09/15/14)
     
  82. ICAAC: Coronary Calcium Scores Similar in HIV+ People and Matched HIV- Controls - Florida community infectious disease office - Mark Mascolini - (09/15/14)
     
  83. ICAAC: Subgroup Analysis of Response to Stribild vs Atripla or Atazanavir: 144 Weeks - Mark Mascolini - (09/15/14)
     
  84. ICAAC: Less Bone Loss With DRV/RAL Than DRV/TDF/FTC at 48 and 96 Weeks - Mark Mascolini - (09/15/14)
     
  85. ICAAC: CD8-Cell Activation, Senescence, Osteoprotegerin Tied to Atherosclerosis in Italian HIV Cohort.... (from jules: senescence marker higher in HIV+ & senescence marker associated with heart disease) - (09/12/14)
     
  86. ICAAC: Switch From RTV to COBI To Boost a PI With Moderate Kidney Impairment - (09/12/14)
     
  87. ICAAC: Tenofovir Nanoparticles in Vaginal Gel Protect 10 of 10 BLT Mice From HIV Challenge - (09/12/14)
     
  88. ICAAC: One Third of HIV+ Women in Spanish Group Have Anal Cancer Precursor - (09/11/14)
     
  89. ICAAC: Stribild Advantages vs Atripla in Blacks Through Trial Week 144 - (09/11/14)
     
  90. Improved Single Copy Assays for Quantification of Persistent HIV-1 Viremia in Patients on Suppressive Antiretroviral Therapy - (09/10/14)
     
  91. Gastrointestinal Tract and the Mucosal Macrophage Reservoir in HIV Infection - (09/10/14)
     
  92. ICAAC: Metabolism, Excretion, and Mass Balance of the HIV Integrase Inhibitor, Cabotegravir (GSK1265744) in Humans - (09/10/14)
     
  93. ICAAC: Effect of Carbamazepine (CBZ) on Dolutegravir (DTG) Pharmacokinetics - (09/10/14)
     
  94. ICAAC: Pharmacokinetics and Drug Interaction Profile of Cobicistat-Boosted Elvitegravir with Carbamazepine - (09/10/14)
     
  95. ICAAC: Elvitegravir Regimen Maintains Virologic Control in Blacks After PI or NNRTI - Written by Mark Mascolini - (09/10/14)
     
  96. ICAAC: Noninduced HIV-1 Proviruses in the Latent Reservoir May Contain Drug Resistance Mutations ......full slide presentation included - Written by Mark Mascolini - (09/10/14)
     
  97. ICAAC: Virologic Response During ART Interruption After CCR5-Cell Modification With SB-728-T (zinc fingers) - Written by Mark Mascolini - (09/10/14)
     
  98. ICAAC: HIV Persists in Lung Macrophages of People on Suppressive ART - Written by Mark Mascolini - (09/10/14)
     
  99. ICAAC: Elvitegravir Regimen Maintains Virologic Control in Blacks After PI or NNRTI - Written by Mark Mascolini - (09/09/14)
     
  100. ICAAC: Four to Five HIV+ Dying in Care Yearly in Philadelphia Are Potential Organ Donors - Written by Mark Mascolini - (09/09/14)
     
  101. ICAAC: GSK Long-Acting ART Integrase inhibitor - Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation - Written by Mark Mascolini - (09/09/14)
     
  102. ICAAC: High-Risk HPV 60% More Frequent in Anus Than Cervix of HIV+ Women in France - Written by Mark Mascolini - (09/09/14)
     
  103. ICAAC: Cholelithiasis (gallstones) among patients exposed to atazanavir, other PIs, and PI-free regimens - (09/09/14)
     
  104. ICAAC: HIV NRTI BMS-986001 in Antiretroviral-Naïve Subjects: Evaluation of Bone and Metabolic Safety Data Through Week 48 - (09/09/14)
     
  105. ICAAC: HIV NRTI BMS-986001 in Antiretroviral-Naïve Subjects: Week 24/48 Analyses - (09/09/14)
     
  106. ICAAC: COPD Prevalence 9% in French HIV Group--and 74% Don't Know - (09/09/14)
     
  107. ICAAC: Drug Interactions Between Tenofovir Alafenamide and HIV Antiretroviral Agents - (09/09/14)
     
  108. ICAAC: Switching from Ritonavir (RTV) to Cobicistat (COBI) in HIV Patients with Renal Impairment Who Are Virologically Suppressed on a Protease Inhibitor based Regimen - (09/09/14)
     
  109. ICAAC: Subcutaneous Ibalizumab in At-Risk Healthy Subjects - (09/09/14)
     
  110. ICAAC: HIV in Resting CD4 Cells May Contain Antiretroviral Resistance Mutations - Written by Mark Mascolini - (09/08/14)
     
  111. ICAAC: Dolutegravir Superior to Efavirenz at 144 Weeks in SINGLE Trial - Written by Mark Mascolini - (09/08/14)
     
  112. ICAAC: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Is Non-Inferior Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes through Week 96 - (09/08/14)
     
  113. ICAAC: Once-Daily Doutegravir + Abacavir/Lamivudine is Superior to Efavirenz/Tenofovir/Emtricitabine in Treatment-Naïve HIV Subjects: 144-Week Results - SINGLE Study (ING114467) - (09/08/14)
     
  114. ICAAC: Acute hepatitis C infection in HIV negative men who have sex with men......in UK - 'sexual HCV transmission/risky sex & drug use behavior/low rates of screening/routine screening recommended for these risk group' - (09/08/14)
     
  115. ICAAC: 48 Week Study of the First PI-based Single Tablet-Regimen (STR) Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) vs. Darunavir (DRV) boosted by Cobicistat (COBI) and Emtricitabine/Tenofovir Disoproxil Fumarate (TVD) in HIV-Infected Treatment-Naïve Adults - (09/08/14)
     
  116. ICAAC: Pooled 144-week Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) with Subgroup Analysis - (09/08/14)
     
  117. ICAAC: Cobicistat versus Ritonavir as Pharmacoenhancers of Atazanavir in Combination with Emtricitabine/Tenofovir DF - Phase 3 Randomized, Blinded, Active-Controlled Trial, Week 144 Results - (09/08/14)
     
  118. ICAAC: Pharmacokinetics (PK) of Doravirine and Exposure-Response Analysis: Efficacy and Safety Implications - (09/08/14)
     
  119. ICAAC: Switch to Elvitegravir/Cobi/FTC/TDF from PI+RTV or NNRTI plus FTC/TDF Maintains HIV Suppression at Week 48 and is Safe in Black Subjects - (09/08/14)
     
  120. ICAAC: Efficacy and Safety of Raltegravir in Racial Groups - (09/08/14)
     
  121. ICAAC: Long-Term Efficacy and Safety of E/C/F/TDF (STB) versus EFV/FTC/TDF (ATR) in HIV-1-Infected Treatment Naïve Black and Non-Black Subjects - (09/08/14)
     
  122. HIV Antibodies Block Infection by Reservoir-Derived Virus in Laboratory Study - (09/05/14)
     
  123. NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus - "Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface" - (09/05/14)
     
  124. Rekindled HIV infection (latent reservoirs) - Perspective - (09/03/14)
     
  125. HIV & Bone Loss/Osteopenia & Osteoporosis & Fractures - (09/03/14)
     
  126. "HIV infection remained independently associated with a higher number of AANCC (OR 1.58) [age-associated non-communicable comorbidity]" HIV+ had more comorbidities & more than 3, 2 & 1 comorbidities respectively vs HIV-neg....new study published confirming prior studies - (09/03/14)
     
  127. Effects of Low-Carbohydrate and Low-Fat Diets: A Randomized Trial -new study...."low-carbohydrate diet resulted in greater weight loss and reduction in cardiovascular risk factors than a low-fat diet among obese black and white adults" - (09/03/14)
     
  128. The early cost of HIV....in the SIV gut....priobiotics: "Early Mucosal Sensing of SIV Infection by Paneth Cells Induces IL-1ß Production and Initiates Gut Epithelial Disruption" - (09/03/14)
     
  129. Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits are Independently Associated with All-cause Mortality - (08/25/14)
     
  130. ViiV Healthcare receives FDA approval for Triumeq® FDC - Dolutegravir/abacavir/3TC - (08/22/14)
     
  131. IAC: Aging, Comorbidities - Inflammation/Activation-Gut, Complications - Bone, Neuro/Brain, Kidney, Heart Disease, HPV, Pnuemococcal disease - Adherence, Tolerability/Adverse Events (50 reports) - (08/22/14)
     
  132. IAC: HIV Cure Reports, "Towards a Cure" Symposium at IAC - (08/21/14)
     
  133. IAC: IAS pre-meeting "Towards a Cure" Symposium - written by David Margolis MD, UNC Chapel Hill - (08/21/14)
     
  134. Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits are Independently Associated with All-cause Mortality - (08/20/14)
     
  135. HCV Treatment & Barriers To Care in HIV/HCV-Coinfected - (08/18/14)
     
  136. Gut/HIV-Vaccines/Neutralizing Antibodies/NIH Grant Process Unfair? - (08/18/14)
     
  137. HIV Destroys Gut Immunity-new study - Gut Flora Influences HIV Immune Response - (08/18/14)
     
  138. HIV and Stem Cell Transplantation - (08/18/14)
     
  139. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study - (08/18/14)
     
  140. Proteinuria is Associated With Neurocognitive Impairment in Antiretroviral Therapy Treated HIV-Infected Individuals - (08/18/14)
     
  141. IAC: Incidence and risk factors of HIV-infection among young men who have sex with men in Bangkok, Thailand - (08/15/14)
     
  142. HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat - (08/15/14)
     
  143. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection - (08/15/14)
     
  144. Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes......HDACis exert negative effects - new study reports - (08/15/14)
     
  145. IAC: Pharmacokinetics of VM-1500 20 mg and 40 mg in Healthy and HIV-Infected Patients - (08/13/14)
     
  146. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 - (08/11/14)
     
  147. CROI: ART in Earliest Stage of HIV Infection Preserves Cells That Maintain Gut Barrier - reverses activation...."argues for early & aggressive ART" - Mark Mascolini (08/11/14)
     
  148. IAC: ART in Acute Infection Quells Inflammation But Does Not Restore Gut CD4s - (08/11/14)
     
  149. IAC: Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. - (08/08/14)
     
  150. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. - (08/08/14)
     
  151. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men - (08/08/14)
     
  152. IAC: FUNCTIONAL CURE AND SEROREVERSION AFTER ADVANCED HIV DISEASE FOLLOWING 7 YEARS OF ANTIRETROVIRAL TREATMENT INTERRUPTION - (08/06/14)
     
  153. IAC: Probiotic and IL-21 Treatment Promotes Th17 Cell Recovery in ARV-Treatment of Pigtail Macaques - (08/06/14)
     
  154. IAC: HIV-Exposed Seronegative Men who have Sex with Men overexpress potential antiviral antiproteases in their rectal mucosa - (08/06/14)
     
  155. IAC: Open label, randomized, crossover, single-dose, bioavailability evaluation of atazanavir/ritonavir FDC tablets 300 mg/100 mg with that of REYATAZ 300 mg and NORVIR 100 mg under fed and fasting conditions - (08/05/14)
     
  156. IAC: Body mass index (BMI) and change in levels of immune activation post- ART initiation in diverse low- and middle-income settings - (08/05/14)
     
  157. IAC: About 40% Who Get Under 50 Copies Have Residual Viremia in French Cohort - Mark Mascolini - (08/04/14)
     
  158. IAC: Recent HIV Testing among U.S. Older Adults Since and Prior to Release of CDC's Routine HIV Testing Recommendations: National Findings based on the Behavioral Risk Factor Surveillance System (BRFSS) - (08/04/14)
     
  159. IAC: IAC Plenary on HIV/Aging & NATAP Reports on HIV/Aging-Complications / HCV /Activation / Inflammation/Kidney/Anal Cancer-HSIL clearance/COPD/Neuro-Cognitive Disorders - (08/04/14)
     
  160. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys - (08/04/14)
     
  161. IAC: High Inflammation/Activation Markers Before and During ART Predict Death in MACS - Mark Mascolini - (08/04/14)
     
  162. IAC: No HIV RNA or DNA, Negative Western Blot, After 7-Year ART Suspension - Mark Mascolini - (08/04/14)
     
  163. IAC: Raltegravir May Offer Gut Microbe Advantages Compared With Nonnucleosides - Mark Mascolini - (08/04/14)
     
  164. IAC: Health Workers Not Following CDC Advice on Testing Older Adults for HIV - Mark Mascolini - (08/04/14)
     
  165. IAC: Sex on PrEP (08/04/14)
     
  166. IAC: The burden of subclinical heart and lung disease detected on thoracic CT scans of HIV-infected individuals on antiretroviral therapy (08/04/14)
     
  167. Cure setbacks force HIV researchers to reset sights - (08/01/14)
     
  168. IAC: Raltegravir Regimen More Durable, Atazanavir Less Durable, Than Single-Tablet Atripla - Mark Mascolini - (08/01/14)
     
  169. IAC: The HIV Care Cascade ("Cascade") Measured Over Multiple Time Periods Varies by Time Period and Method (08/01/14)
     
  170. IAC: HPV VACCINATION IN HIV+ ADOLESCENTS AND YOUNG ADULTS INDUCES STRONG HPV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSES (08/01/14)
     
  171. IAC: HIV Prevention at AIDS 2014 - PrEP, TasP, PMTCT, Key Populations - Jared Baeten, MD PhD Kenneth Ngure, PhD, MPH Connie Celum, MD MPH University of Washington & Jomo Kenyatta University of Agriculture and Technology - (07/31/14)
     
  172. IAC: Effect of monthly calcidiol supplementation on secondary hyperparathyroidism and bone mineral density in HIV-infected patients with vitamin D deficiency (07/31/14)
     
  173. IAC: Darunavir (DRV)/r-based Postexposure Prophylaxis (PEP) versus standard of care (SOC) - quality of life in patients receiving PEP in a randomized study (PEPDar) (07/30/14)
     
  174. IAC: Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14)
     
  175. IAC: Monocyte activation markers remain significantly elevated in virologically suppressed HIV+ individuals to a level equivalent to an additional 4 years of normal ageing (07/30/14)
     
  176. IAC: Safety and Efficacy of the Integrase Inhibitor-Based Stribild Single-Tablet Regimen in HIV-Infected Adolescents Through 24 Weeks of Treatment (07/29/14)
     
  177. IAC: Pharmacokinetics of Boosted-Elvitegravir in Combination with Rifabutin, Utilizing Twice Daily Administration of Cobicistat to Overcome Induction (07/29/14)
     
  178. IAC: Romidepsin HDAC Inhibitor Stimulates HIV from Reservoirs in Hunt to Find HIV Cure (07/29/14)
     
  179. IAC: Treatment with the histone deacetylase inhibitor Panobinostat markedly reduces chronic inflammation in HIV-infected patients (07/29/14)
     
  180. IAC: Real-World Adherence among Patients Receiving Single versus Multiple Tablet Regimens for HIV-1 Infection, and Associations between Adherence and Viral Suppression: A Systematic Literature Review and Meta- Analysis (07/29/14)
     
  181. IAC: Cost-Effectiveness of Single versus Multiple Tablet Regimens for Treatment of HIV-1 Infection in the US (07/29/14)
     
  182. IAC: Do Single Tablet Regimens Translate into More Durable HIV Treatments? Evidence from the Canadian Observational Cohort (CANOC) (07/29/14)
     
  183. IAC: Monthly Vitamin D May Improve Bone Density in People With HIV - Mark Mascolini (07/28/14)
     
  184. Translational challenges in targeting latent HIV infection and the CNS reservoir problem - (07/28/14)
     
  185. Drug Use Among Gay and Bisexual Men at Weekend Dance Parties: The Role of Intentions and Perceptions of Peers' Behaviors - (07/28/14)
     
  186. IAC: Ole, Pre-Exposure Prohylaxis (PrEP) Initiative: Open Label Extension - "Adherence Has To Be Good, Not Perfect," Say MSM PrEP Study Researchers - (07/28/14)
     
  187. IAC: Allogeneic bone marrow transplantation in two HIV-1 infected patients shows no detectable HIV-1 RNA or DNA, and a profound reduction in HIV-1 antibodies - (07/28/14)
     
  188. IAC: Tenofovir(TFV), Emtricitabine(FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Subjects - (07/28/14)
     
  189. IAC: SIV-infected rhesus macaques receiving suppressive cART have continued GI damage, inflammation, immune activation and persistent low-level viral replication within lymphoid tissues..."Suggesting that HIV Cure strategies will need to address sources of residual inflammation/immune activation to be successful" - (07/28/14)
     
  190. IAC: Efficacy and Safety of Dolutegravir Relative to Commonly-Used 3rd-Agents at 96 Weeks in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (07/28/14)
     
  191. IAC: Measuring Patient Views of HIV Treatments: Comparing Dolutegravir With Darunavir/r in the FLAMINGO Study - (07/28/14)
     
  192. IAC: Diminished Physical Function in Older HIV+ Adults Despite Successful Antiretroviral Therapy - (07/28/14)
     
  193. IAC: Week 144 Renal Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) from Two Phase 3 Randomized Controlled Trials - (07/28/14)
     
  194. IAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (07/28/14)
     
  195. IAC: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults through Week 96 with a Favorable Safety Profile for Abnormal Dreams and Dizziness - (07/28/14)
     
  196. IAC: STRATEGY Studies (GS-115 and GS-121): Safety Analysis of Switching to STB from a RTV-Boosted PI or NNRTI Plus TVD Regimen - (07/28/14)
     
  197. IAC: Obesity Doubles Chances of More Inflammation and Monocyte Activation With HIV - written by Mark Mascolini - (07/28/14)
     
  198. IAC: Activation Marker Levels With Undetectable Viral Load Match Those of Uninfected People 4 Years Older - written by Mark Mascolini - (07/28/14)
     
  199. IAC: Time to Viral Suppression With ART for Acute HIV in Pregnancy - written by Mark Mascolini - (07/28/14)
     
  200. IAC: Pneumococcal Disease Rate Drops in HIV Group But Still Far Exceeds HIV-Negative Rate - written by Mark Mascolini - (07/28/14)
     
  201. IAC: Gait Speed in Older HIV Group Not Fast Enough to Cross Street Safely - written by Mark Mascolini - (07/28/14)
     
  202. IAC: SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
     
  203. IAC: Neurocognitive Disorder Rates Differ by US vs Local Standards in Australian MSM - Mark Mascolini - (07/25/14)
     
  204. IAC: No Detectable HIV RNA or DNA in 2 Bone Marrow Transplant Patients Still on ART - Mark Mascolini - (07/25/14)
     
  205. IAC: Why Undiagnosed HIV and HIV Incidence Are Falling in SF MSM and Static in London MSM - Mark Mascolini - (07/25/14)
     
  206. IAC: Resistance Mutations Persist in HIV DNA After 12 Years With Undetectable Viral Load - Mark Mascolini - (07/25/14)
     
  207. IAC: Predictors of Neurocognitive Decline and Rebound in US CHARTER Group - Mark Mascolini - (07/25/14)
     
  208. IAC: HARNESS study: ritonavir-boosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients - (07/25/14)
     
  209. IAC: Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens - (07/25/14)
     
  210. IAC: Longer ART, Better CD4 Gain Protect From Neurocognitive Decline in ACTG Analysis - written by Mark Mascolini - (07/25/14)
     
  211. IAC: Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men (07/25/14)
     
  212. Finding a Cure for HIV: Much Work to Do Editorial - (07/24/14)
     
  213. IAC: MODERN Study - Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN - ViiV Press Release (07/24/14)
     
  214. IAC: Anal Cancer Precursor More Common in HIV+ Than HIV- MSM; Clearance Rate High - written by Mark Mascolini - (07/24/14)
     
  215. IAC: Inflammatory Cytokine/IL-10 Ratios Tied to Regional Brain Atrophy With HIV - written by Mark Mascolini - (07/24/14)
     
  216. IAC: Efavirenz Not Tied to Neurocognitive Impairment in Large Single-Center Study - written by Mark Mascolini - (07/24/14)
     
  217. IAC: Inflammation/Activation Markers Drop With ATV, DRV, RAL, But Not Completely - ACTG Study - written by Mark Mascolini - (07/23/14)
     
  218. IAC: Higher One-Year Risk of CVD or Diabetes Per BMI Unit Gained on ART - written by Mark Mascolini - (07/23/14)
     
  219. IAC: Early Data Show Good Adherence to Intermittent PrEP by MSM in French Trial - written by Mark Mascolini - (07/23/14)
     
  220. IAC: COPD Rate 7% in Global HIV Cohort--Half With COPD Never Smoked - written by Mark Mascolini - (07/23/14)
     
  221. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study - (07/23/14)
     
  222. Moving HIV PrEP from research into practice - Commentary - (07/23/14)
     
  223. IAC: Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir - written by Mark Mascolini - (07/23/14)
     
  224. IAC: Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients - (07/23/14)
     
  225. IAC: Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies - written by Mark Mascolini - (07/23/14)
     
  226. IAC: Switching From First-Line ART When Suppressed Boosts Failure Chance - written by Mark Mascolini - (07/23/14)
     
  227. IAC: Quadrivalent HPV Vaccine Elicits Antibody and Cell Responses in HIV+ Teens, Young Adults - written by Mark Mascolini - (07/23/14)
     
  228. IAC: Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir - written by Mark Mascolini - (07/23/14)
     
  229. IAC: Successful ART Started Under Age 6 Months More Likely to Yield Negative Antibody Test - written by Mark Mascolini - (07/22/14)
     
  230. IAC: Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs (07/22/14)
     
  231. IAC: The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays (07/22/14)
     
  232. IAC: DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance (07/22/14)
     
  233. IAC: Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095) (07/22/14)
     
  234. IAC: cART in First Days of Life Limits Viral Reservoir Size in 4 Canadian Children - written by Mark Mascolini - (07/22/14)
     
  235. IAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
     
  236. IAC: High Response Rates With Triple-DAA Regimen in People With HCV and HIV: Abbvie 3D - ABT-450/ritonavir, ombitasvir, and dasabuvir, with ribavirin - written by Mark Mascolini - (07/21/14)
     
  237. IAC: SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)
     
  238. IAC: High Response Rates With Triple-DAA Regimen in People With HCV and HIV - written by Mark Mascolini - (07/21/14)
     
  239. IAC: SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)
     
  240. IAC: High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 - written by Mark Mascolini - (07/21/14)
     
  241. IAC: Liver Markers Worse in Youth With Than Without HIV and Climb Over Time - Written by Mark Mascolini (07/21/14)
     
  242. Social Discrimination and Resiliency Are Not Associated With Differences in Prevalent HIV Infection in Black and White Men Who Have Sex With Men - "our findings suggest that the perceived social discrimination does not explain the striking racial disparity in HIV infection between black and white MSM" - (07/21/14)
     
  243. "Prostate cancer incidence rates are lower in HIV-positive compared with HIV-negative men, which is not explained by screening differences or the risk factors evaluated." Study reports - (07/21/14)
     
  244. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor - (07/16/14)
     
  245. PrEP Article in New York Magazine published July 13 2014/ new WHO Recommendation/ new CDC Recommendation - (07/16/14)
     
  246. NYS PrEP Plan - (07/16/14)
     
  247. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data - (07/14/14)
     
  248. Has the time come to abandon efavirenz for first-line antiretroviral therapy? - (07/14/14)
     
  249. Reactivation of HIV latency by a newly modified Ingenol derivative - new group of compounds, Ingenol derivatives - (07/14/14)
     
  250. Epicardial adipose tissue and atherogenesis: EAT your heart out EDITORIAL - (07/14/14)
     
  251. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food - (07/14/14)
     
  252. New Lipodystrophy-'Sick Fat' Around the Heart in HIV+ Predicts Heart Disease: bad atypical fat independently predict measures of cardiovascular disease and atherosclerosis in HIV...... - (07/14/14)
     
  253. "Mississippi Baby" Now Has Detectable HIV, Researchers Find - (07/14/14)
     
  254. Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: the SATURN-HIV Trial - heart, kidney, bone diseases, inflammation - (07/14/14)
     
  255. Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection - Review - (07/14/14)
     
  256. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study - (07/14/14)
     
  257. Fracture risk in hepatitis C virus infected persons: Results from the DANVIR cohort study - (06/30/14)
     
  258. Nutrition: Vitamins on trial - (06/30/14)
     
  259. A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, ART-Naive Subjects - (06/23/14)
     
  260. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial - (06/16/14)
     
  261. HIV & Aging: Failure to Normalize Immunity Despite Decade of Successful HAART - (06/16/14)
     
    HIV & Aging: HIV and the aging kidney - (06/16/14)
     
    HIV & Aging: Biologic aging, frailty, and age-related disease in chronic HIV infection - (06/16/14)
     
    HIV & Aging: Immunosenescence and aging in HIV - (06/16/14)
     
    HIV & Aging: Update on metabolic issues in HIV patients - (06/16/14)
     
    HIV & Aging: Coping styles and illicit drug use in older adults with HIV/AIDS - (06/16/14)
     
    HIV & Aging: Psychosocial, mental health, and behavioral issues of aging with HIV - (06/16/14)
     
    HIV & Aging: Demographics of HIV and aging - (06/16/14)
     
    HIV & Aging: African Americans, Hispanics, Caucasians (2 MACS Studies) - (06/09/14)
     
  262. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles county - (06/13/14)
     
  263. ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1 - (06/12/14)
     
  264. Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV - (06/12/14)
     
  265. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy - (06/12/14)
     
  266. Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV - (06/12/14)
     
  267. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy - (06/12/14)
     
  268. 15th Intl Wrkshp Clinical Pharm HIV Therapy The 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/11/14)
     
  269. 15th Intl Wrkshp Clinical Pharm HIV Therapy Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130 - (06/11/14)
     
  270. New HHS HIV ART Guidelines for Adults, Adolescents - (06/11/14)
     
  271. New Exercise/Diet Study.....lower inflammation/better metabolics/more diverse gut microbia - (06/11/14)
     
  272. Intl Wrkshp on Antiviral Drug Resistance: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Primary Week 24 Analysis of Emergent Drug Resistance - (06/09/13)
     
  273. Frailty & aging: African Americans, Hispanics, Caucasians (2 MACS Studies) - (06/09/14)
     
  274. First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir) - (06/09/14)
     
  275. Raltegravir New Formulation Once-Daily PK/Isentress Once-Daily Regimen Phase 3 Enrolling - (06/09/14)
     
  276. HIV treatment [zinc fingers] study clears virus, sends Sangamo stock soaring - (06/09/14)
     
  277. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial - (06/09/14)
     
  278. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial - (06/09/14)
     
  279. HIV immunity goes direct - Gene Therapy - (06/09/14)
     
  280. Research into a functional cure for HIV in neonates: the need for ethical foresight - (06/09/14)
     
  281. Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies - (06/09/14)
     
  282. Frailty in people aging with human immunodeficiency virus (HIV) infection - (06/09/14)
     
  283. Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects (2008) - (06/09/14)
     
  284. Intl Wrkshp on Antiviral Drug Resistance: Doravirine (MK-1439): A Novel HIV-1 NNRTI With a Distinct Resistance Profile (06/06/13)
     
  285. Intl Wrkshp on Antiviral Drug Resistance: Raltegravir (RAL) Resistant Isolates without Primary RAL Integrase (IN) Mutations are Cross-resistant to Elvitegravir (EVG) but not Dolutegravir (DTG) (06/06/13)
     
  286. Intl Wrkshp on Antiviral Drug Resistance: An Analysis of Minor Variants in HIV-1 Integrase (IN) for Subjects With Only Historic Evidence of Integrase Inhibitor (INI) Resistance Enrolled in Study ING112574 (VIKING-3) (slide presentation, poster to follow) (06/06/13)
     
  287. Intl Wrkshp on Antiviral Drug Resistance: Excellent Virological and Immunological Response to Dolutegravir despite Extensive RT, PR and INI Resistance (06/06/13)
     
  288. CROI: NOVEL INTERVENTIONS TO TARGET INCREASED INFLAMMATION IN HIV-INFECTED INDIVIDUALS - (06/05/14)
     
  289. Aging/HIV - Premature aging/Stress, Anxiety, Lifetime/Childhood Trauma, Race/Gender - (06/03/14)
     
  290. Cervical Inflammation and Immunity Associated With Hormonal Contraception, Pregnancy, and HIV-1 Seroconversion - (06/01/14)
     
  291. Social and ethical implications of HIV cure research - (06/01/14)
     
  292. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. - (06/01/14)
     
  293. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV - (05/29/14)
     
  294. HIV-1 Drug Resistance in the iPrEx Pre-Exposure Prophylaxis Trial - (05/29/14)
     
  295. 15th Intl Wrkshp Clinical Pharm HIV Therapy Rectal Tenofovir Gel Yields Much Higher Rectal and Vaginal Levels Than Oral Tenofovir - (05/29/14)
     
  296. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  297. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  298. 15th Intl Wrkshp Clinical Pharm HIV Therapy Raltegravir Levels With Once-Daily Dosing in French Observational Study - Mark Mascolini - (05/27/14)
     
  299. CROI: A Multiple Dose Study of Raltegravir Formulations - (05/27/14)
     
  300. 15th Intl Wrkshp Clinical Pharm HIV Therapy Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/23/14)
     
  301. 15th Intl Wrkshp Clinical Pharm HIV Therapy DRV CONCENTRATIONS AND VIRAL LOAD IN CSF OF PATIENTS ON DRV/r 600/100 OR 800/100 mg ONCE DAILY, PLUS TWO NRTI - (05/23/14)
     
  302. 15th Intl Wrkshp Clinical Pharm HIV Therapy Thorough QT/QTc Trial to Evaluate the Effect of the HIV-1 Attachment Inhibitor BMS-626529, Administered as its Prodrug, BMS-663068, on QTc Intervals - (05/23/14)
     
  303. 15th Intl Wrkshp Clinical Pharm HIV Therapy A Mechanistic SimCYP Simulation Evaluating Dolutegravir and Efavirenz Pharmacokinetics Following a Switch From Once-daily Efavirenz to Once-daily Dolutegravir - (05/22/14)
     
  304. 15th Intl Wrkshp Clinical Pharm HIV Therapy A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate - (05/22/14)
     
  305. 15th Intl Wrkshp Clinical Pharm HIV Therapy Maraviroc and Raltegravir Quickly Distributed in Female Genital Tract - Mark Mascolini (05/22/14)
     
  306. 15th Intl Wrkshp Clinical Pharm HIV Therapy Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/22/14)
     
  307. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetic of raltegravir (800 mg) once-daily in switching strategies in HIV-1-infected patients with suppressed viremia - (05/21/14)
     
  308. 15th Intl Wrkshp Clinical Pharm HIV Therapy Mucosal Tissue Pharmacokinetics of Maraviroc and Raltegravir in Women: Implications for Chemoprophylaxis [PrEP, Mucosal Tissue Compartments PK] - (05/21/14)
     
  309. 15th Intl Wrkshp Clinical Pharm HIV Therapy Reduced Darunavir Dose Is as Effective in Maintaining HIV Suppression as the Standard Dose in Virologically Suppressed HIV-Infected Patients. The DRV600 Study - (05/21/14)
     
  310. 15th Intl Wrkshp Clinical Pharm HIV Therapy In Vitro Drug Interaction Profile of the HIV Integrase Inhibitor, GSK1265744, and Demonstrated Lack of Clinical Interaction with Midazolam - (05/21/14)
     
  311. 15th Intl Wrkshp Clinical Pharm HIV Therapy The Effect of Calcium and Iron Supplements on the Pharmacokinetics of Dolutegravir in Healthy Subjects - (05/21/14)
     
  312. 15th Intl Wrkshp Clinical Pharm HIV Therapy Population PK-PD Analysis of 400 mg vs. 600 mg Efavirenz Once Daily in Treatment-Naïve HIV Patients at 48 Weeks: Results of the ENCORE1 Study - (05/21/14)
     
  313. 15th Intl Wrkshp Clinical Pharm HIV Therapy Estimated Time to Protection and Duration of Protection With Daily TDF/FTC PrEP - written by Mark Mascolini - (05/21/14)
     
  314. Pre-exposure prophylaxis to intensify the fight against HIV (2 publications below); HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial - (05/20/14)
     
  315. 15th Intl Wrkshp Clinical Pharm HIV Therapy Maintenance With Lower-Dose Darunavir in Virologically Suppressed - written by Mark Mascolini - (05/20/14)
     
  316. 15th Intl Wrkshp Clinical Pharm HIV Therapy Efavirenz Dose and Genotype Do Not Affect 48-Week Response in Low/Standard-Dose Trial - written by Mark Mascolini - (05/20/14)
     
  317. 15th Intl Wrkshp Clinical Pharm HIV Therapy Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals - written by Mark Mascolini - (05/20/14)
     
  318. HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy - (05/19/14)
     
  319. Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11) AND COMMENTARY follows below by Lynne M. Mofenson, D. Heather Watts - (05/19/14)
     
  320. Zinc-finger Functional HIV Cure - Zinc-finger endonuclease targeting PSIP-1 inhibits HIV-1 integration - (05/19/14)
     
  321. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection - (05/15/14)
     
  322. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence - (05/15/14)
     
  323. CDC Recommends PrEP Truvada "CDC recommends that PrEP is indicated for people who do not have HIV and are at substantial risk for HIV" - (05/15/14)
     
  324. The transmembrane proteins contribute to immunodeficiencies induced by HIV-1 and other retroviruses - (05/09/14)
     
  325. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 - (05/09/14)
     
  326. Zinc-finger nucleases make the cut in HIV [to Control HIV, "avoid taking drugs for the rest of their lives"] - (05/02/14)
     
  327. CROI: Using HIV Networks to Inform Real Time Prevention Interventions - (05/02/14)
     
  328. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies - (05/01/14)
     
  329. CROI: Natural History of HIV-related Anal Dysplasia: A Multi-state Modeling Analysis - (04/28/14)
     
  330. Risk of Melanoma in People with HIV/AIDS in the Pre- and Post-HAART Eras: A Systematic Review and Meta-Analysis of Cohort Studies - (04/25/14)
     
  331. CROI: Impact of Low CD4 Count and HIV Persistence on Endothelial Function in Patients with Low Plasma RNA - (04/22/14)
     
  332. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study - (04/21/14)
     
  333. CROI: Drug Resistance Mutations in Treatment-Naïve HIV-Infected Patients 2000-2013; [Integrase Mutations Transmitted Low (1)] - (04/21/14)
     
  334. CROI: GSK1265744 Demonstrates Robust in Vitro Activity Against Various Clades of HIV-1 - (04/21/14)
     
  335. CROI: Lessons from the 21st CROI - Integrating Data into Antiretroviral Treatment in the Clinic - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (04/21/14)
     
  336. HIV eradication-from Berlin to Boston - (04/10/14)
     
  337. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV (Zinc fingers) - (04/10/14)
     
  338. Cyclophosphamide Enhances SB-728-T (zinc fingers) Engraftment to Levels Associated with HIV-RNA Control - (04/10/14)
     
  339. Engineering Cellular Resistance to HIV (zinc fingers) - Editorial - (04/10/14)
     
  340. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children - (04/10/14)
     
  341. Persistent HIV infection in newborns: how soon is soon enough? Editorial Comments - (04/10/14)
     
  342. Diet, Dementia, Cognitive Impairment, Diabetes: type of foods & cooking affects impact - (04/07/14)
     
  343. Diet/Diseases/Inflammation/Survival - Oral Glycotoxins (AGEs) Determine the Effects of Calorie Restriction on Oxidant Stress, Age-Related Diseases, and Lifespan - (04/07/14)
     
  344. CROI: Is there continued evidence for an association between abacavir and myocardial infarction risk? - (04/07/14)
     
  345. CROI: HIV, Chronic Inflammation, and CVD: Report back from the 2014 Conference on Retroviruses and Opportunistic Infections - Priscilla Hsue, MD Professor of Medicine, UCSF Cardiology Division - (04/07/14)
     
  346. CROI: Metabolics and Aging at CROI 2014 - David Alain Wohl, MD - The University of North Carolina - (04/06/14)
     
  347. CROI: Inflammation in Acute HIV Infection Correlates with Blood and Gut CD4 T-cell Loss and HIV Viral Burden - (04/05/14)
     
  348. CROI: CMV and HIV: A Double Hit On the CD4/CD8 Ratio - (04/04/14)
     
  349. HIV-Infected Men at Increased Risk for Heart Disease, Large NIH Study Finds - (04/03/14)
     
  350. HIV and Atherosclerosis: Moving From Associations to Mechanisms and Interventions - Editorials - (04/03/14)
     
  351. Diet, Dementia, Cognitive Impairment, Diabetes Intersect - (04/03/14)
     
  352. Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors/Raltegravir - (04/03/14)
     
  353. CROI: Clinical Pharmacology at CROI 2014 Courtney V. Fletcher, Pharm.D. Dean and Professor Anthony T. Podany, Pharm.D. Post-Doctoral Fellow College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/03/14)
     
  354. CROI: CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14)
     
  355. CROI: A Low CD4/CD8 Ratio During Effective ART Predicts Immunosenescence and Morbidity/Mortality - (04/02/14)
     
  356. CROI: PrEP at CROI, Uptake - MSM, IDUs, Meth Use - (04/02/14)
     
  357. CROI: Pharmacokinetics, Efficacy and Safety of an Integrase Inhibitor-Based Single-Tablet Regimen in HIV-Infected Treatment-Naïve Adolescents - (04/01/14)
     
  358. CROI: Sex-related Inflammatory Marker Changes Pre and Post Antiretroviral Treatment (ART) Initiation - (04/01/14)
     
  359. CROI: Rilpivirine pharmacokinetics in HIV-1-infected adolescents: a substudy of PAINT (Phase II trial) - (04/01/14)
     
  360. CROI: HIV-replication control rates needed to prevent Neurocognitive Performance (NP) decline - (04/01/14)
     
  361. CROI: Effective Exposure to Atazanavir during Pregnancy, Regardless of Tenofovir Use - (04/01/14)
     
  362. CROI: Prevalence of Congenital Anomalies in Infants With In Utero Exposure to Antiretrovirals - (04/01/14)
     
  363. CROI: Congenital Anomalies and in utero Antiretroviral Exposure in HIV-exposed Uninfected Infants - (04/01/14)
     
  364. Abnormal Newborn Screens and Acylcarnitines in HIV-exposed and ARV-exposed Infants - (04/01/14)
     
  365. CROI: Abnormal fatty acid oxidation in HIV-exposed, uninfected neonates in the US - (04/01/14)
     
  366. CROI: Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Cobicistat - (04/01/14)
     
  367. CROI: Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Elvitegravir - (04/01/14)
     
  368. CROI: Safety Pharmacokinetics and Efficacy of Dolutegravir in Treatment Experienced HIV + Children - (04/01/14)
     
  369. CROI: Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-Week Results - (04/01/14)
     
  370. CROI: Osteoporosis (bone), Frailty, and Vitamin D: CROI 2014 - Todd T. Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (04/01/14)
     
  371. CROI: Mechanism of Bone Disease in HIV and HCV: Impact of Tenofovir Exposure and Severity of Liver Disease - (04/01/14)
     
  372. Once-Daily Regimens Modestly Improve Adherence, Not Viral Control, in Meta-Analysis - (03/28/14)
     
  373. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials - (03/28/14)
     
  374. Protein Protects Aging Brain....new research published....NIH HIV Brain Research Studies - (03/28/14)
     
  375. CROI: The Kidney at CROI 2014 -Christina M. Wyatt, MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/25/14)
     
  376. CROI: Rosuvastatin Reduces Immune Activation and Inflammation in Treated HIV Infection - (03/28/14)
     
  377. CROI: Rosuvastatin Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: SATURN-HIV - (03/28/14)
     
  378. CROI: Atazanavir and Tenofovir Attenuate the Benefit of Antiretroviral Therapy on Cystatin C: ACTG A5224s - (03/28/14)
     
  379. CROI: Implementation of PrEP in STD Clinics and a Community Health Center: High Uptake and Drug Levels among MSM in the Demo Project - (03/28/14)
     
  380. CROI: Willingness to Use Pre-Exposure Prophylaxis Among Community-Recruited Injection Drug Users - (03/28/14)
     
  381. CROI: Early Adopters: Socio-demographic and Behavioral Correlates of Chemoprophylaxis Use in a Recent National Online Sample of Men who have Sex with Men in the U.S. - (03/28/14)
     
  382. CROI: PrEP Interest, Uptake and Adherence among Young Men Who Have Sex with Men (YMSM) in the United States - (03/28/14)
     
  383. CROI: Contingency Management Facilitates PEP Completion among Stimulant-Using MSM - (03/28/14)
     
  384. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/28/14)
     
  385. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14)
     
  386. CROI: HIV Pathogenesis, Innate Defense against HIV, and HIV Cure at CROI 2014, Boston - By David Margolis MD UNC Chapel Hill & the Collaboratory of AIDS Researchers for Eradication (CARE) (03/25/14)
     
  387. CROI: 21st Conference on Retroviruses and Opportunistic Infections: Review - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/21/14)
     
  388. CROI: Faster Lung Function Decline With HIV Linked to sCD14 Activation Marker - written Mark Mascolini - (03/21/14)
     
  389. CROI: Spine/Hip Bone Density Drops More in 96 Weeks With PIs Than With Raltegravir - written Mark Mascolini - (03/21/14)
     
  390. CROI: FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14)
     
  391. CROI: Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14)
     
  392. CROI: Antiviral Therapy and Smoking Associated with Coronary Vessel Wall Thickening in HIV-Infected Youth - (03/21/14)
     
  393. CROI: Lower CD4 Count, Detectable Viral Load, & Traditional CVD Risk Factors are Associated with Increased Risk of Primary Myocardial Infarction in the CNICS cohort....IDU associated with secondary MI - (03/21/14)
     
  394. CROI: Inflammation/Viral Replication/HIV Persistence....Reservoirs....Anti-Inflammation HIV Cure Strategies....VX-765, a small-molecule inhibitor of caspase-1, a potential anti-inflammatory drug/Cure Strategy to reduce reservoir?????......IP-10.... anti-inflammatory/HIV Cure strategy - (03/21/14)
     
  395. CROI: CROI 2014: Inflammation in HIV.....HIV cure, comorbidities, interventions to reduce inflammation - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine (03/21/14)
     
  396. CROI: Abdominal Obesity, Inflammation, Immune Activation and Neurocognitive Impairment - (03/19/14)
     
  397. CROI: Blood Cell Indices and Neurocognitive Impairment in the HAART Era: A CHARTER Study - (03/19/14)
     
  398. CROI: Determinants of Cognitive Impairment in HIV-positive Men on cART and Uninfected Controls: HIV, immune activation - (03/19/14)
     
  399. CROI: HIV-1 Replication in Central Nervous System Increases over Time on Protease Inhibitor Only Therapy - (03/19/14)
     
  400. CROI: Impact of Smoking on Life Expectancy among HIV-Infected Individuals: The ART Cohort Collaboration - (03/19/14)
     
  401. CROI: Number and Diversity of Gut Microbes Lower With HIV and Tied to Activation - written by Mark Mascolini - (03/19/14)
     
  402. CROI: Lower CD4 Nadir Linked to Geriatric Syndromes in 50-or-Older People - written by Mark Mascolini - (03/19/14)
     
  403. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study; HIV & HCV/HIV Bone Loss - (03/19/14)
     
  404. CROI: Impact of Plasma HIV RNA on Neurocognitive Decline --and Difference With PIs vs NNRTIs - written by Mark Mascolini - (03/18/14)
     
  405. CROI: Greater Bone Deficits Seen in Young US Men Infected at Birth Versus in Adolescence....bone senescence - written by Mark Mascolini - (03/18/14)
     
  406. CROI: Higher Lipids Raise Acute MI Risk 22% to 64% in Untreated HCV RNA+ Veterans - written by Mark Mascolini - (03/18/14)
     
  407. CROI: One Quarter of HIV+ Smoker Group Has COPD--Risk Lower With Higher CD4s - written by Mark Mascolini - (03/18/14)
     
  408. CROI: More Life Years Lost Through Smoking Than HIV in 18,000-Person Analysis - written by Mark Mascolini - (03/18/14)
     
  409. CROI: Low/Moderate Alcohol Drinking Trims Heart Disease-Free Death Risk in HIV+ Swiss - written by Mark Mascolini - (03/18/14)
     
  410. CROI: Partner Support Does Not Improve Second-Line Response in Randomized Trial - written by Mark Mascolini - (03/18/14)
     
  411. CROI: Three ART Regimens Don't Differ in 144-Week "Target Not Detected" Response - written by Mark Mascolini - (03/18/14)
     
  412. CROI: Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV-Infected Patients - (03/14/14)
     
  413. Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine - (03/14/14)
     
  414. CROI: Cancers in HIV+ at CROI - (03/14/14)
     
  415. CROI: Correlation between atazanavir concentrations, clinical covariates and side effects - (03/14/14)
     
  416. CROI: Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures - (03/14/14)
     
  417. CROI: Impact of Smoking on Risk of Cancer among HIV patients Compared to the Background Population - (03/14/14)
     
  418. CROI: GSK1265744 Long-Acting Protects Macaques against Repeated High-Dose Intravaginal Challenges & Depo Provera-treated - (03/14/14)
     
  419. CROI: The Clinical Impact of Viral Load Copy Years in Antiretroviral-Naïve HIV Seroconverters - (03/14/14)
     
  420. CROI: Cumulative Viral Load Predicts All-cause and AIDS-related Mortality After Initiation of ART - (03/14/14)
     
  421. CROI: Brisk Walking Improves Inflammatory Markers in cART-Treated Patients - (03/14/14)
     
  422. CROI: Physical Function Impairment on Quality of Life among Persons Aging with HIV Infection - (03/14/14)
     
  423. CROI: Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine: 96-Week Results From the SINGLE Study (ING114467) - (03/12/14)
     
  424. CROI: Dolutegravir in the French Named Patient Program* in Integrase HIV-2 Resistant Infected Patients - (03/12/14)
     
  425. CROI: Switch from NNRTI plus FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14)
     
  426. CROI: Simplification of PI + RTV + FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14)
     
  427. CROI: HIV Prevention at CROI 2014 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/13/14)
     
  428. CROI: Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14)
     
  429. CROI: HIV-Immune Complex Kidney Disease: Risk Factors and Progression to End-Stage Kidney Disease - (03/12/14)
     
  430. CROI: A Chronic Kidney Disease Risk Score to Determine Tenofovir Safety in a Prospective Cohort of HIV+ Male Veterans - (03/12/14)
     
  431. CROI: End-stage kidney disease and kidney transplantation in HIV positive patients - (03/12/14)
     
  432. CROI: Stopping TDF Before Renal Impairment Boosts Chance of Improving eGFR - written by Mark Mascolini - (03/12/14)
     
  433. CROI: Heavy Popper Use in Gay MACS Cohort Linked to New Heart Disease, Cancer - written by Mark Mascolini - (03/12/14)
     
  434. CROI: Spleen and Bone Marrow May Be Key Players in Arterial Inflammation With HIV - written by Mark Mascolini - (03/12/14)
     
  435. CROI: Drops in AIDS Deaths, Some non-AIDS Deaths Parallel ART Expansion in British Columbia - written by Mark Mascolini - (03/12/14)
     
  436. CROI: HIV Rebounds Detailed in Two Boston Stem Cell Transplant Patients - written by Mark Mascolini - (03/12/14)
     
  437. Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results - (03/10/14)
     
  438. Boosting HIV Treatment Options (Cobi, RTV): Good News, New Challenges - Editorial Comment - (03/10/14)
     
  439. CROI: Atazanavir/Cobicistat Fixed-Dose Combination is Bioequivalent to the Separate Agents - (03/10/14)
     
  440. CROI: Bone quality determination by ultrasonometry in young South African HIV-infected children - (03/10/14)
     
  441. CROI: Geriatric Syndromes are Common Among Older HIV-Infected Adults: in this group over age 50, 50% of participants had frailty or pre-frailty ay higher frequencies than HIV-negatives" - (03/10/14)
     
  442. CROI: Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial - (03/10/14)
     
  443. CROI: Lower Newborn Bone Mineral Content (BMC) Associated with Maternal Use of Tenofovir Disoproxil Fumarate (TDF) - (03/10/14)
     
  444. CROI: Comparison of Two Doses of Zoledronic Acid for the Treatment of Osteoporosis in HIV Infected Patients. Results of a Randomized Open Label Study (VIHZOL Study) - (03/10/14)
     
  445. CROI: Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men: "FT decreased similarly over a 6-year interval in older HIV infected and HIV-uninfected men" - (03/10/14)
     
  446. CROI: Frailty, Inflammation and Mortality among Aging HIV-Infected and At-Risk Injection Drug Users - (03/10/14)
     
  447. CROI: Hand osteoarthritis, a joint disorder frequent and more severe HIV-1 patients : METAFIB OA Study - (03/10/14)
     
  448. CROI: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults "highlighting the potential value of DEXA screening in this population"......median age 42[35-48]....36% osteopenia/2.9% osteoporosis - (03/10/14)
     
  449. CROI: Bone Density Changes after Antiretroviral Initiation with Protease Inhibitors or Raltegravir - (03/10/14)
     
  450. CROI: New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults - (03/10/14)
     
  451. CROI: Cumulative Viral Load Predicts All-Cause and AIDS Death But Not Non-AIDS Death - written by Mark Mascolini - (03/10/14)
     
  452. CROI: Tesamorelin Lowers Hepatic Fat in HIV+ With Excess Visceral Fat - written by Mark Mascolini - (03/10/14)
     
  453. CROI: Arterial Inflammation Tied to High-Risk Coronary Plaques in HIV Group - written by Mark Mascolini - (03/10/14)
     
  454. CROI: PI Regimens Tied to Cerebral Small Vessel Disease--and CSVD Tied to HAND - written by Mark Mascolini - (03/10/14)
     
  455. CROI: Nearly Nil HIV Transmission Risk Without Condoms and (from Jules: in established couples) With HIV+ Partner on Suppressive ART - written by Mark Mascolini - (03/10/14)
     
  456. CROI: Vitamin D/Calcium Supplements Reduce Bone Loss by 50% When Starting EFV/TDF/FTC - written by Mark Mascolini - (03/10/14)
     
  457. CROI: Rosuvastatin Improves Hip Bone Mineral Density but Worsens Insulin Resistance - (03/07/14)
     
  458. CROI: Viral Suppression Induced by Anti-PD-L1 Following ARV-Interruption in SIV-Infected Monkeys - (03/07/14)
     
  459. CROI: Darunavir or Atazanavir vs Raltegravir Lipid Changes are unlinked to Ritonavir Exposure: ACTG 5257 - (03/07/14)
     
  460. CROI: Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14)
     
  461. CROI: Very Early Combination Antiretroviral Therapy in Perinatal HIV Infection: Two Case Studies - "Mississippi" baby followup & 2nd case of infant that appears to have cleared HIV/remains on cART - (03/06/14)
     
  462. CROI: Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in US - written by Mark Mascolini - (03/06/14)
     
  463. CROI: HIV Independently Predicts Cardiovascular Disease in US Women - written by Mark Mascolini - (03/06/14)
     
  464. CROI: US HIV Transmission Network Study Holds Some Surprises About Women and MSM - written by Mark Mascolini - (03/06/14)
     
  465. CROI: Second Swiftly Treated Baby Seems to Have Cleared HIV - written by Mark Mascolini - (03/06/14)
     
  466. CROI: Quadrivalent HPV Vaccine Induces Immune Memory in US Men With HIV - written by Mark Mascolini - (03/06/14)
     
  467. CROI: Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14)
     
  468. CROI: Brain Markers of Inflammation Drop to Normal With Early ART - (03/05/14)
     
  469. CROI: Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257 - (03/05/14)
     
  470. CROI: First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial - (03/05/14)
     
  471. CROI: Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients - (03/05/14)
     
  472. CROI: GSK744 and Rilpivirine as Two Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results - (03/05/14)
     
  473. CROI: HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced Subjects: Week 24 Analysis - (03/05/14)
     
  474. CROI: HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14)
     
  475. CROI: Five Cancers Diagnosed at Later Stage in People With vs Without HIV - written by Mark Mascolini - (03/05/14)
     
  476. CROI: Novel Network Score Tied to HIV Transmission Risk and Outcomes - written by Mark Mascolini - (03/05/14)
     
  477. CROI: Low CD4/CD8 Ratio Predicts non-AIDS Illness in Large Italian Cohort - written by Mark Mascolini - (03/05/14)
     
  478. CROI: Testosterone Falls No More With Than Without HIV Over 6 Years in MACS - written by Mark Mascolini - (03/05/14)
     
  479. CROI: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14)
     
  480. CROI: Viral Suppression Disparities: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14)
     
  481. CROI: Transmitted HIV Resistance Rate Close to 20% in Large Study of US MSM - written by Mark Mascolini - (03/05/14)
     
  482. CROI: Brain Markers of Inflammation Drop to Normal With Early ART - written by Mark Mascolini - (03/05/14)
     
  483. Inflammation, Activation Associated with Reduced Functional Capacity in HIV+ - (03/03/14)
     
  484. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery - (02/27/14)
     
  485. Decline in locomotor functions over time in HIV-infected patients - (02/26/14)
     
  486. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.....AIDS, HCV coinfection, comorbidities--cancers/liver disease, heart disease - (02/26/14)
     
  487. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women - (02/26/14)
     
  488. Pharmacokinetics of raltegravir in the semen of HIV-infected men - (02/26/14)
     
  489. Aggregate Risk of Cardiovascular Disease among Adolescents Perinatally Infected with the Human Immunodeficiency Virus - (02/26/14)
     
  490. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors - (02/25/14)
     
  491. Stribild, Isentress & Tivicay (dolutegravir) Prescribing Information - (02/20/14)
     
  492. What is the significance of posttreatment control of HIV infection vis-a-vis functional cure? - (02/19/14)
     
  493. "These data indicated that lopinavir could potentially be used topically as an anti-HPV therapeutic" - (02/18/14)
     
  494. Switch to raltegravir decreases soluble CD14 [inflammation marker] in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial - (02/18/14)
     
  495. Shot in the HAART: vaccine therapy for HIV; Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial - (02/14/14)
     
  496. 2 New Studies on Disparities in HIV Care: the NA-ACCORD, a large patient cohort & the CDC Report: Blacks Receive Worse Care, Black Men Receive Worse Care than Black Women - (02/11/14)
     
  497. Antibodies Prevent HIV Transmission in Mice - (02/11/14)
     
  498. Disparities in the quality of HIV care when using US Department of Health and Human Services Indicators - blacks, IDUs, females - (02/10/14)
     
  499. Experts warn of rise in gay 'slamming' in London: increased HIV & HCV transmission risk - (02/07/14)
     
  500. Inflammation & HIV.....inflammation in the general population & in HIV+ is associated with non-AIDS comorbidities, so is immune activation - (02/07/14)
     
  501. Inflammation, HIV, HCV & Alcohol in HIV+ - (02/07/14)
     
  502. Immunologic predictors/Inflammation of coronary artery calcium progression in a contemporary HIV cohort - (02/07/14)
     
  503. HIV infection and its association with an excess risk of clinical fractures and: a nation-wide case-control study - (02/07/14)
     
  504. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges - (02/03/14)
     
  505. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues - (01/31/14)
     
  506. Do children infected with HIV receiving HAART need to be revaccinated? - (01/31/14)
     
  507. Immunologic basis for revaccination of HIV-infected children receiving HAART: Immune Reconstitution, Memory Responses & Revaccination Against Measles Virus - (01/31/14)
     
  508. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis - (01/31/14)
     
  509. Extending HIV drug resistance testing to low levels of plasma viremia: 'Reliability and Clinical Relevance of the HIV-1 Drug-Resistance Test in Patients with Low Viremia Levels'; 'Performance of HIV-1 Drug Resistance Testing at Low Level Viraemia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naïve Individuals' - (01/31/14)
     
  510. Association between short leukocyte telomere length and HIV infection in a cohort study; no evidence of a relationship with antiretroviral therapy - (01/31/14)
     
  511. In Vivo Mitochondrial Function in HIV-Infected Persons Treated with Contemporary Anti-Retroviral Therapy: A Magnetic Resonance Spectroscopy Study - (01/31/14)
     
  512. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? - (01/31/14)
     
  513. Uptake of PrEP for HIV slow among MSM - (01/31/14)
     
  514. Association between short leukocyte telomere length and HIV infection in a cohort study; no evidence of a relationship with antiretroviral therapy - (01/24/14)
     
  515. Immunotherapy (monoclonal antibodies) for HIV Infection - (01/23/14)
     
  516. New HIV Cure Research Findings-Radioimmunotherapy Therapy (RIT) - (01/23/14)
     
  517. NYS HIV PEP/PrEP Guidance-Pre & Post Exposure Prophylaxis - (01/22/14)
     
  518. Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012; Dolutegravir Resistance Reports - (01/22/14)
     
  519. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years - (01/22/14)
     
  520. Improving the health of the tuberculosis drug pipeline - (01/22/14)
     
  521. ViiV Healthcare's new HIV medicine Tivicay® (dolutegravir) is approved in Europe - (01/21/14)
     
  522. Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care - (01/21/14)
     
  523. Antiretroviral treatment French guidelines 2013: economics influencing science - (01/21/14)
     
  524. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence - (01/21/14)
     
  525. Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - (01/21/14)
     
  526. Life Expectancy Study in Italy: CD4 Linked with Better Estimated Life Expectancy & Those with CD4 Recovery from nadir/low CD4 to >500 Estimated to have Life Expectancy Close to General Population - (01/21/14)
     
  527. 4th Int HIV & Women: Efficacy and Safety of Raltegravir in Women - (01/21/14)
     
  528. 4th Int HIV & Women: STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF is Safe and Well-Tolerated with Efficacy Comparable to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96 - (01/21/14)
     
  529. Association of Coffee Consumption With All-Cause and Cardiovascular Disease Mortality - written by Mark Mascolini - (01/17/14)
     
  530. Beneficial impact of antiretroviral therapy on non-AIDS mortality: Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals - (01/17/14)
     
  531. 4th Int HIV & Women: Raltegravir Efficacy and Safety Similar in Naive Women and Men at 48 Weeks - written by Mark Mascolini - - (01/16/14)
     
  532. 4th Int HIV & Women: London Women Lag MSM and Heterosexual Men in Antiretroviral Response and Durability - written by Mark Mascolini - - (01/16/14)
     
  533. 4th Int HIV & Women: Response Rates With Complera Versus Atripla in Women at 96 Weeks in STaR - written by Mark Mascolini - - (01/15/14)
     
  534. 4th Int HIV & Women: Immune Response to HPV Vaccine Lower in Girls With Than Without HIV - written by Mark Mascolini - - (01/15/14)
     
  535. 4th Int HIV & Women: Clinical Characteristics and Quality of HIV Care for Women in the United States: Data from the Medical Monitoring Project, 2009 - written by Mark Mascolini - - (01/15/14)
     
  536. 4th Int HIV & Women: Age, Lower CD4s, Winter Predict Missed Clinic Visits by HIV+ Toronto Women - written by Mark Mascolini (01/14/14)
     
  537. 4th Int HIV & Women: US Women With HIV Get Too Little Support on STIs and HIV Transmission, CDC Says - written by Mark Mascolini (01/14/14)
     
  538. Nuts/Lifestyle & Morbidity/Mortality - (01/13/14)
     
  539. HAART & The Brain: "CNS Toxicity of Antiretroviral Drugs", "Can antiretroviral therapy prevent HIV-associated cognitive disorders?" - (01/13/14)
     
  540. HIV Cure: T Memory Stem Cells - Hideouts Of HIV Against Any Antiviral Treatment - new - (01/13/14)
     
  541. Age, Race/Ethnicity, and Behavioral Risk Factors Associated With Per Contact Risk of HIV Infection Among Men Who Have Sex With Men in the United States - (01/12/14)
     
  542. Vitamin D supplementation: bones of contention - commentary - (01/12/14)
     
  543. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. Association of Coffee Consumption With All-Cause and Cardiovascular Disease Mortality - 2 new studies - (12/31/13)
     
  544. How HIV Destroys Immune Cells, Blocking HIV Cell Death with Vertex Drug- 2 new studies. Scientists Discover How Key Immune Cells Die During HIV Infection and Identify Potential Drug to Block AIDS - (12/27/13)
     
  545. Are We Prepped for PrEP? Provider Opinions on the Real-World Use of PrEP in the U.S. and Canada - (12/27/13)
     
  546. Drugs for neuropathic pain - (12/23/13)
     
  547. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis - (12/23/13)
     
  548. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - (12/23/13)
     
  549. Isentress (raltegravir) - FDA Approves New Dosage Form for Oral Suspension for Pediatrics - (12/22/13)
     
  550. HIV Cured In Mice? German Scientists Use Stem Cells To Cut Out Virus With 'Molecular Scissors' - (12/22/13)
     
  551. Dietary Fibre Can reduce Cardiovascular/Heart Disease Risk - (12/22/13)
     
  552. Eat more fibre Editorial (reduces heart disease risk) - (12/22/13)
     
  553. Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function - (12/19/13)
     
  554. Anti-PD-L1 immunotherapy in ARV-suppressed rhesus monkeys - (12/19/13)
     
  555. Farnesyl-Transferase inhibitors: Identification and validation of a class which reactivates HIV latent expression and is synergistic with other mechanisms in vitro - (12/19/13)
     
  556. Highlights on HIV eradication in 2013 - (12/18/13)
     
  557. 6th Intl Workshop on HIV Persistance during Therapy Report Summary - Report by David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) - (12/15/13)
     
  558. Renal safety of atazanavir-based regimens in human immunodeficiency virus (HIV) infected patients - (12/12/13)
     
  559. Effects of interferon-α treatment on anti-HIV-1 intrinsic immunity in vivo - (12/09/13)
     
  560. AASLD: Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV - (12/06/13)
     
  561. HIV virus returns after cure hope rose - (12/06/13)
     
  562. EACS: Low HDL Cholesterol Is Main Lipid Abnormality in HIV+/HIV- Comparison in HIV UPBEAT Study - (12/06/13)
     
  563. VACCINATION IMPORTANT FOR IMMUNOCOMPROMISED PATIENTS - (12/04/13)
     
  564. Where Will Obama Find $100 Million for the New HIV Cure Initiative? - (12/04/13)
     
  565. British scientists to trial potential HIV cure: HDAC Inhibitor + HIV Vaccine - (12/03/13)
     
  566. A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis - (12/03/13)
     
  567. Intravaginal ring could block HIV transmission to women - (12/03/13)
     
  568. Development and Pharmacokinetics of a 90-Day Intravaginal Ring for the Sustained Co-Delivery of the Microbicide Tenofovir and Contraceptive Levonorgestrel ........presented Nov 10 2013 at Annual Meeting for the American Ass. Of Pharmaceutical Scientists - (12/03/13)
     
  569. NIH announces plan to increase funding toward a cure for HIV/AIDS - (12/03/13)
     
  570. Dolutegravir plus Abacavir-Lamivudine vs Efavirenz/TDF/FTC Once Daily for the Treatment of HIV-1 Infection - (12/03/13)
     
  571. HIV Protein Causes Metabolic/Fat Abnormalities, New Study: HIV-1 Vpr Induces Adipose Dysfunction in Vivo Through Reciprocal Effects on PPAR/GR Co-Regulation - (12/03/13)
     
  572. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis (Partners PrEP Study) - (11/20/13)
     
  573. New HIVMA Guidelines/Comorbidities - (11/16/13)
     
  574. New American Heart Association/American College of Cardiology 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk - (11/15/13)
     
  575. Controversy Over Statins for Older Patients/New AHA Guidelines - (11/15/13)
     
  576. Towards an HIV Cure: science and debate from the International AIDS Society 2013 symposium - (11/15/13)
     
  577. AGE: Poor Physical Function in Older Women on ART Tied to Comorbidities, Inflammation - Written by Mark Mascolini - (11/14/13)
     
  578. AGE: Prescriptions Rise With Age in Ontario HIV+, But Drug-Related Problems Don't - Written by Mark Mascolini - (11/14/13)
     
  579. AGE: Cardiovascular Risk Linked to Poor Memory Independently of Age in HIV+ - Written by Mark Mascolini - (11/14/13)
     
  580. AGE: Moderate Exercise Linked to Better Executive Function in Older HIV+ People - Written by Mark Mascolini - (11/03/13)
     
  581. AGE: Prior Meth Use Tied to Worse Neurocognitive Function in Older But Not Younger HIV+ - Written by Mark Mascolini - (11/03/13)
     
  582. AGE: Multimorbidity and Non-AIDS Rates Differ With HIV Duration in Older Adults - Written by Mark Mascolini - (11/03/13)
     
  583. HIV Antibody Infusions Show Promise for Treating SHIV-Infected Monkeys - (11/01/13)
     
  584. 2 New Studies - HIV Antibodies Advance the search for a cure/Supercharged antibodies fight HIV-related virus in monkeys - (10/31/13)
     
  585. AGE: Carotid Plaques Develop More Often With vs Without HIV in Metabolic Syndrome Patients - Written by Mark Mascolini - (10/31/13)
     
  586. AGE: "Successful Cognitive Aging" in Only One Fifth of US HIV Group 50 or Older - Written by Mark Mascolini - (10/31/13)
     
  587. New HIV & HCV Rapid Tests - (10/30/13)
     
  588. Sangamo: Maintained Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks, Data were presented at the Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT and SETGyC Collaborative Congress) which is being held in Madrid from October 25-28, 2013 - (10/30/13)
     
  589. Inflammation Associated with Heart Disease, Cancers, Diabetes, Viral Load & CD4 Count - (10/29/13)
     
  590. EACS: Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation - Written by Mark Mascolini - (10/28/13)
     
  591. EACS: PI Use, Female Gender, HCV, Detectable Sub-50 Viral load Predict Rebound From Under 50 Copies in Italian Group - Written by Mark Mascolini - (10/28/13)
     
  592. Mississippi Baby HIV Cure Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant - (10/28/13)
     
  593. Can HIV Be Cured? - (10/28/13)
     
  594. Is HIV a Model of Accelerated or Accentuated Aging? - (10/28/13)
     
  595. Exercise Benefits Aging Brain - (10/28/13)
     
  596. HIV Increases Risk for Heart Disease; Nadir CD4 & Heart Disease in HIV - (10/28/13)
     
  597. EACS: Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV, HIV UPBEAT Cohort - Written by Mark Mascolini - (10/25/13)
     
  598. EACS: Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference - (10/25/13)
     
  599. EACS: Bone Loss Worse in HIV+ vs HIV-Neg, Lower Body Weight Predicts Bone Loss in MSM: "Prevalence and determinants of reduced bone mineral density in aging HIV-1-positive and HIV-negative individuals" in AGEhIV Cohort Amsterdam - (10/25/13)
     
  600. EACS: Neither HIV Nor Tenofovir Tied to Low Bone Density in Large Amsterdam Study (AGEhIV Cohort) - (10/25/13)
     
  601. EACS: Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV - (10/25/13)
     
  602. IWCADR: Darunavir, atazanavir and lopinavir boosted with ritonavir differentially affect endothelial functions and induce senescence of cultured human endothelial cells. Beneficial effect of pravastatin - (10/23/13)
     
  603. EACS: CHANGES IN BONE TURNOVER MARKERS AND ASSOCIATION WITH DECREASED TOTAL BONE MINERAL DENSITY IN TREATMENT-NAIVE SUBJECTS TAKING LOPINAVIR/RITONAVIR (LPV/r) COMBINED WITH RALTEGRAVIR (RAL) OR TENOFOVIR/EMTRICITABINE (TDF/FTC) - (10/23/13)
     
  604. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial - (10/23/13)
     
  605. SPRING-2 the future of antiretroviral therapy - Commentary - (10/23/13)
     
  606. The challenge of HIV associated neurocognitive disorder - Commentary - (10/23/13)
     
  607. HIV-associated neurocognitive disorder - (10/23/13)
     
  608. EACS: Classic Risk Factors, But Not HIV, Linked to Arterial Stiffness in Middle-Aged - Written by Mark Mascolini - (10/23/13)
     
  609. EACS: Bone Turnover Marker Changes Early in ART Predict Bone Loss After 96 Weeks - Written by Mark Mascolini - (10/23/13)
     
  610. EACS: Statin Use Cuts All-Cause Mortality 75% in Spanish HIV Cohort - Written by Mark Mascolini - (10/23/13)
     
  611. EACS: Meta-Analysis of Dolutegravir vs Guideline-Recommended Agents for Naive - Written by Mark Mascolini - (10/23/13)
     
  612. EACS: Once-Daily ART v Twice-Daily/Pill Burden Meta-Analysis Evaluates Adherence/Viral Control - Written by Mark Mascolini - (10/23/13)
     
  613. EACS: 48 weeks outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: interim analysis results of the MODAt Study - (10/23/13)
     
  614. EACS: Osteoporosis Triples Risk of Later Fracture in 1000-Person US HIV Group - Written by Mark Mascolini - (10/21/13)
     
  615. EACS: Twice-Higher Latest Vitamin D Almost Halves Odds of Death in EuroSIDA - Written by Mark Mascolini - (10/21/13)
     
  616. EACS: Once-Daily Raltegravir for 48 Weeks as Maintenance Therapy in Paris - Written by Mark Mascolini - (10/21/13)
     
  617. EACS: 'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)
     
  618. EACS: Safety and Tolerability of Switching from Twice Daily Raltegravir plus Truvada to STRIBILD in Virologically Suppressed, HIV-1 Infected Subjects - (10/21/13)
     
  619. EACS: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 96 Results - (10/21/13)
     
  620. EACS: Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study - (10/21/13)
     
  621. EACS: Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort - (10/21/13)
     
  622. EACS: Virological Efficacy, Durability and Safety of Darunavir/r plus Etravirine (DRV/r-ETV) Dual Regimen in ART-Experienced Patients - (10/21/13)
     
  623. EACS: Simplification to dual therapy containing raltegravir and darunavir/ritonavir in HIV-infected patients on virologically suppressive therapy including nucleoside/nucleotide analogues and ritonavir-boosted boosted protease inhibitors - (10/21/13)
     
  624. EACS: Substantial rates of Acute Hepatitis C Reinfection in European HIV-positive Patients - (10/21/13)
     
  625. EACS: STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α -2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection - (10/20/13)
     
  626. EACS: Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: Primary analysis of the C212 study - (10/20/13)
     
  627. EACS: Simeprevir with peginterferon/ribavirin in treatment-naïve or experienced patients with chronic HCV genotype 4 infection: Interim results of a Phase III trial - (10/20/13)
     
  628. EACS: Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/4A protease inhibitor - (10/20/13)
     
  629. EACS: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults - (10/20/13)
     
  630. EACS: Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study - (10/18/13)
     
  631. EACS: Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus (Study 652-2-202; NCT01338883) - (10/18/13)
     
  632. EACS: Week 96 Renal Safety Update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Two Phase 3 Randomized Controlled Trials - (10/18/13)
     
  633. EACS: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results - (10/18/13)
     
  634. EACS: Once-Daily Oral GSK1265744 (744) as Part of Combination Therapy in Antiretroviral-Naive Adults: 24-Week Safety and Efficacy Results From the LATTE Study (LAI116482) - (10/18/13)
     
  635. Systemic Effects of Inflammation on Health during Chronic HIV Infection - (10/17/13)
     
  636. Immune clearance of highly pathogenic SIV infection - (10/17/13)
     
  637. EACS: A Single Dose Food Effect Study of Raltegravir (RAL) Formulations Once Daily Tablet - (10/17/13)
     
  638. EACS: Once-Daily Dolutegravir Versus Darunavir/Ritonavir in Antiretroviral Naïve Adults: 48 Week Subgroup Analyses from FLAMINGO - (10/17/13)
     
  639. EACS: 48-Week Efficacy of Dolutegravir Relative to Commonly Used 3rd Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (10/16/13)
     
  640. EACS: Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)
     
  641. EACS: Activity of Dolutegravir (DTG) 50 mg BID vs Placebo (PBO) Over 7 Days of Functional Monotherapy in Patients Harbouring Raltegravir- and/or Elvitegravir-Resistant Virus: Primary Endpoint Results of the VIKING-4 Study (ING116529) - (10/16/13)
     
  642. ID Week: Acute HCV Treatment/HIV+ MSM/HCV Screening/New HCV Therapies: "Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus" - (10/16/13)
     
  643. ID Week: Polypharmacy in HIV: "Differences in calculated adherence rates of ART and non-ART medications among HIV positive veterans" - (10/16/13)
     
  644. IAS: Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome........patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/16/13)
     
  645. ICAAC: Good Results With No-NRTI Strategy in ART Experienced: Small Retrospective Study - Written by Mark Mascolini - (10/16/13)
     
  646. Vitamin D Supplementation New Study/Commentary - (10/16/13)
     
  647. ID Week: ID Week 2103: Polypharmacy in HIV - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  648. ID Week: ID Week 2013: Co-morbidities - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  649. ID Week: ID Week 2013: Antiretroviral Therapy - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  650. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population - (10/15/13)
     
  651. ID Week: (CDC) Differences in Demographic, Behavioral and Clinical Characteristics between HCV Mono-infected and HCV/HIV Co-infected Adults in Outpatient Primary Care - (10/11/13)
     
  652. ID Week: Clinicians May Overlook CD4 Percent in HIV+ When Deciding on PCP Prophylaxis - Written by Mark Mascolini - (10/11/13)
     
  653. ID Week: Barriers to Effective Antenatal Hepatitis C Virus (HCV) Screening - (10/11/13)
     
  654. ID Week: Effects of aging and antiretroviral therapy on B Cell phenotypes in HIV infected subjects - (10/11/13)
     
  655. ID Week: (72% of women had Vit D Deficiency) Vitamin D supplementation increases Vitamin D levels but does not improve inflammatory markers in HIV Infected Women; a Chicago Women's Interagency HIV study (WIHS) study - (10/11/13)
     
  656. ID Week: Metabolic, Bone, Renal, Inflammatory and Lipodystrophic Marker Analysis in INROADS, a Multicenter, Single-Arm, Open-Label Study of a Once-Daily Nucleoside/tide-Sparing Regimen of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (10/11/13)
     
  657. ID Week: HIV TREATMENT CASCADE AMONG TRANSGENDER WOMEN IN A SAN FRANCISCO RESPONDENT DRIVEN SAMPLING STUDY - (10/11/13)
     
  658. ID Week: SPIRIT: Simplification to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Maintains HIV-1 Suppression and Improves Fasting Lipids at Week 48 - (10/10/13)
     
  659. ID Week: Higher Mortality With vs Without HIV After Acute Coronary, But Not With High CD4s - (10/10/13)
     
  660. ID Week: "ART-naïve HIV+ adults, but not controls, had BMD loss at the total hip and trochanter sites over 48 weeks" - ART-Naive Adults More Likely to Lose Trochanter BMD Than HIV-Negatives - Writted by Mark Mascolini - (10/10/13)
     
  661. ID Week: Program for Prescribers Cuts Antiretroviral Errors in Hospital Population - Writted by Mark Mascolini - (10/10/13)
     
  662. ID Week: Cumulative Viral Load Predicts Morbidity/Mortality in Perinatally Infected Children - written by Mark Mascolini - (10/07/13)
     
  663. ID Week: Rash in 10% of Taiwanese Starting Once-Daily Darunavir--and 7% Dropout Rate - written by Mark Mascolini - (10/07/13)
     
  664. ID Week: 15% of HIV+ Adults in NY Clinics Still Seronegative for Measles, Mumps, Rubella - written by Mark Mascolini - (10/07/13)
     
  665. ID Week: Six-Month HIV Suppression Better With Single-Tablet Regimens Than Multitablet Combos - written by Mark Mascolini - (10/07/13)
     
  666. ID Week: Low Risk but Twice Higher Risk of Suicidal Thoughts or Acts on First-Line Efavirenz - written by Mark Mascolini - (10/07/13)
     
  667. ID Week: Lack of ART Tied to Tripled Mortality in Veterans With Community-Acquired Pneumonia - written by Mark Mascolini - (10/07/13)
     
  668. ID Week: Cumulative Viremia-Copy Years Predicts Morbidity and Mortality in Perinatally HIV-Infected Children - (10/07/13)
     
  669. ID Week: Assessing Vitamin D Testing and Supplementation Patterns in a Large Inner City Clinic - (10/07/13)
     
  670. ID Week: Current Alcohol and Substance Use in HIV-infected and HIV/HCV-co-infected Patients in Routine Clinical Care across the U.S. - (10/07/13)
     
  671. ID Week: Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome........patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/07/13)
     
  672. ID Week: Pilot Study to Evaluate Intramyocardial Lipid Accumulation in HIV+ Patients Receiving Highly Active Antiretroviral Therapy (HAART) - (10/07/13)
     
  673. ID Week: Long-Term Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected, Treatment-Naïve, Black Versus Non-Black Subjects - (10/07/13)
     
  674. ID Week: STaR Study: Association of Efficacy Outcomes with Baseline HIV-1 RNA and CD4 Count and Adherence Rate for the Single-Tablet Regimens Rilpivirine/Emtricitabine/Tenofovir DF and Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults - (10/07/13)
     
  675. ID Week: HIV+ Individuals on ART Are At Risk of Polypharmacy: More Medication Increases Mortality - (10/04/13)
     
  676. ID Week: Comorbidity prevalence and its influence on non-ARV comedication burden among HIV positive patients - (10/04/13)
     
  677. ID Week: Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-week Results from IMPAACT P1093 - (10/04/13)
     
  678. ID Week: Outcomes Differ for HIV-Infected Patients Receiving Care at Hospital vs. Community-Based Clinics - (10/04/13)
     
  679. ID Week: "The Clinical Role and Cost-effectiveness of Long-acting Antiretroviral Formulations" - Long-Acting ARV Formulations Could Improve Survival in People With Poor Adherence - written by Mark Mascolini - (10/04/13)
     
  680. ID Week: Comorbidity Rate, Non-ARV Prescriptions Higher in HIV-Positives Than Matched Controls - written by Mark Mascolini - (10/04/13)
     
  681. ID Week: Non-AIDS Death Rate Jumps From Early to Recent ART Era in Large Single-Site Study - written by Mark Mascolini - (10/04/13)
     
  682. ID Week: Higher Intramyocardial Lipids in Antiretroviral-Treated Men Than in HIV-Negatives - written by Mark Mascolini - (10/04/13)
     
  683. ID Week: Dolutegravir Effective at 24 Weeks in Adolescents Replacing Failing Regimen - written by Mark Mascolini - (10/04/13)
     
  684. ID Week: Once-Daily Etravirine Effective Through 24 Weeks in Three-Center Study - written by Mark Mascolini - (10/04/13)
     
  685. ID Week: Community or Hospital HIV Clinic? Patient Profiles, Outcomes Differ in 4-Year Study - written by Mark Mascolini - (10/04/13)
     
  686. SR9009 "counter disturbed sleep that commonly afflicts elderly people/jetlag" - (10/02/13)
     
  687. (SR9009) Regulation of circadian behaviour and metabolism by REV-ERB- and REV-ERB-ß - (10/02/13)
     
  688. Drug discovery (SR9009): Time in a bottle - (10/02/13)
     
  689. SR9009 decreased inflammation (IL-6), decreased cholesterol & triglycerides & plasma glucose & plasma insulin levels..... - (10/02/13)
     
  690. SR9009 Reversed Effect of Mitochondrial Damage, Increased Exercise Capacity in Mice - (10/02/13)
     
  691. ICAAC: Efficacy and Safety of Rilpivirine-Based Regimens in Treatment-Experienced HIV-1 Infected Patients: A Prospective Cohort Study - (09/31/13)
     
  692. ICAAC: Acute C hepatitis in Japanese HIV-infected patients in this decade - (09/31/13)
     
  693. New Tenofovir Intravaginal Ring Protects Monkeys from HIV & In ICAAC Presentation Researchers Report Protection After After High Doses of DMPA - (09/31/13)
     
  694. PrEP/(ART) Update- Once Monthly or Every 3 Months PrEP & ART: Rilpivirine Long-Acting; tenofovir intravaginal ring for PrEP; combination PrEP & ART injections Every Month or 3 Months with 2 long-acting drugs GSK744 - (09/27/13)
     
  695. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention - (09/27/13)
     
  696. Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era? - (09/25/13)
     
  697. HHS: Premiums Under ACA Will Be Lower Than Expected. - (09/25/13)
     
  698. USPSTF Outlines Use of Breast Cancer Prevention Drugs - recommends primary prevention drugs should be offered to high-risk women at low risk for side effects - (09/24/13)
     
  699. ICAAC: Tenofovir Intravaginal Ring - (09/24/13)
     
  700. ICAAC: ICAAC: Pigtailed Macaques Under High Doses of Depot Medroxyprogesterone are Protected from Multiple SHIV Exposures with a Tenofovir Disoproxil Fumarate Intravaginal Ring - (09/24/13)
     
  701. Video of US Senate Hearing on HIV & Aging Sept 18, 2013 - (09/23/13)
     
  702. HIV Infection and Older Americans: The Public Health Perspective - soon 50% of HIV+ will be over 50 yrs old - (09/23/13)
     
  703. Tenofovir Alafenamide (TAF)- Gilead Press Release & Links to TAF Studies - (09/23/13)
     
  704. New LDL Lowering Drugs, Big LDL drops with PCSK9 inhibition in grouped phase-2 studies - "drug reduces LDL cholesterol by 43% to 64%" - (09/20/13)
     
  705. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients - (09/20/13)
     
  706. What Causes Neurological Impairment in HIV+ - (09/20/13)
     
  707. African-Americans & HIV Study Participation: barriers to study participation for African-Americans - (09/20/13)
     
  708. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects - (09/20/13)
     
  709. ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/20/13)
     
  710. ICAAC: Nearly 10% Screened for Syphilis Test Positive at California HIV Clinic - Written by Mark Mascolini - (09/20/13)
     
  711. ICAAC: Almost Half of Pneumocystis Patients in France Already in HIV Care at PCP Diagnosis - Written by Mark Mascolini - (09/20/13)
     
  712. ICAAC: HIV at ICAAC PrEP 2103 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  713. ICAAC: HIV at ICAAC "Mother-To-Child Transmission" 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  714. ICAAC: HIV at ICAAC "HIV Cure" 2013 Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  715. ICAAC: HIV at ICAAC Comorbidities 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  716. ICAAC: HIV at ICAAC TAF 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  717. ICAAC: HIV at ICAAC Dolutegravir 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  718. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study - (09/19/13)
     
  719. (Diet/Exercise/Lifestyle Improve Aging Measure - telomerase) Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study - (09/19/13)
     
  720. Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation - (09/19/13)
     
  721. Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study - (09/19/13)
     
  722. 5-year Safety Evaluation of Maraviroc in HIV-1-Infected, Treatment-Experienced Patients - (09/19/13)
     
  723. ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/18/13)
     
  724. ICAAC: Tenofovir Vaginal Ring Protects 5 of 6 Macaques From SHIV After High-Dose Depo-Provera - Written by Mark Mascolini - (09/18/13)
     
  725. ICAAC: Valacyclovir Has No Impact on CD4s or HIV Load in Placebo Trial of HSV-2+ - Written by Mark Mascolini - (09/18/13)
     
  726. ICAAC: Combinations of HIV-1 Reverse Transcriptase Mutations L100I+K103N/S and L100I+K103R+V179D Reduce Susceptibility to Rilpivirine - (09/18/13)
     
  727. ICAAC: Once-Daily Darunavir/Ritonavir (DRV/r) Versus Atazanavir/Ritonavir (ATV/r) on Insulin Sensitivity in HIV-Infected Persons Over 48 Weeks - (09/18/13)
     
  728. ICAAC: CLINICAL CHARACTERIZATION OF HIV/HCV CO-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRAL AGENTS - (09/18/13)
     
  729. ICAAC: Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/17/13)
     
  730. ICAAC: Identifying High Responder Populations to Crofelemer for Treatment of Noninfectious Diarrhea in HIV+ Individuals - (09/17/13)
     
  731. ICAAC: Single-Tablet Regimen More Effective Impact of HAART Regimen on Adherence and Risk of Hospitalization in HIV/AIDS Patients Using VA Data - (09/17/13)
     
  732. ICAAC: HIV Does Not Affect Chance of HCV Genotype 2 or 3 Responding to PegIFN/RBV - Written by Mark Mascolini - (09/17/13)
     
  733. ICAAC: Raltegravir Safe for Pregnant Women and Their Newborns in 31-Case Study - Written by Mark Mascolini - (09/16/13)
     
  734. ICAAC: Adherence Better, In-Hospital Rate Lower With Single-Tablet ART in US Veterans - Written by Mark Mascolini - (09/16/13)
     
  735. ICAAC: Faster Bone Turnover With Atripla Than With Dolutegravir/ABC/3TC in 48 Weeks - Written by Mark Mascolini - (09/16/13)
     
  736. ICAAC: SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients - Written by Mark Mascolini - (09/16/13)
     
  737. ICAAC: Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13)
     
  738. ICAAC: Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13)
     
  739. ICAAC: Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T - (09/16/13)
     
  740. ICAAC: Functional Control of Viremiain CCR5-Δ32 Heterozygous (Δ32HZ) HIV+ Subjects Following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (09/16/13)
     
  741. ICAAC: 48 Week Study of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each in a Single Tablet Regimen (STR) with Elvitegravir, Cobicistat, and Emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for Initial HIV Treatment - (09/16/13)
     
  742. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Patients ≥50 Years at Week 96 - (09/16/13)
     
  743. ICAAC: Dolutegravir in Key Demographic Subgroups of Treatment-Experienced HIV-Infected Populations - (09/16/13)
     
  744. ICAAC: Simplification to Abacavir/Lamivudine (ABC/3TC) + Atazanavir (ATV) From Tenofovir/Emtricitabine (TDF/FTC) + ATV/Ritonavir (r) Maintains Viral Suppression and Improves Bone Biomarkers: 48 Week ASSURE - (09/16/13)
     
  745. ICAAC: SPIRIT: Simplifying to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Regimen Maintains HIV Suppression in the Black Subgroup Week 48 Results - (09/16/13)
     
  746. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Naïve HIV Patients - (09/16/13)
     
  747. ICAAC: STaR: Virologic Outcomes and Safety in ART-Naïve Adult Females for Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF at Week 48 - (09/16/13)
     
  748. ICAAC: Multicentre Open-Label Study of Switching from Atripla to Eviplera for Possible Efavirenz Associated CNS Toxicity* - (09/16/13)
     
  749. ICAAC: Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food - (09/16/13)
     
  750. ICAAC: Pharmacokinetics (PK) and Safety of Dolutegravir (DTG) in Subjects With Severe Renal Impairment and Healthy Controls - (09/16/13)
     
  751. ICAAC: Pharmacokinetics (PK) and PK-Pharmacodynamic (PD) Relationship of Dolutegravir (DTG) in Integrase Inhibitor (INI)-Naive Subjects - (09/16/13)
     
  752. ICAAC: Similar Cognition Outcomes After 48 Weeks for Tenofovir (TDF)/Emtricitabine (FTC) + Atazanavir/Ritonavir (ATV/r)-Experienced HIV+ Patients or Those Simplifying to Abacavir (ABC)/Lamivudine (3TC) + ATV - (09/16/13)
     
  753. ICAAC: Fosamprenavir/Ritonavir (FPV/r) in Hepatically Impaired Subjects: An Observational Multi-Cohort Study - (09/16/13)
     
  754. ICAAC: Efficacy and Safety of Raltegravir Among Latin American Patients in STARTMRK - (09/16/13)
     
  755. ICAAC: Strong Correlation Between The Reduction Of Cellular HIV-DNA Load And Achievement Of HIV Plasma Viremia<2.5 Copies/ml In An Observation Period Of 4 Years Of Effective Antiretroviral Therapy In Naïve Patients - (09/16/13)
     
  756. ICAAC: Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir - (09/12/13)
     
  757. ICAAC: Hepatitis C Eradication Reduces Liver Decompensation, HIV progression, and Death in HIV/HCV-coinfected Patients with non-Advanced Liver Fibrosis - (09/12/13)
     
  758. ICAAC: Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13)
     
  759. ICAAC: Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13)
     
  760. ICAAC: One in 5 HIV+ Women in Spanish Group Has Anal Dysplasia, Predicted by Warts - Written by Mark Mascolini - (09/14/13)
     
  761. ICAAC: Routine Vaccination Rates Highly Variable in French Adults With HIV - Written by Mark Mascolini - (09/14/13)
     
  762. ICAAC: Adverse Event Rates Similar With High-Dose ATV/r and LPV/r During Pregnancy - Written by Mark Mascolini - (09/14/13)
     
  763. ICAAC: Raltegravir Top PIs and NNRTIs in Retrospective Look at Cancer Patients - Written by Mark Mascolini - (09/14/13)
     
  764. ICAAC: TAF Comparable to TDF in Once-Daily Pill for ART-Naive: 48-Week Results - Written by Mark Mascolini - (09/14/13)
     
  765. ICAAC: Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/14/13)
     
  766. ICAAC: Darunavir and Atazanavir Have Similar Modest Impact on Insulin Sensitivity - Written by Mark Mascolini - (09/14/13)
     
  767. ICAAC: Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/14/13)
     
  768. ICAAC: Stribild and Comparison Combinations Have Similar Efficacy in Over-50s and Under-50s - Written by Mark Mascolini - (09/14/13)
     
  769. ICAAC: HPV-39 Predicts AIN and Anal Cancer in Spanish Group of Men With HIV - Written by Mark Mascolini - (09/14/13)
     
  770. ICAAC: Dolutegravir Superior to Darunavir at 48 Weeks in Open-Label ART-Naive Trial (The FLAMINGO Study) - Written by Mark Mascolini - (09/14/13)
     
  771. ICAAC: 48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial - (09/13/13)
     
  772. ICAAC: Raltegravir Top PIs and NNRTIs in Retrospective Look at Cancer Patients - Written by Mark Mascolini - (09/12/13)
     
  773. ICAAC: Erectile Dysfunction Drug Use Doubles Odds of Syphilis in US Men With HIV - Written by Mark Mascolini - (09/12/13)
     
  774. ICAAC: Complera Not Inferior to Atripla Among Men and Women in 786-Person Trial - Written by Mark Mascolini - (09/12/13)
     
  775. ICAAC: Crofelemer Effective for Severe or PI-Related Diarrhea in Placebo Trial - Written by Mark Mascolini - (09/12/13)
     
  776. ICAAC: Status of Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: An Early Drug Utilization Analysis - (09/12/13)
     
  777. ICAAC: Meta-analysis of Safety Data From 8 Clinical Studies With GSK1265744, an HIV Integrase Inhibitor, Dosed Orally or as Injection of Long-Acting Parenteral Nanosuspension (LAP) - (09/12/13)
     
  778. ICAAC: Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: Efficacy and Pharmacokinetics - (09/12/13)
     
  779. ICAAC: Lack of Effect of Tenofovir Alafenamide (TAF) on Primary Osteoblasts In Vitro at Clinically Relevant Drug Concentrations - (09/12/13)
     
  780. ICAAC: Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects - (09/12/13)
     
  781. ICAAC: Burden of Illness in a US Commercially Insured HIV Population: Treatment Patterns and Costs - (09/12/13)
     
  782. ICAAC: Single-Pill Rilpivirine Regimen Maintains Suppression After Switch From Boosted PI - Written by Mark Mascolini - (09/11/13)
     
  783. ICAAC: Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/11/13)
     
  784. ICAAC: Cellular HIV DNA Predicts Plasma Load Under 2.5 Copies in 181-Person Study - Written by Mark Mascolini - (09/11/13)
     
  785. ICAAC: Safety Analysis Gives Edge to Elvitegravir vs Efavirenz or Atazanavir at 96 Weeks - Written by Mark Mascolini - (09/11/13)
     
  786. ICAAC: Good Safety Profile With Long-Acting Integrase Inhibitor, GSK744 - Written by Mark Mascolini - (09/11/13)
     
  787. ICAAC: TAF, a Tenofovir Prodrug, Not Preferentially Loaded or Toxic in Osteoblasts - Written by Mark Mascolini - (09/11/13)
     
  788. ICAAC: TDF/FTC-to-ABC/3TC Switch Maintains Viral Suppression, Eases Bone Markers - Written by Mark Mascolini - (09/11/13)
     
  789. ICAAC: Almost Half of Early US PrEP Are Women, Often in Southern States - Written by Mark Mascolini - (09/11/13)
     
  790. ICAAC: Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects - Written by Mark Mascolini - (09/11/13)
     
  791. ICAAC: Novel Mutation Combinations Linked to Resistance to Rilpivirine - Written by Mark Mascolini - (09/11/13)
     
  792. ICAAC: Tricky Pharmacokinetics May Not Matter in Switch From Efavirenz to Stribild - Written by Mark Mascolini - (09/11/13)
     
  793. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery - (09/11/13)
     
  794. Cancers in HIV - (09/10/13)
     
  795. Cancers in HIV+, recent published studies - (09/10/13)
     
  796. Endurance Athletes/Exercise & Longevity in Tour de France Cyclcists & Risk of arrhythmias in 52 755 long-distance cross-country skiers & Relation of Vigorous Exercise to Risk of Atrial Fibrillation (3 studies) - (09/09/13)
     
  797. Increased risk of neurological, cognitive deficits in youth with HIV - (08/30/13)
     
  798. Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma - (08/30/13)
     
  799. Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068 - (08/30/13)
     
  800. Safety and Tolerability of Tenofovir for Preexposure Prophylaxis Among Men Who Have Sex With Men - Editorial - (08/30/13)
     
  801. Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States - (08/30/13)
     
  802. Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing - (08/30/13)
     
  803. Physical exercise is associated with less neurocognitive impairment among HIV-infected adults - (08/29/13)
     
  804. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial - (08/29/13)
     
  805. The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/μL in the Post-Combination Antiretroviral Therapy Era - (08/29/13)
     
  806. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft - (08/28/13)
     
  807. African-Americans & HIV Study Participation - (08/28/13)
     
  808. New US Fed HIV Post Exposure Prophylaxis Guidelines (PEP) - (08/19/13)
     
  809. FDA approves new drug Integrase Dolutegravir to treat HIV infection - (08/19/13)
     
  810. Risk of AIDS-defining cancers among HIV1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort - (08/16/13)
     
  811. Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women - (08/14/13)
     
  812. New York state - UPDATE: HIV Prophylaxis Following Occupational Exposure - (08/14/13)
     
  813. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis - (08/14/13)
     
  814. Switching to Unboosted Atazanavir Combined with Tenofovir and Emtricitabine Is Effective as Maintenance Therapy - (08/14/13)
     
  815. Life Expectancy in HIV - (08/14/13)
     
  816. Dolutegravir Global Access ViiV's new HIV drug wins US approval - (08/14/13)
     
  817. Recent Bone/aging Studies - (08/14/13)
     
  818. ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1 - (08/13/13)
     
  819. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men - (08/12/13)
     
  820. Use of Highly Active Antiretroviral Therapy Is Associated With Lower Prevalence of Anal Intraepithelial Neoplastic Lesions and Lower Prevalence of Human Papillomavirus in HIV-Infected Men Who Have Sex With Men - (08/12/13)
     
  821. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system - (08/12/13)
     
  822. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men - (08/12/13)
     
  823. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009 - (08/12/13)
     
  824. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily - (08/12/13)
     
  825. CD4 Decline Is Associated With Increased Risk of Cardiovascular Disease, Cancer, and Death in Virally Suppressed Patients With HIV - (08/12/13)
     
  826. IAS: IAS Towards an HIV Cure Symposium, 29th-30th June 2013, Kuala Lumpur - Written for NATAP by David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) - (08/05/13)
     
  827. How Exercise Changes Fat and Muscle Cells - (07/31/13)
     
  828. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons - (07/30/13)
     
  829. IAS: Cure Strategies: "Viral and Immune-Targeted Interventions: Hit Me with Your Best Shot" - Oral Session at IAS 2013 Kulala Lumpur June 30-July 3 - (07/30/13)
     
  830. HPV Vaccine Reduced Oral HPV Prevalence - new study - (07/26/13)
     
  831. CROI: HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (07/24/13)
     
  832. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study - (07/24/13)
     
  833. Antiretroviral therapy: dolutegravir sets SAIL(ING) - Comment - (07/24/13)
     
  834. Natural history of oral papillomavirus infection in men - (07/24/13)
     
  835. IAS: Maraviroc Safety & Efficacy in Children Aged 2-18 - (07/24/13)
     
  836. IAS: Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2-<18 years - (07/24/13)
     
  837. IAS: Transmitted NNRTI Resistance Rate Climbing in US But Flat in Big European Countries - (07/24/13)
     
  838. IAS: Number of regimens rather than cumulative exposure to antiretrovirals associated with lower bone mineral density in HIV-positive subjects - (07/22/13)
     
  839. U.S. Congress Moves Closer to Lifting Ban on Transplanting Organs From HIV-Positive Donors - (07/22/13)
     
  840. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis - (07/22/13)
     
  841. High sensitive CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: The MrOS Sweden study - (07/20/13)
     
  842. IAS: In Utero HAART Exposure Associated with Decreased Growth among HIV-Exposed Uninfected Breast Fed Infants in Botswana - (07/20/13)
     
  843. Evaluation of Risk for Late Language Emergence after In Utero Antiretroviral Drug Exposure in HIV-Exposed Uninfected Infants - (07/20/13)
     
  844. IAS: Risk of cancer among HIV-positive women in British Columbia, Canada: Importance of screening and detection programs - (07/20/13)
     
  845. IAS: Telaprevir Regimen for HIV/HCV Patients With PegIFN/RBV Failure and Cirrhosis - written by Mark Mascolini - (07/20/13)
     
  846. IAS: Switching HIV Clinics Linked to Higher Mortality in Large Austrian Study - written by Mark Mascolini - (07/20/13)
     
  847. IAS: Number of ART Regimens But Not Time on ART or Tenofovir Tied to Low Bone Density - written by Mark Mascolini - (07/20/13)
     
  848. IAS: Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/20/13)
     
  849. IAS: ART Linked to Lower Sexual (But Not Drug-Injecting) Risk Behavior in Meta-Analysis - written by Mark Mascolini - (07/20/13)
     
  850. IAS: MSM HIV Sex/Substance Abuse Risk Intervention in South Florida: Single 1-on-1 Session Works as Well as 4 Group Sessions in Trimming MSM Risk Behavior - written by Mark Mascolini - (07/20/13)
     
  851. IAS: Rates of 2 Non-AIDS Cancers Higher With HIV in British Columbia Women - written by Mark Mascolini - (07/19/13)
     
  852. IAS: Less Education Linked to Later HIV Diagnosis, Higher Mortality in 13-Cohort European Study - written by Mark Mascolini - (07/19/13)
     
  853. IAS: No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial - written by Mark Mascolini - (07/19/13)
     
  854. IAS: Additional Vaccine-Covered HPV Genotypes Found Yearly in Older HIV+/HIV- Gay Men - written by Mark Mascolini - (07/19/13)
     
  855. IAS: Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/19/13)
     
  856. IAS: Boosted PI (Kaletra) + NNRTIs Successful as 2nd-Line ART in Africa: EARNEST Study - "A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial" - (07/18/13)
     
  857. IAS: Obesity Rate Differs by HIV Status, Gender, Race, and ARV Use in North Carolina - written by Mark Mascolini - (07/18/13)
     
  858. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/18/13)
     
  859. IAS: Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers - (07/18/13)
     
  860. IAS: Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents receiving long-term antiretroviral therapy - (07/18/13)
     
  861. IAS: HPV-16 Tied to Development and Clearance of Anal Cancer Precursor in Gay HIV+/HIV- Men - written by Mark - (07/18/13)
     
  862. Interview with Study Investigator Andrea Savarino MD. "New HIV Cure Drug Combination Study - Drug-free remission of AIDS in monkeys: from anecdotal reports towards a globally scalable strategy" - "Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS" - (07/17/13)
     
  863. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/16/13)
     
  864. Link Between Omega-3 Fatty Acids & Increased Prostate Cancer Risk - (07/16/13)
     
  865. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey (HIV+ Men/heterosexual discordant couples) - (07/16/13)
     
  866. New HIV Cure Combination Drug Study - (07/16/13)
     
  867. IAS: Provider-Initiated Testing Turns Up Large Portion of Acute HIV Cases in MSM - (07/15/13)
     
  868. IAS: Intimate Partner Violence in Half of US MSM Group Affects Condom-Negotiating Skills - (07/15/13)
     
  869. IAS: In HIV-Discordant Gays, Viral Load Perception Strongly Linked to Unprotected Anal Sex - (07/15/13)
     
  870. IAS: "Evolutionary Dead-End" After Emergence of Primary Dolutegravir Resistance Mutation? - (07/15/13)
     
  871. IAS: HIV infection was associated with an increased risk of hip fracture, independently of age, gender and co-morbidities: a population-based cohort study - (07/15/13)
     
  872. IAS: High Transplacental Transfer of Atazanavir But No Hyperbilirubinemia in Neonates - (07/15/13)
     
  873. IAS: Efavirenz, Tenofovir, and FTC Levels Higher in Colonic Tissue Than Blood - (07/15/13)
     
  874. Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers - (07/13/13)
     
  875. IAS: The Effect of HIV Infection, ART and Ageing on Renal Function in PLHIV, Chelsea and Westminster Hospital London, UK 1996-2012 - (07/13/13)
     
  876. IAS: Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial - (07/13/13)
     
  877. IAS: Intelence and prezista Once A Day Study (INROADS): A Multicenter, Single-Arm, Open-Label Study of Once Daily Combination of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (07/13/13)
     
  878. IAS: Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial - (07/12/13)
     
  879. IAS: ART Started in Primary Infection May "Block Immunologic Storm" in French OPTIPRIM - (07/12/13)
     
  880. IAS: Starting ART Above 500 CD4s Cuts HIV DNA in PBMCs, Prompts Bigger CD4 Rebound - written by Mark Mascolini - (07/12/13)
     
  881. IAS: Standard Triple Therapy Controls HIV Better Than Raltegravir/Darunavir at 48 Weeks RADAR Study - written by Mark Mascolini - (07/12/13)
     
  882. IAS: High Levels of Two Antiretrovirals With Monthly or Quarterly Injections in Healthy Volunteers: GSK744 LAP + TMC278 LA - written by Mark Mascolini - (07/12/13)
     
  883. IAS: Long term therapeutic success of etravirine in switch and naive patients - written by Mark Mascolini - (07/12/13)
     
  884. FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - (07/10/13)
     
  885. Interleukin-7 promotes HIV persistence during antiretroviral therapy - "IL-7 does not represent a suitable candidate therapeutic strategy for HIV eradication"....(AIDS Clinical Trials Group protocol 5214) - (07/10/13)
     
  886. IAS: Association between HMG-CoA reductase inhibitors (statins) use and cancer occurrence among HIV-1 treated patients - Statin use reduced incidence of cancers - (07/11/13)
     
  887. IAS: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine (STB) and Cobicistat (COBI) in HIV Infected Patients with Mild to Moderate Renal Impairment - (07/11/13)
     
  888. IAS: Early initiation of antiretroviral therapy for individuals with HIV infection: A systematic review - (07/11/13)
     
  889. IAS: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Integrated Week 96 Subgroup Analyses - (07/11/13)
     
  890. IAS: EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF) TO ABACAVIR (ABC)-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), WITH OR WITHOUT ATAZANAVIR - (07/11/13)
     
  891. IAS: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes - (07/11/13)
     
  892. IAS: Lower bone mineral density independently associated with both increased bone turnover and HIV-1 infection in HIV-positive subjects compared to HIV-negative subjects - (07/11/13)
     
  893. IAS: HIV Prevention at IAS 2013 - Jared Baeten, MD PhD Andrew Mujugira, MBChB MSc MPH Connie Celum, MD MPH University of Washington - (07/10/13)
     
  894. IAS: Non-Infectious Complications of HIV and Antiretroviral Therapy - IAS 2013 (Kuala Lumpur, Malaysia) written by Roger Bedimo, MD VA North Texas Health Care System - (07/10/13)
     
  895. IAS: Stem-cell transplants may purge HIV..... Post-Transplant and Off Drugs, H.I.V. Patients Are Apparently Virus-Free - (07/10/13)
     
  896. IAS: Dolutegravir is Non-Inferior to Raltegravir and Shows Durable Response Through 96 Weeks: Results From the SPRING-2 Trial - (07/09/13)
     
  897. IAS: Lower Peak Viral Load, Higher CD4/CD8 Ratio Linked to Low PBMC Reservoir - written by Mark Mascolini - (07/09/13)
     
  898. IAS: BIT225, a Novel Assembly Inhibitor, Cuts HIV Load in Monocyte Reservoir - written by Mark Mascolini - (07/09/13)
     
  899. IAS: Independent Predictors of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, & Inflammatory Markers (poster) - (07/09/13)
     
  900. IAS: Independent Predictors (slides) of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, and Inflammatory Markers (slide presentation) - (07/09/13)
     
  901. IAS: Overall First-Line ART Efficacy Only 60% at 82 Weeks in Meta-Analysis - written by Mark Mascolini - (07/09/13)
     
  902. IAS: Life Expectancy With HIV Jumps 15 Years From 2000-2002 to 2006-2007 in US, Canada - written by Mark Mascolini - (07/09/13)
     
  903. IAS: Sustained Response to Dolutegravir Through 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/09/13)
     
  904. IAS: Different Predictors of ART Switches in IDUs and non-IDUs - written by Mark Mascolini - (07/09/13)
     
  905. IAS: Higher Rate of Triple-Class Failure in Pernitally Infected Than Heterosexually Infected - written by Mark Mascolini - (07/09/13)
     
  906. IAS: Quick CNS Improvement After Switch From Efavirenz to Raltegravir - written by Mark Mascolini - (07/05/13)
     
  907. IAS: Maintenance Therapy With Raltegravir/Etravirine: Virologic Failure Rate 5% at 12 Months - written by Mark Mascolini - (07/05/13)
     
  908. IAS: Bid to cure HIV ramps up, New Baby Cure Study/IMPAACT - (07/05/13)
     
  909. IAS: First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults - (07/05/13)
     
  910. IAS: In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoirs' depletion (HIV-DNA) and T cell count restoration - (07/05/13)
     
  911. IAS: Short-Term ART in Primary HIV-Infection & Decrease in HIV-DNA...... "....showed that 12 or 48 weeks of ART significantly decreases the cell-associated HIV-DNA. Also that viral load at 'baseline' associates with HIV-DNA levels at baseline and after therapy" - (07/05/13)
     
  912. IAS: HIV[ART] and HCV infections independently contribute to lower bone mineral density but have different effects on bone turnover markers - (07/05/13)
     
  913. IAS: Less Bone Loss With Raltegravir Than NRTIs in Second-Line Regimens - written by Mark Mascolini - (07/05/13)
     
  914. IAS: Low-Dose (400-mg) Efavirenz vs Standard 600-mg Dose Studied, Found Non-Inferior Low-Dose (400-mg) Efavirenz Not Inferior to Standard 600-mg Dose - written by Mark Mascolini - (07/05/13)
     
  915. IAS: Kidney Function Improves With TDF-to-ABC Switch Regardless of Atazanavir Use - written by Mark Mascolini - (07/05/13)
     
  916. IAS: Dolutegravir Effective at 24/48 Weeks in People With Integrase Inhibitor Mutations - written by Mark Mascolini - - (07/03/13)
     
  917. IAS: Dolutegravir Superior to Raltegravir at 48 Weeks in Integrase Inhibitor Naive - written by Mark Mascolini - - (07/03/13)
     
  918. IAS: Renal Safety Similar With Dolutegravir, Raltegravir, and Efavirenz in Antiretroviral Naive - written by Mark Mascolini - - (07/03/13)
     
  919. IAS: Two Boston Stem-Cell Transplant Patients Stop Antiretrovirals With No Rebound - written by Mark Mascolini - - (07/03/13)
     
  920. IAS: Dolutegravir (DTG) is Superior to Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: Week 48 Results From SAILING (ING111762) - (07/03/13)
     
  921. IAS: Once-Daily Dolutegravir (DTG; GSK1349572) Has a Renal Safety Profile Comparable to Raltegravir (RAL) and Efavirenz in Antiretroviral (ART)-Naive Adults: 48 Week Results From SPRING-2 (ING113086) and SINGLE (ING114467) - (07/03/13)
     
  922. IAS: WHO issues new ART HIV recommendations calling for earlier treatment - More Conservative Than HHS ART Guidelines - (07/03/13)
     
  923. IAS: Aging & Cure - a talk by Steve Deeks, MD at the IAS Conference in Kuala Lumpur - (07/03/13)
     
  924. IAS: Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled - (07/03/13)
     
  925. IAS: New HIV 'Cure' Drug To Activate HIV Replication Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial - (07/03/13)
     
  926. IAS: SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13)
     
  927. IAS: End-Stage Renal Disease Incidence 2 to 4 Times Higher With HIV in North America - written by Mark Mascolini - (07/02/13)
     
  928. IAS: Systemic Review Sees Evidence for Advantage to Starting ART Above 500 CD4s - written by Mark Mascolini - (07/02/13)
     
  929. IAS: Immune Activation Tied to Viral Blips in People Taking Suppressive ART - written by Mark Mascolini - (07/02/13)
     
  930. IAS: Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals - (07/02/13)
     
  931. IAS: Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (07/02/13)
     
  932. IAS: Functional cure after long term HAART initiated during early HIV infection - a case study - (07/02/13)
     
  933. IAS: 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection - (07/02/13)
     
  934. IAS: Effects of renal tubular dysfunction on bone - (07/02/13)
     
  935. IAS: Cardiac steatosis (the fatty heart) in cardiovascularly asymptomatic persons with HIV infection - (07/02/13)
     
  936. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/01/13)
     
  937. IAS: Efficacy and Tolerability of Maraviroc for Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)
     
  938. IAS: Acute Retroviral Syndrome Score Correlates With Signals of Progression - written by Mark Mascolini - (07/01/13)
     
  939. IAS: New HIV Life Expectancy study: Women and Aboriginals in British Columbia Fall Far Short of Normal Life Expectancy - written by Mark Mascolini - (07/01/13)
     
  940. IAS: Low CD4/CD8 Ratio Predicts Non-AIDS Morbidity, Mortality in ART Responders - written by Mark Mascolini - (07/01/13)
     
  941. IAS: Good 48-Week Response to Darunavir in Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)
     
  942. IAS: Low-Dose Lopinavir/Ritonavir Tablet Noninferior to Full Dose in Thai Children - written by Mark Mascolini - (07/01/13)
     
  943. IAS: Long-term virological outcome in HIV-infected children on ART in the UK/Ireland - Higher Failure Rate With Nevirapine Than Efavirenz or PIs in Children in UK and Ireland - written by Mark Mascolini - (07/01/13)
     
  944. HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact - Editorial - (06/27/13)
     
  945. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study - CD4 & viral load matter: restore or maintain the CD4 count above 500; early treatment initiation - (06/26/13)
     
  946. Kidney-injury analysis "reassuring" for high-potency statins in PROVE-IT, A to Z - (06/26/13)
     
  947. Invasive Meningococcal Disease in Men Who Have Sex With Men - (06/26/13)
     
  948. CROI: CMV and HIV Infections Have Opposite Effects on CD8+ T Cell Differentiation and Proliferation - (06/23/13)
     
  949. CROI: Phenotypic CD8+ T cell Defects in Treated HIV Infection are Distinct from Those of Aging, Predict Mortality, and May Be Prevented by Earlier ART - (06/23/13)
     
  950. IDU Tenofovir PrEP Study Commentaries - (06/23/13)
     
  951. Universal Antiretroviral Therapy for HIV Infection: Should U.S. Treatment Guidelines Be Applied to Resource-Limited Settings? - (06/23/13)
     
  952. HIV/Aging >50 Majority in SF/More Comorbidities in HIV+ vs HIV- Study - (06/23/13)
     
  953. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population - (06/23/13)
     
  954. ResisWksp: Report on International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 4-8, 2013 Toronto, Canada written by Mark A. Wainberg McGill University AIDS Centre, Montreal, Canada (06/17/13)
     
  955. World Health Organization Issues Interim Guidance on Bedaquiline - (06/17/13)
     
  956. HIV pre-exposure prophylaxis in injecting drug users - Comment - (06/17/13)
     
  957. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial - (06/14/13)
     
  958. A cure for HIV: where we've been, and where we're headed - (06/14/13)
     
  959. Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1-Infected Subjects & BMS626529 Attachment Inhibitor - (06/14/13)
     
  960. ResisWksp: Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens (06/14/13)
     
  961. ResisWksp: Genotypic Analyses of Pre-Existing HIV-1 Drug Resistance in Proviral HIV-1 DNA from PBMCs in Suppressed Patients Switching to RPV/FTC/TDF (06/14/13)
     
  962. ResisWksp: Primary and Secondary Analyses of Emergent Drug Resistance through Week 96 from the Phase 3 Studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (06/14/13)
     
  963. AGE: Comorbidities and coinfections among HIV patients 50 years and older compared to HIV-negs in large US healthcare database - (06/12/10)
     
  964. ResisWksp: Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B (06/12/13)
     
  965. Vegetarian diet linked to longer life, less CVD - (06/12/13)
     
  966. ResisWksp: Advanced Mechanistic Studies of GSK1265744, a New HIV Integrase Inhibitor (INI) Dosed by Oral Administration or Long-Acting Parenteral Injection (06/11/13)
     
  967. ResisWksp: Integrase Genotypic and Phenotypic Predictors of Antiviral Response to Dolutegravir (DTG) in Subjects With Resistance to Integrase Inhibitors (INIs) (06/11/13)
     
  968. ResisWksp: Evolution of Integrase in Virus at Protocol-Defined Virologic Failure From the VIKING-3 Study (06/11/13)
     
  969. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics, Metabolism and Excretion of Tenofovir Alafenamide (TAF) - (06/11/13)
     
  970. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (06/11/13)
     
  971. CROI: CROI 2013 Adult Neurology Presentation and Abstracts Written for NATAP by Kevin R. Robertson, Ph.D.1, Charles Upton2 contributions by Jules Levin - (06/10/13)
     
  972. ResisWksp: Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target cells (06/09/13)
     
  973. ResisWksp: Analysis and Characterization of treatment-Emergent Resistance in ART-Experienced, Integrase Inhibitor-Naïve Subjects With Dolutegravir (DTG) vs Raltegravir (RAL) in SAILING (ING111762) (06/09/13)
     
  974. ResisWksp: Epidemiology of Dolutegravir (DTG) Resistance in ~700 RAL-Resistant Isolates (06/09/13)
     
  975. Lactobacillus Bacteremia Associated With Probiotic Use in a Pediatric Patient With Ulcerative Colitis - (06/05/13)
     
  976. Coenzyme Q10 supplementation reduces HF admissions and improves survival: Q-SYMBIO - (06/05/13)
     
  977. 'People Think It's Over' - Spared Death, Aging People With H.I.V. Struggle to Live - (06/05/13)
     
  978. Probiotic Safety and Risk Factors - (06/04/13)
     
  979. Frequency and implications of HIV superinfection - (05/31/13)
     
  980. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials - (05/31/13)
     
  981. Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification - (05/31/13)
     
  982. People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010 - (05/29/13)
     
  983. Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV-Coinfected Adults With Persistent HBV Viremia - (05/29/13)
     
  984. Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach (WIHS) - (05/29/13)
     
  985. Two studies address diabetes risks with statins-one good news, one so-so - (05/29/13)
     
  986. Autonomic Nervous System Dysfunction & Inflammation: Autonomic-mediated immunomodulation and potential clinical relevance - (05/29/13)
     
  987. CROI: CROI 2013: Comorbidities- Aging/Kidney/Heart/Belly Fat/HCV/Bone/Statins/Frailty - (05/27/13)
     
  988. CROI: Very Early Viral Infection of the Central Nervous System without Evidence of Compartmentalization During Acute HIV-1 Infection - (05/27/13)
     
  989. CROI: VLA-4 (Tysabri) Treatment Blocks Virus Traffic to the Gut and Brain Early, and Stabilizes CNS Injury Late in Infection - (05/27/13)
     
  990. CROI: Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (05/27/13)
     
  991. CROI: Symptoms of Autonomic Dysfunction in HIV-Infected Patients Receiving Stable ART: "The biggest difference was seen within the male sexual dysfunction domain with 47% of the HIV group experiencing symptoms, compared to 11% of the control group experiencing symptoms" - (05/27/13)
     
  992. Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability - (05/27/13)
     
  993. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1 infected men who have sex with men - (05/27/13)
     
  994. Grand Challenges: Improving HIV Treatment Outcomes by Integrating Interventions for Co-Morbid Mental Illness - (05/27/13)
     
  995. Fish oils to prevent CHD . . . it's now official: A definite "no go" - (05/27/13)
     
  996. Underestimate of HIV reservoirs threatens purging approach - (05/27/13)
     
  997. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Maraviroc, Boceprevir, Telaprevir PK in Healthy Volunteers: The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers - (05/26/13)
     
  998. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Dolutegravir, Boceprevir, Telaprevir PK: The effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics, in Healthy Adult Subjects - (05/26/13)
     
  999. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (05/26/13)
     
  1000. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml - (05/26/13)
     
  1001. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (05/26/13)
     
  1002. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients - (05/26/13)
     
  1003. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Pharmacodynamics of Once-Daily Etravirine and Darunavir/Ritonavir in Early Treatment-Experienced Subjects - (05/26/13)
     
  1004. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents in healthy volunteers - (05/26/13)
     
  1005. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics, Metabolism and Excretion of Tenofovir Alafenamide (TAF) - (05/26/13)
     
  1006. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (05/26/13)
     
  1007. Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T - (05/22/13)
     
  1008. CROI: Aging with HIV: Where do we stand after CROI 2013? David Alain Wohl, MD - Associate Professor, Division of Infectious Diseases, The University of North Carolina at Chapel Hill - (05/20/13)
     
  1009. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Clinical Pharmacology at the 14th Workshop on Clinical Pharmacology of HIV Therapy and HCV - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (05/20/13)
     
  1010. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Darunavir Dosing Determined for Naive and Experienced Children and Teens - written by Mark Mascolini - (04/29/13)
     
  1011. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy No Clinically Significant Interactions Between Boceprevir or Telaprevir and Dolutegravir - written by Mark Mascolini - (04/29/13)
     
  1012. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist - written by Mark Mascolini - (04/29/13)
     
  1013. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Ribavirin Trough Affects Early HCV Response With Unfavorable IL28B Profile - written by Mark Mascolini - (04/29/13)
     
  1014. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Once-Daily Etravirine Plus Darunavir/Ritonavir With No NRTIs: 48-Week PKs - written by Mark Mascolini - (04/25/13)
     
  1015. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Tenofovir Exposure Moderately Higher With vs Without Cobicistat in Healthy Volunteers - written by Mark Mascolini - (04/25/13)
     
  1016. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Split Dosing Versus Single Dose of Long-Acting Injected Integrase Inhibitor - written by Mark Mascolini - (04/24/13)
     
  1017. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Gender and Weight Affect Long-Acting Rilpivirine Levels in Healthy Volunteers - written by Mark Mascolini - (04/24/13)
     
  1018. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Labs Inaccurate in 18% of Darunavir, Etravirine, or Raltegravir Measures - written by Mark Mascolini - (04/23/13)
     
  1019. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Variable Boceprevir Impact on Levels of Atazanavir and Raltegravir - written by Mark Mascolini - (04/23/13)
     
  1020. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Higher Maraviroc Levels With HCV Agents Boceprevir and Telaprevir - written by Mark Mascolini - (04/23/13)
     
  1021. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy In-Hospital Antiretroviral Prescribing Errors Common and Often Uncorrected - written by Mark Mascolini - (04/23/13)
     
  1022. Using Ultradeep Pyrosequencing to Study HIV-1 Co-receptor Usage in Primary and Dual Infection - (04/20/13)
     
  1023. Effect of HIV on Liver Fibrosis Among HCV-Infected African Americans - (04/20/13)
     
  1024. HIV-1 Concentrations in Human Breast Milk Before and After Weaning 'ART recommended' - (04/19/13)
     
  1025. A light in the cognitive fog? Editorial on CPE/ART Neuro Penetraion - (04/19/13)
     
  1026. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia - (04/19/13)
     
  1027. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (04/16/13)
     
  1028. L-Carnitine - Good or Bad for Your Heart? Culprit in Heart Disease Goes Beyond Meat's Fat (there are 3 articles in this report) - (04/15/13)
     
  1029. A New Endorsement for Fish - (04/15/13)
     
  1030. Association of Functional Impairment with Inflammation and Immune Activation in HIV-1-Infected Adults on Effective Antiretroviral Therapy - (04/15/13)
     
  1031. Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age - (04/15/13)
     
  1032. Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV-1 Transmission and Drug Resistance in South Africa/Editorial - (04/15/13)
     
  1033. Molecule in meat may increase heart disease risk - (04/15/13)
     
  1034. L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis - (04/15/13)
     
  1035. Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults: A Cohort Study - (04/15/13)
     
  1036. Interferon-a as a "Curative Strategy" or Harmful? - (04/12/13)
     
  1037. Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation - (04/11/13)
     
  1038. HIV and Recent Illicit Drug Use Interact to Affect Verbal Memory in Women - (04/11/13)
     
  1039. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis - (04/11/13)
     
  1040. About That Baby Who Was 'Cured' of HIV - (04/10/13)
     
  1041. A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007) - see published study below - (04/10/13)
     
  1042. CROI: Neuroimaging Correlates of Prior Immunosuppression and Cognitive Status in HIV - (04/10/13)
     
  1043. CROI: Gold Nanoparticles to Improve Drug Delivery to the Central Nervous System - (04/10/13)
     
  1044. CROI: Research Spotlight: Nanomedicines for HIV therapy - (04/10/13)
     
  1045. CROI: Small Magnetite Antiretroviral (SMART) Nanoparticles for Targeted Drug Delivery to Viral Reservoirs - (04/10/13)
     
  1046. CROI: Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles...."Studies to determine whether bioequivalence can be obtained with a lower dose of SDN are now planned in healthy volunteers" - (04/10/13)
     
  1047. CROI: New Approaches to ART Drug Delivery: long-acting ARTs, nanoparticles - (04/10/13)
     
  1048. Framingham scores could predict cognitive decline better than a standard dementia score - (04/09/13)
     
  1049. Molecule in meat may increase heart disease risk - (04/09/13)
     
  1050. CROI: High Grade Liver Steatosis and Cognitive Impairment in HIV+ patients - (04/09/13)
     
  1051. CROI: Cognitive Rehabilitation Protocol in HIV/AIDS outpatients with ANI and MND: results and clinical applicability - (04/09/13)
     
  1052. CROI: Associations Between Regional Fat Deposition and Neurocognitive Function in the Multicenter AIDS Cohort Study - (04/09/13)
     
  1053. CROI: Detectable HIV DNA is Associated with Reduced Cerebellar and Subcortical Gray Matter Volumes - (04/08/13)
     
  1054. Amount of HIV DNA in Peripheral Blood Mononuclear Cells is Proportional to the Severity of HIV-1-Associated Neurocognitive Disorders - (04/08/13)
     
  1055. Regional Cortical Thinning Associated with Detectable Levels of HIV DNA....."Our findings support initiation of HAART during the primary phase of infection for optimal depletion of the PBMC HIV DNA reservoir" - (04/08/13)
     
  1056. CROI: Maraviroc plus Raltegravir dual Therapy in Aviremic HIV infected Patients with Lipodystrophy : Results from the ROCnRAL ANRS 157 Study. - (04/07/13)
     
  1057. CROI: Maraviroc Intensification in Virally Suppressed HIV Infected Subjects Leads to Improvement in Neurocognitive Test Performance and Declines in Immune Activation - (04/07/13)
     
  1058. CROI: Impact of Interleukin 7 and Raltegravir plus Maraviroc intensification on total HIV DNA reservoir: Results from ERAMUNE 01 - (04/07/13)
     
  1059. CROI: HIV Controllers Have Inflammation & ART Should Be "Considered", study investigators say - (04/06/13)
     
  1060. CROI: Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/05/13)
     
  1061. CROI: Clinical Pharmacology at CROI 2013 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/04/13)
     
  1062. CROI: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MK-1439, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects - (04/04/13)
     
  1063. CROI: SINGLE AND MULTIPLE DOSE DOLUTEGRAVIR PHARMACOKINETICS IN THE GENITAL TRACT AND COLORECTUM OF HIV NEGATIVE MEN AND WOMEN - (04/04/13)
     
  1064. CROI: Dolutegravir Has No Effect on the Pharmacokinetics of Methadone or Oral Contraceptives With Norgestimate and Ethinyl Estradiol - (04/04/13)
     
  1065. Sustained Viral Suppression and Higher CD4+ T-Cell Count Reduces the Risk of Persistent Cervical High-Risk Human Papillomavirus Infection in HIV-Positive Women - (04/04/13)
     
  1066. Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study - (04/04/13)
     
  1067. Nephrotoxicity of Antiretroviral Agents: Is the List Getting Longer? Editorial - (04/04/13)
     
  1068. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs - (04/03/13)
     
  1069. CROI: A Longitudinal Study of the Effects of Ageing and HIV-1 Infection on Cognitive Performance - (04/02/13)
     
  1070. CROI: Follow-up of HIV-Associated Neurocognitive Disorders in the cART Era: the Neuradapt Study - (04/02/13)
     
  1071. CROI: Pharmacokinetic study of raltegravir in HIV-infected patients with end stage liver disease: LIVERAL ANRS 148 study - (04/02/13)
     
  1072. CROI: Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010, The ANRS EN20 Mortalite 2010 Survey: the 3rd leading cause of death was liver disease 10.8%, non-AIDS cancers 22.1%, AIDS 25%, CVD deaths/sudden deaths 13.6% - (04/02/13)
     
  1073. CROI: Hodgkin Lymphoma Is Almost As Prevalent As Non-Hodgkin Lymphoma in HIV+ Patients With Sustained Viral Suppression And Limited Immune Deficiency - (04/01/13)
     
  1074. The cost-effectiveness of expanded HIV screening in the United States (more frequent testing recommended, every 3 months for high-risk individuals) - (04/01/13)
     
  1075. Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers - (04/01/13)
     
  1076. HIV and the Kidney Review - (03/31/13)
     
  1077. Chronic Kidney Disease: A Clinical Model of Premature Aging - (04/01/13)
     
  1078. Talk of HIV cure goes viral - (04/01/13)
     
  1079. CROI: Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-Infection - (04/01/13)
     
  1080. CROI: Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13)
     
  1081. CROI: Factors Associated with Tenofovir-related Adverse Events and Drug Exposure in HIV-positive Patients - (04/01/13)
     
  1082. CROI: Common Conditions - Age, Low BMI, Mild Renal Impairment, Ritonavir Use - Increase Tenofovir Exposure in a Large Unselected Cohort of HIV+ Women - (04/01/13)
     
  1083. CROI: Hype and the HIV cure (baby/CROI) - (04/01/13)
     
  1084. CROI: Doctors claim to have cured girl of HIV (baby/CROI) - (04/01/13)
     
  1085. CROI: Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13)
     
  1086. CROI: Protease Inhibitor Monotherapy Is Not Associated with a Higher Rate or a Different Pattern of Neurocognitive Impairment than Triple Drug Therapy - (04/01/13)
     
  1087. CROI: HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (04/01/13)
     
  1088. CROI: 25-hydroxy Vitamin D and Bone Mineral Density (BMD) Increased with Intermittent ART versus Continuous ART in the SMART Body Composition Substudy - (04/01/13)
     
  1089. CROI: Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/01/13)
     
  1090. CROI: Changing CSF Concentrations of Neurofilament Light Chain, Tau and Amyloid Proteins, Characterize Evolving CNS Injury in HIV-1 Infection - (04/01/13)
     
  1091. CROI: Low-Level HIV RNA Declines Over Time in CSF but not in Plasma, "HIV between 2-50 c/ml .....worse cognitive functioning" - (04/01/13)
     
  1092. CROI: Reduced Region-Specific Corpus Callosum Volumes Correlate with Low Nadir CD4 an Decreased Cognition in HIV-Infected Carriers of the ApoE4 Allele - (04/01/13)
     
  1093. CROI: Continued Declines in AIDS and non-AIDS Related Mortality with Persistently Higher Death Rates among Blacks and the Publicly Insured in the HIV Outpatient Study (HOPS), 1996-2009 - (04/01/13)
     
  1094. CROI: Prevalence of Chronic Kidney Disease Among HIV-infected Adults in Care in the United States Medical Monitoring Project, 2009 - (04/01/13)
     
  1095. CROI: Update from 20th CROI: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Association Professor of Medicine and Epidemiology Division of Endocrinology and Metabolism Johns Hopkins University - (04/01/13)
     
  1096. CROI: A Randomized, Controlled Trial of a CNS-Targeted Antiretroviral Therapy (ART) Strategy for HIV-Associated Neurocognitive Disorders - (03/29/13)
     
  1097. CROI: Triple Combination Therapy Telaprevir vs Boceprevir, in Spain, Early Results, in Mono- and Coinfected - (03/29/13)
     
  1098. CROI: HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/28/13)
     
  1099. CROI: Proteinuria is Associated with Neurocognitive Impairment in HIV Infected Subjects Enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinal Cohort Study (ALLRT) - (03/28/13)
     
  1100. CROI: Cardiac function is altered in Aged Transgenic AIDS Mice in vivo: Insights into Age-related HIV-1 Changes in Patients - (03/28/13)
     
  1101. CROI: Increased Hot Flash Severity and Burden among Perimenopausal HIV-infected Women - (03/28/13)
     
  1102. CROI: Change in Lean Body Mass and Association with Bone Mineral Density Change in Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (03/28/13)
     
  1103. CROI: Fracture Among Older and Younger HIV+ Medicare Beneficiaries - (03/28/13)
     
  1104. CROI: HIV+ Status, Low Income, and Active Hepatitis C Virus Infection are Associated with Shorter Leukocyte Telomere Length in a Cohort of HIV+ and HIV- Adults - (03/28/13)
     
  1105. CROI: SECOND-LINE: Ritonavir-Boosted-Lopinavir with 2-3N(t)RTI or Raltegravir in HIV-Positive Subjects Virologically Failing First-Line NNRTI/2N(t)RTI antiretroviral therapy - (03/28/13)
     
  1106. CROI: Reversibility of tenofovir-associated decline in renal function - (03/22/13)
     
  1107. CROI: Tenofovir Alafenamide Pharmacokinetics in Renal Impairment: Potential for Administration without Dose Adjustment - (03/22/13)
     
  1108. CROI: End Organ HIV Reservoirs - Integrated HIV DNA and Associated Histiocyte Marker mRNA in Autopsy Samples of Non-lymphoid Tissue Including the CNS - (03/22/13)
     
  1109. CROI: The Kidney A Potential HIV Reservoir - Bidirectional Passage of HIV Between T cells and Renal Epithelial cells through Virological Synapse Formation - (03/22/13)
     
  1110. CROI: Evaluation of Glomerular Function, Renal Blood Flow, and Exposure-Safety Relationship Following Administration of EVG/COBI/FTC/TDF - (03/21/13)
     
  1111. CROI: The Kidney at CROI 2013 - Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/21/13)
     
  1112. CROI: Statin therapy and mortality in HIV-infected individuals; A Danish nationwide population-based cohort study. - (03/20/13)
     
  1113. CROI: Every Year of Statin Therapy Boosts Diabetes Risk 10% in US HIV Cohort - written by Mark Mascolini - (03/20/13)
     
  1114. CROI: Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study - (03/20/13)
     
  1115. CROI: Is Statin Use Associated with Incident Diabetes Mellitus among Patients in the HIV Outpatient Study (HOPS)? - (03/20/13)
     
  1116. CROI: Neuropsychological Performance in Acute HIV - (03/20/13)
     
  1117. CROI: Complications of HIV and its treatment, Impressions from the 20th CROI - Pablo Tebas, MD University of Pennsylvania - (03/20/13)
     
  1118. CROI: CROI REPORT: New Drugs for HIV Treatment and other random thoughts - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/20/13)
     
  1119. CROI: Revealing the Reservoir, and A Second Cure? - Ronald Swanstrom PhD, UNC Chapel Hill - (03/18/13)
     
  1120. French Study Indicates Some Patients Can Control H.I.V. After Stopping Treatment, 'Functional Cure', Visconti Study - NY Times - (03/19/13)
     
  1121. CROI: NEW HIV DRUGS at CROI - (03/19/13)
     
  1122. CROI: IL-6 Plus D-dimer Predict Non-AIDS Diagnoses and Death in 3-Cohort HIV Group - written by Mark Mascolini - (03/19/13)
     
  1123. CROI: The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy - (03/19/13)
     
  1124. CROI: The Effect of Statins on Immune activation and Inflammation in HIV-Infected Subjects on Antiretroviral Therapy: a Randomized Placebo Controlled Trial - (03/19/13)
     
  1125. CROI: Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART - (03/19/13)
     
  1126. Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients - (03/18/13)
     
  1127. CROI: HIV Care Cascade Analysis Not So Dire in Large US Healthcare System - written by Mark Mascolini - (03/18/13)
     
  1128. CROI: Noncalcified Coronary Plaque and Macrophage Activation are Increased in HIV-Infected Women - (03/18/13)
     
  1129. CROI: HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/18/13)
     
  1130. CROI: Trends in and factors associated with virological failure among women conceiving on cART in Western Europe - (03/18/13)
     
  1131. CROI: CROI Report 2013: Observations on the "Cure Agenda" - By David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) (03/18/13)
     
  1132. CROI: 20th Conference on Retroviruses and Opportunistic Infections: Eradication/Cure, Prevention, Novel Strategies for administration of PrEP (delivery alternatives) Antiretroviral Therapy/drug resistance/new drugs/Comorbidities - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/17/13)
     
  1133. CROI: HCV at CROI - (03/17/13)
     
  1134. CROI: Heart Disease/CROI - (03/17/13)
     
  1135. CROI: European cART Failure Rate During Pregnancy 19% and Falling Fast - written by Mark Mascolini - (03/17/13)
     
  1136. CROI: One Quarter of US Pregnant Insured Women Not Tested for HIV, Despite CDC Advice - written by Mark Mascolini - (03/17/13)
     
  1137. CROI: Lower Pretreatment CD4s Tied to More Bone Loss After 96 Weeks of ART - written by Mark Mascolini - (03/17/13)
     
  1138. CROI: Bisexual HIV+ US Men Differ in Key Ways from HIV+ Heterosexuals and Gays - CDC Study - written by Mark Mascolini - (03/17/13)
     
  1139. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/16/13)
     
  1140. CROI: Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals - (03/16/13)
     
  1141. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study - (03/15/13)
     
  1142. A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial - (03/15/13)
     
  1143. CROI: Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 - (03/15/13)
     
  1144. CROI: Weight Gain Inflates Diabetes Risk More in Veterans With Than Without HIV - written by Mark Mascolini - (03/15/13)
     
  1145. CROI: Lower Current CD4s--But Not Tenofovir--Predict Advanced CKD/ESRD in D:A:D - written by Mark Mascolini - (03/15/13)
     
  1146. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study.....[from Jules: HCV Viremia Increased Fibrosis/Immune-Dysregulation; HIV Drives Immune Activation but HCV Contributes to Immune Activation] - (03/15/13)
     
  1147. CROI: Non-AIDS Cancer Rate Higher With Longer PI (But Not NNRTI) Therapy in D:A:D - written by Mark Mascolini - (03/14/13)
     
  1148. CROI: HIV and HIV/HCV Boost Risk of Venous Thromboembolism in Large Veterans Cohort - written by Mark Mascolini - (03/14/13)
     
  1149. CROI: Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested US clinical samples: 2006 to 2012 - (03/14/13)
     
  1150. CROI: High Prevalence and Severity of Pulmonary Emphysema is Associated with Cardiovascular Morbidity - (03/14/13)
     
  1151. CROI: HIV and Coronary Artery Calcium Score: Comparison of the Hawaii Aging with HIV Cardiovascular Study (HAHC-CVD) and the Multi-Ethnic Study of Atherosclerosis (MESA) - (03/14/13)
     
  1152. CROI: Human Immunodeficiency Virus Infection and Risk of Venous Thromboembolism - (03/14/13)
     
  1153. CROI: Older Age and Neurocognitive Function in the Multi-Center AIDS Cohort Study - (03/14/13)
     
  1154. CROI: Homology models of the attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action - (03/13/13)
     
  1155. CROI: Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients - (03/13/13)
     
  1156. CROI: Soluble Markers of Inflammation & Coagulation, but not T-Cell Activation, Predict Non-AIDS Defining Events During Suppressive Antiretroviral Therapy (ART) - (03/13/13)
     
  1157. CROI: The Contribution of Intestinal Epithelial Cell Damage, Microbial Translocation, and HIV Status to an Inflammaging Phenotype - (03/13/13)
     
  1158. CROI: Obesity Affects Almost One Quarter of HIV-Positive US People in Care in CDC Analysis - written by Mark Mascolini - (03/13/13)
     
  1159. CROI: HIV Prevention at CROI 2013 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/13)
     
  1160. CROI: Virologic Failure in 40% of Perinatally Infected US Children--Regimen Switching Slow - written by Mark Mascolini - (03/12/13)
     
  1161. CROI: Framingham Score May Underestimate CHD Risk With HIV, HCV, and HIV/HCV - written by Mark Mascolini - (03/12/13)
     
  1162. CROI: Long-Term Changes in Renal Parameters in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Sub-study of A5202 - (03/12/13)
     
  1163. CROI: Projecting CVD risks in HIV-infected individuals in the US: competing risks and premature aging - (03/12/13)
     
  1164. CROI: Inflammation, Monocyte Activation in CVD & Non-AIDS Events - (03/12/13)
     
  1165. CROI: Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010 - The ANRS EN20 Mortalite 2010 Survey - (03/12/13)
     
  1166. CROI: Soluble CD14 Declines in Virologically Suppressed Women Switching from PI or NNRTI to Raltegravir: The Women, Integrase, and Fat Accumulation Trial - (03/12/13)
     
  1167. CROI: Inflammation and HIV at CROI 2013: Focus on the Monocyte/Macrophage Axis and Innate Immunity - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/11/13)
     
  1168. CROI: CROI 2013: Cardiovascular Disease and Co-morbidities in HIV - written by David H. Shepp, MD Associate Professor of Medicine, Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/11/13)
     
  1169. CROI: The Incidence of AIDS Defining Events (ADEs) at a Current CD4 Count > 200/mm3 in the Post Combination Antiretroviral Therapy Era - (03/11/13)
     
  1170. CROI: A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects Against Repeated SHIV Vaginal Challenge in Nonhuman Primates - (03/11/13)
     
  1171. 50% Increased Risk for Myocardial Infarction (MI) Rate in HIV+ in Veterans Cohort (VACS) - (03/11/13)
     
  1172. CROI: HIV-Infected Adults Are at Greater Risk for Myocardial Infarction (MI), End-stage Renal Disease (ESRD), and Non-AIDS-defining Cancers, But Events Occur at Similar Ages Compared to HIV-uninfected Adults (VA) - (03/11/13)
     
  1173. CROI: Subclinical Heart Disease is Greater Among HIV+ vs HIV- & Increases with Age in MACS - (03/11/13)
     
  1174. CROI: Short-Term Mortality After Heart Attack With HIV Fell Over Past Decade in D:A:D - written by Mark Mascolini - (03/11/13)
     
  1175. CROI: Proportion of HIV Deaths Due to Heart Disease Almost Doubles in France From 2000 to 2010 - written by Mark Mascolini - (03/11/13)
     
  1176. CROI: Fewer CD4s at HIV Diagnosis Tied to Higher Risk of non-AIDS Deaths - written by Mark Mascolini - (03/11/13)
     
  1177. CROI: Resistance to Darunavir Falling Since Approval of the Protease Inhibitor in 2006 - written by Mark Mascolini - (03/11/13)
     
  1178. CROI: Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (03/09/13)
     
  1179. CROI: Prevalence of CSF Alzheimer's Disease-like profiles in middle-aged HIV+ individuals, relation to APOE genotyping and HIV disease markers - (03/09/13)
     
  1180. CROI: Rise in Heart Disease Risk With Age Slightly Greater With HIV Than in General Population.......[DAD study also shows that reducing risk factors can have a big impact on reducing heart disease] - written by Mark Mascolini - (03/09/13)
     
  1181. CROI: Over 10% in Older HIV Group Fit Alzheimer's Biomarker Risk Profile - written by Mark Mascolini - (03/08/13)
     
  1182. CROI: Tenofovir in Intravaginal Ring Protects 6 of 6 Macaques From SHIV Challenge - written by Mark Mascolini - (03/08/13)
     
  1183. CROI: Longitudinal Association of HIV-associated neurocognitive disorder (HAND) with Frailty in HIV+ Men - (03/08/13)
     
  1184. CROI: New HIV Rate High After iPrEx Men Stop Truvada PrEP (or Placebo): when taking Truvada PrEP it works - written by Mark Mascolini - (03/08/13)
     
  1185. CROI: CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs Efavirenz in ART-Naive - written by Mark Mascolini - (03/08/13)
     
  1186. CROI: Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus - (03/08/13)
     
  1187. CROI: Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study - (03/07/13)
     
  1188. CROI: Long-Term Efavirenz Use is Associated with Worse Neurocognitive Functioning - (03/07/13)
     
  1189. CROI: PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys - (03/07/13)
     
  1190. CROI: Higher CD4 Gains With 2nd-Line Regimen Excluding NRTIs in Randomized Trial - written by Mark Mascolini - (03/07/13)
     
  1191. CROI: CD4 Count Affects Non-AIDS Risk in People Yet to Start Antiretrovirals - written by Mark Mascolini - (03/07/13)
     
  1192. CROI: Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study - (03/07/13)
     
  1193. CROI: Similar Cognition Outcomes After 24 Weeks for Tenofovir/FTC + Atazanavir/r (ATV/r)-Experienced HIV+ Subjects or Those Simplifying to Abacavir/3TC+ATV - (03/06/13)
     
  1194. CROI: Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13)
     
  1195. CROI: Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13)
     
  1196. CROI: Baby Cure at CROI - (03/06/13)
     
  1197. CROI: NRTI-Sparing Second-Line Regimen Holds Its Own in Randomized Trial - written by Mark Mascolini - (03/06/13)
     
  1198. CROI: Peak Bone Mass Lower in Young HIV+ vs HIV- Men--and Bone Structure Abnormal - written by Mark Mascolini - (03/06/13)
     
  1199. CROI: Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13)
     
  1200. CROI: Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus - written by Mark Mascolini - (03/06/13)
     
  1201. CROI: Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13)
     
  1202. CROI: Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop - written by Mark Mascolini - (03/05/13)
     
  1203. CROI: Smoking Rate Twice Higher With Than Without HIV in First National US Study - written by Mark Mascolini - (03/05/13)
     
  1204. CROI: Long-Term Efavirenz Linked to Worse Neurocognitive Function in US CHARTER Group - written by Mark Mascolini - (03/05/13)
     
  1205. CROI: Coronary Artery Danger Signals More Common in Young HIV+ Men Than HIV- Men - written by Mark Mascolini - (03/05/13)
     
  1206. CROI: Comparative Study of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each with Elvitegravir, Cobicistat, and Emtricitabine, for HIV Treatment - (03/05/13)
     
  1207. CROI: New tenofovir prodrug virologically equivalent to TDF--and easier on kidneys and bone - written by Mark Mascolini - (03/05/13)
     
  1208. LA JOLLA INSTITUTE IDENTIFIES MOLECULAR SWITCH ENABLING IMMUNE CELLS TO BETTER FIGHT DISEASE - (03/05/13)
     
  1209. CROI: Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)
     
  1210. CROI: Higher MI, ESRD, Cancer Rates With HIV--But Not Necessarily at Younger Age - written by Mark Mascolini - (03/05/13)
     
  1211. CROI: Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)
     
  1212. CROI: Was An Infant Cured Of HIV? - (03/04/13)
     
  1213. CROI: For First Time, Baby Is Cured of H.I.V., Doctors Say - (03/04/13)
     
  1214. CROI: Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV - written by Mark Mascolini - (03/04/13)
     
  1215. CROI: HIV Prevention Fails in All Three VOICE Arms, as Daily Truvada PrEP Falls - written by Mark Mascolini - (03/04/13)
     
  1216. CROI: "Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth - written by Mark Mascolini - (03/04/13)
     
  1217. Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis - (03/01/13)
     
  1218. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study - (03/01/13)
     
  1219. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women - (02/28/13)
     
  1220. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml - (02/28/13)
     
  1221. Renal Impairment in Patients Receiving a Tenofovir-cART Regimen: Impact of Tenofovir Trough Concentration - (02/27/13)
     
  1222. Cognitive Neurorehabilitation of HIV-associated Neurocognitive Disorders: A Qualitative Review and Call to Action - (02/25/13)
     
  1223. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring - (02/25/13)
     
  1224. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis - (02/25/13)
     
  1225. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure - (02/25/13)
     
  1226. New FDA Approval Process: "Breakthrough therapy" - (02/22/13)
     
  1227. Updating the HIV-Testing Guidelines - A Modest Change with Major Consequences Perspective - (02/21/13)
     
  1228. Routine HIV Testing, Public Health, and the USPSTF - An End to the Debate Perspective - (02/21/13)
     
  1229. When to Start ART in Africa - An Urgent Research Priority Perspective - (02/21/13)
     
  1230. The Final Word on Proton Pump Inhibitors and Osteoporosis? - editorial - (02/20/13)
     
  1231. ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection - (02/19/13)
     
  1232. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A Pilot Study - (02/15/13)
     
  1233. Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses - (02/19/13)
     
  1234. Differential Penetration of Raltegravir throughout Gastrointestinal Tissue: Implications for Eradication and Cure - (02/15/13)
     
  1235. HIV Coreceptor Tropism With Reflex to Ultradeep Sequencing - (02/15/13)
     
  1236. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Updated Feb 12 2013 - (02/15/13)
     
  1237. Markers of microbial translocation and risk of AIDS-related lymphoma - (02/13/13)
     
  1238. Microbial translocation and AIDS-associated lymphomas: crux of the problem "....Chronic inflammation..." - Editorial - (02/13/13)
     
  1239. Monitoring cellular immune markers in HIV infection: from activation to exhaustion - (02/11/13)
     
  1240. Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein - (02/11/13)
     
  1241. Increased Coronary Atherosclerotic Plaque Vulnerability by Coronary Computed Tomography Angiography in HIV-Infected Men - (02/11/13)
     
  1242. Monitoring cellular immune markers in HIV infection: from activation to exhaustion - (02/08/13)
     
  1243. Soluble biomarkers of HIV transmission, disease progression and comorbidities - (02/08/13)
     
  1244. Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population......"Overall, 21.0% of patients linked to appropriate care within 1 year of the Test...." - (02/06/13)
     
  1245. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort - (02/04/13)
     
  1246. Treating HIV Very Early Enhances Immunity - (02/04/13)
     
  1247. Trends and Predictors of Non AIDS-Defining Cancers in Men and Women With Hiv-Infection. A Single-Institution Retrospective Study Before and After the Introduction of Haart - (02/04/13)
     
  1248. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (02/04/13)
     
  1249. Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up - (02/04/13)
     
  1250. Lipids in 2012: HDL cholesterol studies-more of the same? - (01/31/13)
     
  1251. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts - (01/31/13)
     
  1252. Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration - (01/25/13)
     
  1253. Interferon Alfa Therapy: Toward an Improved Treatment for HIV Infection Editorial - (01/25/13)
     
  1254. New Studies Show Which Anti-HIV Drug Combinations Work Better Than Others -- And Why And How They Do It - (01/24/13)
     
  1255. Disparities in Study Findings on Neurologic Function in HIV - (01/24/13)
     
  1256. New assays for monitoring residual HIV burden in effectively treated individuals - (01/22/13)
     
  1257. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy - (01/22/13)
     
  1258. An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses - (01/22/13)
     
  1259. Immune modulatory effects of cyclooxygenase type 2 inhibitors (NSAIDS) in HIV patients on combination antiretroviral treatment - (01/22/13)
     
  1260. Persistent immune activation in chronic HIV infection: do any interventions work? (cure research) - (01/22/13)
     
  1261. 3rd Intl Wrkshp on HIV & Women: SAFETY AND EFFICACY OF LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN PREGNANT WOMEN: A SYSTEMATIC REVIEW - (01/17/12)
     
  1262. Short-Course Antiretroviral Therapy in Primary HIV Infection - (01/17/13)
     
  1263. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy - (01/17/13)
     
  1264. Antiretroviral Therapy in Early HIV Infection - - (01/17/13)
     
  1265. Safety, efficacy and pharmacokinetic of Darunavir/Ritonavir containing regimen in pregnant HIV-infected women - (01/16/13)
     
  1266. A Comparison of the Pharmacokinetics of Darunavir, Atazanavir and Ritonavir during Pregnancy and Post-partum - (01/16/13)
     
  1267. Generic Antiretrovirals and the Uncertain Future of HIV Care in the United States - Editorial & study - (01/16/13)
     
  1268. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review - (01/16/13)
     
  1269. 3rd Intl Wrkshp on HIV & Women: Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (01/16/12)
     
  1270. 3rd Intl Wrkshp on HIV & Women: Nine-Study Review Raises No Lopinavir Efficacy or Safety Concerns in Pregnancy - written by Mark Mascolini (01/16/12)
     
  1271. 3rd Intl Wrkshp on HIV & Women: High Rate of Obstetric Problems in HIV+ Ottawa Women With Free Care - written by Mark Mascolini (01/16/12)
     
  1272. 3rd Intl Wrkshp on HIV & Women: Twice-Daily Darunavir/Ritonavir in Regimens for Pregnant Women - written by Mark Mascolini (01/16/12)
     
  1273. 3rd Intl Wrkshp on HIV & Women: Risk of Progression to Fibrosis Twice Higher in Women Than Men With HCV/HIV - written by Mark Mascolini (01/16/12)
     
  1274. 3rd Intl Wrkshp on HIV & Women: Lower Cognitive Scores in Women With HCV/HIV Than With HIV Alone - written by Mark Mascolini - (01/15/12)
     
  1275. 3rd Intl Wrkshp on HIV & Women: Psych and Substance Abuse Disorders Frequent and Persistent in US Mothers With HIV - written by Mark Mascolini - (01/15/12)
     
  1276. 3rd Intl Wrkshp on HIV & Women: Depression Scores Rise Yearly After Age 40 for HIV+ Women But Not Men - written by Mark Mascolini - (01/15/12)
     
  1277. 3rd Intl Wrkshp on HIV & Women: HIV Transmission Risk Essentially 0 if Heterosexual Partner Has Undetectable Viral Load - written by Mark Mascolini - (01/15/12)
     
  1278. Tenofovir-associated proteinuria - (01/14/13)
     
  1279. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals - (01/14/13)
     
  1280. Cognitive disorders in HIV-infected patients: are they HIV-related? - (01/14/13)
     
  1281. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART Body Composition substudy - (01/12/13)
     
  1282. Dolutegravir for treatment of HIV: SPRING forwards? Commentary - (01/12/13)
     
  1283. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study - (01/12/13)
     
  1284. New Therapeutic HIV Vaccine Study Results.. A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication - (01/10/13)
     
  1285. Low Bone Mineral Density, Regardless of HIV Status, in Men Who Have Sex With Men - (01/07/13)
     
  1286. FDA approves first anti-diarrheal drug for HIV/AIDS patients - (01/07/13)
     
  1287. Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era - - (01/03/13)
     
  1288. Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-infected Men after Primary HCV Infection - (01/04/13)
     
  1289. Effect Of HCV Infection On Cause-Specific Mortality Following HIV Seroconversion Before And After 1997 - (01/04/13)
     
  1290. 2 Studies reporting increased heart disease risk in HIV+ using Framingham Score & Imaging/Markers (Glasgow 2012) - (01/03/13)
     
  1291. Endothelial Function-what is it? - (01/03/13)
     
  1292. The Rising Challenge of Non-AIDS-Defining Cancers in HIV-Infected Patients - (01/03/13)
     
  1293. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease: nadir CD4 <350 associated with worse endothelial CVD function - (01/03/13)
     
  1294. Mortality Attributable to Smoking Among HIV-1-Infected Individuals: A Nationwide, Population-Based Cohort Study: smokers have 5-fold increased risk for death caused by heart disease & cancer, shorter life expectancy by 15 years & loss of life-years for smokers was twice as high as HIV...."60% of deaths in cohort due to smoking" - (01/03/13)
     
  1295. Resveratrol Improves Intrahepatic Endothelial Dysfunction and Reduces Hepatic Fibrosis and Portal Pressure in Cirrhotic Rats - (01/03/13)
     
  1296. Higher Dose Flu Vaccine in HIV+ - Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons: A Single-Center, Parallel, Randomized Trial - (01/03/13)
     
  1297. HIV-Infection Incidence in Women in Inner Urban Cities Similar Rates to in Africa, Higher (0.32%) than CDC Estimates (0.05%) for Black Women in USA - (01/03/13)
     
  1298. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort (ACTG) - (12/20/12)
     
  1299. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients (Spain): role of antiretroviral therapy HCV/HIV Coinfection 2nd Most Frequent Event...aging cirrhotics - (12/20/12)
     
  1300. Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers - (12/20/12)
     
  1301. Raltegravir based post exposure prophylaxis (PEP): A safe, well tolerated alternative regimen (Glasgow 2012) - (12/20/12)
     
  1302. Effect of hepatitis C treatment with interferon and ribavirin in body composition measurement by DEXA in HIV/HCV coinfected patients (Glasgow 2012) - (12/19/12)
     
  1303. Neurocognitive Impairment (NCI), Depression, and Anxiety in HIV-1 Infected Patients Across Western Europe and Canada, The CRANIum Study- Ethnicity analysis (Glasgow 11/2012) - (12/19/12)
     
  1304. Safety and efficacy of a raltegravir based dual antiretroviral therapy in clinical practice (Glasgow 2012) - (12/19/12)
     
  1305. IDUs 2.6% of US Population, MSM 3.9%/6.9% Ever Engaged - CDC - (12/19/12)
     
  1306. Raltegravir 800 mg Once Daily Is Efficacious in Patients Already Virologically Suppressed (Glasgow 2012) - (12/19/12)
     
  1307. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study - (12/19/12)
     
  1308. Maraviroc: A Drug Used to Treat HIV Might Defuse Deadly Staph Infections - (12/18/12)
     
  1309. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection - (12/18/12)
     
  1310. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Clinically Significant Drug Interaction Between Colchicine and Ritonavir in Healthy Adults - (12/14/12)
     
  1311. Pharmacokinetic and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir in the ODIN trial - (12/13/12)
     
  1312. Kidney Disease Review: The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew - (12/13/12)
     
  1313. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis - Review - (12/13/12)
     
  1314. Have You Missed Diagnosing HIV Among The Aging Population? Learn From The Experience of Washington, D.C. - (12/10/12)
     
  1315. Diabetes-Statin Link Hinges on Risk Factors - (12/10/12)
     
  1316. Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain - (12/03/12)
     
  1317. Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection - (12/03/12)
     
  1318. Prescription of physical activity: an undervalued intervention - irrespective of whether dyslipidaemic patients took statins exercise reduced death by 60-70% - (11/30/12)
     
  1319. New practical guidance for improved patient care in HIV-associated neurocognitive disorder - Assessment, Diagnosis and Treatment of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders (HAND): A Consensus Report of the Mind Exchange Program - (11/30/12)
     
  1320. Grapefruit-Drug Interaction Seen With More Drugs - (11/29/12)
     
  1321. 11th Intl Congress Drug Therapy HIV Infection: Raltegravir switch improves Hepatitis C transaminitis in HIV-1 and Hepatitis C (HCV) co-infected individuals - (11/29/12)
     
  1322. Improvement in the Health of HIV-Infected Persons in Care: Reducing Disparities - HIV & HCV Health Disparities, HIV Life Expectancy/Aging, Hopkins Moore Clinic, Ryan White Care Act future - (11/28/12)
     
  1323. HCV in MSM, ex-US vs USA Politics/Inner City HCV - Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic - (11/28/12)
     
  1324. 3rd Wrkshp on HIV & Aging: Higher VACS Index Linked to Neurocognitive Impairment With HIV - Written by Mark Mascolini (11/26/11)
     
  1325. 11th Intl Congress Drug Therapy HIV Infection: Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (11/26/12)
     
  1326. 11th Intl Congress Drug Therapy HIV Infection: Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ ritonavir 800/100mg treatment in the Phase III trials, ARTEMIS and ODIN - (11/26/12)
     
  1327. 11th Intl Congress Drug Therapy HIV Infection: Rilpivirine efficacy, virology and safety in antiretroviral treatment-naïve patients with baseline viral load ≤100,000 HIV-1 RNA copies/mL: ECHO and THRIVE 96-week pooled dataset - (11/26/12)
     
  1328. 11th Intl Congress Drug Therapy HIV Infection: Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of a prodrug - (11/20/12)
     
  1329. 11th Intl Congress Drug Therapy HIV Infection: Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of a prodrug - (11/20/12)
     
  1330. 11th Intl Congress Drug Therapy HIV Infection: Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 - (11/20/12)
     
  1331. 11th Intl Congress Drug Therapy HIV Infection: The HIV NRTI BMS-986001 does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle and subcutaneous fat - (11/20/12)
     
  1332. 3rd Wrkshp on HIV & Aging: Less Resilient Older HIV-infected Persons Evidence Instrumental Activities of Daily Living Declines - (11/19/11)
     
  1333. 3rd Wrkshp on HIV & Aging: Accelerated Cardiovascular Aging in Treated HIV Males: Analysis of the Difference Between Chronologic & Vascular Age - (11/19/11)
     
  1334. 11th Intl Congress Drug Therapy HIV Infection: STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results - (11/16/12)
     
  1335. 11th Intl Congress Drug Therapy HIV Infection: Gilead 's Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients - (11/16/12)
     
  1336. 11th Intl Congress Drug Therapy HIV Infection: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Efavirenz/Emtricitabine/Tenofovir DF (ATR) in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)
     
  1337. 11th Intl Congress Drug Therapy HIV Infection: Gilead 's Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients - press release - (11/16/12)
     
  1338. 11th Intl Congress Drug Therapy HIV Infection: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)
     
  1339. 11th Intl Congress Drug Therapy HIV Infection: Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B and/or C Virus: Complete Data from Phase III Double-Blind Studies - (11/16/12)
     
  1340. 11th Intl Congress Drug Therapy HIV Infection: ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected with HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks - (11/16/12)
     
  1341. 3rd Wrkshp on HIV & Aging: Inflammatory Markers Linked to Frailty in HIV-Positive MACS Men - Written by Mark Mascolini (11/16/11)
     
  1342. 3rd Wrkshp on HIV & Aging: "Lung Age" 3 Years Older in Middle-Aged HIV+ Versus HIV- IDU Group - Written by Mark Mascolini (11/16/11)
     
  1343. 3rd Wrkshp on HIV & Aging: Tenofovir May Speed Bone Mineral Loss in First Years After Menopause - Written by Mark Mascolini (11/16/11)
     
  1344. 3rd Wrkshp on HIV & Aging: Higher VACS Index Linked to Neurocognitive Impairment With HIV - Written by Mark Mascolini (11/16/11)
     
  1345. 11th Intl Congress Drug Therapy HIV Infection: ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults - (11/16/12)
     
  1346. 11th Intl Congress Drug Therapy HIV Infection: Antiviral Activity of Dolutegravir in Subjects with Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results from VIKING-3 (2) Oral - (11/16/12)
     
  1347. 11th Intl Congress Drug Therapy HIV Infection: Antiviral Activity of Dolutegrevir in Subjects With Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results From VIKING-3 (1) Poster - (11/16/12)
     
  1348. 11th Intl Congress Drug Therapy HIV Infection: Increasing Subject Compliance in Pivotal Phase III Clinical Trials of Dolutegravir (DTG, S/GSK1349572) in HIV-Infected, ART-Naive Subjects - (11/16/12)
     
  1349. 11th Intl Congress Drug Therapy HIV Infection: Dolutegravir Treatment Response by Baseline Viral Load and NRTI Backbone in Treatment-Naive, HIV-Infected Individuals - (11/16/12)
     
  1350. 11th Intl Congress Drug Therapy HIV Infection: LONG TERM DURABILITY OF NEVIRAPINE BASED ART IN A COHORT OF 84 PATIENTS AFTER INDUCTION WITH PROTEASE INHIBITOR TREATMENT - (11/16/12)
     
  1351. 11th Intl Congress Drug Therapy HIV Infection: Long-term (96 and 144 Week) Efficacy and Safety From the VERxVE Trial Comparing Nevirapine Extended-Release (NVP XR) 400 mg Once a Day to Nevirapine Immediate- Release (NVP IR) 200 mg Twice a Day in Combination With Emtricitabine/Tenofovir in Treatment-Naïve HIV-1 Patients - (11/16/12)
     
  1352. 3rd Wrkshp on HIV & Aging: The Prevalence of a Positive Screen for Neurocognitive Impairment and Anxiety/Depression in HIV-1 Infected Patients Across Western Europe and Canada - The CRANIum Study: Age Analysis - (11/08/11)
     
  1353. 3rd Wrkshp on HIV & Aging: Comparable Efficacy With QUAD, Atripla, ATV/r in Younger and Older Groups - Written by Mark Mascolini - (11/08/11)
     
  1354. 3rd Wrkshp on HIV & Aging: Vascular Age Exceeds Actual Age in HIV-Positive Men in Metabolic Clinic - Written by Mark Mascolini - (11/08/11)
     
  1355. 3rd Wrkshp on HIV & Aging: AIDS, Depression, Diabetes, Kidney Disease Predict Frailty in HIV-Positive Gays: frailty double in HIV+ MSM in MACS - Written by Mark Mascolini - (11/08/11)
     
  1356. 3rd Wrkshp on HIV & Aging: Response Rates Similar With Rilpivirine and Efavirenz Above and Below 50 Years of Age - Written by Mark Mascolini - (11/07/11)
     
  1357. 3rd Wrkshp on HIV & Aging: HIV+ People Over 50 Have No More Depression or Anxiety Than Younger Adults - Written by Mark Mascolini - (11/07/11)
     
  1358. HIV infection: what should be considered in approaches for a cure? - (11/07/12)
     
  1359. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? - (11/07/12)
     
  1360. Heart Disease & Blacks - (11/07/12)
     
  1361. High Cardiovascular Risk Factors Among Hispanics/Lainos - (11/07/12)
     
  1362. Fractures after antiretroviral initiation - (11/07/12)
     
  1363. 3rd Wrkshp on HIV & Aging: Effect of Aerobic Exercise Training in Older HIV-Infected Patients: Exercise Strategies Needed to Target Aging/HIV Pathogenesis' - (11/08/11)
     
  1364. 3rd Wrkshp on HIV & Aging: HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker - Written by Mark Mascolini - (11/08/11)
     
  1365. 3rd Wrkshp on HIV & Aging: Exercise Program Improves Aerobic Function and Endurance in Older HIV+ Men - Written by Mark Mascolini - (11/08/11)
     
  1366. 3rd Wrkshp on HIV & Aging: Muscle, Fat Predict Functional Status Better Than BMD in HIV+ 45- to 65-Year-Olds - Written by Mark Mascolini - (11/08/11)
     
  1367. 3rd Wrkshp on HIV & Aging: Less Resilience in Older People With vs Without HIV Tied to Drops in Daily-Living Activities - Written by Mark Mascolini - (11/08/11)
     
  1368. 3rd Wrkshp on HIV & Aging: HIV Neurocognitive Disorder Linked to Frailty in Study of US Gay Men - Written by Mark Mascolini - (11/08/11)
     
  1369. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis - (11/08/12)
     
  1370. The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults - (11/08/12)
     
  1371. Anal cancer rate still high in HIV, even with combination ART - (10/29/12)
     
  1372. IDSA: Lopinavir/Ritonavir Monotherapy Pilot Study: the MONDAKAL Study - (10/29/12)
     
  1373. IDSA: Analysis of EVG/COBI/FTC/TDF Compared to EFV/FTC/TDF By Race in Treatment Naïve Patients - (10/29/12)
     
  1374. IDSA: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF in Patients with Adherence <95% and <90% - (10/29/12)
     
  1375. Kidney stones and kidney function loss: a cohort study - (10/23/12)
     
  1376. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy - (10/23/12)
     
  1377. IDSA: Simeprevir (TMC435) in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (PILLAR and ASPIRE Trials) - (10/23/12)
     
  1378. IDSA: National trends in hospitalization and mortality for patients with HIV, HCV, or HIV/HCV co-infection: HCV Hospitalization Rates Increasing - (10/23/12)
     
  1379. IDSA: Describing the Burden of Hepatitis C (HCV) in a large public health care system (Chicago); Initial response to the National Viral Hepatitis Action Plan - (10/23/12)
     
  1380. Neurologic disorders incidence in HIV+ vs HIV- men - (10/22/12)
     
  1381. IDSA: Correlates of HIV, HCV and HIV/HCV Co-Infection in a Northeastern Inner City Population - (10/22/12)
     
  1382. IDSA: Recovery of Renal Function and Virologic Suppression Following Tenofovir Discontinuation - (10/22/12)
     
  1383. IDSA: Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study - (10/22/12)
     
  1384. IDSA: Inflammatory Biomarkers in HIV Patients in Vermont - (10/22/12)
     
  1385. IDSA: Association Between Emergent Antiretroviral Drug Resistance and Baseline CD4 Cell Count in Treatment-Naive Patients Initiating Protease-Inhibitor-Based Therapy in Clinical Trials - (10/22/12)
     
  1386. IDSA: HIV-infected adults with suppressed viremia on antiretroviral therapy have dysfunctional HDL that is associated with T cell activation - (10/22/12)
     
  1387. IDSA: The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)
     
  1388. IDSA: Effects of adherence and baseline viral load on virologic response, with resistance, dyslipidemia/lipodystrophy and bone mineral density analyses, among women compared to men in the Phase III Week 96 ECHO and THRIVE trials - (10/19/12)
     
  1389. IDSA: The Pharmacokinetics of Telaprevir and Selected ART Medications in HCV/HIV Coinfected Patients - (10/19/12)
     
  1390. IDSA: [poor] Quality of Hepatitis C care at an urban tertiary medical center - (10/19/12)
     
  1391. Brain on stress: How the social environment gets under the skin ......key to aging: managing stressors of physical & mental health..... - (10/17/12)
     
  1392. Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older - (10/16/12)
     
  1393. Predicting Cognitive Decline by Neuroimaging: Amyloid-ß assessed by florbetapir F 18 PET and 18-month cognitive decline - (10/16/12)
     
  1394. Predicting Cognitive Decline with Neuroimaging: From Alois to Amyvid - Editorial - (10/16/12)
     
  1395. Neuroimging to Predict.... Alzheimer's: Amyloid Eclipses Genetic Risk - (10/16/12)
     
  1396. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study - (10/15/12)
     
  1397. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (10/15/12)
     
  1398. HRT cuts CVD by 50%, latest "unique" data show - new study - (10/15/12)
     
  1399. Rhabdomyolysis after co-prescription of statin and fusidic acid - (10/15/12)
     
  1400. Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China: HCV/HIV coinfection rate; HCV sexual transmission - (10/09/12)
     
  1401. ICAAC: Zinc Finger CD4 Increases: Preferential Expansion of Transitional and Central Memory CD4 T-cells following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (10/09/12)
     
  1402. ICAAC: HCV/HIV co-infection and the degree of liver fibrosis as risk factors of HAART-associated nephrotoxicity - (10/09/12)
     
  1403. Association of kidney disease measures with poor outcomes - (10/09/12)
     
  1404. Relationship Between a Frailty-Related Phenotype and Progressive Deterioration of the Immune System in HIV-Infected Men: CD4 predicted frailty in MACS, viral load associated - (10/09/12)
     
  1405. Investigating A Sexual Network of Black Men Who Have Sex with Men: Implications for Transmission and Prevention of HIV Infection in the United States- 29% HIV Prevalence - (10/09/12)
     
  1406. HIV Helps Explain Rise of Anal Cancer in US Males - (10/09/12)
     
  1407. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients - (10/09/12)
     
  1408. Another Use for Rapid Home H.I.V. Test: Screening Sexual Partners - (10/09/12)
     
  1409. Association of kidney disease measures with poor outcomes - (10/05/12)
     
  1410. Dendritic spine injury induced by the 8-hydroxy metabolite of Efavirenz - (10/05/12)
     
  1411. Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV - (10/04/12)
     
  1412. Infectious Complications of Bio-Alcamid Filler Used for HIV-Related Facial Lipoatrophy - (10/04/12)
     
  1413. Increasing Exercise Performance - Serotonin and central nervous system fatigue: nutritional considerations - (10/04/12)
     
  1414. Merck's HPV Vaccine Gardasil Shown Safe in Kaiser Study - (10/02/12)
     
  1415. Increased Risk of Stomach and Esophageal Malignancies in People With AIDS - (10/02/12)
     
  1416. Aspirin and Chemoprevention of Cancer: Reaching Beyond the Colon - (10/02/12)
     
  1417. Predicting Early HIV Disease Progression: Early HLA-B*57-Restricted CD8+ T Lymphocyte Responses Predict HIV-1 Disease Progression - (10/01/12)
     
  1418. New Study Suggests HIV Causes Lipodystrophy - Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1-Infected Long-Term Nonprogressors: Significant Alterations Despite Low Viral Burden - (10/01/12)
     
  1419. New York State Guidelines Kidney Disease Mgt in HIV Sept 18 2012 - (09/24/12)
     
  1420. Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States: Implications for Event-Based Intermittent Pre-Exposure Prophylaxis - (09/24/12)
     
  1421. Transmitted Drug Resistance and Phylogenetic Relationships Among Acute and Early HIV-1-Infected Individuals in New York City - (09/24/12)
     
  1422. Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004) - (09/24/12)
     
  1423. ICAAC: A Switch from FTC/TDF to Raltegravir in Patients on a Boosted Protease Inhibitor Is Effective in Reducing Proteinuria and Increasing GFR - (09/23/12)
     
  1424. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care - (09/23/12)
     
  1425. ICAAC: PREVALENCE AND RISK FACTORS OF LOW GRADE PROTEINURIA IN HIV INFECTED PATIENTS - (09/21/12)
     
  1426. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors - (09/21/12)
     
  1427. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients - (09/21/12)
     
  1428. HHS Adult ARV Guidelines Panel: Use of EVG/COBI/TDF/FTC - (09/20/12)
     
  1429. Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function - (09/20/12)
     
  1430. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial - (09/20/12)
     
  1431. Quad's in it for antiretroviral therapy? Comment - (09/20/12)
     
  1432. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks - (09/20/12)
     
  1433. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients - (09/20/12)
     
  1434. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? - (09/20/12)
     
  1435. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events, A Systematic Review and Meta-analysis - (09/13/12)
     
  1436. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection......'HCV/HIV Coinfected Death Rates 11 Times Higher than in the general population in Spain' - (09/13/12)
     
  1437. ICAAC: High Anal Intraepithelial Neoplasia Progression in Spanish Gay/Bisexual Men - written by Mark Mascolini - (09/14/12)
     
  1438. ICAAC: Antiretrovirals Do Not Stop HSV Shedding in Genital or Anal Tract in Canada - written by Mark Mascolini - (09/14/12)
     
  1439. ICAAC: Pneumococcal Disease Risk 30 Times Higher With Than Without HIV in Denmark - written by Mark Mascolini - (09/14/12)
     
  1440. Underutilization of Aspirin for Primary Prevention of Cardiovascular Disease among HIV-Infected Patients - (09/13/12)
     
  1441. No Association of Abacavir Use with Myocardial Infarction: Findings of an FDA Meta-analysis - (09/13/12)
     
  1442. ICAAC: CD4 Gains and Side Effect Rates Differ With Age in Phase 3 QUAD Trials - written by Mark Mascolini - (09/13/12)
     
  1443. ICAAC: Older Patients Showed Similar Efficacy and Safety Results Compared With Younger Patients Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naïve HIV-1-Infected Patients Treated With Rilpivirine or Efavirenz - (09/13/12)
     
  1444. ICAAC: Virological Profiling of GS 7340, a Next-generation Tenofovir Prodrug with Superior Potency over Tenofovir DF - (09/13/12)
     
  1445. ICAAC: Atazanavir (ATV) and Darunavir (DRV) Cristalluria and High ATV and DRV Concentrations in Urine of Asymptomatic Patients Receiving ATV and DRV Based Regimens - (09/13/12)
     
  1446. ICAAC: HIV/HCV Coinfected and HCV Monoinfected Patients Have Similar Early Hepatitis C Viral Kinetics with the Potent HCV Nucleotide Polymerase Inhibitor Sofosbuvir (SOF) - (09/13/12)
     
  1447. ICAAC: Persistent Low-level Viraemia in HIV-1-infected Patients: Swiss HIV Cohort Study - (09/13/12)
     
  1448. ICAAC: BONE STATUS ASSESSMENT IN HIV-INFECTED PATIENTS : AN OBSERVATIONAL STUDY OF 199 PATIENTS - (09/12/12)
     
  1449. ICAAC: Lack of Pharmacokinetic (PK) Interaction Between Rilpivirine and the Integrase Inhibitors Dolutegravir and S/GSK1265744 - (09/12/12)
     
  1450. ICAAC: Prevalence of HIV-1 Seminal Shedding in HIV-1 Infected Men who Have Sex with Men (MSM) and Association with the Size of Intracellular HIV-1 Reservoir (ANRS EP49): "We show that HIV RNA can be detected in semen of HIV-1 infected MSM despite sustained successful cART, with a significantly higher prevalence than in heterosexual men (7.6 vs 3.1% p=0.016)" - (09/12/12)
     
  1451. ICAAC: Pharmacokinetics of Cobicistat-Boosted Elvitegravir Administered in Combination with Methadone or Buprenorphine/Naloxone - (09/12/12)
     
  1452. ICAAC: GS-7340 Stronger Than TDF in Human Serum, Synergistic With Other ARVs - written by Mark Mascolini - (09/12/12)
     
  1453. ICAAC: Raltegravir Efficacy and Safety Through 3 to 5 Years With HBV or HCV Coinfection - written by Mark Mascolini - (09/12/12)
     
  1454. ICAAC: Resistance Findings on Experimental S/GSK Long-Acting Integrase Inhibitor - written by Mark Mascolini - (09/12/12)
     
  1455. ICAAC: RNA and CD4 Responses, Side Effect Rates, Similar Across Age Groups in Rilpivirine Trials - written by Mark Mascolini - (09/12/12)
     
  1456. ICAAC: Ongoing HIV Infection of CD4s May Explain Poor CD4 Gains With Sub-50 Load - written by Mark Mascolini - (09/12/12)
     
  1457. ICAAC: HIV in Semen of More than 1 in 10 Gay Men With Sub-50 Plasma Load - written by Mark Mascolini - (09/12/12)
     
  1458. ICAAC: Over 10% With Persistent Low-Level Viremia Have Virologic Failure Within Year - written by Mark Mascolini - (09/12/12)
     
  1459. ICAAC: Raltegravir Level at End of Dosing Interval High in Male and Female Genital Tract - written by Mark Mascolini - (09/12/12)
     
  1460. ICAAC: Hospital Admission May Not Signal Poor Healthcare Engagement in DC HIV Group - written by Mark Mascolini - (09/11/12)
     
  1461. ICAAC: Tenofovir Replacing AZT of ABC, Keeping 3TC, Suppresses HBV DNA - written by Mark Mascolini - (09/11/12)
     
  1462. ICAAC: Integrase Inhibitor Dolutegravir First ARV Superior to Efavirenz in ART-Naive - written by Mark Mascolini - (09/11/12)
     
  1463. ICAAC: 4-in-1 Pill With Elvitegravir/Cobicistat Versus Atripla or Atazanavir Regimen - written by Mark Mascolini - (09/11/12)
     
  1464. ICAAC: New gp41 Fusion Inhibitor Has Long Half-Life, Anti-HIV Activity in HIV+ Naïve - written by Mark Mascolini - (09/11/12)
     
  1465. ICAAC: Chart Review Confirms Worse Virologic Response to PIs Than Efavirenz in Women - written by Mark Mascolini - (09/11/12)
     
  1466. ICAAC: Bone Markers Improve After Switch From TDF/FTC to ABC/3TC, While Dropping RTV - written by Mark Mascolini - (09/11/12)
     
  1467. ICAAC: Blacks Have 50% Lower Chance of HIV Control Than Nonblacks in 6-Study Analysis - written by Mark Mascolini - (09/11/12)
     
  1468. ICAAC: MK-1439, a New NNRTI, Has Good Resistance Profile in Cell Studies - written by Mark Mascolini - (09/11/12)
     
  1469. ICAAC: Low-Grade Proteinuria in German HIV Group Tied to Tenofovir, ART Duration - written by Mark Mascolini - (09/11/12)
     
  1470. ICAAC: Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients - (09/11/12)
     
  1471. ICAAC: Renal Safety Profile of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) and of Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF in HIV Patients - (09/11/12)
     
  1472. ICAAC: Cobicistat Does Not Affect the In Vitro Renal Transport or Cytotoxicity of Tenofovir - (09/11/12)
     
  1473. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Patients ≥50 Years - (09/11/12)
     
  1474. ICAAC: Gender Stratification Analysis of HIV-1 Infected Patients Receiving Atazanavir (ATV) Compared to ATV/Ritonavir (RTV), Each in Combination With Abacavir/Lamivudine (ABC/3TC), After Initial Suppression With ABC/3TC + ATV/RTV Through 144 Weeks on Therapy - (09/11/12)
     
  1475. ICAAC: Prevalence of HLA-B*5701 Allele in HIV-Infected Subjects in North America and Reductions in Risk for Development of Abacavir Associated Hypersensitivity Reaction - (09/11/12)
     
  1476. ICAAC: Safety & Efficacy of Raltegravir Over 3-5 Years in Patients Co-infected With HIV and Hepatitis B and/or C Virus - (09/11/12)
     
  1477. ICAAC: Comparison of In-Hospital Mortality From Acute Myocardial Infarction in HIV Sero-Positive Versus Sero-Negative Individuals - (09/11/12)
     
  1478. ICAAC: In-Hospital Mortality from Acute Myocardial Infarction: HIV Seropositive vs. Seronegative Individuals - (09/10/12)
     
  1479. ICAAC: Antiviral Characteristics Of S/GSK1265744, An HIV Integrase Inhibitor (INI) Dosed By Oral Or Long-acting Parenteral Injection....once monthly or 3 months dosing/PrEP/HAART - (09/10/12)
     
  1480. ICAAC: Integrated Week 48 Analysis of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF - (09/10/12)
     
  1481. ICAAC: Switching to the Single-Tablet Regimen (STR) Emtricitabine / Rilpivirine / Tenofovir DF from a Ritonavir-boosted Protease Inhibitor & 2 NRTI Regimen Maintains HIV Suppression and is Well Tolerated in HIV+ Subjects at Week 24 Regardless of Age: SPIRIT Study - (09/10/12)
     
  1482. ICAAC: Simplification to Abacavir/Lamivudine + Atazanavir from Tenofovir/Emtricitabine + Atazanavir/Ritonavir Maintains Viral Suppression and Improves Bone Biomarkers - (09/10/12)
     
  1483. ICAAC: Antiviral Activity and In Vitro Mutation Development Pathways of MK-1439: A Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) - (09/10/12)
     
  1484. ICAAC: Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467) - (09/10/12)
     
  1485. ICAAC: Osteopenia/Osteoporosis Linked to Age and BMI, But Not TDF, in French Cohort - Written by Mark Mascolini - (09/09/12)
     
  1486. ICAAC: Poorly Controlled HIV Infection Raises Risk of Pneumococcal Disease in French Study - Written by Mark Mascolini - (09/09/12)
     
  1487. ICAAC: In-Hospital Mortality With Acute MI Higher With Than Without HIV - Written by Mark Mascolini - (09/09/12)
     
  1488. ICAAC: Partial or No Antiretroviral Adherence Raises Chance of Hospital Stay 50% in US Study - Written by Mark Mascolini - (09/09/12)
     
  1489. ICAAC: Late Catheterization and Significant Coronary Artery Disease in US HIV Group - Written by Mark Mascolini - (09/09/12)
     
  1490. IAC: HIV Treatment 19th International AIDS Conference July 22-27, 2012 Washington, D.C. - written by Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (09/09/12)
     
  1491. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects - (09/07/12)
     
  1492. U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 - (09/07/12)
     
  1493. IAC: Effects of Raltegravir (RAL) Combined with Tenofovir (TDF) and Emtricitabine (FTC) on Body Shape, Bone Density and Lipids in HIV+ African-Americans Initiating Therapy: Metabolic Outcomes of The UNC-REAL Study - (09/04/12)
     
  1494. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Incidence of hypertriglyceridemic waist (HTW) phenotype in a randomized prospective trial comparing atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive HIV-1 infected subjects, a sub-study of CASTLE - (09/03/12)
     
  1495. IAC: Metabolics/Inflammation and Such At IAC - written by David Alain Wohl, MD - The University of North Carolina (09/03/12)
     
  1496. IAC: Obese HIV-infected Persons have Higher Levels of Select Inflammatory Markers and Co-Morbid Illnesses - (09/03/12)
     
  1497. IAC: Unexpected Complications: High 30 Day Readmission Rates among Persons Living with HIV - (09/03/12)
     
  1498. IAC: Non-AIDS, AIDS events and death in a cohort of antiretroviral naïve HIV-infected patients with a CD4 T cell count above 500 cells/mm3 in Barcelona, Spain: nadir CD4 <350 & detectable viral load predict non-AIDS events: cancers/cardiovascular/neuropsych/liver/end-stage renal; "data suggest earlier ART could prevent nonAIDS events in viral controllers" - (09/03/12)
     
  1499. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic: increasing incidence rate among HIV+ MSM - (08/30/12)
     
  1500. IAC: New Agents for the Treatment of HIV-1: Is the pipeline opening up? - written by Joe Eron, MD University of North Carolina - (08/27/12)
     
  1501. Detectable Viral Load Aggravates Immunosenescence Features of CD8 T-Cell Subsets in Vertically HIV-Infected Children - (08/23/12)
     
  1502. Racial/Ethnic Disparities in ART Adherence in the United States: Findings From the MACH14 Study - (08/23/12)
     
  1503. Osteonecrosis of Jaw & Bone Drug Bisphosphonate Triggered by Dental Work - (08/21/12)
     
  1504. IAC: Type 2 diabetes is associated with lower cognitive performances in a cohort of HIV-infected patients. ANRS CO3 Aquitaine Cohort, Bordeaux, France, 2007-2009 - (08/20/12)
     
  1505. IAC: Severity of Illness and Fracture Risk: risk factors in HIV for bone fracture in Veterans & Aging Cohort/Men - (08/20/12)
     
  1506. IAC: Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy (ART): AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (08/20/12)
     
  1507. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Renal function improves with long-term telbivudine therapy in patients with chronic hepatitis B Analysis of the Clinical data Base - (08/20/12)
     
  1508. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Increased Risk of Serious non-AIDS defining Events and Mortality among Immunological Non-Responders to Antiretroviral Therapy - (08/20/12)
     
  1509. Pathogenesis of HIV in the Central Nervous System: Cognitive impairment persists despite effective cART - (08/20/12)
     
  1510. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors - (08/20/12)
     
  1511. Green Tea/Dark Choc NeuroProtective??: Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway - (08/20/12)
     
  1512. IAC: Effect of Second Generation Antipsychotics on Metabolic Variables in HIV-infected Adults on Long Term Antiretroviral Therapy - (08/17/12)
     
  1513. IAC: Very Early Initiation of Combination Antiviral Therapy Results in Normalization of Markers of Immune Activation - (08/17/12)
     
  1514. Exercise Reduces Inflammation Markers CRP & IL-6 - new study - (08/17/12)
     
  1515. IAC: Co-Morbidities Report from 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV and XIX International AIDS Conference -Written by Todd Brown, MD, PhD Associate Professor of Medicine and Epidemiolog Johns Hopkins University - (08/17/12)
     
  1516. IAC: Carotid artery intima-media thickness and coronary artery calcium progress in HIV-infected participants over 6 years of follow-up - (08/15/12)
     
  1517. IAC: Incidence and clinical features of cerebrovascular events in HIV-infected adults in the Southeastern United States - (08/15/12)
     
  1518. IAC: HIV & Black MSM - (08/14/12)
     
  1519. IAC: Will and Should Women in the U.S. Use PrEP? Findings from a Focus Group Study of At-risk HIV-negative Women in Oakland, Memphis, San Diego, and Washington, DC - (08/13/12)
     
  1520. IAC: Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202 - (08/10/12)
     
  1521. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs - (08/10/12)
     
  1522. Synergistic Effects of HIV Infection and Older Age on Daily Functioning - (08/10/12)
     
  1523. IAC: Trends in Aggregate Plasma HIV RNA Levels at a Public Health HIV/AIDS Clinic in San Francisco from 2001-2011 - (08/09/12)
     
  1524. IAC: Impact of single tablet regimens on the HIV switch market - (08/09/12)
     
  1525. IAC: The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S. - (08/09/12)
     
  1526. IAC: Transmission of HIV-1 Exhibiting Resistance to Protease, Reverse Transcriptase and Integrase Inhibitors in a Previously Documented HIV-1 Negative Patient - (08/08/12)
     
  1527. IAC: CDC Reports: Disparities in Health in HIV: "BLACKS TENDED TO HAVE WORSE CONTINUUM OF CARE COMPARED TO WHITES" - (08/08/12)
     
  1528. IAC: SBI for HIV Diarrhea - (08/08/12)
     
  1529. IAC: Exposure to nucleoside reverse transcriptase inhibitors (NRTIs) induces genotoxicity persistent for up to three years in Erythrocebus patas monkeys - (08/07/12)
     
  1530. Does Perinatal Antiretroviral Therapy Create an Iatrogenic Cancer Risk? Commentary - (08/07/12)
     
  1531. IAC: Low-Dose Aspirin for Activation: Increased platelet activity and immune activation in HIV-positive subjects on antiretroviral therapy is attenuated with low-dose aspirin - (08/06/12)
     
  1532. IAC: HIV Prevention at AIDS 2012 -written Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/06/12)
     
  1533. IAC: International AIDS Society (IAS) Symposium "Towards an HIV Cure" July 20-21 2012 Wash DC - written for NATAP by David Margolis MD, University of North Carolina - (08/06/12)
     
  1534. IAC: Low Level Viral Load Detection in Blood and Mucosal Sites in Elite Controllers and HAART suppressed Women Enrolled in the Women's Interagency HIV (WIHS) Cohort - (08/06/12)
     
  1535. IAC: Similar prevalence of baseline HIV-1 minority variants among responders and virologic failures, as well as increased detection of HIV-1 minority variants at treatment failure, in rilpivirine patients from the ECHO and THRIVE Phase III studies - (08/06/12)
     
  1536. IAC: Prevalence of rilpivirine resistance-associated mutations in US samples received for routine resistance testing - (08/06/12)
     
  1537. IAC: Gender Differences in Virologic Outcomes in a Meta-Analysis of Randomized Controlled Clinical Trials in HIV-1-Infected Patients on Antiretroviral Therapy - 'Women 28% Less Likely to Achieve <50 c/ml' - (08/06/12)
     
  1538. IAC: A Meta-Analysis of the Differences in ART Virologic Failure Rates in Randomized Clinical Trials: Do Blacks Consistently Have Lower ART Efficacy and Poor Treatment Outcomes? - (08/06/12)
     
  1539. IAC: 2 New Studies at IAC Finding 'Functional Cure' - (08/03/12)
     
  1540. IAC: "scientists optimistic about a cure"......argument for treating patients with HAART early" - (08/03/12)
     
  1541. IAC: HCV/HIV Coinfection Higher Rates of Hepatic Decompnsation, Liver Cancer & Severe Liver Events - (08/01/12)
     
  1542. Janssen's HIV Cure Effort: High throughput screening for HIV reactivating compounds - (08/01/12)
     
  1543. IAC: Immune Activation, Inflammation and Complications of HIV 19th IAC 2012: Written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine - (07/31/12)
     
  1544. IAC: IMPAACT P1066: Raltegravir (RAL) safety and efficacy in HIV infected (+) youth 2 to 18 years of age through week 48 - (07/31/12)
     
  1545. IAC: Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-Containing Regimens in HIV-Infected 4 Weeks to <2-Year-Old Children 48-Week Data From Study APV20002 - (07/31/12)
     
  1546. IAC: Evidence of Coronary Vessel Wall Thickening in Asymptomatic Young HIV-Infected Patients Using Non-invasive MRI - (07/31/12)
     
  1547. IAC: Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir-Containing Regimens in HIV-Infected 2 to 18 Year-Old Children (48-Week Data, Study APV29005, a Prospective, Open-label, Multi-centre, 48-Week Cohort Study) - (07/31/12)
     
  1548. IAC: Drug Resistance and Mutational Profile in Fosamprenavir-Treated HIV-Infected Children Aged 2 Months to 18 Years at Start of Therapy - (07/31/12)
     
  1549. IAC: HCV viremia affects immune phenotypes in Elite controllers of HIV infection- A Women's Interagency HIV Study - (07/30/12)
     
  1550. IAC: HIV & Aging Plenary at IAC by Judy Currier: Intersection of Non-Communicable Diseases (comorbidities) and Ageing in HIV - (07/30/12)
     
  1551. IAC: Stroke in human immunodeficiency virus (HIV) infected patients - (07/30/12)
     
  1552. IAC: Slower Time to AIDS and TB in Immediate-Treatment Arm of HPTN 052 - Written by Mark Mascolini - (07/30/12)
     
  1553. IAC: Predictors of HIV Transmission in a US Test-and-Treat Population: 29% in care don't use condoms - Written by Mark Mascolini - (07/30/12)
     
  1554. IAC: Differences in CD4+ T-cell Immune Activation in HIV, Hepatitis C (HCV), and HIV/HCV Coinfection are Influenced by HIV and HCV Infection Status - (07/30/12)
     
  1555. IAC: Incident bone fracture in men with, or at risk for, HIV-infection in the Multicenter AIDS Cohort Study (MACS), 1996-2011 - (07/30/12)
     
  1556. Going door-to-door to fight HIV in Philadelphia - (07/30/12)
     
  1557. IAC: Factors associated with elevated D-dimer levels in HIV-infected individuals: 'viral replication associated with D-dimer' - (07/30/12)
     
  1558. IAC: Gold nanoparticles to improve drug delivery to the CNS: Targeting HIV reservoirs in the brain (raltegravir) - (07/30/12)
     
  1559. IAC: A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12)
     
  1560. IAC: Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results - (07/27/12)
     
  1561. IAC: Comorbidity and ageing with HIV A prospective comparative cohort study - (07/27/12)
     
  1562. IAC: Low Rates of Integrase Resistance for Elvitegravir and Raltegravir through Week 96 in the Phase 3 Clinical Study GS-US-183-0145 - (07/27/12)
     
  1563. IAC: Reduced skeletal muscle mitochondrial function in older HIV-infected men is associated with low aerobic exercise capacity - (07/27/12)
     
  1564. HPV Testing in HIV-Positive Women May Help Reduce Frequent Cervical Cancer Screening - (07/27/12)
     
  1565. AIDS Cure Quest Advances as Cancer Drug Finds Hidden HIV - (07/27/12)
     
  1566. IAC: Survey Challenges Assumptions About Aging With HIV in United States - Written by Mark Mascolini - (07/27/12)
     
  1567. IAC: Aspirin Quiets Platelet and Immune Activation in Antiretroviral Responders - Written by Mark Mascolini - (07/27/12)
     
  1568. IAC: Age at Stroke 15 Years Younger in HIV-Positives vs Negatives in New York City - Written by Mark Mascolini - (07/27/12)
     
  1569. IAC: Non-AIDS Illness Rate Higher in Older HIV-Positives Than in Similar non-HIV Group - Written by Mark Mascolini - (07/27/12)
     
  1570. IAC: Chances of Virologic Response Halved in Blacks vs Nonblacks in ART Trials - Written by Mark Mascolini - (07/27/12)
     
  1571. IAC: Diabetes Linked to Poor Cognitive Function in HIV-Positive Adults - Written by Mark Mascolini - (07/27/12)
     
  1572. IAC: Inflammation Markers Predict AIDS and non-AIDS Disease in ACTG Study - Written by Mark Mascolini - (07/27/12)
     
  1573. IAC: A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12)
     
  1574. IAC: Once-Daily Dolutegravir(DTG; S/GSK1349572) is Non-Inferior to Raltegravir (RAL) in Antiretroviral-naïve Adults. 48 Week results from SPRING-2 (ING113086) - (07/26/12)
     
  1575. IAC: Effect of Early versus Delayed Initiation of Antiretroviral Therapy (ART) on Clinical Outcomes in the HPTN 052 Randomized Clinical Trial - (07/26/12)
     
  1576. IAC: Adding Nitazoxanide to PEG/RBV Does Not Improve SVR With HIV/HCV Genotype 1 - Written by Mark Mascolini - (07/26/12)
     
  1577. IAC: Maraviroc Plus Darunavir Vulnerable With Pretreatment Load Above 100,000? - Written by Mark Mascolini - (07/26/12)
     
  1578. IAC: Good 4-Week Dolutegravir Response in Experienced Adolescents--PKs Comparable to Adults - Written by Mark Mascolini - (07/26/12)
     
  1579. IAC: HIV Prevalence and Risks in a New Generation of US Injection Drug Users - Written by Mark Mascolini - (07/26/12)
     
  1580. IAC: Systematic Review Finds HPV Doubles HIV Risk in Women and Men - Written by Mark Mascolini - (07/26/12)
     
  1581. IAC: Quadrivalent HPV Vaccine Immunogenic in HIV+ Women With CD4s Over 200 - Written by Mark Mascolini - (07/26/12)
     
  1582. IAC: Obesity Linked to Inflammation, cIMT, Low Vitamin D in US HIV Group - Written by Mark Mascolini - (07/26/12)
     
  1583. IAC: Robust Response to Quadrivalent HPV Vaccine in Young HIV-Positive Women - Written by Mark Mascolini - (07/26/12)
     
  1584. IAC: Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/26/12)
     
  1585. IAC: Depression Risk Steers MDs From EFV, But EFV Takers Still Have Higher Depression Rate - Written by Mark Mascolini - (07/26/12)
     
  1586. IAC: Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children, and Adolescents: P1093 - (07/26/12)
     
  1587. IAC: Analysis of Efficacy by Baseline HIV RNA - Week 48 Results from a Phase 3 Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects - (07/26/12)
     
  1588. IAC: Risk of common cancers by age 60 for HIV-infected patients in the United States and Canada - (07/26/12)
     
  1589. Coronary Artery Walls Thicker in Young Adults With Early-Acquired HIV - (07/25/12)
     
  1590. Public health: Towards a cure for HIV - (07/25/12)
     
  1591. Radical Prostatectomy versus Observation for Localized Prostate Cancer - (07/25/12)
     
  1592. Aging and HIV-Related Cognitive Loss - (07/25/12)
     
  1593. Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection - Editorial - (07/25/12)
     
  1594. Arterial Inflammation in Patients With HIV - (07/25/12)
     
  1595. IAC: ART Soon After Infection Yields Normal Immune Activation Markers in Small Study - Written by Mark Mascolini - (07/25/12)
     
  1596. IAC: Timely ART Start Rates Climbing Steadily Across US and Canada - Written by Mark Mascolini - (07/25/12)
     
  1597. IAC: Response to Etravirine Regimen in Experienced Children and Adolescents - Written by Mark Mascolini - (07/25/12)
     
  1598. IAC: Raltegravir Formulations Effective for ART-Experienced Teens and Children - Written by Mark Mascolini - (07/25/12)
     
  1599. IAC: Antiretroviral Treatment of Adult HIV Infection2012 Recommendations of the International Antiviral Society-USA Panel - (07/25/12)
     
  1600. IAC: Long-Term Safety and Efficacy of Raltegravir (RAL)-Based VersusEfavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-1 Infected Patients:Final 5-Year Double-Blind Results from STARTMRK - (07/25/12)
     
  1601. IAC: Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory Analysis of Late Outcomes Based on Early Virologic Response - (07/25/12)
     
  1602. IAC: THE HIV NRTI BMS-986001 DOES NOT DEGRADE MITOCHONDRIAL DNA IN LONG TERM PRIMARY CULTURES OF CELLS ISOLATED FROM HUMAN KIDNEY, MUSCLE AND SUBCUTANEOUS FAT - (07/25/12)
     
  1603. IAC: Activity of the HIV-1 attachment inhibitor BMS-626529 against HIV-1 envelopes resistant to other entry inhibitors - (07/25/12)
     
  1604. IAC: Analysis of Efficacy by Baseline Viral Load: Phase 3 Study Comparing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Week 48 Results - (07/25/12)
     
  1605. IAC: Absence of renal and bone toxicity in non-clinical studies of BMS-986001, a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus (HIV) - (07/25/12)
     
  1606. IAC: Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults - (07/25/12)
     
  1607. IAC: Fractures at Earlier Age in HIV+ Men Versus HIV-Negatives in MACS - Written by Mark Mascolini - (07/24/12)
     
  1608. IAC: PIs, Proton Pump Inhibitors, Stroke Raise Fracture Risk in HIV+ Veterans - Written by Mark Mascolini - (07/24/12)
     
  1609. IAC: Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/24/12)
     
  1610. IAC: Observational Studies Confirm Preventive Impact of ART in HIV-Discordant Couples: transmission rate cut by 98% when CD4>350 - Written by Mark Mascolini - (07/24/12)
     
  1611. IAC: Antiretroviral-Treated People in HPTN 052 Start Having Safer Sex - Written by Mark Mascolini - (07/24/12)
     
  1612. IAC: Poor CD4 Responders Have Almost Doubled Risk of Non-AIDS Disease - Written by Mark Mascolini - (07/24/12)
     
  1613. IAC: CD4 Count Under 700 Linked to All-Cause Mortality in Veterans Cohort - Written by Mark Mascolini - (07/24/12)
     
  1614. IAC: Hospital Readmission Rate in HIV Group 44% Higher Than in US Population - Written by Mark Mascolini - (07/24/12)
     
  1615. IAC: Maraviroc vs TDF/FTC + Reyataz/r - Written by Mark Mascolini - (07/24/12)
     
  1616. IAC: Cobicistat Noninferior to Ritonavir as Atazanavir Booster at 48 Weeks - Written by Mark Mascolini - (07/24/12)
     
  1617. IAC: Switch From Boosted PI to Single-Tablet Rilpivirine/TDF/FTC Maintains Suppression - Written by Mark Mascolini - (07/24/12)
     
  1618. IAC: Elvitegravir Noninferior to Raltegravir at Week 96 in Treatment-Experienced - Written by Mark Mascolini - (07/24/12)
     
  1619. IAC: Efficacy and Safety Results from a Randomized, Double-Blind, Active-Controlled Trial of Elvitegravir (Once-Daily) vs. Raltegravir (Twice-Daily) in Treatment-Experienced HIV-Infected Patients: Long Term 96-Week Data - (07/24/12)
     
  1620. IAC: Cobicistat versus Ritonavir as Pharmacoenhancers in Combination with Atazanavir Plus Tenofovir DF/Emtricitabine: Phase 3 Randomized, Double Blind, Active-Controlled Trial, Week 48 Results - (07/24/12)
     
  1621. IAC: SPIRIT Study: Switching boosted PI to Rilpivirine In Combination with Truvada as a Single-Tablet Regimen Week 24 Results (07/24/12)
     
  1622. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Estimated Glomerular Filtration Rates (eGFR) through 144 Weeks on Therapy in HIV-infected Subjects Receiving Atazanavir/ Ritonavir and Abacavir/Lamivudine or Simplified to Unboosted Atazanavir/Abacavir/Lamivudine - (07/23/12)
     
  1623. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Effects on post-prandial lipids and arterial stiffness of atazanavir/ritonavir versus darunavir/ritonavir in HIV-uninfected adults - (07/23/12)
     
  1624. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Skeletal muscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults - (07/23/12)
     
  1625. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: The Impact of Raltegravir and Lopinavir/ritonavir on lipid subfractions, vascular and inflammatory markers in HIV Negative Subjects - (07/23/12)
     
  1626. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: SPIRIT Study: Switching boosted PI to Rilpivirine In-combination with Truvada as a Single-Tablet Regimen Week 24 Results - (07/23/12)
     
  1627. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Predicting Risk of Cancer During HIV Infection: The Role of Inflammatory and Coagulation Biomarkers - (07/23/12)
     
  1628. NIH to test maraviroc-based drug regimens for HIV prevention - (07/19/12)
     
  1629. The Ethics of Switch/Simplify in Antiretroviral Trials: Non-Inferior or Just Inferior? - (07/19/12)
     
  1630. Physical Activity Is the Key Determinant of Skeletal Muscle Mitochondrial Function in Type 2 Diabetes - 'exercise reversed mitochondrial dysfynction in diabetics'....so perhaps exercise would reverse mitochondrial dysfunction in HIV+: from Jules - (07/17/12)
     
  1631. FDA Approves First Medication Truvada to Reduce HIV Risk - (07/17/12)
     
  1632. Exercise Improves The Brain - How HIV Causes Brain Damage - (07/16/12)
     
  1633. Chronic Anxiety Speeds Aging - (07/16/12)
     
  1634. Bringing HIV Out Of Hiding - new HIV cure research - (07/16/12)
     
  1635. Potential cause of HIV-associated dementia revealed - (07/13/12)
     
  1636. How HIV Affects the Brain-new study: Human Immunodeficiency Virus Type 1 Alters Brain-Derived Neurotrophic Factor Processing in Neurons - (07/12/12)
     
  1637. Herpes Zoster among Persons Living with HIV in the Current ART Era - (07/12/12)
     
  1638. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana - (07/12/12)
     
  1639. 3 Newly Published PrEP Studies: Preexposure Prophylaxis for HIV Infection among African Women - (07/12/12)
     
  1640. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women - (07/12/12)
     
  1641. Preexposure Prophylaxis Case Studies for HIV Prevention - (07/12/12)
     
  1642. Preexposure Prophylaxis for HIV (PrEP)- Where Do We Go from Here? Editorial - (07/12/12)
     
  1643. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients - "routine screening for insulin resistance among co-infected persons may be warranted" - (07/10/12)
     
  1644. The rising challenge of Non-AIDS Defining Cancers in HIV-infected patients - (07/10/12)
     
  1645. New Zinc-Therapy Gene Therapy: Targeted gene knockout by direct delivery of zinc-finger nuclease proteins - (07/10/12)
     
  1646. Vitamin D - Baseline Status and Effective Dose - Editorial - (07/9/12)
     
  1647. Carotid Intima-Media Thickness (IMT) Among Human Immunodeficiency Virus-Infected Patients Without Coronary Calcium: subclinical heart disease in HIV+ - (07/9/12)
     
  1648. Comparison of Ischemic Stroke Incidence in HIV-Infected and Non-HIV-Infected Patients in a US Health Care System - (07/9/12)
     
  1649. Therapeutic strategies for the eradication of persistent viral reservoirs.... - (07/9/12)
     
  1650. Time to Initiate Antiretroviral Therapy Between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-Infected Patients: Results From the TIME Study - (07/9/12)
     
  1651. Use of Highly Active Antiretroviral Therapy Is Associated With Lower Prevalence of Anal Intraepithelial Neoplastic Lesions and Lower Prevalence of Human Papillomavirus in HIV-Infected Men Who Have Sex With Men - (07/9/12)
     
  1652. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals - (07/9/12)
     
  1653. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl - (07/9/12)
     
  1654. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals - (07/9/12)
     
  1655. HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group - (06/27/12)
     
  1656. A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model: 'functional cure?' - (06/25/12)
     
  1657. Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection : functional cure - (06/27/12)
     
  1658. TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 - (06/27/12)
     
  1659. Researchers identify cervical cells most susceptible to HPV infection - (06/27/12)
     
  1660. Gilead HIV Eradication Program - (06/27/12)
     
  1661. Intl Wksp HIV/Hep Drug Resist: Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance associated variants at baseline (part II) (06/26/12)
     
  1662. Intl Wksp HIV/Hep Drug Resist: Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline (06/26/12)
     
  1663. Immunosenescence and HIV - (06/25/12)
     
  1664. Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection - (06/21/12)
     
  1665. Bone Loss in Young HIV+ Men 'Lifestyle Risk' - (06/20/12)
     
  1666. Intl Wksp HIV/Hep Drug Resist: Jak inhibitors exhibit a novel mechanism of HIV inhibition in primary human and rhesus macaque macrophages and lymphocytes: 'functional cure?' (06/20/12)
     
  1667. Intl Wksp HIV/Hep Drug Resist: Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 2nd Report, June 5-9 2012 Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada (06/20/12)
     
  1668. 1st Report - Intl Wksp HIV/Hep Drug Resist: Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 5-9 June 2012, Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada (06/19/12)
     
  1669. Diagnoses of HIV Infection Among Hispanics/Latinos in 40 States and Puerto Rico, 2006-2009 - (06/19/12)
     
  1670. Mitochondrial Evolution in HIV-Infected Children Receiving First- or Second-Generation Nucleoside Analogues - (06/19/12)
     
  1671. A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults - (06/19/12)
     
  1672. Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies- Review - (06/14/12)
     
  1673. Intl Wksp HIV/Hep Drug Resist: Reverse transcriptase connection-domain mutations were not associated with virologic failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (Week 96 analysis) (06/18/12)
     
  1674. Intl Wksp HIV/Hep Drug Resist: Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials (06/18/12)
     
  1675. Intl Wksp HIV/Hep Drug Resist: Integrated Analysis of Emergent Drug Resistance from the HIV-1 Phase 3 QUAD Studies through Week 48 (06/18/12)
     
  1676. Intl Wksp HIV/Hep Drug Resist: Effect of Primary Elvitegravir Resistance Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness (06/18/12)
     
  1677. Intl Wksp HIV/Hep Drug Resist: Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 (06/15/12)
     
  1678. Intl Wksp HIV/Hep Drug Resist: The in vitro cross-resistance profile of the NRTI BMS-986001 against known NRTI resistance mutations (06/15/12)
     
  1679. Intl Wksp HIV/Hep Drug Resist: Resistance and Potency of GS-7340, a Next-Generation Tenofovir Prodrug (06/15/12)
     
  1680. Intl Wksp HIV/Hep Drug Resist: Switching the NNRTI or the PI/r to Maraviroc in Aviremic Subjects Infected with RS HIV by V3 Loop Population Sequencing: 48 week, Prospective, Controlled, Pilot Study (06/15/12)
     
  1681. Intl Wksp HIV/Hep Drug Resist: Combinations of Primary and Secondary Integrase Mutations in the VIKING Pilot Study: Effects on and Rationale for Dolutegravir Dissociation (06/15/12)
     
  1682. Intl Wksp HIV/Hep Drug Resist: Dolutegravir Treatment of HIV Subjects With Raltegravir Resistance: Integrase Resistance Evolution in Cohort II of the VIKING Study (06/15/12)
     
  1683. Intl Wksp HIV/Hep Drug Resist: High Barrier to Resistance for Dolutegravir (DTG, S/GSK1349572) Against Raltegravir-Resistant Y143 Mutants: An In Vitro Passage Study (06/15/12)
     
  1684. Traces Of Virus In Man Cured Of HIV Trigger Scientific Debate - (06/13/12)
     
  1685. Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial - (06/13/12)
     
  1686. The Berlin Patient: New Research Presented at the HIV Resistance Workshop in Sitges, Spain Two Days Ago - (06/12/12)
     
  1687. Evidence That Man Cured of HIV Harbors Viral Remnants Triggers Confusion - Commentary Science Mag - (06/12/12)
     
  1688. The Critical Role of Metabolic Pathways in Aging - (06/12/12)
     
  1689. Guidelines Ease Up on Glycemic Control for Some Patients With Type 2 Diabetes - (06/12/12)
     
  1690. 13th Intrntl Wrkshp Clinical Pharm HIV: Differential Exposure of Raltegravir Throughout Gut---associated Lymphoid Tissue: "High concentrations of raltegravir within GALT.......Raltegravir may be useful for combination with eradication strategies" - (06/12/12)
     
  1691. The Rates of HIV Superinfection and Primary HIV Incidence in a General Population in Rakai, Uganda - (06/08/12)
     
  1692. Number of Cancer Cases Worldwide Could Go Up by 75% by 2030, New Study in The Lancet Reports: "Cancer is set to become a major cause of morbidity and mortality in the coming decades in every region of the world" - (06/05/12)
     
  1693. (PrEP/PEP) Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence - (06/03/12)
     
  1694. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis: "HBV, HCV, HPV, and H pylori were together responsible for 1·9 million cases worldwide" - (06/05/12)
     
  1695. Mortality Due to HCV-Related Disease in HIV+ - (06/03/12)
     
  1696. Calcium supplements: bad for the heart? Editorial - (06/01/12)
     
  1697. HCV Sustained Viral Response in HIV Coinfected Reduces Non-Liver Related Mortality & Liver-Related Disease: cancers/CVD - (06/01/12)
     
  1698. Bispohosphonates Bone Therapy: duration of therapy; new study on atypical femoral fracture risk, commentary - (05/23/12)
     
  1699. PrEP FDA Hearing May 10 2012: US HIV Epidemiology & Risk, Susan Buchbinder MD SF Dept of Public Health, UCSF - (05/23/12)
     
  1700. Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants? Editorial - (05/23/12)
     
  1701. Effects of Contemporary ART Regimens on Inflammatory Markers - (05/23/12)
     
  1702. Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir - (05/23/12)
     
  1703. Glitazones & Bladder Cancer - (05/23/12)
     
  1704. 13th Intrntl Wrkshp Clinical Pharm HIV: Population Pharmacokinetics of Cobicistat-Boosted Elvitegravir in Adult Healthy Subjects and HIV-infected Patients - (04/21/12)
     
  1705. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of Elvitegravir and Cobicistat in Subjects with Severe Renal Impairment - (04/21/12)
     
  1706. 13th Intrntl Wrkshp Clinical Pharm HIV: Safety/Tolerability, Pharmacokinetics, and Boosting of Twice-daily Cobicistat Administered Alone or in Combination with Darunavir or Tipranavir - (04/21/12)
     
  1707. 13th Intrntl Wrkshp Clinical Pharm HIV: Lack of Clinically Relevant Drug Interactions Between GS-7340 and Efavirenz - (04/21/12)
     
  1708. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics, Safety, and Tolerability of the HIV Integrase Inhibitor Dolutegravir Co-Administered with Rifabutin in Healthy Subjects - (04/21/12)
     
  1709. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-Elvitegravir with Atazanavir, Rosuvastatin or Rifabutin - (04/21/12)
     
  1710. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of a Novel EVG/COBI/FTC/GS-7340 Single Tablet Regimen - (04/21/12)
     
  1711. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine Has No Effect on the Pharmacokinetics of S/GSK1265744, a Novel HIV Integrase Inhibitor - (04/21/12)
     
  1712. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of EVG/COBI/FTC/TDF Single Tablet Regimen following Treatment with EFV/FTC/TDF (Atripla) in Healthy Subjects - (04/21/12)
     
  1713. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with Hepatic Impairment - (04/18/12)
     
  1714. 13th Intrntl Wrkshp Clinical Pharm HIV: Metabolism & Drug-Drug Interaction Profile of Dolutegravir (DTG, S/GSK1349572) - (04/21/12)
     
  1715. Bisphosphonates for Osteoporosis - Where Do We Go from Here?/Duration of Therapy - Perspective - (05/17/12)
     
  1716. Doubt Cast on the 'Good' in 'Good Cholesterol' - 2 Lancet articles below - (05/17/12)
     
  1717. Statins benefit those at much lower CV risk - 2 Lancet articles below - (05/17/12)
     
  1718. PrEP Truvada/2nd Generation; FDA Advisors Endorse Truvada PrEP--But Big Questions Remain - (05/16/12)
     
  1719. HIV Linked to Risk of Sudden Cardiac Death - (05/15/12)
     
  1720. A New Equation to Estimate Glomerular Filtration Rate - (05/15/12)
     
  1721. FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV - (05/15/12)
     
  1722. Intermittent Prophylaxis with Oral (Gel) Truvada Protects Macaques from Rectal SHIV Infection - (05/15/12)
     
  1723. 13th Intrntl Wrkshp Clinical Pharm HIV: Clinical Pharmacology at the 13th Workshop on Clinical Pharmacology of HIV Therapy - Courtney V. Fletcher, Pharm.D. - (05/14/12)
     
  1724. CROI: INTRAVAGINAL RING DELIVERY OF THE PYRIMIDINEDIONE IQP-0528 RESULTS IN PROTECTIVE CONCENTRATIONS IN VAGINAL BIOPSIES OF PIGTAILED MACAQUES - NOVEL MODELS TO ASSESS PK/PD - (04/14/12)
     
  1725. CROI: Intermittent Oral PrEP with Truvada Prevents Vaginal SHIV Transmission in Macaques - (04/14/12)
     
  1726. CROI: Safety, Acceptability and Pharmacokinetic Assessment (Adherence) of Monthly Dapivirine Vaginal Microbicide Rings (Ring-004) for HIV Prevention - (04/14/12)
     
  1727. CROI: Next/2nd Generation PrEP for Men & Women: intravaginal rings, injectables, long-acting, rectal gel, intermittent PrEP - (04/14/12)
     
  1728. FDA Advisors Vote Overwhelmingly to Recommend Truvada for PrEP written by Mark Mascolini - (05/11/12)
     
  1729. FDA Offers Generally Favorable Review of Truvada for PrEP written by Mark Mascolini - (05/10/12)
     
  1730. How Working the Muscles May Boost Brainpower - (05/09/12)
     
  1731. Rapid HIV tests: from meta-analysis to field application - (05/09/12)
     
  1732. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis - (05/09/12)
     
  1733. Premature Aging with HIV Infection: More Evidence AIDS - (05/09/12)
     
  1734. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial - (05/09/12)
     
  1735. Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir? - (05/07/12)
     
  1736. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus - (05/07/12)
     
  1737. HIV & Sleep Disturbances - (05/04/12)
     
  1738. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges - Editorial - (05/04/12)
     
  1739. Prevalence and Factors Associated With Sleep Disturbances Among Early-Treated HIV-Infected Persons: 'Forty-six percent of HIV-infected persons had insomnia, 38% in HIV-unifected, no statistical difference found' - (05/04/12)
     
  1740. Combination Treatment (metformin, rosi, lifestyle intervetion) New Study- For Diabetic Kids - (05/04/12)
     
  1741. TODAY - A Stark Glimpse of Tomorrow, Editorial Combination Therapy for Diabetes for Kids - (05/04/12)
     
  1742. HIV as an independent risk factor for incident lung cancer - (05/04/12)
     
  1743. 13th Intrntl Wrkshp Clinical Pharm HIV: Twice-Daily Cobicistat Effect Differs With Darunavir and Tipranavir - written by Mark Mascolini - (04/25/12)
     
  1744. 13th Intrntl Wrkshp Clinical Pharm HIV: Efavirenz PKs Highly Variable and Driven by CYP2B6 Genotype in Youngsters - written by Mark Mascolini - (04/25/12)
     
  1745. 13th Intrntl Wrkshp Clinical Pharm HIV: Switching to QUAD After Atripla Has No Telling Impact on Elvitegravir Levels - written by Mark Mascolini - (04/25/12)
     
  1746. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine Levels 25% Lower With HCV Protease Inhibitor Boceprevir - written by Mark Mascolini - (04/18/12)
     
  1747. 13th Intrntl Wrkshp Clinical Pharm HIV: Lack of a clinically significant drug interaction between BMS-663068, a novel HIV-1 attachment inhibitor, and tenofovir disoproxil fumarate when administered in combination at steady state - written by Mark Mascolini - (04/18/12)
     
  1748. 13th Intrntl Wrkshp Clinical Pharm HIV: Cobicistat Doubles to Triples Exposure of GS-7340 (a Tenofovir Prodrug) and Resulting Tenofovir - written by Mark Mascolini - (04/18/12)
     
  1749. 13th Intrntl Wrkshp Clinical Pharm HIV: Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -1 - (04/18/12)
     
  1750. 13th Intrntl Wrkshp Clinical Pharm HIV: Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -2 - (04/18/12)
     
  1751. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine With 300/100 or 400/100 mg of ATV/r in Treatment-Experienced People - written by Mark Mascolini - (04/18/12)
     
  1752. 13th Intrntl Wrkshp Clinical Pharm HIV: Darunavir/Cobicistat Formulation Yields Darunavir Level Close to Darunavir/Ritonavir - written by Mark Mascolini - (04/18/12)
     
  1753. 13th Intrntl Wrkshp Clinical Pharm HIV: No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine - written by Mark Mascolini - (04/18/12)
     
  1754. HIV Raises Anal Cancer Risk in Women: "High Prevalence of High Grade Anal Intraepithelial Neoplasia in HIV-infected Women Screened for Anal Cancer".... "Given the high rate of high grade AIN in screened HIV-infected women, as well as an aging population of HIV-infected patients, measures to increase routine AC screening should be strongly considered" - (04/17/12)
     
  1755. 13th Intrntl Wrkshp Clinical Pharm HIV: Raltegravir 400 mg Once Daily With Atazanavir/Ritonavir Plus 2 NRTIs - written by Mark Mascolini - (04/17/12)
     
  1756. 13th Intrntl Wrkshp Clinical Pharm HIV: Injected Rilpivirine for PrEP Stays in Plasma for 84 Days in Women and Men - written by Mark Mascolini - (04/17/12)
     
  1757. 13th Intrntl Wrkshp Clinical Pharm HIV: Rifabutin Cuts Elvitegravir Levels, But No Critical Elvitegravir Interactions With Atazanavir or Rosuvastatin - written by Mark Mascolini - (04/17/12)
     
  1758. 13th Intrntl Wrkshp Clinical Pharm HIV: Impact of Atazanavir/Ritonavir on Antifungal Depends on CYP2C19 Genotype - written by Mark Mascolini - (04/17/12)
     
  1759. 13th Intrntl Wrkshp Clinical Pharm HIV: Drug Interactions With Integrase Inhibitor Dolutegravir Identified - written by Mark Mascolini - (04/17/12)
     
  1760. 13th Intrntl Wrkshp Clinical Pharm HIV: Good Virologic Response in 10-Day Study of Festinavir, a New NRTI - written by Mark Mascolini - (04/17/12)
     
  1761. 13th Intrntl Wrkshp Clinical Pharm HIV: Efavirenz Concentrations Do Not Signal Discontinuation in Swiss Study - written by Mark Mascolini - (04/17/12)
     
  1762. CROI: Brain tCho/Cr is Elevated in Acute HIV within the First Month of Infection: 'brain inflammation in acute infection/immediate HAART may normalize or improve inflammation or perhaps prevent damage' - (04/16/12)
     
  1763. CROI: Mortality in Patients with Well Controlled HIV and High CD4 Counts in the Continuous ART Arms of the SMART and ESPRIT Trials Compared to the General Population - (03/16/12)
     
  1764. CROI: Distribution of age at death and effects of immunosuppression and ART duration vary according to cause of death in HIV-1 positive people - (03/16/12)
     
  1765. HIV Suppressed, Cd4s Increased with New Stem Cell Based Gene Therapy in Mice - (04/16/12)
     
  1766. Prevent Drug Craving and Relapse: A Memory Retrieval-Extinction Procedure - New Published Research - (04/16/12)
     
  1767. CROI: Earlier Initiation of Antiretroviral Therapy Results in Better Neurocognitive Functioning - (04/13/12)
     
  1768. CROI: Signs of Peripheral Neuropathy Associate with Elevated Inflammatory Biomarkers in Blood and Cerebrospinal Fluid in Primary HIV Infection - (04/13/12)
     
  1769. CROI: Older Subjects with HIV Infection Have increased Memory Deficit Compared to Younger Subjects - (04/13/12)
     
  1770. CROI: Cancer Stage, Age at Diagnosis and Survival Comparing HIV(+) and HIV(-) Individuals with Common Non-AIDS-Defining Cancers - (04/11/12)
     
  1771. CROI: DISPARITIES IN RATES OF HIV TREATMENT INITIATION AND VIRAL LOAD SUPPRESSION ACROSS U.S. STATES, 2001-2007 - (04/11/12)
     
  1772. CROI: Early Missed Office Visits Post-HIV Diagnosis and Mortality in a Large Healthcare System - (04/11/12)
     
  1773. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men - (04/11/12)
     
  1774. Should statins be used in primary prevention? - (04/11/12)
     
  1775. Predicting and Preventing Cardiovascular Disease in HIV-Infected Patients Perspective - (04/10/12)
     
  1776. Flavonoids- Apple A Day Improves Brain(prevent Parkinsons) & Orange A Day Improves Inflammation-CVD - (04/10/12)
     
  1777. HIV and Aging (Developing World/Africa)- Preparing for the Challenges Ahead - Perspective - (04/05/12)
     
  1778. CROI: Mutation Y188L of HIV-1 Reverse Transcriptase is Strongly Associated with Reduced Susceptibility to Rilpivirine - (04/05/12)
     
  1779. CROI: HIV Infection Is Associated with Greater Amounts of Non-Calcified Coronary Artery Plaque: the Multicenter AIDS Cohort Study (MACS) - (04/04/11)
     
  1780. The Association of Race, Sociodemographic, and Behavioral Characteristics With Response to Highly Active Antiretroviral Therapy in Women: 'depression, black/latino women, HAART discontinuation, higher death rates, drug use all related' - (04/03/12)
     
  1781. Comparison of risk-assessment strategies favors "statins for all" - (04/03/12)
     
  1782. CROI: CROI 2012: "The Long & Winding Road of HIV Complications" - (04/04/12)
     
  1783. CROI: Metabolics, Inflammation, Complications, and Aging at CROI - written by David Alain Wohl, MD - The University of North Carolina - (04/03/12)
     
  1784. CROI: Intima Media Thickness Is Associated with Residual Plasma Viremia in Treated Patients with Controlled HIV Infection - (04/03/12)
     
  1785. CROI: Higher Levels of Interleukin-6 and Soluble Tumor Necrosis Factor-Alpha Receptor I are Associated with Increased Coronary Atherosclerotic Plaque in the Multicenter AIDS Cohort Study (MACS) - (04/03/12)
     
  1786. CROI: Progression of Atherosclerosis: Understanding RAGE (Receptor for Advanced Glycation Endproducts): NWCS 332 - (04/03/12)
     
  1787. CROI: The Association of Race with Death from AIDS in Continuous HAART Users in the Women's Interagency HIV Study (WIHS): Being Black, death, depression, history of illicit drug use & non-adherence are all associated - (04/03/12)
     
  1788. CROI: Rate and Predictors of Carotid Intima Media Thickness Progression in ARV-Naïve HIV-Infected and Uninfected Adults: A 48-Week Prospective Matched Cohort - (04/02/12)
     
  1789. CROI: Ultrasonographic Measures of Cardiovascular Disease Risk in a Modern Cohort of Antiretroviral Treatment (ART)-Naïve Individuals with HIV Infection: Baseline Results from ACTG Study 5260s - (04/02/12)
     
  1790. CROI: Subclinical Carotid Atherosclerosis Is Related to HIV Infection and Low Adherence to a Mediterranean Diet - (04/02/12)
     
  1791. CROI: Comprehensive Cardiac Magnetic Resonance Reveals HIV is Associated with a High Burden of Myocardial Disease - (04/02/12)
     
  1792. CROI: D:A:D Sees No Link Between Atazanavir and Myocardial Infarction or Stroke - (03/30/12)
     
  1793. CROI: Kidney Function in D:A:D With TDF, ATV, and LPV - (03/30/12)
     
  1794. Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267 - (03/30/12)
     
  1795. Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial - (03/30/12)
     
  1796. NEW HIV Guidelines Recommends HAART When CD4 >500 (BIII: moderate recommendation based on expert opinion) & Aging UPDATE.... - (03/30/12)
     
  1797. Women & HIV: Medical Care for Menopausal and Older Women With HIV Infection - (03/29/12)
     
  1798. Women & HIV: Testosterone & HIV+ Women - adverse events - (03/29/12)
     
  1799. Women & HIV: Gender Gap in CVD: The Epidemiology of Cardiovascular Disease in Postmenopausal Women-see article below - (03/29/12)
     
  1800. Women & HIV: Sex Differences in the Pharmacologic Effects of Antiretroviral Drugs: Potential Roles of Drug Transporters and Phase 1 and 2 Metabolizing Enzymes - (03/29/12)
     
  1801. Women & HIV: Women & HIV: Black Women in USA; trauma; childhood sex abuse; heart disease in HIV+ women - (03/29/12)
     
  1802. Women & HIV: Heart Disease & Women HIV+, inflammation: Obesity and Dyslipidemia in Behaviorally HIV-Infected Young Women: Adolescent Trials Network Study 021 - (03/29/12)
     
  1803. Women & HIV: Gender differences in the treatment of HIV infection - review - (03/29/12)
     
  1804. In this trial, temporary cART during PHI was found to transiently lower the viral set point and defer the restart of cART during chronic HIV infection. - (03/28/12)
     
  1805. Starting HAART Reduces Endothelial Dysfunction Marker ADMA. ADMA higher levels is associated with CVD & mortality in general population..... - (03/28/12)
     
  1806. New Monoclonal Antibody Lowers LDL: Biologic Wows for Lipid Lowering - (03/28/12)
     
  1807. Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol - (03/28/12)
     
  1808. CROI: Comparison of Gut-Associated Lymphoid Tissue HIV RNA and DNA Levels in HIV-infected Controllers, Non-controllers, and HAART-suppressed Individuals: 'Untreated non-controllers have reservoir....lymphoid tissues are an active reservoir of HIV in controllers.....treatment should be considered for these individuals' - (03/28/12)
     
  1809. CROI: Hyperparathyroidism Associated with Vitamin D Deficiency in HIV-Infected Adults - (03/28/12)
     
  1810. CROI: Clinical Pharmacology at CROI 2012 PrEP, HCV, Cure(residual replication in reservoirs), TB-dolutegravir, orally inhaled steroids, GS-7340, older age CSF ART levels, TDF levels/bone/renal - written by - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (03/27/12)
     
  1811. CROI: CROI Summary 2012 Inflammation, metabolic complications and strategies for eradication. - written by  Pablo Tebas University of Pennsylvania (03/26/12)
     
  1812. CROI: HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine (ADMA), A Novel Marker of Endothelial Dysfunction (HAART Improves Endothelial Dysfunction Marker ADMA which in the general pop is associated with CVD & mortality) - (03/26/12)
     
  1813. CROI: HAART Reduces Endothelial Activation: Asymmetric dimethylarginine (ADMA) concentrations decrease in patients with HIV infection under antiretroviral therapy - (03/26/12)
     
  1814. CROI: Lower CD4+ Counts and Detectable HIV Viral Load are Associated With Elevated Levels of ADMA in HIV+ Patients - (03/26/12)
     
  1815. CROI: Vitamin D deficiency may impair CD4 recovery among Women's Interagency HIV Study (WIHS) participants on HAART - (03/26/12)
     
  1816. CROI: ADMA Levels are Associated With Elevated Pulmonary Artery Pressure in HIV-Infected Individuals - (03/26/12)
     
  1817. CROI: Morphine Induction of HIV Co-receptors and its Role in HIV Disease Progression - (03/26/12)
     
  1818. CROI: Gut Epithelial Barrier Dysfunction, Inflammation, and Coagulation Predict Higher Mortality during Treated HIV/AIDS - (03/26/12)
     
  1819. CROI: Gender Difference in Mucosal Integrity Impacts Response to HAART in HIV Infection - (03/26/12)
     
  1820. CROI: Effect of Combined Antiretroviral Therapy (cART) on Bacterial Translocation, Inflammation, Coagulation and Immune Activation in Advanced (<100 CD4+ cells/mm3) Antiretroviral-Naïve Patients at Week 48 (EFV or Reyataz/r) - (03/26/12)
     
  1821. CROI: Gut Epithelium is an Early Target of the Virus in the SIV Model of AIDS - (03/26/12)
     
  1822. CROI: Immune activation in HIV-1 patients experiencing transiently detectable viremia during antiretroviral treatment - (03/26/12)
     
  1823. CROI: CD4+ T Cells and Th17 Cells Repopulation in ART-Treated HIV-Infected Individuals - (03/26/12)
     
  1824. CROI: Gut Mucosa T Lymphocyte Restoration in Chronically HIV+ Patients Treated with Recombinant Interleukin-7 - (03/26/12)
     
  1825. CROI: Probiotic Supplementation of ARV Treatment during SIV Infection of Pigtail Macaques Results in Enhanced GI Tract CD4+ T Cell Frequency and Immunological Function - (03/26/12)
     
  1826. CROI: Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Bone Mineral Density and Bone Metabolism in Virologically Suppressed HIV-1+ Patients: A Sub-study of the PREPARE Study - (03/26/12)
     
  1827. CROI: OLDER AGE IS ASSOCIATED WITH HIGHER ANTIRETROVIRAL CONCENTRATIONS IN CEREBROSPINAL FLUID IN HIV-INFECTED INDIVIDUALS - (03/26/12)
     
  1828. The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus - (03/23/12)
     
  1829. The Pervasive Effects of Childhood Sexual Abuse: Challenges for Improving HIV Prevention and Treatment Interventions EDITOIRAL - (03/23/12)
     
  1830. Childhood Trauma and Health Outcomes in HIV-Infected Patients: An Exploration of Causal Pathways - (03/23/12)
     
  1831. Associations of Sexual Identity or Same-Sex Behaviors With History of Childhood Sexual Abuse and HIV/STI Risk in the United States - (03/23/12)
     
  1832. Study of the Day: 1 in 4 Adults With HIV Were Sexually Abused as Kids - (03/23/12)
     
  1833. CROI: Peripheral Neuropathy in ART-experienced Patients: Prevalence and Risk Factors - (03/23/12)
     
  1834. CROI: CNS Penetration Effectiveness of cART and Neuropsychological Outcomes: Cross-sectional Results from the OHTN Cohort Study - (03/23/12)
     
  1835. CROI: Microbial Translocation Independently Predicts Future Hypertension in HIV-Infected Individuals - (03/23/12)
     
  1836. CROI: HIV Status, Burden of Comorbid Disease and Biomarkers of Inflammation, Altered Coagulation and Microbial Translocation-VA Study: important study because it finds cd4 & viral load & comorbid conditions independently associated with inflammation - (03/23/12)
     
  1837. CROI: Improved Low Bone Mineral Density and Bone Turnover Markers with Switch from Tenofovir to Raltegravir in Virologically Suppressed HIV-1+ Adults at 48 Weeks: The TROP Study - (03/22/12)
     
  1838. CROI: Changes in Inflammation and Endothelial Activation Markers in ARV-naïve Subjects Randomized to Abacavir/Lamivudine or Tenofovir/Emtricitabine along with Efavirenz or Atazanavir/ritonavir: AIDS Clinical Trials Group A5224s, a Sub-study of ACTG A5202 - (03/22/12)
     
  1839. CROI: The Impact of Elevated and Pre-hypertensive Systolic Blood Pressure and the Risk of Acute Myocardial Infarction in HIV+ and HIV- Veterans - (03/22/12)
     
  1840. Recent Trauma is Associated with Antiretroviral Failure and HIV Transmission Risk Behavior Among HIV-Positive Women and Female-Identified Transgenders - (03/20/12)
     
  1841. Trauma Drives HIV Epidemic in Women - (03/20/12)
     
  1842. CROI: HIV Latency and Eradication at CROI 2012 -written by   David Margolis, MD University of North Carolina - (03/19/12)
     
  1843. CROI: CROI Report: Bones, Frailty, and Vitamin D -written by   Todd Brown, MD, PhD Associate Professor of Medicine Division of Endocrinology and Metabolism Johns Hopkins University - (03/19/12)
     
  1844. CROI: ACEi or HMG-CoA Reductase Inhibitor (Statin) Treatment as Adjunct Therapy for Persons with HIV infection: A Pilot Study - (03/20/12)
     
  1845. CROI: Changes in Cardiovascular Biomarkers in Subjects Switching from Ritonavir- Boosted Protease Inhibitors to Raltegravir: The SPIRAL Study - (03/20/12)
     
  1846. CROI: Longitudinal analysis of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy - (03/20/12)
     
  1847. CROI: End-Stage Renal Disease Up in Whites, Down in Blacks in 22-Year German Study - written by Mark Mascolini - (03/19/12)
     
  1848. CROI: Untreated Depression and Refusing ART Common in Seattle-Area HIV+ Deaths - written by Mark Mascolini - (03/19/12)
     
  1849. CROI: NNRTI Treatment Breaks Boost Risk of Resistant HIV RNA in Female Genital Tract - written by Mark Mascolini - (03/19/12)
     
  1850. CROI: CROI 2012: HIV Persistence, Latency and Eradication - written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/19/12)
     
  1851. CROI: Antiretroviral Therapy at CROI - PHASE III, PHASE II, PHASE I -written by Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/19/12)
     
  1852. CROI: Pharmacokinetics of Dolutegravir in Subjects With Moderate Hepatic Impairment - (03/19/12)
     
  1853. CROI: Pharmacokinetics of a Dolutegravir Pediatric Granule Formulation in Healthy Adult Subjects - (03/19/12)
     
  1854. CROI: Interferon-alpha & Inflammation: interferon stimulates activation/inflammation, therapies to quell activation - (03/19/12)
     
  1855. Interferon-alpha & Inflammation: interferon stimulates activation/inflammation, therapies to quell activation - (03/19/12)
     
  1856. HIV infection and aging: enhanced Interferon- and Tumor Necrosis Factor-alpha production by the CD8+ CD28- T subset - (03/19/12)
     
  1857. Innate immune responses contribute to immune activation and inflammation in HIV infected women: Distinct role of IFN-a in chronic HIV Infection - (03/19/12)
     
  1858. CROI: Incomplete HIV Control During ART Triples Risk of non-Hodgkin Lymphoma - written by Mark Mascolini - (03/16/12)
     
  1859. CROI: Oral Cancer Rate Higher With HIV--Lower CD4s Implicated in People Over 49 - written by Mark Mascolini - (03/16/12)
     
  1860. CROI: Glucose-Lowering Drugs May Limit Progression to Symptomatic Peripheral Neuropathy - written by Mark Mascolini - (03/16/11)
     
  1861. CROI: Antiretrovirals May Cut Neurosyphilis Risk and Improve Response to Neurosyphilis Therapy - written by Mark Mascolini - (03/16/12)
     
  1862. CROI: Cardiovascular Risk Tied to MRS-Defined Brain Injury in 45-and-Older Men With HIV - written by Mark Mascolini - (03/16/12)
     
  1863. CROI: Over Half of HIV+ 60 and Older Have Cognitive Deficit in San Francisco Study - written by Mark Mascolini - (03/16/11)
     
  1864. CROI: Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/16/12)
     
  1865. CROI: Sub-100 Latest CD4 Count Tied to Stroke and Cardiovascular Disease in D:A:D - written by Mark Mascolini - (03/16/12)
     
  1866. CROI: Pilot Study Explores ACE Inhibitor and Statin as Anti-inflammatory Therapy for HIV - written by Mark Mascolini - (03/16/12)
     
  1867. CROI: Associations between Anatomic Fat Depots with Total, Calcified, Non-Calcified and Mixed Coronary Plaque in the Multicenter AIDS Cohort Study (MACS) - (03/16/12)
     
  1868. CROI: The Effect of a Local "Universal Antiretroviral Therapy" Policy on HIV RNA levels among Patients Entering Care with a CD4 Count Greater than 500/µl in a Public Health Clinic Setting - (03/16/12)
     
  1869. CROI: Impact of HAART Initiation on Immune Regulation (activation/senescence) in Aging HIV-infected Women -Women's Interagency HIV Study - (03/16/12)
     
  1870. CROI: Metformin Prevented CAC Progression But Lifestyle Modification Did Not - (03/16/12)
     
  1871. CROI: 19th Conference on Retroviruses and Opportunistic Infections Report: prevention/PrEP, eradication, the brain, new HIV antiretroviral drugs - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine - (03/16/12)
     
  1872. CROI: CROI 2012: Studies on Inflammation in HIV - written by   David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/16/12)
     
  1873. CROI: NeuroAIDS at CROI 2012 - written by David Alain Wohl, MD - The University of North Carolina - (03/16/12)
     
  1874. CROI: Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/15/12)
     
  1875. CROI: Cerebrospinal Fluid Concentrations of Key Antiretrovirals Increase With Age - written by Mark Mascolini - (03/15/12)
     
  1876. CROI: Predictors of Overall and Late-Onset Lab Abnormalities With Contemporary Regimens - written by Mark Mascolini - (03/15/12)
     
  1877. CROI: Virologic Impact of Starting ART Above 500 CD4s at San Francisco General Hospital - written by Mark Mascolini - (03/15/12)
     
  1878. CROI: Drop in Transmitted Drug Resistance May Have Stopped in UK After 2005: may be increasing except for NNRTIs - written by Mark Mascolini - (03/15/12)
     
  1879. CROI: Respiratory Disease May Be Underdiagnosed in Men With HIV - written by Mark Mascolini - (03/15/12)
     
  1880. CROI: HIV Independently Raises Risk of Ischemic Stroke in 4300-Person US Study - written by Mark Mascolini - (03/15/12)
     
  1881. CROI: "Asymptomatic" HIV Neurocognitive Impairment Not So Benign After All? - written by Mark Mascolini - (03/15/12)
     
  1882. CROI: Elvitegravir-Containing Quad Noninferior to Atazanavir Regimen at 48 Weeks - written by Mark Mascolini - (03/15/12)
     
  1883. CROI: TDF/FTC and TDF Alone Slash HIV Risk in Partners PrEP HIV-Discordant Couples - written by Mark Mascolini - (03/15/12)
     
  1884. CROI: Longer D-Drug Exposure and Higher Glucose Boost Risk of Steatosis Progression - written by Mark Mascolini - (03/15/12)
     
  1885. CROI: Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/14/12)
     
  1886. CROI: David Margolis, UNC researchers find cancer drug that may help fight HIV - (03/14/12)
     
  1887. CROI: Zinc Fingers 'Cure' Therapy - (03/14/12)
     
  1888. CROI: Renal Update CROI 2012 - Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine - (03/14/12)
     
  1889. CROI: HEPATITIS C INCIDENCE IN THE SWISS HIV COHORT STUDY: A CHANGING EPIDEMIC - (03/14/12)
     
  1890. CROI: HIV Prevention at CROI 2012 - written by Jared Baeten, MD PhD, Connie Celum, MD MPH, University of Washington - (03/14/12)
     
  1891. CROI: Biomarkers of Microbial Translocation and Macrophage Activation Are Associated with Progression of Atherosclerosis in HIV Infection: ACTG NWCS 332/A5078 Study - (03/14/12)
     
  1892. CROI: HIV Incidence in Women at Risk for HIV Acquisition in the United States: HPTN 064 (ISIS Study): 5x higher HIV rates in USA women of color than CDC estimates, comparable to HIV rates in sub-Saharan Africa. Webinar Update see details below. - (03/14/12)
     
  1893. New HIV Eradication Research paper Published by Siliciano et al: Johns Hopkins breakthrough may end AIDS patients' need for lifelong drugs below - (03/11/12)
     
  1894. CROI: Safety, Tolerability, and PK of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin - Results of a Phase 1 Study among Healthy Volunteers - (03/11/12)
     
  1895. CROI: Relationship between combination of baseline viral load and CD4 cell count, and Week 48 or 96 responses to rilpivirine (RPV)or efavirenz (EFV) in treatment-naïve HIV-1-infected adults: pooled analysis from the Phase III ECHO and THRIVE trials - (03/11/12)
     
  1896. CROI: Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-Accidental Death in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Cohort - (03/11/12)
     
  1897. CROI: Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/11/11)
     
  1898. CROI: Low muscle mass in HIV infected patients: prevalence, predictors and clinical implication: change in leg fat (surrogate for lipoatrophy) predicted low muscle mass, & low muscle mass predicts mortality; low muscle mass may be part of aging phenotype in HIV+ - (03/11/12)
     
  1899. CROI: FRAILTY AND PRE-FRAILTY IN A CONTEMPORARY COHORT OF HIV-INFECTED INDIVIDUALS IN THE SUN STUDY - (03/11/12)
     
  1900. CROI: HIV Eradication Study by David Margolis: Administration of Vorinostat, cancer drug, Disrupts HIV-1 Latency in Patients on ART - (03/11/12)
     
  1901. CROI: Lack of Resistance Development to the HIV-1 Attachment Inhibitor BMS-626529 During Short-Term Monotherapy with its Prodrug BMS-663068 - (03/9/12)
     
  1902. CROI: Colonoscopy Spots Abnormalities in 60% of German HIV Group--and Cancer in 4% - written by Mark Mascolini - (03/9/12)
     
  1903. CROI: Central Obesity Raises Neurocognitive Impairment Risk in US CHARTER Cohort - written by Mark Mascolini - (03/9/12)
     
  1904. CROI: GS-7340 25 mg and 40 mg Demonstrate Greater Antiviral Activity Compared with TDF 300 mg in a 10-Day Monotherapy Study of HIV-1 Infected Patients - (03/9/12)
     
  1905. CROI: DATA SHOW GILEAD'S QUAD REGIMEN FOR HIV NON-INFERIOR TO PROTEASEBASED REGIMEN AT 48 WEEKS IN SECOND PIVOTAL PHASE 3 STUDY - (03/9/12)
     
  1906. CROI: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF "Quad" Compared to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Treatment Naive HIV-1 Infected Subjects - (03/9/12)
     
  1907. CROI: Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ - (03/9/12)
     
  1908. CROI: Higher Death Rate With 350-499 CD4s vs 500+ in Virologic Responders - written by Mark Mascolini - (03/8/12)
     
  1909. CROI: Low-Dose, Cell-Homing Tenofovir Prodrug Outdoes TDF in 10-Day Study - written by Mark Mascolini - (03/8/12)
     
  1910. CROI: Not Taking Antiretrovirals Linked to 60% Higher Risk of Neurocognitive Decline in US - written by Mark Mascolini - (03/8/12)
     
  1911. CROI: Kidney Renal Markers Signal Linked to Higher Tenofovir Plasma Levels - written by Mark Mascolini - (03/8/12)
     
  1912. CROI: Higher Rate and Extent of Noncalcified Coronary Artery Plaque in HIV+ MACS Men - written by Mark Mascolini - (03/8/12)
     
  1913. CROI: Quad Not Inferior to Efavirenz Combo at 48 Weeks in Phase 3 Trial - written by Mark Mascolini - (03/8/12)
     
  1914. CROI: GILEAD'S QUAD SINGLE TABLET REGIMEN FOR HIV NON-INFERIOR TO ATRIPLA® IN PIVOTAL PHASE 3 STUDY - (03/8/12)
     
  1915. CROI: The Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102 - (03/8/12)
     
  1916. CROI: Dolutegravir ViiV Integrase Inhibitor phase 2b SPRING Study 96-Week Results in Treatment-Naives - (03/8/12)
     
  1917. CROI: Poor Adherence May Explain FEM-PrEP Failure to Find Protection From HIV With Truvada - written by Mark Mascolini - (03/7/12)
     
  1918. CROI: CD8 Activation and Naive CD4s Predict CD4 Gains Through 10 to 15 Years of ART - written by Mark Mascolini - (03/7/12)
     
  1919. CROI: Black Women in US Have Doubled Risk of AIDS Death, Regardless of Adherence - written by Mark Mascolini - (03/7/12)
     
  1920. CROI: HIV Risk in US Black MSM Traced to Age Issues and Care Barriers--Not to Risk Behavior - written by Mark Mascolini - (03/7/12)
     
  1921. CROI: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/12)
     
  1922. CROI: Rectal Tenofovir Gel Clears Hurdle of Safety and Acceptability Study - written by Mark Mascolini - (03/7/12)
     
  1923. CROI: Over Half of US HIV+ People in Care Are Sexually Active, But Most Take Precautions - written by Mark Mascolini - (03/7/12)
     
  1924. CROI: Studies Disagree on Danger in Detectable Viral Load Under 50 Copies - written by Mark Mascolini - (03/7/12)
     
  1925. CROI: Slower Virologic Response in Pregnant Women Starting ART in France - written by Mark Mascolini - (03/7/12)
     
  1926. CROI: Tenofovir PrEP Reduces HIV Transmission Risk By Up To 99%: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/12)
     
  1927. CROI: CDC: HIV Rate in Young US MSM Twice Higher Than in Sub-Saharan Africa - written by Mark Mascolini - (03/7/12)
     
  1928. CROI: The Effect of CD4+ T-Cell Count on Cardiovascular Risk in Treated HIV Disease - (03/7/12)
     
  1929. CROI: Suppression of Formation Threatens Delayed-Phase Bone Loss in Virologically Suppressed HIV-infected Individuals on Chronic ART - (03/7/12)
     
  1930. Hormonal Contraception & HIV Transmission Risk: 3 Recent Studies Published, 'Condoms Critical To Prevent Transmission' - (03/03/12)
     
  1931. WHO World Health Organization Reviews Contraception in light of 3 recent studies published: 'Condoms Best Protection'....Dual Protection Recommended - (03/03/12)
     
  1932. Intrinsic HIV/antiviral immunity: recent advances in understanding of the roles of intrinsic antiviral factors that restrict infection by HIV and influenza virus - (02/28/12)
     
  1933. HIV Protein called SAMHD1: New HIV Research Advance Reveals How Protein Protects Cells from HIV Infection - Potential New Drug Therapy - (02/28/12)
     
  1934. Quantifying ARTs & Combination Effectiveness by R Silciano et al - (02/25/12)
     
  1935. Mortality Risk Quantified for Diabetes Plus Kidney Disease - (02/25/12)
     
  1936. A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs - (02/25/12)
     
  1937. Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV - Perspective - (02/25/12)
     
  1938. A quantitative basis for antiretroviral therapy for HIV-1 infection by R Siliciano et al - (02/23/12)
     
  1939. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy - (02/16/12)
     
  1940. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors: VA Study/risk factors - (02/16/12)
     
  1941. Mediterranean Diet Appears to Protect Brain & Small Vessel Disease/Reduce the Risk for Stroke & Memory Loss: Mediterranean Diet and White Matter Hyperintensity Volume in the Northern Manhattan Study - (02/15/12)
     
  1942. Belly Fat Linked to Cognitive Deficits in HIV, new published study in Neurology from HIV CHARTER Study - (02/15/12)
     
  1943. 2nd International Workshop on HIV & Women Reports/Presentations Orals - (02/14/12)
     
  1944. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial - (02/14/12)
     
  1945. Electrode Zap to Brain Boosts Memory, 'Maybe Used to Improve Memory in Aging & Early Alzheimers' - (02/13/12)
     
  1946. Kidney/TDF Study Authors: Tenofovir: Q&A for Patients and Providers - (02/13/12)
     
  1947. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn - (02/13/12)
     
  1948. Association of tenofovir exposure with kidney disease risk in HIV infection - (02/13/12)
     
  1949. E138K Mutation & M184I/V, Etravirine - (02/10/12)
     
  1950. Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes - (02/10/12)
     
  1951. Rilpivirine Drug Resistance: E138K, 184I, M184V, Interactions Between E138K & M184I - (02/10/12)
     
  1952. The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness - (02/10/12)
     
  1953. Independent Effects of HIV, Aging, and HAART on Brain Volumetric Measures: 'HIV Atrophies Brain Despite HAART/HIV Aged Brain 17 Yrs Faster/Evaluation Tests' - (02/09/12)
     
  1954. 11C-PiB Imaging of Human Immunodeficiency Virus-Associated Neurocognitive Disorder: biomarker for Alzheimers in HIV - (02/09/12)
     
  1955. HIV infection induces age-related changes to monocytes and innate immune activation in young males which persist despite cART - (02/08/12)
     
  1956. Fractures/Bone Loss in HIV: 'traditional risk factors more important' but HIV & ARV exposure have some impact, Vit D may Improve Bone Health & Reduce Fracture Risk, New Studies - (02/08/12)
     
  1957. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case control analysis in a health-insured population - (02/08/12)
     
  1958. Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study: "Among patients infected with oncogenic HPV, qHPV was associated with decreased risk of recurrent HGAIN at 2 years after study entry" - pdf attached - (02/07/12)
     
  1959. Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence - Review - (02/07/12)
     
  1960. Vitamin D and UVB Radiation: How Much Is Necessary? "Exposure to a UVB dose of 1 SED every second week to ~88% body area is sufficient for maintaining summer 25(OH)D levels during the winter." - pdf attached - (02/03/12)
     
  1961. Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke D.A.D - (01/24/12)
     
  1962. Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection - (01/23/12)
     
  1963. Vitamin D Supplementation, HIV, HAART, Bone Health, Fractures - (01/23/12)
     
  1964. Vitamin D Improves Bone Health/Reduces Fracture Risk-Bone Loss: IOM, Endocrine Society - How Much Vit D Supp?/Calcium - (01/23/12)
     
  1965. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection - (01/19/12)
     
  1966. Coping with HIV/Aging: managing health & psychological factors & HCV - (01/15/12)
     
  1967. 2nd Intl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/14/12)
     
  1968. Viral Load Key to HIV Transmission - (01/13/12)
     
  1969. Probability of Heterosexual HIV-1 Transmission per Coital Act in Sub-Saharan Africa - Editorial - (01/13/12)
     
  1970. Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples - (01/13/12)
     
  1971. 2nd Intl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
     
  1972. 2nd Intl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
     
  1973. Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough? - Editorial - - (01/10/12)
     
  1974. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy - (01/10/12)
     
  1975. 2nd Intl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
     
  1976. 2nd Intl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
     
  1977. 2nd Intl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
     
  1978. 2nd Intl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
     
  1979. 2nd Intl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
     
  1980. 2nd Intl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
     
  1981. 2nd Intl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
     
  1982. 2nd Intl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
     
  1983. (Issentress) Raltegravir for Pediatrics: Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years - CROI 2011 Presentation & attached FDA Label containing pediatric safety, PK, dosing, efficacy - (01/09/12)
     
  1984. Herpes simplex virus: a new era? commentary - shedding persisted in study despite acyclovir, valaciclovir therapy - (01/09/12)
     
  1985. Efficacy Results of a Trial of a Herpes Simplex Vaccine - HSV2 Efficacy Not Observed - (01/09/12)
     
  1986. Hi Fat Diet Injures Brain in mice - Obesity is associated with hypothalamic injury in rodents and humans - (01/09/12)
     
  1987. Hi Fat Diet May Injure Brain - Alteration of hypothalamic cellular dynamics in obesity - Commentary - (01/09/12)
     
  1988. Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice - (01/09/12)
     
  1989. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - (01/07/12)
     
  1990. Electrocautery Ablation of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Negative and HIV-Positive Men who have sex with Men - (01/07/12)
     
  1991. A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine - (01/05/12)
     
  1992. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons - (01/04/12)
     
  1993. Preventing Deaths in Persons With HIV/Hepatitis B Virus Coinfection: A Call to Accelerate Prevention and Treatment Efforts - EDITORIAL - (01/02/12)
     
  1994. Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters - (01/02/12)
     
  1995. The Economic Cost of Advanced Liver Disease - (01/02/12)
     
  1996. Breakthrough of the Year, 2011 Science 23 December 2011: "in May of this year, the 052 clinical trial conducted by the HIV Prevention Trials Network reported that ARVs reduced the risk of heterosexual transmission by 96% - (01/02/12)
     
  1997. A New Link Between Aging Cells and Aging People - (01/02/12)
     
  1998. Vitamin D, Calcium Intakes Guidelines - 3 Reports - (01/02/12)
     
  1999. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force - (01/02/12)
     
  2000. AntiAging Cancer Drug - Ageing: A midlife longevity drug? - (01/02/12)
     
  2001. Blocking Vif, HIV protein, Can Block HIV Replication - (01/02/12)
     
  2002. Global landscape of HIV-human protein complexes: "We aimed to identify host proteins associated with HIV-1 proteins" - (01/02/12)
     
  2003. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
     
  2004. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial - (01/02/12)
     
  2005. Testosterone replacement therapy and polycythemia in HIV-infected patients - (01/02/12)
     
  2006. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use: 'comorbidities cause work cessation' - (01/02/12)
     
  2007. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging - (01/02/12)
     
  2008. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer - (12/22/11)
     
  2009. First data to show antihypertensive therapy prolongs life - (12/21/11)
     
  2010. Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival - (12/21/11)
     
  2011. HIV Persistence during Therapy 5th International Workshop (Dec 6-9 2011 St Martin, West Indies) - Written by David Margolis MD, University of North Carolina at Chapel Hill (12/21/11)
     
  2012. How might HPV testing be integrated into cervical screening? - (12/17/11)
     
  2013. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial - (12/17/11)
     
  2014. HPV Screen Detects Lesions Earlier than Pap Test - (12/17/11)
     
  2015. 3 Integrase Inhibitors..... - (12/17/11)
     
  2016. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells - (12/17/11)
     
  2017. Treating HIV Early After Infection - new study - (12/16/11)
     
  2018. Neither Branded Nor Generic Lopinavir/Ritonavir Produces Adequate Lopinavir Concentrations at a Reduced Dose of 200/50 mg Twice Daily - (12/15/11)
     
  2019. A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz - (12/15/11)
     
  2020. Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects - (12/15/11)
     
  2021. Men Who Have Sex With Men Have a 140-Fold Higher Risk for Newly Diagnosed HIV and Syphilis Compared With Heterosexual Men in New York City - (11/30/11)
     
  2022. HIV+ & HIV/HCV(tripled) Have Higher Fracture Rates Compared to General Population in Denmark - (11/28/11)
     
  2023. Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults: "We conclude that there is little association of low level viremia with levels of CRP, fibrinogen, and IL-6" - (11/28/11)
     
  2024. Projected life expectancy of people with HIV according to timing of diagnosis - (11/28/11)
     
  2025. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer: 'cd4 & viral load implicated as risk factors' - (11/28/11)
     
  2026. HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users (ALIVE Study): unrecognized high rates of of multucomordibities - (11/28/11)
     
  2027. Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors? - (11/21/11)
     
  2028. NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN) - (11/21/11)
     
  2029. A Randomized, Controlled, Open-Label Study of the Long-Term Effects of NGX-4010, a High-Concentration Capsaicin Patch, on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers - (11/21/11)
     
  2030. A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-associated Distal Sensory Polyneuropathy - (11/21/11)
     
  2031. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy: "results suggest that NGX-4010 could provide a promising new treatment for painful HIV neuropathy" - (11/21/11)
     
  2032. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders - (11/04/11)
     
  2033. Aging/Wk: Statin Blocks PIs' Negative Impact on Bone Formation in Cell Studies - Written by Mark Mascolini - (11/03/11)
     
  2034. EACS: Pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy (11/02/11)
     
  2035. IDSA: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study - (11/02/11)
     
  2036. IDSA: A Seven-Year Review of AIDS and Non-AIDS related Malignancies in a Large HIV/AIDS Center in New York - (11/02/11)
     
  2037. IDSA: Treatment of high grade anal lesions in high risk patients: outcome at an urban community health center - (11/02/11)
     
  2038. Aging/Wk: Antiretroviral Levels With Two Common Regimens in Nonfrail Older Patients - see slides below report - Written by Mark Mascolini - (11/01/11)
     
  2039. Aging/Wk: Cognitive Therapy Gives Boost to 50-Year-Olds With Long-Term HIV - Written by Mark Mascolini - (11/01/11)
     
  2040. IDSA: Risk of Muscle Breakdown in HIV - see slides below article - (11/01/11)
     
  2041. IDSA: Prevalence and Patterns of Echocardiographic Abnormalities in HIV-Infected, Black Individuals in an Inner City Teaching Hospital in Washington DC - (11/01/11)
     
  2042. Early HIV Therapy in Patients With TB Saves Lives - (11/01/11)
     
  2043. Integration of Antiretroviral Therapy with Tuberculosis Treatment - (11/01/11)
     
  2044. Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis - (10/28/11)
     
  2045. Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis - (10/31/11)
     
  2046. IDSA: Peripheral mechanisms of CD4 T cell regeneration in HIV-1 elite controllers: naïve CD4s are severely depleted in elite controllers - (10/31/11)
     
  2047. Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias: "Patients with AD were around half as likely to be prescribed ARBs" - (10/31/11)
     
  2048. Aging/Wk: Half of HIV+ Middle-Aged Meet Social Security Disability Threshold in Walk Test - Written by Mark Mascolini - (10/31/11)
     
  2049. Aging/Wk: CD4 Changes on Effective ART Similar in People Under and Over 50 Years Old - Written by Mark Mascolini - (10/31/11)
     
  2050. Aging/Wk: CMV Antibody Levels Linked to Heart Disease Markers in Women On and Off ART - Written by Mark Mascolini - (10/31/11)
     
  2051. Aging/Wk: HIV Linked to Frailty in Middle-Aged IDUs, Especially With Poor HIV Control - Written by Mark Mascolini - (10/31/11)
     
  2052. Aging/Wk: Renal Function Drops With Age--and More With PIs--in London HIV Clinic - Written by Mark Mascolini - (10/31/11)
     
  2053. Testosterone replacement therapy and polycythemia in HIV-infected patients - - (10/28/11)
     
  2054. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (10/28/11)
     
  2055. Aging/Wk: Duration of ART and Specific Antiretrovirals Tied to Hypophosphatemia and Albuminuria - Written by Mark Mascolini - (10/28/11)
     
  2056. Aging/Wk: Drug Interaction Rate No Higher With HIV Than Without in French Group Over 60 - Written by Mark Mascolini - (10/28/11)
     
  2057. Aging/Wk: Falling Rate Similar in 45-to-65-Year-Olds With HIV and HIV-Negatives Over 65 - Written by Mark Mascolini - (10/28/11)
     
  2058. 4 Aging Published Reports This Week: - (10/27/11)
     
  2059. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia - (10/27/11)
     
  2060. IDSA: Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network - (10/25/11)
     
  2061. IDSA: Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials - (10/25/11)
     
  2062. IDSA: Analysis of lipid levels and neuropsychiatric events in treatment-naïve HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in ECHO and THRIVE - (10/25/11)
     
  2063. IDSA: Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials - (10/24/11)
     
  2064. Updated NYS Syphillis in HIV+ Guidelines - (10/24/11)
     
  2065. Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients - (10/24/11)
     
  2066. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study - published The Lancet - (10/24/11)
     
  2067. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial - (10/24/11)
     
  2068. Assessment of population-level effect of Avahan, an HIV-prevention initiative in India - (10/24/11)
     
  2069. EACS: High non-AIDS-related mortality among a cohort of HIV-positive men who have sex with men (MSM) in Stockholm Insulin resistance is a strong predictor of mortality- a 12 year follow (10/24/11)
     
  2070. IDSA: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/23/11)
     
  2071. IDSA: Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRK - (10/23/11)
     
  2072. EACS: Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/23/11)
     
  2073. EACS: Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy (10/20/11)
     
  2074. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses - (10/21/11)
     
  2075. Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters - (10/21/11)
     
  2076. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study - (10/21/11)
     
  2077. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population - (10/21/11)
     
  2078. Screening for Cognitive Impairment in Human Immunodeficiency Virus - (10/20/11)
     
  2079. Viremia Copy-Years (Cumulative Viral Load Exposure) Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy - (10/20/11)
     
  2080. EACS: Rilpivirine vs Efavirenz for 96 Weeks: Baseline Viral Load and Side Effect Details - Written by Mark Mascolini (10/19/11)
     
  2081. EACS: IL28B gene polymorphisms and all-cause mortality in HIV infected patients (10/19/11)
     
  2082. EACS: IL28B Genotype Linked to All-Cause Mortality in HIV+ People on cART - written by Mark Mascolini - (10/18/11)
     
  2083. EACS: Half With Undetectable Plasma Load Have Neurocognitive Impairment in UK Group - written by Mark Mascolini - (10/18/11)
     
  2084. EACS: Dolutegravir (GSK/ViiV Integrase) Treatment (with 50mg Once & Twice Daily) of HIV Subjects with Raltegravir Resistance & 3-Class ART Resistance: viral suppression at Week 24 in the VIKING Study (10/17/11)
     
  2085. Gut Bacteria Influence Statin Treatment Response - (10/17/11)
     
  2086. (Gut Bacteria) Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment - (10/17/11)
     
  2087. EACS: Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir DisoproxilFumarate(FTC/RPV/TDF) STR in VirologicallySuppressed, HIV-1 Infected Subjects (10/17/11)
     
  2088. EACS: Sustained Efficacy with Low and Similar Rates of Virologic Failures in Second Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis (10/17/11)
     
  2089. EACS: Non-AIDS Cancer Incidence Remains the Same Over 2004-2010 in D:A:D Study Group - written by Mark Mascolini - (10/17/11)
     
  2090. EACS: Half of HIV+ in France Still Coming to Care Late--With High Death Risk written by Mark Mascolini (10/17/11)
     
  2091. EACS: Body Fat Distribution Changes After 96 Weeks of Therapy with Lopinavir/ritonavir (LPV/r) Plus Raltegravir (RAL) Compared with LPV/r Plus Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral (ARV)-Naïve, HIV-1-Infected Subjects from the PROGRESS Study (10/17/11)
     
  2092. EACS: Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients (10/17/11)
     
  2093. EACS: Pilot study evaluating an intensification of antiretroviral therapy with maraviroc in HIV-1-infected patients with controlled viral load exhibiting insufficient immune restoration (10/17/11)
     
  2094. EACS: The incidence of serious non-AIDS bacterial infections in the EuroSIDA cohort (10/17/11)
     
  2095. EACS: Interleukin-6 and C-reactive Protein Levels after 144 Weeks of Efficacy of Darunavir /Ritonavir Monotherapy versus DRV/r + 2NRTIs in the MONET Trial for Patients with HIV RNA < 50 Copies/mL at Baseline: COINFECTED PATIENTS HAD HIGHER IL-6, INFLAMMATION LEVELS (In SMART >3 mg/L was associated with progression), YOU CAN SEE 15% to 19% of PATIENTS HAD VERY HIGH hs-CRP (inflammation) (>3 mg/L), INFLAMMATION WAS MORE LIKELY TO BE HIGHER IF VIRAL LOAD WAS DETECTABLE (10/17/11)
     
  2096. EACS: Long-term Efficacy of Raltegravir or Efavirenz Combined with TDF/FTC in Treatment-naïve HIV-1-infected Patients: Week-192 Subgroup Analyses from STARTMRK (10/14/11)
     
  2097. Life expectancy in HIV - EDITORIAL, Better, but not good enough - (10/13/11)
     
  2098. HIV Life Expectancy Increases In UK - 'life expectancy still 15 years lower with HIV compared to general population....starting HAART earlier matters' - (10/13/11)
     
  2099. Initial Viral Decay (predicts viral suppression) to Assess the Relative Antiretroviral Potency of PI-, NNRTI- and NRTI-Sparing Regimens for First Line Therapy of HIV Infection - (10/12/11)
     
  2100. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study - (10/11/11)
     
  2101. Vitamin and Mineral Supplement Use in Relation to All-Cause Mortality in the Iowa Women's Health Study - Comment on "Dietary Supplements and Mortality Rate in Older Women" - (10/11/11)
     
  2102. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  2103. ICAAC: Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome - (10/10/11)
     
  2104. HIV Found in New Brain Cells, Should HAART Start Earlier To Prevent Brain Damage - (10/09/11)
     
  2105. Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters - (10/09/11)
     
  2106. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  2107. Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? - (10/07/11)
     
  2108. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types - May Explain Persistent HIV Brain Damage - (10/07/11)
     
  2109. ICAAC: Significant Reductions in the Prevalence of Protease Inhibitor and 3-Class Resistance: Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase Database - (10/08/11)
     
  2110. ICAAC: Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients - (10/08/11)
     
  2111. Vitamin D, cardiovascular disease and mortality - (10/06/11)
     
  2112. Vitamin B12, cognition, and brain MRI measures - - (10/05/11)
     
  2113. Vitamins B12, B6, and folic acid Supplementationfor cognition in older men - (10/05/11)
     
  2114. Hormonal contraception and HIV: an unanswered question EDITORIAL - (10/05/11)
     
  2115. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study - (10/05/11)
     
  2116. Oral Contraceptive Increases HIV Risk (for both men & women) - (10/05/11)
     
  2117. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy - (10/05/11)
     
  2118. ICAAC: Kidney Function Change With Cobicistat Calculated in HIV-Negative Volunteers - Written by Mark Mascolini - (09/30/11)
     
  2119. ICAAC: Intracellular Raltegravir Concentrations Better With Twice-Daily Than Once-Daily Dosing - Written by Mark Mascolini - (09/30/11)
     
  2120. ICAAC: TMC435 in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection: Week 24 interim analyses of Phase IIB PILLAR and ASPIRE trials - (09/30/11)
     
  2121. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients - (09/29/11)
     
  2122. ICAAC: HAART Treatment Interruption Following Adoptive Transfer of Zinc Finger Nuclease (ZFN) CCR5 Modified AutologousCD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load - (09/29/11)
     
  2123. ICAAC: ICAAC 2011: Medically Important Highlights - David H Shepp, MD, Hofstra NSLIJ Medical School Division of Infectious Diseases North Shore University Hospital - Manhasset- (09/29/11)
     
  2124. ICAAC: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011 Chicago, IL - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/29/11)
     
  2125. ICAAC: Responder-relapser (RR) patients might obtain benefit in liver fibrosis, after anti-HCV chemotherapy, in comparison to non-responders (NR) or non-treated (control) HIV- HCV coinfected patients - (09/27/11)
     
  2126. ICAAC: Longitudinal assessment of liver fibrosis (LF) by non-invasive methods in HIV- HCV coinfected patients, after HCV chemotherapy - (09/27/11)
     
  2127. ICAAC: Dolutegravir vs Resistant Mutants: Selective Advantage Profiles of HIV-1 Integrase Mutants in the Presence of Dolutegravir - (09/26/11)
     
  2128. ICAAC: Liver Stiffness (LS) change in HIV/Hepatitis C (HCV) co-infected patients treated with CCR5 inhibitor based antiretroviral Therapy - (09/26/11)
     
  2129. ICAAC: Under 10% in Large Canadian Cohort Reach Normal CD4/CD8 Ratio - (09/26/11)
     
  2130. ICAAC: An Open-Label, Placebo-controlled Study to Evaluate the Effect of Dolutegravir (DTG, S/GSK1349572) on Iohexol and Para-aminohippurate Clearance in Healthy Subjects - Written by Mark Mascolini - (09/26/11)
     
  2131. ICAAC: Dolutegravir & Creatinine Clearance - Written by Mark Mascolini - (09/26/11)
     
  2132. ICAAC: Pharmacokinetic analysis of nevirapine extended release 400 mg QD vs immediate release 200 mg BID in patients with HIV-1 infection - (09/24/11)
     
  2133. ICAAC: Nevirapine Concentrations With Once- Versus Twice-Daily Dosing - Written by Mark Mascolini - (09/24/11)
     
  2134. ICAAC: Fosamprenavir/RTV Cuts Dolutegravir Levels: No Dose Change Needed for Naive - Written by Mark Mascolini - (09/24/11)
     
  2135. ICAAC: HCV and Homocysteine Boost Risk of Covert Atherosclerosis in Spanish HIV Group - Written by Mark Mascolini - (09/24/11)
     
  2136. ICAAC: Novel Boehringer-Ingelheim Integrase Inhibitor Retains Full Activity Against Raltegravir-Resistant Virus - Written by Mark Mascolini - (09/24/11)
     
  2137. ICAAC: Effect of Fosamprenavir/Ritonavir on the Pharmacokinetics of the Integrase Inhibitor, Dolutegravir, in Healthy Subjects - (09/24/11)
     
  2138. ICAAC: Safety, Tolerability, and Efficacy of Raltegravir (RAL) in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study - (09/22/11)
     
  2139. ICAAC: Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race - (09/21/11)
     
  2140. ICAAC: Durable and Consistent Efficacy of Raltegravir (RAL) With Tenofovir (TDF) and Emtricitabine (FTC) Across Demographic and Baseline Prognostic Factors In Treatment-naïve Patients (pts) From STARTMRK at Wk 156 - (09/22/11)
     
  2141. ICAAC: Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies - (09/22/11)
     
  2142. ICAAC: Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T-cells (SB-728-T) to Aviremic HIV-infected Subjects with Suboptimal CD4 Counts (200-500 cells/mm3) - (09/22/11)
     
  2143. ICAAC: Safety, Efficacy, and Pharmacokinetics of Ibalizumab in Treatment-Experienced HIV-1 Infected Patients: a Phase 2b Study - (09/22/11)
     
  2144. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  2145. ICAAC: Recruiting Young LA Gays for HIV Survey by Social-Networking App - Written by Mark Mascolini (09/21/11)
     
  2146. ICAAC: ART-HCV Protease Inhibitor BI-201335 Interactions - (09/21/11)
     
  2147. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/21/11)
     
  2148. ICAAC: Sangamo HIV Gene Therapy Data Reported at ICAAC Sept 19 2011 - (09/21/11)
     
  2149. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  2150. ICAAC: (New BI Integrase Inhibitor) Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers - (09/21/11)
     
  2151. ICAAC: BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1 - (09/21/11)
     
  2152. ICAAC: Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system - (09/21/11)
     
  2153. ICAAC: Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor - (09/21/11)
     
  2154. ICAAC: Effect of Cobicistat on Glomerular Filtration Rate in Subjects with Normal and Impaired Renal Function - (09/21/11)
     
  2155. ICAAC: HIV Risk Perception Does Not Match PrEP Interest in US Heterosexual Group - (09/21/11)
     
  2156. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/21/11)
     
  2157. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/20/11)
     
  2158. ICAAC: Randomized Switch From Suppressive PI to Etravirine Safe and Effective - Written by Mark Mascolini - (09/20/11)
     
  2159. ICAAC: Insulin Resistance Quadruples Liver Cancer Risk in People With HIV/HCV - Written by Mark Mascolini - (09/20/11)
     
  2160. ICAAC: Switching From TDF/FTC to Raltegravir Improves Kidney Markers - Written by Mark Mascolini - (09/20/11)
     
  2161. ICAAC: Higher Osteoprotegerin Linked to Lower Atherosclerosis Risk in Men With HIV - Written by Mark Mascolini - (09/20/11)
     
  2162. ICAAC: Switching From Atripla to Complera Safe and Effective in 12-Week Study - Written by Mark Mascolini - (09/20/11)
     
  2163. ICAAC: Risk of Neurosyphilis With Early Syphilis in German Group With HIV - Written by Mark Mascolini - (09/20/11)
     
  2164. ICAAC: PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful - Written by Mark Mascolini - (09/20/11)
     
  2165. ICAAC: High Rates of SVR24 for BMS-790052, an NS5A Replication Complex Inhibitor, in Combination With PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in Treatment-Naive HCV Genotype 1 Subjects - (09/19/11)
     
  2166. ICAAC: BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients - (09/19/11)
     
  2167. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/19/11)
     
  2168. ICAAC: Better 1-Month Safety With Rilpivirine Than Efavirenz in Treatment-Naive - (09/19/11)
     
  2169. ICAAC: Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects - (09/19/11)
     
  2170. ICAAC: Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants - (09/19/11)
     
  2171. ICAAC: PI and 3-Class Resistance Drop Sharply in Monogram Database: 2003-2010 - Written by Mark Mascolini - (09/19/11)
     
  2172. ICAAC: "Ultradeep" Detection of Pretreatment Mutations Has Little Impact on Long-Term PI (Reyataz/r) Response - Written by Mark Mascolini - (09/19/11)
     
  2173. ICAAC: One Penicillin Dose as Good as Three for Early Syphilis in Men With HIV - Written by Mark Mascolini - (09/19/11)
     
  2174. ICAAC: Adding Maraviroc May Reduce Liver Stiffness in People With HCV and HIV - Written by Mark Mascolini - (09/19/11)
     
  2175. ICAAC: Some Lipids Improve With Switch From ABC/3TC to TDF/FTC, HIV Control Rates Similar - Written by Mark Mascolini - (09/19/11)
     
  2176. ICAAC: Resistance Rates and Patterns Similar With Extended- and Immediate-Release Nevirapine - Written by Mark Mascolini - (09/19/11)
     
  2177. ICAAC: Hospital Rate Lower With Atripla Than Other Combos in Medicaid Patients - Written by Mark Mascolini - (09/19/11)
     
  2178. ICAAC: Delayed HIV Care Persists in Chicago Minorities Years After CDC Screening Advice - Written by Mark Mascolini - (09/19/11)
     
  2179. ICAAC: Chicago Hospital Study Finds 11+ HIV Prescribing Errors Per 100 Patient-Days - Written by Mark Mascolini - (09/19/11)
     
  2180. ICAAC: Gender or Race Does Not Affect Raltegravir Response in Diverse Group - Written by Mark Mascolini - (09/19/11)
     
  2181. ICAAC: Dropping Inactive NRTI Does Not Compromise 4- or 5-Drug Salvage Combos - Written by Mark Mascolini - (09/19/11)
     
  2182. ICAAC: "Selective Advantage" Analysis Sees Low Risk of Cross-Resistance With Dolutegravir - Written by Mark Mascolini - (09/19/11)
     
  2183. ICAAC: Zinc Finger-Modified CD4-Cell Booster Transplant Working in Pilot Trial - Written by Mark Mascolini - (09/19/11)
     
  2184. ICAAC: Pretreatment Mutations Do Not Affect Etravirine or Efavirenz Response in SENSE - Written by Mark Mascolini - (09/19/11)
     
  2185. ICAAC: Large Sample Analysis Confirms Impact of Known Rilpivirine Mutations - Written by Mark Mascolini - (09/19/11)
     
  2186. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons - (09/09/11)
     
  2187. Hepatitis delta in HIV-infected individuals in Europe - (09/07/11)
     
  2188. The Brittleness of Aging Bones - more than a Loss of Bone mass - (09/07/11)
     
  2189. First study to quantify benefits of exercise on CHD risk Dose Response Between Physical Activity (15/day, 150, 300, 750-week minutes) and Risk of Coronary Heart Disease [reduced 14-25%] - (09/07/11)
     
  2190. Menopause Role in Heart Risk Disputed (see editorial, full text below) - (09/07/11)
     
  2191. HIV-Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (09/07/11)
     
  2192. Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of "Heart Positive," a Randomized, Controlled Trial - (09/07/11)
     
  2193. Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262) - (09/07/11)
     
  2194. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults - (09/06/11)
     
  2195. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy: "initiation of CART as early as possible might reduce the risk of developing HAND, the most common source of NPI among HIV-infected individuals" - (09/06/11)
     
  2196. Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naive patients: 48 week results - (09/06/11)
     
  2197. Cholesterol Lowering Diet Foods Reduce LDL-Cholesterol by 14% - (08/24/11)
     
  2198. Coronary Calcium Better than CRP to Stratify Risk - (08/20/11)
     
  2199. Even Short Workout (15 minutes) Could Extend Life Expectancy - (08/19/11)
     
  2200. Minimum amount (15 minutes) of physical activity for reduced mortality and extended life expectancy: a prospective cohort study - (08/19/11)
     
  2201. Editorial - Survival benefit associated with low-level physical activity: "the direct health benefits of exercise are irrefutable. Exercise can reduce cardiovascular mortality and, in particular, coronary mortality by many mechanisms, including improvements in endothelial function, autonomic tone, inflammation, and risk-factor control" - (08/19/11)
     
  2202.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy - (08/19/11)
     
  2203. Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines/for HIV-infected children - (08/18/11)
     
  2204. Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy - (08/17/11)
     
  2205. Depression Increases Stroke Risk in Older Women - (08/15/11)
     
  2206. HIV Cure Discovery: Functional HIV Cure in Rhesus Macaque Monkey Can Be Model for Humans - (08/15/11)
     
  2207. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease - (08/15/11)
     
  2208. Phase 2 Study of Cobicistat versus Ritonavir each with Atazanavir plus Fixed-Dose Emtricitabine/Tenofovir DF in the Initial Treatment of HIV Infection - (08/06/11)
     
  2209. Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients: statins improve mortality - (08/04/11)
     
  2210. IAS: Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6 to <18 years): Week 24 primary analysis of the Phase II PIANO study - (08/04/11)
     
  2211. IAS: The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA <50 copies/mL at baseline - (08/04/11)
     
  2212. IAS: The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients - (08/04/11)
     
  2213. IAS: Long-term safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in ARTEMIS - (08/04/11)
     
  2214. IAS: STEAL Study 2 Yrs Followup: Tenofovir Speeds BMD Loss vs Abacavir, But Does Not Raise Fracture Risk Over 2 Years Followup; Lower Fat Mass Also Predicts Bone Loss - written by Mark Mascolini - (08/01/11)
     
  2215. IAS: HIV Complications & It's Treatment, Opportunistic Infections, New ART Drugs, Preventing HIV Transmission: IAS. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome 17-20 July, 2011 Written by Pablo Tebas, MD University of Pennsylvania. - (08/01/11)
     
  2216. Relative Muscle Mass Is Inversely Associated with Insulin Resistance and Prediabetes. Findings from The Third National Health and Nutrition Examination Survey - (08/01/11)
     
  2217. IAS: Women With HIV Have Lower Mortality Than Men in Europe, But Not in North America - written by Mark Mascolini - (08/01/11)
     
  2218. IAS: Bone Loss Boosts Cardiovascular Risk 77% in French Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  2219. IAS: Kidney Risk & ARTs in Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  2220. IAS: HIV Prevention Report at IAS 2011 by Jared Baeten, MD & Connie Cellum, MD - (08/01/11)
     
  2221. IAS: High Rates of Airflow Obstruction, Emphysema in Heavy-Smoking Spanish Group: average age 45...37% emphysema...marijuana doubled risk - (07/29/11)
     
  2222. The Effect of Vitamin D on Falls: A Systematic Review and Meta-Analysis - (07/28/11)
     
  2223. IAS: Microbial Translocation and Hepatitis C Disease Progression among HIV-infected Women - (07/27/11)
     
  2224. IAS: Efficacy of maraviroc administered once-daily or twice-daily with boosted protease inhibitors to treatment-experienced patients - (07/27/11)
     
  2225. IAS: 48 Week Results of Once-Daily Maraviroc (MVC) 150 mg in Combination with Ritonavir-Boosted Atazanavir (ATV/r) Compared to Emtricitabine/Tenofovir (FTC/TDF) + ATV/r in Treatment-Naïve Patients Infected with R5 HIV-1 (Study A4001078) - (07/27/11)
     
  2226. IAS: Biomarkers Predict Hepatic Flares and Death in Hepatitis-Coinfected People Starting ART - written by Mark Mascolini - (07/26/11)
     
  2227. IAS: Age, Race, Gender--But Not HIV--Tied to Hearing Loss in HIV+ People - written by Mark Mascolini - (07/26/11)
     
  2228. IAS: Short-Term ART After Early Infection Does Not Delay AIDS or Death - written by Mark Mascolini - (07/26/11)
     
  2229. IAS: Virologic Failure Rate Plummets From 31% to 5% in France From 1997 Through 2009 - written by Mark Mascolini - (07/26/11)
     
  2230. IAS: Progressive Histological Liver Improvement After SVR in HCV/HIV Coinfected Patients Using Transient Elastography (Fibroscan) - (07/25/11)
     
  2231. IAS: Temporal Trends in Liver-Related Mortality in a Prospective Cohort of HIV-Infected Patients in Spain 1997-2008: HCV/HIV Coinfected Death Rates Increase While Rates Decline Among HCV-/HIV+ - (07/25/11)
     
  2232. IAS: Sustained Efficacy and Tolerability of Raltegravir after 240 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients: Final Analysis of Protocol 004 - (07/25/11)
     
  2233. IAS: DIONE - 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-na·ve adolescents, 12 to <18 years - (07/25/11)
     
  2234. IAS: Cognitive Impairment Persists: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  2235. IAS: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  2236. IAS: Doubled Rate of Nonmelanoma Skin Cancer With HIV in California Comparison - written by Mark Mascolini - (07/24/11)
     
  2237. IAS: Minority species resistance (Ultra-Deep Sequencing) present at screening does not affect outcomes at Week 48 in lersivirine (UK-453,061) Phase 2b study A5271015 in treatment-naïve patients - (07/24/11)
     
  2238. IAS: Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase 2b trial (Study A5271015) - (07/23/11)
     
  2239. IAS: More Than 25% in HIV-Positive SUN Study Cohort Have Insulin Resistance - written by Mark Mascolini - (07/22/11)
     
  2240. IAS: CD4 Gains on cART Lower AIDS/Death Risk Even With High Starting CD4 Count - written by Mark Mascolini - (07/22/11)
     
  2241. IAS: TDF/FTC PrEP Durable in MSM, But MSM and Transgender Responses Differ - written by Mark Mascolini - (07/22/11)
     
  2242. IAS: Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008 - (07/23/11)
     
  2243. IAS: Safety Profile of Dolutegravir (DTG, S/GSK1349572), a Next Generation Integrase Inhibitor (INI) in Combination Therapy in Antiretroviral (ART)-naïve and ART-experienced Adults from Phase 2b Studies - (07/23/11)
     
  2244. IAS: Switching from ABC/3TC to TDF/FTC Trims Risk of Virologic Failure - written by Mark Mascolini - (07/22/11)
     
  2245. IAS: SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) - (07/22/11)
     
  2246. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men --- New York City, 2005--2010 - (07/22/11)
     
  2247. IAS: ViiV 'Next Generation' Integrase Dolutegravir, 48 Weeks SPRING-1 Study Naives - (07/21/11)
     
  2248. IAS: First-Line Once-Daily Maraviroc Plus ATV/r Versus Triple Therapy - written by Mark Mascolini - (07/20/11)
     
  2249. IAS: A Look Back at Once-Daily 150-mg Maraviroc for Experienced in MOTIVATE Trials - written by Mark Mascolini - (07/20/11)
     
  2250. IAS: Frailty Rate in HIV+ mid-50 Women Matches Rate in 70-Year-Olds Without HIV - written by Mark Mascolini - (07/20/11)
     
  2251. IAS: Heart Disease Signal and Low Femoral Density Linked in People With HIV - written by Mark Mascolini - (07/20/11)
     
  2252. IAS: Elvitegravir Not Inferior to Raltegravir in Treatment-Experienced: Phase 3 - written by Mark Mascolini - (07/20/11)
     
  2253. IAS: Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults - (07/20/11)
     
  2254. IAS: IAS: PrEP Results Surprised Researchers - (07/20/11)
     
  2255. IAS: Elvitegravir Once Daily is Non-Inferior to Raltegravir Twice Daily in Treatment-Experienced Patients: 48 Week Results From a Phase 3 Multicenter, Randomized Double-Blind Study - (07/20/11)
     
  2256. IAS: Natural controllers of HIV infection are susceptible to immune perturbations similar to those associated with normal aging - implications for women aging with HIV infection - (07/20/11)
     
  2257. IAS: Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults - (07/20/11)
     
  2258. IAS: Interaction of Vascular and Bone Disease in HIV Infected Patients: Coronary Artery Calcification is associated with femoral but not lumbar spine mineral density - (07/19/11)
     
  2259. IAS: Atazanavir Without Ritonavir as Simpler Maintenance: 144-Week ARIES Results - written by Mark Mascolini - (07/19/11)
     
  2260. IAS: Late HIV Diagnosis Raises ICU Admission Rate 5 Times in London Group - written by Mark Mascolini - (07/19/11)
     
  2261. IAS: Two More Randomized Trials Show that Daily TDF/FTC Protects From HIV - written by Mark Mascolini - (07/19/11)
     
  2262. IAS: Good Kidney and Liver Transplant Results in Large Study of People With HIV - written by Mark Mascolini - (07/19/11)
     
  2263. IAS: Slow Drop in HIV Neurocognitive Disorder in Italian HIV Cohort: 'cognitive impairment persists in HIV-positive people.....' - written by Mark Mascolini - (07/19/11)
     
  2264. IAS: Rilpivirine (TMC278) vs Efavirenz at 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/19/11)
     
  2265. IAS: Lersivirine, a New NNRTI, Versus Efavirenz as First-Line Therapy: 48 Weeks - written by Mark Mascolini - (07/19/11)
     
  2266. IAS: Similar 48-Week Response Rates With New Integrase Inhibitor and Efavirenz in Naives - written by Mark Mascolini - (07/19/11)
     
  2267. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - written by Mark Mascolini - (07/18/11)
     
  2268. IAS: Brain-Breaching Antiretroviral Score Not Tied to Neuropsych Function in Canada - written by Mark Mascolini - (07/18/11)
     
  2269. IAS: Antiretroviral Therapy Lowers HIV Transmission Risk in HIV+/HIV- Couples: "96% reduction in HIV transmission risk to an HIV-negative partner..... definitive proof of the concept that antiretroviral therapy lowers the risk HIV transmission" - written by Mark Mascolini - (07/18/11)
     
  2270. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - (07/18/11)
     
  2271. Immediate ART No Better Than Deferred in Asian Kids With Moderate CD4 Loss ! - Written by Mark Mascolini - (07/17/11)
     
  2272. TMC278, Rilpivirine: 2 Phase 3 Studies ECHO/THRIVE Published & Commentary pdfs attached - (07/17/11)
     
  2273. Intl Wrkshp Advrse Reactions & Comorbids HIV: Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat - (07/17/11)
     
  2274. Intl Wrkshp Advrse Reactions & Comorbids HIV: Bone Mineral Density (BMD) Analysis in Antiretroviral (ART)-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS Study - (07/17/11)
     
  2275. Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells - pdf attached - (07/13/11)
     
  2276. Neurocognitive Impact of Substance Use in HIV Infection - (07/13/11)
     
  2277. New MRI Protocol Refines CAD Risk Assessment - full text pdf publication attached - (07/13/11)
     
  2278. CT Scan Detects Silent CV Risk (coronary calcium buildup) - (07/12/11)
     
  2279. A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men - pdf attached - (07/05/11)
     
  2280. Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (07/05/11)
     
  2281. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans - (07/05/11)
     
  2282. Aging, Persistent Viral Infections, and Immunosenescence: Can Exercise ''Make Space''? - (07/05/11)
     
  2283. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: Report on the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  2284. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  2285. Mitochondria are sensors for HIV drugs - (06/28/11)
     
  2286. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway - (06/28/11)
     
  2287. HIV Itself Causes Mitochondrial Damage - (06/28/11)
     
  2288. Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors - (06/28/11)
     
  2289. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations - (06/27/11)
     
  2290. (AZT Shortens Telomerase)Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines - (06/27/11)
     
  2291. (AZT Shortens Telomerase) The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena - (06/27/11)
     
  2292. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study - (06/27/11)
     
  2293. Increases in T Cell Telomere Length in HIV Infection after Antiretroviral Combination Therapy for HIV-1 Infection Implicate Distinct Population Dynamics in CD4+ and CD8+ T Cells - (06/27/11)
     
  2294. T cell activation predicts carotid artery stiffness among HIV-infected women - (06/27/11)
     
  2295. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis - (06/21/11)
     
  2296. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients - (06/20/11)
     
  2297. Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States - (06/20/11)
     
  2298. Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study - (06/20/11)
     
  2299. IL-32 and HIV Persistence - (06/20/11)
     
  2300. HIV Reservoir Size - (06/20/11)
     
  2301. Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide population-based cohort study - (06/17/11)
     
  2302. Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis - (06/17/11)
     
  2303. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study: Vit D levels associated with HIV progression & mortality - (06/13/11)
     
  2304. Premature aging seen as issue for AIDS survivors - (06/13/11)
     
  2305. Increased Metabolic Rate May Lead to Accelerated Aging - (06/10/11)
     
  2306. Sirtuins, Aging, and Medicine - (06/10/11)
     
  2307. (Vitamin D Guidelines) Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline - (06/09/11)
     
  2308. 'Exercise Cuts Stroke Risk in Elderly' - (06/09/11)
     
  2309. Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy (ATHENA Cohort): "Cumulative exposure to CD4+ cell counts <200 cells/mm3 during cART was associated with an increased risk of infection-related non-AIDS-defining malignancies." - (06/01/11)
     
  2310. High Calcium Intake No Better for Bone Health - full text pdf below - (05/25/11)
     
  2311. Men Who Have Sex With Men, Risk Behavior, and HIV Infection: Integrative Analysis of Clinical, Epidemiological, and Laboratory Databases - (05/25/11)
     
  2312. Past as Prologue: The Refractory and Evolving HIV Epidemic Among Men Who Have Sex With Men editorial - (05/25/11)
     
  2313. Increasing Clarity on Bone Loss Associated With Antiretroviral Initiation - editorial - (05/24/11)
     
  2314. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women - (05/24/11)
     
  2315. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - pdf attached - (05/24/11)
     
  2316. Researchers Develop Molecular (gene therapy) Microbicide Protection Against HIV Infection: put gene therapy into CD4s in mice & this prevented HIV transmission - (05/23/11)
     
  2317. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up - pdf attached Original Article - (05/21/11)
     
  2318. Calcium supplements and cardiovascular risk - 2 Letters To Editor (response below) - (05/21/11)
     
  2319. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals: 'and to CD4 change after starting ART' - pdf attached - (05/19/11)
     
  2320. Low Vitamin D Levels Seen in Parkinson's Patients - full text of study below - - (05/19/11)
     
  2321. Vitamin D Status of HIV-Infected Women and Its Association with HIV Disease Progression, Anemia, and Mortality: "Women in the highest vitamin D quintile had a 42% lower risk of all-cause mortality, compared to the lowest quintile. Vitamin D status had a protective association with HIV disease progression, all-cause mortality" - (05/19/11)
     
  2322. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons - (05/18/11)
     
  2323. Cancer survivorship and sexual orientation - pdf attached - (05/11/11)
     
  2324. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors - pdf attached - (05/10/11)
     
  2325. Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy - pdf attached - (05/10/11)
     
  2326. Could we - should we - calculate a risk exposure score for an HIV-negative individual in a serodiscordant couple? Editorial Comment - (05/09/11)
     
  2327. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients - (05/09/11)
     
  2328. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 - (05/09/11)
     
  2329. Prostate cancer risk (and Metabolics) in the Swedish AMORIS study - pdf attached - (05/09/11)
     
  2330. Metabolic risk factors in prostate cancer - Editorial - (05/09/11)
     
  2331. Vaginal Microbicide Gel New NNRTI for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1 - pdf attached - (05/09/11)
     
  2332. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft - (05/07/11)
     
  2333. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure - (05/04/11)
     
  2334. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? - (05/02/11)
     
  2335. HIV Infection Ups Heart Failure Risk: "rate of incident heart failure was 7.12 per 1,000 person-years among those with HIV and 4.82 per 1,000 person-years in the rest of the cohort.....But the risk was not seen if baseline and recent HIV levels were less than 500 copies/mL" - (04/26/11)
     
  2336. Wrkshp Clin Pharm HIV: 12th International Workshop on Clinical Pharmacology of HIV Therapy Report by Courtney Fletcher, PharmD - Courtney V. Fletcher, Pharm.D. - (04/26/11)
     
  2337. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  2338. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  2339. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  2340. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  2341. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  2342. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  2343. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  2344. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  2345. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  2346. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  2347. How TRIM5 fights HIV - pdf attached - (04/20/11)
     
  2348. Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice: HIV invades CNS within 1-2 weeks after infection, progressive viral infection correlated with loss of neuronal integrity. - pdf attached - (04/20/11)
     
  2349. Wrkshp Clin Pharm HIV: Food and Fat Have Little Impact on Dolutegravir, a New Integrase Inhibitor - written by Mark Mascolini - (04/18/11)
     
  2350. Wrkshp Clin Pharm HIV: Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir - written by Mark Mascolini - (04/18/11)
     
  2351. Wrkshp Clin Pharm HIV: Lopinavir Troughs Lower in Children on Once-Daily Dose Plus Efavirenz - written by Mark Mascolini - (04/18/11)
     
  2352. Wrkshp Clin Pharm HIV: Atazanavir Levels Indicate Need for Higher Dose During Pregnancy - written by Mark Mascolini - (04/18/11)
     
  2353. Wrkshp Clin Pharm HIV: Four-in-One Drug Affects Levels of Oral Contraceptives Components - written by Mark Mascolini - (04/18/11)
     
  2354. Wrkshp Clin Pharm HIV: Older Age May Slow Clearance of Once-Daily Darunavir, Which Penetrates Cells Well - written by Mark Mascolini - (04/18/11)
     
  2355. Wrkshp Clin Pharm HIV: Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily - written by Mark Mascolini - (04/18/11)
     
  2356. Wrkshp Clin Pharm HIV: Impact of Stomach Acid Reducers on Cobicistat and Elvitegravir - written by Mark Mascolini - (04/18/11)
     
  2357. Wrkshp Clin Pharm HIV: Levels of Novel HIV Attachment Inhibitor With or Without Ritonavir - (04/15/11)
     
  2358. Wrkshp Clin Pharm HIV: Half-Dose Lamivudine Not Equivalent to Full Dose in Plasma or Cells - (04/15/11)
     
  2359. Wrkshp Clin Pharm HIV: HIV Infection Affects Cellular Pharmacology of Zidovudine and Lamivudine: 3TC for prevention - (04/15/11)
     
  2360. Wrkshp Clin Pharm HIV: Cobicistat Has Little Impact on Key Drug-Metabolizing Enzymes - (04/14/11)
     
  2361. Wrkshp Clin Pharm HIV: No Dolutegravir (GSK572, integrase) Dose Adjustment Needed With Efavirenz or Tipranavir/Ritonavir - (04/14/11)
     
  2362. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/13/11)
     
  2363. Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission - pdf attached - (04/13/11)
     
  2364. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/12/11)
     
  2365. CROI: Inflammation and Intervention: how does HIV cause AIDS and how does it cause disease despite ART - David Margolis, MD University of North Carolina - (04/11/11)
     
  2366. CROI: Vitamin D3 Supplementation Decreases Parathyroid Hormone (PTH) in HIV-Infected Youth Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: Randomized, Double-blind, Placebo-controlled Multicenter Trial Adolescent Trials Network (ATN) study 063 - (03/29/11)
     
  2367. CROI: No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis - (03/29/11)
     
  2368. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues - (03/29/11)
     
  2369. "Test and Treat": Is It Enough? - (03/28/11)
     
  2370. The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection - (03/28/11)
     
  2371. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT - (03/28/11)
     
  2372. CROI: Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)
     
  2373. CROI: Bone and Vitamin D at CROI 2011 - By Todd T. Brown, MD, PhD - (03/26/11)
     
  2374. CROI: Changes in Body Composition after Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir in Virologically Suppressed HIV-1-Infected Patients (SPIRAL-LIP substudy) - (03/26/11)
     
  2375. CROI: Bone & HIV CROI 2011 - (03/26/11)
     
  2376. CROI: COMPREHENSIVE LIPID EVALUATION IN PATIENTS SWITCHING FROM RITONAVIR BOOSTED PROTEASE INHIBITOR (PI/r)-BASED TO RALTEGRAVIR-BASED ANTIRETROVIRAL THERAPY: THE SPIRAL-met SUBSTUDY - (03/26/11)
     
  2377. CROI: Antiretroviral CNS Penetration-Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma - (03/24/11)
     
  2378. CROI: Early HAART in TB-Treated Patients Recommended in 2 Studies at CROI for Patients with <50 CD4s - (03/24/11)
     
  2379. CROI: Turnover Following Viral Control Correlates with Markers of Microbial Translocation in Treatment-Naïve Patients Receiving Raltegravir (RAL)- based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248 - (03/24/11)
     
  2380. CROI: CD4 Nadir Drives Persistence of Monocytes and T Lymphocytes Activation in Virologically Suppressed HIV-infected Patients - (03/24/11)
     
  2381. CROI: Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART - (03/24/11)
     
  2382. Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality J Am Coll Cardiol, March 29 2011 - (03/23/11)
     
  2383. Calcium and C-Reactive Protein Hot Enough to Predict the Future? - (03/23/11)
     
  2384. CROI: Bone Loss in HIV-Negatives in PrEP Study: 'a surprising percent of HIV-neg MSM had low bone mineral density before starting TDF, drug use associated with bone mineral density loss - vitamin D/calcium supplementation was protective'; in some HIV+ persons low BMD likely predated HIV-infection....in summary Kathy Mulligan said "it is not known whether there will be any long-term clinically important effects of PrEP with TDF/3TC (Truvada) on bone health" - (03/23/11)
     
  2385. CROI: CROI 2011 Immunology Report - written by David Margolis, MD, University of North Carolina (03/22/11)
     
  2386. CROI: BMD Loss in HIV TDF PrEP - 2 studies - (03/22/11)
     
  2387. CROI: Advances in PrEP - (03/22/11)
     
  2388. CROI: Adding Maraviroc Does Not Boost CD4s or Quiet T-Cell Activation - written by Mark Mascolini - (03/22/11)
     
  2389. CROI: Risk of Stage 1 AIDS Dementia 12% Over 2 Years in Asymptomatic People - written by Mark Mascolini - (03/22/11)
     
  2390. CROI: Sustained Response to Anti-HCV Therapy Higher During Acute Infection in HIV Positives - written by Mark Mascolini - (03/22/11)
     
  2391. CROI: Boceprevir Boosts Sustained Virologic Response Rate With HCV Genotype 1 - written by Mark Mascolini - (03/22/11)
     
  2392. CROI: Boceprevir Improves SVR With PegIFN/RBV After Failure or Relapse With HCV-1 - written by Mark Mascolini - (03/22/11)
     
  2393. Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients: "MVC achieves concentrations within the EC90 range in CSF. All patients with undetectable plasma viral load although receiving nucleoside-sparing regimens including new drugs showed viral suppression in CSF." - (03/21/11)
     
  2394. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/21/11)
     
  2395. CROI: HIV Affects Brain Immediately After Infection with HIV RNA in the CSF & Inflammation & Brain Injury Continues Unfolding During Chronic Infection & There is a Need for Routine Monitoring - (03/21/11)
     
  2396. CROI: Lowest CD4 Count Below 200, by Itself, Raises Heart Disease Risk With HIV: HIV Is a Risk Factor for Heart Disease - (03/21/11)
     
  2397. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors - (03/21/11)
     
  2398. CROI: High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam - (03/21/11)
     
  2399. CROI: Therapeutic Darunavir and Etravirine Concentrations in Cerebrospinal Fluid - (03/21/11)
     
  2400. CROI: Early Clearance of HCV RNA in HCV Genotype 1 Treatment-naïve Patients Treated with Telaprevir, Peginterferon and Ribavirin: Pooled Analysis of the Phase 3 Trials ADVANCE and ILLUMINATE - (03/21/11)
     
  2401. CROI: Trunk and Visceral Fat Gains With Atazanavir & Efavirenz in ACTG A5224s - written by Mark Mascolini - (03/20/11)
     
  2402. CROI: Vitamin D Supplements May Limit Tenofovir Bone Toxicity - written by Mark Mascolini - (03/20/11)
     
  2403. CROI: Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members - (03/19/11)
     
  2404. CROI: Comprehensive Lipid Evaluation in Patients Switching from PI/r-based cART to a RAL-based cART: The SPIRAL Substudy - (03/19/11)
     
  2405. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/19/11)
     
  2406. CROI: On-Treatment Viral Loads Fell Steadily Since 1997 in Large US-Canadian Analysis: diaparities for Blacks & IDUs - written by Mark Mascolini - (03/19/11)
     
  2407. CROI: Minocycline Does Not Improve HIV-Associated Neurocognitive Disorder - written by Mark Mascolini - (03/19/11)
     
  2408. CROI: Early Brain Injury Visualized in People With Recent HIV Infection - written by Mark Mascolini - (03/19/11)
     
  2409. CROI: Carotid Atherosclerosis Is Related to HIV Duration and Anti-inflammatory Profile and Not to ARV Exposure: The CHIC Controlled Study - (03/17/11)
     
  2410. CROI: D-dimer Levels Correlate with Inflammatory and Endothelial Activation Markers in HIV-infected Adults - (03/17/11)
     
  2411. CROI: (NIH Study) Circulating Markers of Endothelial Dysfunction, Coagulation and Tissue Fibrosis Prior to Incident Venous Thromboembolism in Patients with HIV Infection - (03/17/11)
     
  2412. CROI: Kinetics of Platelet Counts following Interruption of ART: Results from the SMART Study (coagulation pathways, HIV replication itself or inflammation) - (03/17/11)
     
  2413. CROI: Switch and Stop Rates 25% and 12% in First ART Year in 18-Cohort Study - written by Mark Mascolini - (03/17/11)
     
  2414. CROI: ATN 083: Longitudinal Changes in Cardiovascular Risk Markers among HIV Infected and at Risk Adolescents: "Endothelial dysfunction as measured by sVCAM-1 is higher in HIV+ adolescents than HIV- individuals" - (03/16/11)
     
  2415. CROI: Endothelial Dysfunction More Common in HIV-Positive Than Negative Adolescents - written by Mark Mascolini - (03/16/11)
     
  2416. CROI: Mortality With Acute Coronary Syndrome Higher in People With HIV - written by Mark Mascolini - (03/15/11)
     
  2417. CROI: Coronary Artery Plaque Linked to Low Fat in MACS Men With HIV - written by Mark Mascolini - (03/15/11)
     
  2418. CROI: Integrating Integrase Inhibitors and other antiretroviral stories - Joe Eron MD Professor of Medicine; UNC Chapel Hill - (03/15/11)
     
  2419. CROI: The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/15/11)
     
  2420. CROI: Low CD4 Count on Effective HAART is Associated With Immunologic and Vascular Dysfunction - (03/15/11)
     
  2421. CROI: Clinical Pharmacology at CROI 2011 (HIV & HCV) - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center (03/14/11)
     
  2422. CROI: Viral Load (But Not Antiretrovirals) and HCV Tied to 10-Year Fracture Risk: fracture risk higher in HIV+ vs HIV-neg - written by Mark Mascolini - (03/14/11)
     
  2423. CROI: Survival After Cancer Diagnosis Improves in US HIV Cohort: 'Incidence (new diagnoses) of AIDS cancers dropped, as did incidence of non-AIDS infection-related cancers. But incidence of non-AIDS cancers not related to infection rose since the arrival of triple antiretroviral therapy' - written by Mark Mascolini - (03/14/11)
     
  2424. CROI: Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy (ART) initiation (03/14/11)
     
  2425. CROI: Firstline HAART Causes Bone Loss (03/14/11)
     
  2426. CROI: Glycated Hemoglobin A1C as Screening for Diabetes Mellitus in HIV Infected Individuals (03/13/11)
     
  2427. CROI: Update on the "cure" and metabolic complications - written by Pablo Tebas MD University of Pennsylvania (03/13/11)
     
  2428. CROI: LOW BONE MASS IN BEHAVIORALLY HIV-INFECTED YOUNG MEN ON ANTIRETROVIRAL THERAPY: Adolescent Trials Network (ATN) Protocol 021B (03/13/11)
     
  2429. CROI: HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS (03/13/11)
     
  2430. CROI: Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation (03/13/11)
     
  2431. CROI: Recombinant Interleukin-7 (CYT107) Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-Infected Immunological Non-Responder Patients (03/13/11)
     
  2432. Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006 - pdf attached - (03/12/11)
     
  2433. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection (SMART Study): - pdf attached - (03/12/11)
     
  2434. CROI: Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks (03/12/11)
     
  2435. CROI: Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 datafrom the randomized, double-blind, Phase III ECHO and THRIVE trials (03/12/11)
     
  2436. Mediterranean [and exercise] Diet Helps Prevent Metabolic Syndrome, Abdominal Obesity, Elevated Lipids, Hypertension - pdf attached - (03/11/11)
     
  2437. CROI: Bone Effects of Rosiglitazone in HIV-Infected Patients with Lipoatrophy (03/11/11)
     
  2438. CROI: Recombinant IL-7 Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-infected Immunological Non-responder Patients (03/11/11)
     
  2439. CROI: Chronic Inflammation and HIV: CROI 2011 - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine (03/10/11)
     
  2440. HIV and Cancer in Germany - pdf attached - (03/10/11)
     
  2441. CROI: Nutritional Intervention with NR100157 Restores Gut Microbiota in HIV-1-infected Adults Not on HAART and Reduces Systemic Immune Activation (03/10/11)
     
  2442. CROI: Prompt, Significant Reduction of Activation and Proliferation Markers in CD4+ and CD8+ T Cell Subsets despite Incomplete Viral Suppression: Proof-of-Concept for AV-HALT-A New Class of Anti-HIV Therapeutics Inhibiting Both HIV Replication and Immune Activation (03/10/11)
     
  2443. CROI: Immunomodulatory Effects of Hydroxychloroquine in HIV-Infected ART-Treated Immunological Non Responders: 'reduces inflammation & activation' (03/10/11)
     
  2444. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors (03/10/11)
     
  2445. CROI: Diabetes Mellitus in Treated HIV-Infected Patients: Incidence over Ten Years in 1,046 patients from the ANRS CO8 APROCO-COPILOTE Cohort (03/10/11)
     
  2446. CROI: Invasive Anal Cancer Seen With Relatively High CD4s and Low HIV Loads - written by Mark Mascolini - (03/9/11)
     
  2447. CROI: Statins May Lower Risk of non-Hodgkin Lymphoma in People With HIV - written by Mark Mascolini - (03/9/11)
     
  2448. CROI: Earlier Occurrence of the Frailty Phenotype in HIV-1-infected Men than in HIV-uninfected Men in the Multicenter AIDS Cohort Study (MACS) - (03/9/11)
     
  2449. CROI: Prevalence and Prognostic Factors of Chronic Kidney Disease in HIV-infected Patients, HIV-NAT 006 Cohort, Thailand: "high prevalence of advanced chronic kidney disease...more diabetes/hypertension" - pdf attached - (03/9/11)
     
  2450. CROI: Aging and Non-HIV-associated Co-morbidity in HIV+ Persons: The SHCS - pdf attached - (03/9/11)
     
  2451. CROI: Microbial Translocation (MT)-induced Immune Activation Associates to Atherosclerosis in cART treated HIV pos Patients - (03/9/11)
     
  2452. CROI: Immunologic Failure Despite Suppressive ART Is Related to Increased Inflammation and Evidence of Microbial Translocation and Inflammation & Activation Persist Even Despite Immune Success - (03/9/11)
     
  2453. CROI: Renal Insufficiency among HIV-infected, ART-naïve Individuals in Lilongwe, Malawi: Implications for Tenofovir use in antiretroviral treatment and prevention of mother to child transmission programs. - (03/9/11)
     
  2454. CROI: Earlier Occurrence of the Frailty Phenotype in HIV+ Men than in HIV- Men: The MACS - (03/9/11)
     
  2455. CROI: Renal Insufficiency, Nephrotoxicity, and Mortality among HIV-infected Adults on TDF in a South African Cohort: A Marginal Structural Models Analysis - pdf attached - (03/9/11)
     
  2456. CROI: Cystain C - 'Lipid Particle Concentrations and Markers of Renal Disease: SMART' - Unfavorable lipoprotein levels were associated with elevated cystatin C levels, but not with impaired eGFR. Cystatin C may better detect earlier reductions in kidney function - (03/9/11)
     
  2457. CROI: Changing Patterns of Causes of Death in the Swiss HIV Cohort Study (SHCS) 2005-2009 - (03/9/11)
     
  2458. CROI: QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts) - (03/9/11)
     
  2459. CROI: CROI 2011 Report Selected Topics - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine - (03/8/11)
     
  2460. CROI: Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)
     
  2461. CROI: Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)
     
  2462. CROI: Liver Death Rate Twice Higher With HBV Than HCV in Gay HIV+ Men of MACS - written by Mark Mascolini - (03/8/11)
     
  2463. CROI: HIV, Black Race, and Multiple Partners Raise Risk of Repeat Syphilis in California Gays - written by Mark Mascolini - (03/8/11)
     
  2464. CROI: CD4 Decline Before ART Faster in More Recent Years in ATHENA Cohort: "may have implications for planning on when to start cART." - written by Mark Mascolini - (03/8/11)
     
  2465. CROI: The Kidney at CROI - Christina M. Wyatt, MD Assistant Professor, Medicine Nephrology Mount Sinai School of Medicine New York, NY - (03/8/11)
     
  2466. CROI: HIV Prevention at CROI 2011 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/8/11)
     
  2467. CROI: Steady-state pharmacokinetic parameters of nevirapine extended release formulation tablets in children with HIV-1 infection: an open-label, multiple-dose, cross-over study - (03/7/11)
     
  2468. CROI: Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years of Treatment (Tx): 156 Week (Wk) Results from STARTMRK - (03/7/11)
     
  2469. CROI: Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial - (03/7/11)
     
  2470. CROI: The Effect of Bimonthly Supplementation with Oral Cholecalciferol and Calcium on 2 Year Bone Mass Accrual in HIV-infected Children and Adolescents - (03/7/11)
     
  2471. CROI: Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration? - (03/7/11)
     
  2472. CROI: Central Fat Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202 - (03/7/11)
     
  2473. CROI: Decreased Limb Muscle and Increased Central Adiposity Are Associated with 5-Year All-cause Mortality in HIV Infection - (03/7/11)
     
  2474. CROI: Predictors of Chronic Kidney Disease in the SMART trial - (03/7/11)
     
  2475. Safety Review update of Abacavir: no statistically significant association seen between myocardial infarction and ABC - (03/05/11)
     
  2476. CROI: Maraviroc 300mg Once Daily + Darunavir/Ritonavir 800/100mg Once Daily Provides Maraviroc Trough Concentrations Comparable to Trough Concentrations in HIV-1 Patients Taking Maraviroc 300mg Twice Daily + Truvada: Implications for Phase 3 Studies - (03/5/11)
     
  2477. Once Daily Administration of Maraviroc Submitted to EMA & FDA - (03/05/11)
     
  2478. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy - pdf attached - (03/05/11)
     
  2479. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient: 2nd case report - pdf attached - (03/05/11)
     
  2480. Commentary Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule - pdf attached - (03/05/11)
     
  2481. CROI: Genotypic Analysis of Cellular HIV V3 DNA to Predict Virologic Response to Maraviroc: Performance of Population-based and 454 Deep V3 Sequencing - (03/5/11)
     
  2482. CROI: Gut-associated Lymphoid Tissue Fibrosis Is Associated with CD4+ T Cell Activation and Poor HIV-specific CD8+ T cell Responses During Suppressive Antiretroviral Therapy - (03/5/11)
     
  2483. CROI: Impaired Endothelial Function Is Associated with Increased Frequencies of CCR5+ and HIV-specific T cells During Treated HIV Infection - (03/5/11)
     
  2484. CROI: The Immunomodulatory Effects of Maraviroc Intensification among ART-suppressed Patients with Incomplete CD4 Recovery - (03/5/11)
     
  2485. CROI: Antiretroviral Therapy Initiation during Acute/Early HIV Infection vs. Later ART Initiation is Associated with Improved Immunologic and Virologic Parameters during Suppressive ART - (03/5/11)
     
  2486. CROI: Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients - (03/4/11)
     
  2487. CROI: Neuroprotective MVC Monotherapy in SIV-infected Macaques - (03/4/11)
     
  2488. CROI: Relative performance of ESTA, Trofile, 454 deep sequencing and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy experienced patients - (03/4/11)
     
  2489. CROI: Interrupted Antiretrovirals Raise Chronic Kidney Disease Risk 50% in SMART - written by Mark Mascolini - (03/4/11)
     
  2490. CROI: New Integrase Inhibitor Controls Toughest Raltegravir-Resistant Virus - written by Mark Mascolini - (03/4/11)
     
  2491. CROI: Diabetes Incidence in People With HIV Falling Since 1999-2000 in France - written by Mark Mascolini - (03/4/11)
     
  2492. CROI: Male-Female and White-Black ART Disparities Persist in US - written by Mark Mascolini - (03/4/11)
     
  2493. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks - written by Mark Mascolini - (03/4/11)
     
  2494. CROI: Post-Menopausal Women Have increased HIV transmission risk and Higher TDF Blood Levels - (03/3/11)
     
  2495. CROI: Creating an HIV-resistant Immune System: Using CXCR4 ZFN to Edit the Human Genome - (03/3/11)
     
  2496. CROI: Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/2/11)
     
  2497. CROI: Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011 - (03/2/11)
     
  2498. CROI: Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients - (03/2/11)
     
  2499. CROI: GSK1349572 Integrase in Raltegravir Resistant Patients - (03/2/11)
     
  2500. CROI: GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects - (03/2/11)
     
  2501. CROI: Diabetes and cIMT Linked to Worse Neurocognitive Performance With HIV written by Mark Mascolini - (03/2/11)
     
  2502. CROI: Poor CD4 Response Despite Undetectable Load Marked by Vascular and T-Cell Dysfunction written by Mark Mascolini - (03/2/11)
     
  2503. CROI: Vitamin D3 Supplements May Thwart Diabetes Emergence in People With HIV written by Mark Mascolini - (03/2/11)
     
  2504. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks written by Mark Mascolini - (03/2/11)
     
  2505. CROI: Duration of PIs or NNRTIs Has No Consistent Impact on Non-AIDS Cancer Rates written by Mark Mascolini - (03/2/11)
     
  2506. CROI: Low Limb Muscle, High Visceral Fat Double 5-Year Risk of Death in US Cohort written by Mark Mascolini - (03/2/11)
     
  2507. CROI: Vitamin D Boost Does Not Improve Endothelial Function With HIV written by Mark Mascolini - (03/2/11)
     
  2508. CROI: FDA Trial Meta-Analysis Does Not See Higher MI Risk With Abacavir written by Mark Mascolini - (03/2/11)
     
  2509. CROI: Cancer Risk Remains High for People Who Had AIDS as a Child written by Mark Mascolini - (03/2/11)
     
  2510. CROI: Sangamo's Gene Therapy for HIV is Safe, Helps Immune Cells in Early Trial - (03/2/11)
     
  2511. CROI: Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)
     
  2512. CROI: Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)
     
  2513. CROI: Lower "Community Viral Load" in SF Linked to Fewer New HIV Cases written by Mark Mascolini - (03/1/11)
     
  2514. CROI: Higher Fracture Rate With HIV + HCV Than With Either Virus Alone written by Mark Mascolini - (03/1/11)
     
  2515. CROI: Intensification With Raltegravir Has No Impact on Reservoir of Replicating Virus written by Mark Mascolini - (03/1/11)
     
  2516. CROI: Viral Load and CD4 Changes With Ritonavir-Boosted and Unboosted Attachment Inhibitor written by Mark Mascolini - (03/1/11)
     
  2517. CROI: HIV Duration, Not ART, Tied to Atherosclerosis Marker in Large Case-Control Study written by Mark Mascolini - (03/1/11)
     
  2518. CROI: Black Race Tied to Virologic Failure in ACTG Trials--But Blacks Gained More CD4s written by Mark Mascolini - (03/1/11)
     
  2519. CROI: Lower CD4 Count Before ART Tied to Higher Risk of Three Non-AIDS Diseases written by Mark Mascolini - (03/1/11)
     
  2520. CROI: In Gay Men Over 50, Frailty More Common With HIV Than Without (MACS) written by Mark Mascolini - (03/1/11)
     
  2521. CROI: Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, a Potentially First-in-Class Oral HIV Attachment Inhibitor - (03/1/11)
     
  2522. High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial - pdf attached - (02/26/11)
     
  2523. Statins as Anti-inflammatory Therapy in HIV Disease? Editorial - pdf attached - (02/26/11)
     
  2524. The Dual Impact of HIV-1 Infection and Aging on Naïve CD4+ T-Cells: Additive and Distinct Patterns of Impairment - From the Multicenter AIDS Cohort - (02/26/11)
     
  2525. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial - pdf attached - (02/18/11)
     
  2526. Testosterone Treatment of Older Men-Why Are Controversies Created? Editorial - (02/18/11)
     
  2527. Do the Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, And Quality of Life Persist Six Months after Treatment in Intermediate-Frail and Frail Elderly Men? - pdf attached - (02/18/11)
     
  2528. Why Is Androgen Replacement in Males Controversial? - CLINICAL REVIEW- pdf attached - (02/18/11)
     
  2529. HIV Regimens Similar but Not Equivalent - ACTG5202 efavirenz vs Reyataz/r + TDF/FTC or abacavir/3TC - (02/17/11)
     
  2530. Weighing the Benefits and Costs of HPV Vaccination of Young Men Perspective - (02/14/11)
     
  2531. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males - pdf attached - (02/14/11)
     
  2532. Gardasil in Older Women Aged 24-45 yrs old - (02/14/11)
     
  2533. HAART Reduces HPV - (02/14/11)
     
  2534. HIV CareLink newsletter for HIV/AIDS Primary Care Providers (Florida/Caribbean AIDS Education and Training Center - (02/14/11)
     
  2535. Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection - pdf attached - (02/14/11)
     
  2536. 'HIV Exposure Harms Infant Immunity' Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants - pdf attached - (02/14/11)
     
  2537. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis - pdf attached - (02/14/11)
     
  2538. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression - pdf attached - (02/14/11)
     
  2539. FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women - (02/12/11)
     
  2540. Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period - (02/12/11)
     
  2541. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry - pdf attached - (02/12/11)
     
  2542. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death - pdf attached - (02/12/11)
     
  2543. Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis - pdf attached - (02/06/11)
     
  2544. Association of Dietary Patterns With Albuminuria and Kidney Function Decline in Older White Women: A Subgroup Analysis From the Nurses' Health Study - pdf attached - (01/26/11)
     
  2545. HIV Infection, Inflammation, Immunosenescence, and Aging - pdf attached - (02/06/11)
     
  2546. 1st Int. Workshop on HIV & Aging Published REPORT pdf attached. 4 -5 October 2010, Baltimore, USA - (01/27/11)
     
  2547. Bone Mineral Density and Testicular Failure: Evidence for a Role of Vitamin D 25-Hydroxylase in Human Testis - pdf attached - (01/27/11)
     
  2548. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - pdf attached - (01/27/11)
     
  2549. What Do We Tell Our Patients about Calcium and Vitamin D Supplementation? EDITORIAL pdf attached - (01/27/11)
     
  2550. New Research Finds HIV causes rapid aging in key infection-fighting cells: "Successful ART treatment does not fully reconstitute the CD31-CD4+ naive T-cell subset"- pdf attached - (01/27/11)
     
  2551. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients - pdf attached - (01/24/11)
     
  2552. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy - pdf attached - (01/24/11)
     
  2553. Increasing incidence of ischemic stroke in patients with HIV infection: HIV, HAART, metabolics, median age 50, absolute numbers small - pdf attached - (01/20/11)
     
  2554. Gender, South, Race Affect Health Outcomes in HIV: - (01/19/11)
     
  2555. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
     
  2556. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
     
  2557. Triple antiretroviral prophylaxis during pregnancy and breastfeeding is safe and reduces the risk of HIV transmission to infants. pdf attached - (01/16/11)
     
  2558. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
     
  2559. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
     
  2560. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
     
  2561. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
     
  2562. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
     
  2563. Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population - pdf attached (this was presented in poster at CROI) - (01/14/11)
     
  2564. The Effect of Antiretrovirals on Vitamin D - pdf attached - (01/14/11)
     
  2565. HIV & Aging Slide Talk CME - (01/12/11)
     
  2566. Immune Activation & HCV-Infection: Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection - pdf attached - (01/12/11)
     
  2567. Fractures In Aging >50 Yrs Old: associated with antiepileptic drugs, comorbidities, hypertension osteoprotective - pdf attached - (01/12/11)
     
  2568. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
     
  2569. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
     
  2570. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
     
  2571. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
     
  2572. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - (01/11/11)
     
  2573. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - (01/11/11)
     
  2574. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - (01/11/11)
     
  2575. Liver Disease (ALTs/Fatty Liver) a Possible Predictor of Stroke - (01/11/11)
     
  2576. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort - pdf attached - (01/11/11)
     
  2577. Eradication/CNS Penetration: 'Eradication of HIV from the brain: reasons for pause' - pdf attached - (01/11/11)
     
  2578. Immune Senescence & Activation Associated with Heart Disease in HIV+ editorial - (01/11/11)
     
  2579. T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women - pdf attached - (01/11/11)
     
  2580. Aging with HIV: As HIV population grows older, diseases of aging are a new dilemma New Aging Study/Clinic at SFGH - (01/08/11)
     
  2581. Male circumcision and HPV transmission to female partners - Editorial - (01/08/11)
     
  2582. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda - pdf attached - (01/08/11)
     
  2583. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml - published pdf attached - (01/08/11)
     
  2584. Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study - pdf attached - (01/07/11)
     
  2585. Inflammation (lipodystrophy) Associated with Physical Performance Decline - (01/05/11)
     
  2586. Gait speed was associated with survival in older adults - (01/05/11)
     
  2587. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease - published pdf attached - (01/03/11)
     
  2588. Inflammation & Kidney Disease - (01/03/11)
     
  2589. Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl: kidney anti-inflammation drug - (01/03/11)
     
  2590. Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease - press release - (01/03/11)
     
  2591. 'Urinary Protein & Albumin Both Predict Mortality & Renal Outcomes' - Comparison of Urinary Albumin and Urinary Total Protein as Predictors of Patient Outcomes in CKD - (01/03/11)
     
  2592. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
     
  2593. Preventing Cancer in HIV+: keep CD4 >700 & viral load undetectable, start HAART Early, control inflammation - (12/30/10)
     
  2594. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  2595. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
     
  2596. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  2597. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
     
  2598. Editorial NeuroAIDS review - pdf attached - (12/22/10)
     
  2599. Brain Research Urged in Paper in AIDS: "HIV-1 infection and cognitive impairment in the cART-era: a review" - "studies....report abnormal scores on neuropsychological assessments in 15 - 50% of patients.....clinical course should be followed closely in large cohorts of patients.....promising therapies should be studied" - published pdf attached - (12/22/10)
     
  2600. Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer Disease - pdf attached - (12/22/10)
     
  2601. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health (vit D insufficiently defined)- publication pdf attached - (12/22/10)
     
  2602. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  2603. Alternate Marker (Cystatin C) Picks Out High-Risk CKD Patients - published text below, pdf attached - (12/19/10)
     
  2604. Lipoatrophy/Metabolics & Genetics: European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142 - pdf attached - (12/19/10)
     
  2605. Mitochondrial damage in adipose tissue of untreated HIV-infected patients - publication pdf attached - (12/19/10)
     
  2606. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations - publication pdf attached - (12/19/10)
     
  2607. Update on U.S. Prescribing Information for ZERIT (stavudine) - (12/19/10)
     
  2608. Capsid: New Class of HIV Drugs - (12/14/10)
     
  2609. Testosterone Deficiency and Replacement in Older Men - Editorial - (12/09/10)
     
  2610. Adverse Events Associated with Testosterone Administration - publication pdf attached - (12/09/10)
     
  2611. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study: 40-83% Neuro Impaired/33% asymptomatic/low nadir cd4 predicts/comorbidities contribute - published pdf attached - (12/08/10)
     
  2612. The persistence of HIV-associated neurocognitive dysfunction and the effects of comorbidities - Editorial - (12/08/10)
     
  2613. Insulin metabolism and the risk of Alzheimer disease - full txt from Neurology below pdf attached - (12/05/10)
     
  2614. 10th Congress Drug Therapy HIV: Nevirapine Versus Ritonavir-Boosted Atazanavir CombinedWith Tenofovir/ Emtricitabine in First-LineTherapy: NEWART 48-Week Data - (12/05/10)
     
  2615. Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System - published pdf attached - (12/02/10)
     
  2616. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - publication pdf attached - (12/02/10)
     
  2617. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study - pdf attached - (12/01/10)
     
  2618. mtDNA Damage & Heart Disease/End Organ Disease: Role of Pyrimidine Depletion in the Mitochondrial Cardiotoxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors - pdf attached - (12/01/10)
     
  2619. A randomized crossover study to compare efavirenz and etravirine treatment - pdf attached - (12/01/10)
     
  2620. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine - published pdf attached - (12/01/10)
     
  2621. Surgical correction of HIV-associated facial lipoatrophy - publication pdf attached - (12/01/10)
     
  2622. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort - pdf attached - (12/01/10)
     
  2623. Merck Reports Initial Results of Phase III Study of ISENTRESS® (raltegravir) Investigational Once-Daily Dosing in Treatment-Naïve Adult Patients Infected with HIV-1 - (11/30/10)
     
  2624. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men - publication pdf attached - (11/29/10)
     
  2625. Oral Preexposure Prophylaxis for HIV - Another Arrow in the Quiver? Editorial - (11/29/10)
     
  2626. Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection - published pdf attached - (11/29/10)
     
  2627. The Lesser-Known Complications (Bone) of HIV/AIDS (aging, complications) - (11/29/10)
     
  2628. Telomerase reverses ageing process (full text; published pdf attached) - (11/29/10)
     
  2629. 10th Congress Drug Therapy HIV: Analysis of BENCHMRK-1&2 Using PhenoSense Assay for Darunavir (DRV/r) Resistance and Exploration of Functional Monotherapy with RAL vs DRV - (11/29/10)
     
  2630. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) (2) - (11/22/10)
     
  2631. Race/ethnic differences in bone mineral densities in older men - pdf attached - (11/21/10)
     
  2632. Kidney Transplants in HIV+ Study published in NEJM: Tackling the Unknowns in HIV-Related Kidney Diseases/Editorial - full published study follows editorial below - pdf attached - (11/21/10)
     
  2633. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (11/18/10)
     
  2634. 10th Congress Drug Therapy HIV: Population and Ultra-Deep Sequencing for Tropism Determination Are Correlated With Trofile-ES. Genotypic Re-Analysis of the A4001078 Maraviroc Study - (11/18/10)
     
  2635. 10th Congress Drug Therapy HIV: No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects - (11/18/10)
     
  2636. 10th Congress Drug Therapy HIV: The 10-Year Safety and Efficacy of Tenofovir DF (TDF)-Containing HAART in Antiretroviral Naïve Patients - (11/18/10)
     
  2637. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  2638. 10th Congress Drug Therapy HIV: The 5 Year Safety and Efficacy of the Once-Daily Antiretroviral-Naïve Patient Regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) - (11/18/10)
     
  2639. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  2640. 10th Congress Drug Therapy HIV: Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) Plus EFV Leads to Improved Perceptions of Treatment: Results from the ROCKET 1 Study - (11/18/10)
     
  2641. 10th Congress Drug Therapy HIV: New Nonnucleoside Retains Activity Against Some Virus Resistant to Etravirine - (11/18/10)
     
  2642. 10th Congress Drug Therapy HIV: Activity of Integrase Inhibitor, S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Week 24 Results of VIKING Study (ING112961) - (11/17/10)
     
  2643. 10th Congress Drug Therapy HIV: PK/PD Modeling Supports Dose Escalation Decision in VIKING (50 mg twice-daily for highly raltegravir resistant patients) - (11/17/10)
     
  2644. 10th Congress Drug Therapy HIV: Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile (activity vs etravirine resistance) - (11/17/10)
     
  2645. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc, Zidovudine and Lamivudine (CBV) in Treatment-Naive Patients - (11/17/10)
     
  2646. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients - (11/17/10)
     
  2647. 10th Congress Drug Therapy HIV: Once-Daily S/GSK1349572 Combination Therapy in Antiretroviral-Naïve Adults: Rapod and Potent 24-Week Antiviral Responses on SPRING-1 Antiviral Responses - (11/17/10)
     
  2648. 10th Congress Drug Therapy HIV: The SENSE trial: Etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients - (11/16/10)
     
  2649. 10th Congress Drug Therapy HIV: Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE - (11/16/10)
     
  2650. 10th Congress Drug Therapy HIV: Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III ECHO and THRIVE trials - (11/16/10)
     
  2651. 10th Congress Drug Therapy HIV: Neuropscyh Side Effect Rate Lower With Etravirine Than Efavirenz at 12 Weeks - Written by Mark Mascolini - (11/15/10)
     
  2652. 12th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Comparison of Bone and Renal Toxicities in the ASSERT Study: Final 96-Week Results From a Prospective Randomised Safety Trial - (11/15/10)
     
  2653. 10th Congress Drug Therapy HIV: METABOLIK: Week 48 Comparison of Metabolic Parameters and Biomarkers in Subjects Receiving Darunavir/ritonavir or Atazanavir/ritonavir - (11/15/10)
     
  2654. 10th Congress Drug Therapy HIV: Switching from Kivexa (KVX) + Efavirenz (EFV) to Atripla (ATR) Reduces Total Cholesterol in Hypercholesterolemic Subjects: Final Results of a 24-week, Randomised Study - (11/15/10)
     
  2655. 10th Congress Drug Therapy HIV: Pooled Week 48 safety and efficacy results from the ECHO and THRIVE Phase III trials comparing TMC278 vs efavirenz in treatment-naïve HIV-1-infected patients - (11/15/10)
     
  2656. 10th Congress Drug Therapy HIV: European Panel Recommends Either Geno (g2p) or Pheno (ESTA) for Tropism Testing - Written by Mark Mascolini - (11/12/10)
     
  2657. 10th Congress Drug Therapy HIV: New S/GSK Integrase Inhibitor Looks Good at 24 Weeks in Phase 2 Trial - Written by Mark Mascolini - (11/12/10)
     
  2658. 10th Congress Drug Therapy HIV: Higher AIDS and non-AIDS Rates With Uncontrolled HIV Despite CD4s Over 350 - Written by Mark Mascolini - (11/12/10)
     
  2659. 10th Congress Drug Therapy HIV: Major and Minor PI Mutations in MONET Darunavir Monotherapy Trial - Written by Mark Mascolini - (11/12/10)
     
  2660. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in EuroSIDA Linked to All-Cause Mortality and AIDS - Written by Mark Mascolini - (11/12/10)
     
  2661. 10th Congress Drug Therapy HIV: Long-Term T-cell Changes With Maraviroc in Four Randomized Trials - Written by Mark Mascolini - (11/12/10)
     
  2662. 10th Congress Drug Therapy HIV: Adding Maraviroc Does Not Boost CD4s in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  2663. 10th Congress Drug Therapy HIV: Pretreatment Coreceptor Preference Affects Virologic Response in Naive - Written by Mark Mascolini - (11/12/10)
     
  2664. 10th Congress Drug Therapy HIV: Atazanavir/RTV Stopped Less Than Other Key First-Line Drug in Large French Analysis - Written by Mark Mascolini - (11/12/10)
     
  2665. 10th Congress Drug Therapy HIV: Muscle Weakness or Pain Analyzed as Possible Raltegravir Side Effect - Written by Mark Mascolini - (11/12/10)
     
  2666. 10th Congress Drug Therapy HIV: Switch to Twice-Daily Unboosted Atazanavir Outdoes Switch to Once-Daily Dose - Written by Mark Mascolini - (11/12/10)
     
  2667. 10th Congress Drug Therapy HIV: Switching From ABC/3TC to TDF/FTC Cuts Lipids in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  2668. 10th Congress Drug Therapy HIV: Dual Combo of Darunavir/Ritonavir and Etravirine Assessed in London Clinic - Written by Mark Mascolini - (11/10/10)
     
  2669. 10th Congress Drug Therapy HIV: NRTI Exposure Tied to Age-Linked Mitochondrial DNA Deletions - Written by Mark Mascolini - (11/10/10)
     
  2670. 10th Congress Drug Therapy HIV: Anemia in SMART Study Tied to Risk of non-AIDS Disease and Death - Written by Mark Mascolini - (11/10/10)
     
  2671. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in HCV/HIV-Coinfected People in the UK - Written by Mark Mascolini - (11/10/10)
     
  2672. 10th Congress Drug Therapy HIV: Differing HCV Response Rates Depending on HIV in Prospective German Cohort - Written by Mark Mascolini - (11/10/10)
     
  2673. 10th Congress Drug Therapy HIV:Extensive Three-Class Resistance May No Longer Predict Progression or Death - Written by Mark Mascolini - (11/09/10)
     
  2674. 10th Congress Drug Therapy HIV:Darunavir Mutation Rate Dropping in Large Clinical Sample Survey - Written by Mark Mascolini - (11/09/10)
     
  2675. 10th Congress Drug Therapy HIV:More Drugs in Regimen--Not Just More Pills--Hurt Adherence - Written by Mark Mascolini - (11/09/10)
     
  2676. 10th Congress Drug Therapy HIV:PI MONOTHERAPY - Darunavir Monotherapy Equivalent to Triple Therapy in Meta-Analysis - Written by Mark Mascolini - (11/09/10)
     
  2677. 10th Congress Drug Therapy HIV:Switch From Suppressive PI to Abacavir Combo Not Effective in French Cohort Study - Written by Mark Mascolini - (11/09/10)
     
  2678. 10th Congress Drug Therapy HIV:Small But Significant CD4 Gains When Switching Antiretrovirals With Sub-50 Load - Written by Mark Mascolini - (11/09/10)
     
  2679. 10th Congress Drug Therapy HIV:One Third in Large UK HIV Survey Have Fractures, 14% of Them Osteoporotic - Written by Mark Mascolini - (11/09/10)
     
  2680. 10th Congress Drug Therapy HIV: Lifetime Spine Fracture Risk Greater With Than Without HIV in UK Comparison - Written by Mark Mascolini - (11/08/10)
     
  2681. 10th Congress Drug Therapy HIV: Long-Term Resistance Rate Low When Starting ART Within Year of HIV Diagnosis - Written by Mark Mascolini - (11/08/10)
     
  2682. 10th Congress Drug Therapy HIV: Good Adherence Lowers Hospital Risk 40% in Insured US Patients With HIV - Written by Mark Mascolini - (11/08/10)
     
  2683. FDA and CONRAD Chart U.S. Regulatory Path for 1% Tenofovir Gel for HIV Prevention: FDA has granted Fast Track approval designation for 1% tenofovir gel - (11/01/10)
     
  2684. Aspirin to prevent colorectal cancer: time to act? Editorial - (10/28/10)
     
  2685. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials - pdf attached - (10/28/10)
     
  2686. Calcium & Heart Disease - (10/28/10)
     
  2687. Cancer and viral infections in immunocompromised individuals - pdf attached - (10/26/10)
     
  2688. Cancer incidence and risk factors after solid organ transplantation - pdf attached - (10/26/10)
     
  2689. Excess Mortality for Non-AIDS-Defining Cancers among People with AIDS - (10/22/10)
     
  2690. Novel Bone Drug (odanacatib, cathepsin K inhibitor) Found Safe After Four Years - (10/22/10)
     
  2691. Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study - pdf attached - (10/22/10)
     
  2692. Low Bone Mineral Density with Tenofovir: Does Statistically Significant Mean Clinically Significant? - EDITORIAL COMMENTARY - (10/22/10)
     
  2693. Immunosenescence & Aging in HIV - (10/22/10)
     
  2694. Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens - pdf attached - (10/22/10)
     
  2695. Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV - pdf attached - (10/22/10)
     
  2696. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals: does low-level viremia cause non-AIDS comorbidities? - (10/21/10)
     
  2697. Mixed Analysis Findings Adds to Evidence of Unusual Bone Fractures and Bisphosphonates - (10/21/10)
     
  2698. Early Bone Loss Marker Predicts Fracture Risk Later - (10/21/10)
     
  2699. Low-Carb Diets and Mortality - (10/20/10)
     
  2700. Teriparatide for Bone Loss in the Jaw - Editorial - (10/19/10)
     
  2701. "initiating HAART at higher CD4 cell counts for older individuals may be useful- NA-ACCORD Study" - pdf attached - (10/18/10)
     
  2702. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw - (10/18/10)
     
  2703. Teriparatide and Osseous Regeneration in the Oral Cavity - (10/18/10)
     
  2704. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/18/10)
     
  2705. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/16/10)
     
  2706. Boosting Dose Ritonavir Does Not Alter Peripheral Insulin Sensitivity in Healthy HIV-Seronegative Volunteers - (10/16/10)
     
  2707. Biomarkers of impaired renal function - pdf attached - (10/16/10)
     
  2708. Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort - pdf attached - (10/16/10)
     
  2709. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey - pdf attached - (10/16/10)
     
  2710. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study - pdf attached - (10/14/10)
     
  2711. Aging Wrkshp: CD4 Counts Lower on Entry Into Care Among People 50 and Older: NA-ACCORD - (10/13/10)
     
  2712. ICAAC: A Phase-Ib/IIa dose-escalation study for evaluation of the safety, tolerability, and pharmacokinetics of OBP-601 (4'-ethynyl-d4T, Festinavir) in treatment-experienced, HIV-1-infected patients - (10/13/10)
     
  2713. Insulin Resistance a Possible Causal and Treatable Risk Factor for Ischemic Stroke - editorial - pdf attached - full text from original study below - (10/13/10)
     
  2714. HCV Neurotoxicity & Inflammation Additive in Brain in HIV+ Person - pdf attached - (10/13/10)
     
  2715. Aging Wrkshp: Low Vitamin D Not Linked to Bone Density or Liver Fibrosis in HIV/HCV Group - Written by Mark Mascolini - (10/08/10)
     
  2716. Aging Wrkshp: Multiple non-AIDS Diseases More Frequent in Aging IDUs With Versus Without HIV - Written by Mark Mascolini - (10/08/10)
     
  2717. Aging Wrkshp: Family History of Dementia Predicts Worse Neuropsych Function With HIV (dementia defined below) - Written by Mark Mascolini - (10/08/10)
     
  2718. Severe Hypoglycemia and Risks of Vascular Events and Death - (10/07/10)
     
  2719. Aging Wrkshp: Aging HIV+ Hospitalized More Often: Non-AIDS Infections, Heart and GI Disease Explain Most Hospitalizations in Over-50 People With HIV - Written by Mark Mascolini - (10/07/10)
     
  2720. Aging Wrkshp: HIV-Infected in 40s Have Multiple Non-HIV Illnesses as Often as HIV-Negatives in 50s - Written by Mark Mascolini - (10/07/10)
     
  2721. Aging Wrkshp: Comorbidity Rates Higher in Over-49 HIV Group Than in Matched HIV Negatives - Written by Mark Mascolini - (10/07/10)
     
  2722. HIV and Premature Aging: A Field Still in Its Infancy - Editorial: "Age at Cancer Diagnosis Among Persons With AIDS in the United States" (pdf of published study attached) - (10/06/10)
     
  2723. Aging Wrkshp: Sexual Function Worse With HIV Than Diabetes or No Chronic Illness in Older Men - Written by Mark Mascolini - (10/06/10)
     
  2724. Aging Wrkshp: Older Age, HIV, and Antiretrovirals Linked to Neurodegenerative Marker - Written by Mark Mascolini - (10/06/10)
     
  2725. Aging Wrkshp: More Non-HIV Illnesses With HIV Than Without, But Less Treatment; New HCV therapy will add to burden - Written by Mark Mascolini - (10/06/10)
     
  2726. Aging Wrkshp: Older Women With HIV Report "Premature Aging" Strikingly More Often Than Men - Written by Mark Mascolini - (10/06/10)
     
  2727. Aging Wrkshp: Higher Risk of Potential Drug-Drug Interactions in Toronto HIV Patients Over 60 - Written by Mark Mascolini - (10/05/10)
     
  2728. Aging Wrkshp: Lipoatrophy and Efavirenz Tied to Vitamin D Deficiency in Ontario - Written by Mark Mascolini - (10/05/10)
     
  2729. Aging Wrkshp: Pretreatment CD4s and CD4/CD8 Ratio Lower in Trial Participants Over 50 - Written by Mark Mascolini - (10/05/10)
     
  2730. Aging Wrshp: Age Raises Fracture Risk More in People With Than Without HIV - Written by Mark Mascolini - (10/05/10)
     
  2731. The new face of HIV/AIDS in Jacksonville (Black women): Rising disease rates strip away our stereotypes - (10/04/10)
     
  2732. ICAAC: ICAAC 2010 Report by David Margolis MD University of North Carolina - (10/04/10)
     
  2733. ICAAC: Associations between Protease Inhibitors (PIs) and QTc and PR Interval Durations in the Strategies for Management of Antiretroviral Therapy (SMART) Trial - poster pdf attached - (10/04/10)
     
  2734. ICAAC: Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients: "Early vRNA decay is significantly correlated with greater increases in CD4 (absolute and %) change from baseline at Wk 96" - (10/04/10)
     
  2735. ICAAC: HIV At ICAAC 2010: Complications & Co-Infections - Written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (09/28/10)
     
  2736. Early HAART, Within 6 Months of Infection Preserves Immunity Better Than HAART in Chronic Infection - (09/27/10)
     
  2737. Osteoporosis: adherence needs to top two-thirds to cut fracture risk - (09/27/10)
     
  2738. Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus (this can work in HIV for anyone) - pdf attached - (09/27/10)
     
  2739. Diabetes, Alzheimer disease, and vascular dementia: Diabetes at baseline doubled the incidence of dementia, AD, and VaD, and increased mortality - pdf attached - (09/27/10)
     
  2740. ICAAC: ICAAC PK Report - (09/26/10)
     
  2741. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues - pdf attached - (09/25/10)
     
  2742. Body Fat & Bone Loss: lipoatrophy & belly fat accumulation BOTH lead to bone loss - (09/25/10)
     
  2743. Bisphosphonates and Reports of Unusual Broken Bones in the Femur (Thigh Bone) - (09/24/10)
     
  2744. GRACE Study in HIV+ Women of Color: racial & gender health disparities in HIV - (09/24/10)
     
  2745. GRACE Study: Sex-Based Outcomes (88% of women were women of color in the study, 67% black women, so results reflect on needs of black women with HIV in the USA) were of Darunavir-Ritonavir Therapy A Single-Group Trial - pdf attached - (09/24/10)
     
  2746. Coronary Aging in HIV-Infected Patients - (09/23/10)
     
  2747. Coronary Aging in HIV-Infected Patients: "Increased vascular age was observed in 162 patients (40.5%), with an average increase of 15 years"...."you are 50 years old but your heart's age is 65" - pdf attached - (09/23/10)
     
  2748. Immune senescence in aged nonhuman primates Review - (09/23/10)
     
  2749. Prevalence and Correlates of Sexual Behavior and Risk Management Among HIV-Positive Adults Over 50 - pdf attached - (09/23/10)
     
  2750. Persistence of Racial Differences in Attitudes Toward Homosexuality in the United States.....may help to explain disparities in HIV-infection rates between black & white MSM - pdf attached - (09/23/10)
     
  2751. ICAAC: Once-Daily Nevirapine XR Noninferior to Continued Twice-Daily Nevirapine - Written by Mark Mascolini - (09/19/10)
     
  2752. ICAAC: Clinical, Virological and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 (09/19/10)
     
  2753. ICAAC: Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population (09/19/10)
     
  2754. ICAAC: 48-week resistance and efficacy subgroup analysis of once- versus twice-daily darunavir/ritonavir in ODIN (09/19/10)
     
  2755. ICAAC: Comparison of Quest Diagnostics to Trofile and Trofile-ES Coreceptor Tropism Assays for Predicting Virologic Response to Maraviroc (MVC), a CCR5 Antagonist (09/19/10)
     
  2756. ICAAC: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the MERIT Study (09/19/10)
     
  2757. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
     
  2758. ICAAC: Advanced Fibrosis Triples All-Cause Mortality With HCV and HIV - Written by Mark Mascolini - (09/16/10)
     
  2759. ICAAC: CCR5 Antagonists Have No Special CD4-Boosting Power in Meta-Analysis (from Jules: I don't buy this) - Written by Mark Mascolini - (09/16/10)
     
  2760. ICAAC: Once-Daily Nevirapine Noninferior to Twice-Daily Dose in Treatment Naive - Written by Mark Mascolini - (09/16/10)
     
  2761. Ageing and HIV/AIDS (Aging/HIV Clinic in London): A dedicated clinical service for HIV-infected individuals over 50 years of age (09/16/10)
     
  2762. Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers - pdf attached - "we recommend a DXA scan for all HIV-infected post-menopausal women and men >50 years" - (09/17/10)
     
  2763. ICAAC: 48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients (09/15/10)
     
  2764. ICAAC: Efficacy and Long-Term Safety of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat (09/15/10)
     
  2765. ICAAC: The Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; "QUAD") Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks (09/15/10)
     
  2766. Development of new HIV drug targeting a cofactor of the cell - Ledgins - Pfizer - pdf attached - (09/15/10)
     
  2767. ICAAC: Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected - Written by Mark Mascolini - (09/15/10)
     
  2768. ICAAC: GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy - Written by Mark Mascolini - (09/15/10)
     
  2769. ICAAC: Atazanavir Without Ritonavir Sustains Virologic Suppression 120 Weeks in ARIES - Written by Mark Mascolini - (09/15/10)
     
  2770. ICAAC: Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla - Written by Mark Mascolini - (09/15/10)
     
  2771. ICAAC: Final Results from Stage 1 of a Double-Blind, Placebo-Controlled Trial with TMC207 in Patients with Multi-Drug Resistant (MDR) Tuberculosis (TB) (09/15/10)
     
  2772. ICAAC: Switching from ABC/3TC + Efavirenz [EFV] to TDF/FTC/EFV [Atripla, ATR] Reduces Cholesterol in Hypercholesterolemic Subjects: 24-Week Final Results of a Randomised Study (09/15/10)
     
  2773. ICAAC: New GSK761 NNRTI (09/15/10)
     
  2774. ICAAC: GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies (09/15/10)
     
  2775. ICAAC: TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine - Written by Mark Mascolini - (09/15/10)
     
  2776. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release (09/15/10)
     
  2777. ICAAC: Four-Drug Single-Pill Antiretroviral Equivalent to Atripla at 48 Weeks - Written by Mark Mascolini - (09/15/10)
     
  2778. ICAAC: High Rates of Bone Loss and Progression With HIV in Longitudinal Study - Written by Mark Mascolini - (09/15/10)
     
  2779. ICAAC: Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir - Written by Mark Mascolini - (09/15/10)
     
  2780. ICAAC: Raltegravir Re-Use Response After Failure Depends on Mutation Pattern - Written by Mark Mascolini - (09/15/10)
     
  2781. ICAAC: Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure - Written by Mark Mascolini - (09/15/10)
     
  2782. ICAAC: Longer Antiretroviral Therapy Favors Return to Normal HDL-C - Written by Mark Mascolini - (09/15/10)
     
  2783. ICAAC: Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir - Written by Mark Mascolini - (09/15/10)
     
  2784. ICAAC: Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE - (09/15/10)
     
  2785. ICAAC: 24 Wk Efficacy and Safety of Transitioning Virologically Stable HIV-1 Patients from IR Nevirapine 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (09/15/10)
     
  2786. ICAAC: Induction/Maintenance-Simplification: Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial - (09/15/10)
     
  2787. ICAAC: TMC-207 New TB Drug from Tibotec - New Drug Speeds Response in MDR TB - (09/15/10)
     
  2788. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release - (09/14/10)
     
  2789. ICAAC: Two Doses of Hep A Vaccine in HIV+ Men Equivalent to One Dose in HIV- Men - Written by Mark Mascolini - (09/14/10)
     
  2790. ICAAC: Reduction in Visceral Adipose Tissue (VAT) with Tesamorelin Correlates with Changes in Anthropometric, and Patient-Reported Outcome (PRO) Parameters in HIV+ Patients with Excess Abdominal Fat - (09/14/10)
     
  2791. ICAAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (09/14/10)
     
  2792. ICAAC: Vitamin D Deficiency & Bone Loss in Europe - (09/14/10)
     
  2793. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid - published pdf attached - (09/13/10)
     
  2794. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells - (09/13/10)
     
  2795. AIDS Cure Quest to Kill 'Sleeping' Viruses Enlists Merck Cancer Medicine - (09/13/10)
     
  2796. PARKINSONISM IN HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY - (09/13/10)
     
  2797. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort - (09/13/10)
     
  2798. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection - pdf attached - (09/13/10)
     
  2799. Aging Exacerbates Extrapyramidal Motor Signs in the Era of HAART - (09/13/10)
     
  2800. ICAAC: ECG Abnormalities With PIs Versus NNRTIs in SMART Trial - Written by Mark Mascolini - (09/13/10)
     
  2801. ICAAC: One Third on First-Line Antiretrovirals Have Clinically Significant Drug Interactions - Written by Mark Mascolini - (09/13/10)
     
  2802. ICAAC: Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (low troughs, a few viral rebounds) - Written by Mark Mascolini - (09/13/10)
     
  2803. ICAAC: Staph Rate Falling in HIV+ Danes, But Still High vs General Population - Written by Mark Mascolini - (09/13/10)
     
  2804. Microalbuminuria Is Associated With All-Cause and AIDS Mortality in Women With HIV Infection - pdf attached - (09/10/10)
     
  2805. New UCSF Anal Cancer Information Website - (09/09/10)
     
  2806. Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice - (09/09/10)
     
  2807. Oral bisphosphonates and oesophageal cancer - 'evidence inconclusive' Editorial - (09/09/10)
     
  2808. Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer - 2nd study 'no difference in risk' - (09/09/10)
     
  2809. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (09/07/10)
     
  2810. Nevirapine Reuse Possible in Exposed Children With HIV - (09/07/10)
     
  2811. IAC: Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP - (07/23/10)
     
  2812. IAC/Vienna AIDS Conference: Encouraging Advances Amid Funding Worries for Global Treatment - JAMA - (09/07/10)
     
  2813. 'Low' viral load depletes CD4s: Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion - pdf attached - (09/07/10)
     
  2814. 'hypercholesterol, hypertension, prior CVD associated with poor neurologic performance in SMART' factors: 'reported Increased vascular aging in HIV, inflammation, Hepatitis, immunosenescence, insulin resistance...... - (09/07/10)
     
  2815. 'IL28B Predicts SVR in Coinfection, Associated With 2-Fold Higher Rate of SVR' - published pdf attached - (09/07/10)
     
  2816. Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/µL? - (08/30/10)
     
  2817. High Rates of Asymptomatic Neurocognitive Impairment in Vertically Acquired HIV-1-Infected Adolescents Surviving to Adulthood - (08/29/10)
     
  2818. High prevalence of reduced bone mineral density in primary HIV-1-infected men - (08/29/10)
     
  2819. CD4 Predicts acute renal failure: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure - (08/29/10)
     
  2820. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses - (08/29/10)
     
  2821. Opioid Use & Bone Loss: Prospective study of bone mineral density changes in aging men with or at risk for HIV infection - (08/29/10)
     
  2822. IAC: Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV - (08/29/10)
     
  2823. Neurologic disease burden in treated HIV/AIDS predicts survival A population-based study - (08/26/10)
     
  2824. Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor - published pdf attached - (08/25/10)
     
  2825. Potential HIV Drug Keeps Virus out of Cells: "PIE12-trimer is an entry-inhibitor, has the potential to work as a microbicide to prevent people from contracting HIV and as a treatment for HIV infected people." published study pdf attached - (08/25/10)
     
  2826. Development of National and Multiagency HIV Care Quality Measures - (08/19/10)
     
  2827. Quality of Care for Patients Infected with HIV - EDITORIAL COMMENTARY - (08/19/10)
     
  2828. IAC: IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina - (08/16/10)
     
  2829. IAC: A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results - (08/15/10)
     
  2830. IAC: Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy - (08/15/10)
     
  2831. IAC: Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks - (08/15/10)
     
  2832. HIV and Low CD4 Increases Risk for Heart Disease - (08/13/10)
     
  2833. After CAPRISA 004: time to re-evaluate the HIV lexicon - 'oral PrEP has greater likelihood for success' - (08/13/10)
     
  2834. Cardiovascular effects of marine omega-3 fatty acids - Review - publication pdf attached - (08/13/10)
     
  2835. Cognitive Decline Biomarkers-HIV Studies Needed !!!! - (08/13/10)
     
  2836. Plasma β-Amyloid and Cognitive Decline - publication pdf attached - (08/12/10)
     
  2837. Raltegravir Intensification Did Not Reduce Residual Viremia PLoS Medicine published - (08/11/10)
     
  2838. IAC: SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment - (08/10/10)
     
  2839. IAC: The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients - (08/10/10)
     
  2840. Persistent Microbial Translocation and Immune Activation in HIV-1-Infected South Africans Receiving Combination Antiretroviral Therapy - (08/10/10)
     
  2841. Can HIV be cured with stem cell therapy? commentary - (08/10/10)
     
  2842. IAC: Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses - (08/10/10)
     
  2843. IAC: The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients - (08/10/10)
     
  2844. IAC: Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks - (08/10/10)
     
  2845. IAC: A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results - (08/10/10)
     
  2846. IAC: HBV related complications in HIV positive patients during HAART therapy - LAM resistance and high serum HBV-DNA & advancd liver disease - (08/10/10)
     
  2847. IAC: Vienna Declaration: 'decriminalize illicit drug use as an HIV prevention measure' - (08/10/10)
     
  2848. High prevalence of reduced bone mineral density in primary HIV-1-infected men - publication pdf attached - (08/08/10)
     
  2849. C-Reactive Protein Levels Increase During HIV-1 Disease Progression in Rakai, Uganda, Despite the Absence of Microbial Translocation - publication pdf attached - (08/07/10)
     
  2850. HPV-associated head and neck cancer: a virus-related cancer epidemic Review - pdf attached - (08/07/10)
     
  2851. Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1-Infected Patients - publication pdf attached - (08/07/10)
     
  2852. Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy - publication pdf attached - (08/07/10)
     
  2853. IAC: Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10)
     
  2854. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  2855. Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury - (08/04/10)
     
  2856. Heart Disease in HIV: 64-slice multidetector row computed tomography coronary angiography predicts outcome, are we evaluating risk for heart disease in HIV correctly? - (08/04/10)
     
  2857. Failing Heart Linked to Failing Brain - attached are both pdfs, the article & a commentary from the Jnl of the Am Heart Ass Epub - (08/04/10)
     
  2858. Following is a statement by the National Osteoporosis Foundation on Bone Mineral Density Testing - (08/04/10)
     
  2859. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (08/04/10)
     
  2860. IAC: Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF - (08/04/10)
     
  2861. IAC: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (08/04/10)
     
  2862. IAC: Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) - (08/04/10)
     
  2863. IAC: Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study - (08/04/10)
     
  2864. IAC: The impact of switching to etravirine on efavirenz-related CNS toxicity - (08/04/10)
     
  2865. IAC: Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 - (08/04/10)
     
  2866. IAC: Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population - (08/04/10)
     
  2867. IAC: Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program - (08/04/10)
     
  2868. IAC: Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: "34% Reduction in Mortality in Early Arm" - (08/04/10)
     
  2869. IAC: Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data - (08/04/10)
     
  2870. IAC: Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 - written by Mark Mascolini - (07/29/10)
     
  2871. IAC: HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10)
     
  2872. Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients - full text pdf attached - (07/27/10)
     
  2873. IAC: Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada - written by Mark Mascolini - (07/27/10)
     
  2874. IAC: Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir - written by Mark Mascolini - (07/27/10)
     
  2875. IAC: Tenofivir Once-Daily PrEP in MSM Friday Late Breaker - (07/27/10)
     
  2876. IAC: The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline - (07/27/10)
     
  2877. IAC: Abacavir vs Tenofovir - Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration - (07/27/10)
     
  2878. IAC: Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms - written by Mark Mascolini - (07/27/10)
     
  2879. IAC: Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen - written by Mark Mascolini - (07/26/10)
     
  2880. IAC: Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir - written by Mark Mascolini - (07/26/10)
     
  2881. IAC: HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women's Study - (07/26/10)
     
  2882. IAC: Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic - (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) - (07/26/10)
     
  2883. IAC: Infection With Resistant Virus More Than Doubles Risk of Virologic Failure - (07/26/10)
     
  2884. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
     
  2885. IAC: 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10)
     
  2886. IAC: Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10)
     
  2887. IOF position statement: vitamin D recommendations for older adults - Position Paper - (07/23/10)
     
  2888. IAC: Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine - (07/23/10)
     
  2889. IAC: HIV Raises Heart Disease Risk 60% in People Over 49 - (07/23/10)
     
  2890. IAC: HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on 'When To Start' - (07/23/10)
     
  2891. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  2892. IAC: Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System - (07/23/10)
     
  2893. IAC: Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study - (07/23/10)
     
  2894. IAC: Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era - (07/23/10)
     
  2895. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  2896. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats - pdf attached - (07/22/10)
     
  2897. IAC: HPV Vaccine Prevents HPV Lesions and Infection in Men - written by Mark Mascolini - (07/22/10)
     
  2898. IAC: Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER - written by Mark Mascolini - (07/22/10)
     
  2899. IAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
     
  2900. IAC: Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis - (07/22/10)
     
  2901. IAC: The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects - (07/22/10)
     
  2902. IAC:VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation - BI press release - (07/22/10)
     
  2903. IAC: Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients - (07/22/10)
     
  2904. IAC: TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures - written by Mark Mascolini - (07/22/10)
     
  2905. IAC: Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) - (07/22/10)
     
  2906. IAC: S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive - written by Mark Mascolini - (07/22/10)
     
  2907. IAC: Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER - written by Mark Mascolini - (07/22/10)
     
  2908. IAC: Two to Three Times Higher Hodgkin Risk in First Months of ART - written by Mark Mascolini - (07/22/10)
     
  2909. IAC: Five Times Higher Risk of Intracranial Hemorrhage With HIV - written by Mark Mascolini - (07/22/10)
     
  2910. IAC: Types of Kidney Problems May Be Changing as HAART Era Matures - written by Mark Mascolini - (07/22/10)
     
  2911. IAC: Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 - (07/22/10)
     
  2912. IAC: Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients - (07/22/10)
     
  2913. IAC: METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks - (07/22/10)
     
  2914. IAC: Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study - (07/22/10)
     
  2915. IAC: New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients - written by Mark Mascolini - (07/21/10)
     
  2916. Tesamorelin FDA Briefing Document pdf attached - (07/21/10)
     
  2917. IAC: Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis - written by Mark Mascolini - (07/21/10)
     
  2918. IAC: CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV - written by Mark Mascolini - (07/21/10)
     
  2919. IAC: Cancer Rates in HIV+ in Atlanta: 'Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV' - written by Mark Mascolini - (07/21/10)
     
  2920. IAC: A Year of ART Does Not Ease Anal Cancer Harbingers in Men - written by Mark Mascolini - (07/21/10)
     
  2921. IAC: Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival - written by Mark Mascolini - (07/21/10)
     
  2922. IAC: HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study - written by Mark Mascolini - (07/21/10)
     
  2923. IAC: Congresswoman Barbara Lee Calls for $6 Billion for Global Fund - (07/21/10)
     
  2924. IAC: S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates - (07/21/10)
     
  2925. IAC: Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs - (07/21/10)
     
  2926. IAC: HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study - (07/21/10)
     
  2927. IAC: 'Start HIV Therapy Earlier, IAS-USA Panel Recommends' - (07/20/10)
     
  2928. IAC: Bill Clinton on HIV/AIDS: Much More Needs to be Done - (07/20/10)
     
  2929. IAC: Bill Clinton, Gates: Fight AIDS more efficiently - (07/20/10)
     
  2930. IAC: Tenofovir AIDS gel protects women in study - (07/20/10)
     
  2931. IAC: Tenofovir Gel found to reduce AIDS risk in women - (07/20/10)
     
  2932. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  2933. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  2934. IAC: Number Globally of HIV-positive in treatment rose by a quarter last year - (07/20/10)
     
  2935. IAC: Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum - written by Mark Mascolini - (07/20/10)
     
  2936. IAC: Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study - written by Mark Mascolini - (07/20/10)
     
  2937. IAC: Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative - written by Mark Mascolini - (07/20/10)
     
  2938. IAC: Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups - written by Mark Mascolini - (07/20/10)
     
  2939. IAC: Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort - written by Mark Mascolini - (07/20/10)
     
  2940. IAC: HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/20/10)
     
  2941. IAC: Once- Versus Twice-Daily Raltegravir When Switching From a PI - written by Mark Mascolini - (07/19/10)
     
  2942. IAC: Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial - written by Mark Mascolini - (07/19/10)
     
  2943. IAC: Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL - written by Mark Mascolini - (07/19/10)
     
  2944. IAC: Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint - Abbott Press Release - (07/19/10)
     
  2945. IAC: Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid - (07/19/10)
     
  2946. IAC: TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation - (07/19/10)
     
  2947. IAC: Tenofovir Gel Reduced HIV Transmission - pdf of Science Mag publication attached - (07/19/10)
     
  2948. IAC: First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive - written by Mark Mascolini - (07/19/10)
     
  2949. IAC: Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10)
     
  2950. IAC: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10)
     
  2951. IAC: Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 - written by Mark Mascolini - (07/19/10)
     
  2952. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection - Editorial Review - (07/19/10)
     
  2953. Untreated HIV: harmful even at high CD4 cell counts - Editorial - 'When To Begin HAART' - (07/19/10)
     
  2954. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per µL in Europe and North America: a pooled cohort observational study - (07/19/10)
     
  2955. IAC: New Guidelines Urge Earlier Therapy for HIV Patients - (07/19/10)
     
  2956. IAC: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study - (07/19/10)
     
  2957. IAC: AIDS group fears annual HIV costs may hit $35 bln - (07/19/10)
     
  2958. IAC: HIV/AIDS numbers from around the world - (07/19/10)
     
  2959. IAC: CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate - (07/19/10)
     
  2960. IAC: Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV - (07/19/10)
     
  2961. IAC: 18th Int'l AIDS Conference opens in Vienna - (07/19/10)
     
  2962. IAC: World AIDS Conference (IAC) Opens -to hear progress on drugs, money worries - (07/19/10)
     
  2963. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes - (07/15/10)
     
  2964. Early vs Standard HAART Start in Haiti Randomized Study NEJM - pdf attached - (07/15/10)
     
  2965. Alzheimer disease and HIV A tangled story - Editorial - (07/15/10)
     
  2966. Geron Provides Update on Telomerase Anti-Aging Therapy Activation Program - (07/15/10)
     
  2967. HIV & Alzheimers: are HIV+ At Greater Risk for Alzheimers - pdf full text attached - (07/14/10)
     
  2968. HIV/Aging & Antiaging Therapy - (07/12/10)
     
  2969. CD4 Predicts Cardiovascular Disease (CVD), nadir cd4 too perhaps - (07/12/10)
     
  2970. Model Forecasting Test & Treat Impact - CID August 2010 - pdf attached - (07/12/10)
     
  2971. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients - pdf of full text attached - (07/12/10)
     
  2972. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors - (07/10/10)
     
  2973. NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells - 2 pdfs attaced of both Science mag published reports - (07/10/10)
     
  2974. HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals - Review - pdf attached - (07/10/10)
     
  2975. Advance in Quest for HIV Vaccine - (07/10/10)
     
  2976. Inflammation Predicts Mortality in FRAM - (07/08/10)
     
  2977. Telomere Length and Risk of Incident Cancer and Cancer Mortality - (07/08/10)
     
  2978. Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data - (07/07/10)
     
  2979. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment - (07/07/10)
     
  2980. Depressive symptoms and risk of dementia - The Framingham Heart Study - (07/07/10)
     
  2981. New Gene Therapy Zinc Fingers Research Published: 'doctors may someday control HIV virus using stem cells without using anti-retroviral drugs' - (07/07/10)
     
  2982. Raltegravir Switch from PI Effective - Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study - pdf attached - (07/05/10)
     
  2983. Long-term use of anabolic steroids associated with reduced LV ejection fraction - (07/04/10)
     
  2984. Neurological Symptoms-HIV ART Drug Resistance & Discordant CNS & Plasma Viral Load, Patients Suppressed on ART - pdf attached - (07/04/10)
     
  2985. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication - pdf of publication attached - (07/02/10)
     
  2986. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia - (07/01/10)
     
  2987. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study - (06/30/10)
     
  2988. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - (06/30/10)
     
  2989. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients - (06/30/10)
     
  2990. Immunosenescence and Vaccination - Commentary - (06/29/10)
     
  2991. Mechanisms of immunosenescence Short report - (06/29/10)
     
  2992. New Inhaled Insulin for Diabetes 2 - (06/25/10)
     
  2993. Hypertension Strongest Predictor of Stroke: and includes waist-to-hip ratio, regular exercise, smoking, diabetes, depression, stress - (06/23/10)
     
  2994. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/23/10)
     
  2995. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics - (06/23/10)
     
  2996. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes' - (06/23/10)
     
  2997. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation - (06/23/10)
     
  2998. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/22/10)
     
  2999. HIV-associated lipodystrophy: from fat injury to premature aging - Review - pdf of article attached - (06/22/10)
     
  3000. Mitochondrial Dysfunction in HIV+ CNS/Muscular Organ Systems Disorders in HIV+ Children, and perhaps related to accelerated aging in older HIV+ adults - (06/20/10)
     
  3001. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - poster - (06/18/10)
     
  3002. ResisWksp: Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster - (06/18/10)
     
  3003. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment "Deep" Sequencing Results - poster - (06/18/10)
     
  3004. ResisWksp: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the Merit Study - (06/18/10)
     
  3005. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era - (06/16/10)
     
  3006. ResisWksp: Intl Resistance Workshop Report by Mark Wainberg, PhD, McGill University, Montreal - (06/16/10)
     
  3007. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression - MAJOR ARTICLE - (06/11/10)
     
  3008. Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression - (06/11/10)
     
  3009. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  3010. (Test & Treat) HIV Prevention, Diagnosis and Treatment A Best Practices Symposium at Albert Einstein School of Medicine, Bronx, NY -pdf attached
     
  3011. ResisWksp: Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 - (06/15/10)
     
  3012. ResisWksp: Strong Inhibition of Wild-type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, poster report: "S/GSK1349572 had stronger and faster binding to mutant IN than RAL" - (06/15/10)
     
  3013. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  3014. ResisWksp: HIV Integrase Resistance Profiles and S/GSK1349572 Baseline Phenotypic Susceptibility for Subjects Experiencing Virologic Failure on Raltegravir (RAL) in the VIKING Study (ING112961) - (06/15/10)
     
  3015. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir When Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  3016. ResisWksp: Structural Models of HIV-1 Integrase and DNA in Complex with S/GSK1349572, Raltegravir and Elvitegravir: Structure-based Rationale for INI Resistance Profiles - (06/15/10)
     
  3017. Study reveals promise for New/Improved HIV testing & Reporting Results on Internet - (06/15/10)
     
  3018. Common genetic determinants of vitamin D insufficiency: a genome-wide association study - (06/15/10)
     
  3019. A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation: ACTG A5217, the SETPOINT Study - (06/12/10)
     
  3020. ResisWksp: Only Two Major PI Mutations (But No Resistance) in Darunavir Monotherapy Trial - written by Mark Mascolini - (06/12/10)
     
  3021. ResisWksp: US/Canadian HIV Transmission Clusters Largely Male, White, and Gay - written by Mark Mascolini - (06/12/10)
     
  3022. ResisWksp: Infection With 3TC/FTC Mutant Virus Favors Lower Pretreatment Viral Load - written by Mark Mascolini - (06/12/10)
     
  3023. ResisWksp: Treatment Success Rates High, Resistance Rates Lower, in France in 2009, but integrase resistance is present among failures - written by Mark Mascolini - (06/12/10)
     
  3024. ResisWksp: HIV CSF/Plasma Ratio and Genetic Distance in People With Neurologic Disorders - written by Mark Mascolini - (06/12/10)
     
  3025. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment Deep Sequencing Results - (06/11/10)
     
  3026. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - (06/11/10)
     
  3027. ResisWksp: Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1) - (06/11/10)
     
  3028. ResisWksp: Mutation Rate in Antiretroviral-Naive Falling in One US Patient Population (GSK studies in USA) - written by Mark Mascolini - (06/11/10)
     
  3029. ResisWksp: Are Single Transmitted Mutants the Tip of a Resistance Iceberg? - written by Mark Mascolini - (06/11/10)
     
  3030. ResisWksp: New Mutations Found in 43% of People With Low But Detectable Viral Loads - written by Mark Mascolini - (06/11/10)
     
  3031. ResisWksp: Study Clarifies Risk of Switch to Raltegravir From Suppressive PI - written by Mark Mascolini - (06/11/10)
     
  3032. ResisWksp: Truvada Protects Macaques From Rectal Exposure to FTC-Resistant Virus - written by Mark Mascolini - (06/11/10)
     
  3033. ResisWksp: Transmitted Resistance Imperils First-Line Response in 10,000-Person Study - written by Mark Mascolini - (06/11/10)
     
  3034. ResisWksp: "Deep" Sequencing Finds X4 Virus in Screening Samples of Maraviroc Failures - written by Mark Mascolini - (06/10/10)
     
  3035. ResisWksp: Pairwise Comparison of genotypic tropism prediction between one reference center and 10 European laboratories - (06/10/10)
     
  3036. ResisWksp: Better Etravirine Response Predicted After Efavirenz Than Nevirapine - written by Mark Mascolini - (06/10/10)
     
  3037. ResisWksp: Over Half of European Raltegravir Failures Without Apparent Integrase Mutations - written by Mark Mascolini - (06/10/10)
     
  3038. ResisWksp: GSK Integrase Following Raltergavir Use: When Is It Risky to Use S/GSK1349572 After Raltegravir? - written by Mark Mascolini - (06/10/10)
     
  3039. ResisWksp: Debate Follows Data on Genotypic Predictions of HIV Tropism - written by Mark Mascolini - (06/10/10)
     
  3040. Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks - (06/10/10)
     
  3041. The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of Diabetes Mellitus in the Women's Interagency HIV Study: history of opiate use & HCV both increase risk for diabetes - (06/10/10)
     
  3042. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials - (06/10/10)
     
  3043. ResisWksp: Resistance Emergence With Raltegravir Versus Efavirenz in Treatment Naive - written by Mark Mascolini - (06/10/10)
     
  3044. ResisWksp: Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients - (06/10/10)
     
  3045. ResisWksp: Differing Integrase Dissociation Rates With S/GSK1349572 and Raltegravir - written by Mark Mascolini - (06/10/10)
     
  3046. Beyond Hemoglobin A1c-Need for Additional Markers of Risk for Diabetic Microvascular Complications - commentary - (06/08/10)
     
  3047. Does Lipoatrophy Persist ? - Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - pdf attached (I suggest reading the pdf closely) - (06/07/10)
     
  3048. Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria - pdf full text attached - (06/07/10)
     
  3049. Circulating mitochondrial DAMPs cause inflammatory responses to injury - (06/07/10)
     
  3050. "mitochondria.....might initiate inflammation....mitochondria are probably released in patients with infectious disease" - (06/07/10)
     
  3051. Immunology & Mitochondria - Clinical immunology: Culprits with evolutionary ties - (06/07/10)
     
  3052. The Mitochondrion - A Trojan Horse That Kicks Off Inflammation? - (06/07/10)
     
  3053. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study - (06/03/10)
     
  3054. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia - (06/03/10)
     
  3055. HIV-associated neurocognitive disorders: is there a hidden epidemic? - Editorial Comment - (06/03/10)
     
  3056. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening - (06/03/10)
     
  3057. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens - (06/03/10)
     
  3058. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (05/30/10)
     
  3059. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada - (05/30/10)
     
  3060. The Gap between Human Immunodeficiency Virus (HIV) Infection and Advances in HIV Treatment - EDITORIAL - (05/30/10)
     
  3061. HPV and Therapeutic Vaccines: Where are We in 2010? - pdf attached - (05/29/10)
     
  3062. M2010: Press briefings at International Microbicides Conference, May 22-25 - (05/28/10)
     
  3063. M2010: Using ARVs to Prevent HIV Could Result in Drug Resistance if Routine Screening is Not Done New Research Presented at International Microbicides Conference - (05/28/10)
     
  3064. M2010: Researchers Searching For New Ways (micobicides: tablets, gel, film, vaginal rings) To Protect Women Against HIV - (05/28/10)
     
  3065. M2010: Lubricant Use May Raise HIV Infection Risk During Anal Sex - (05/28/10)
     
  3066. M2010: Vaginal gel with integrase inhibitor shows promise in monkeys; Darunavir/Maraviroc/NNRTis/Fusion - (05/28/10)
     
  3067. M2010: New ARTs Research Takes The Lead: HIV Microbicides Conference Report - (05/28/10)
     
  3068. In this analysis of almost 3400 HIV-1 serodiscordant heterosexual couples from seven African countries, ART use by the infected person was accompanied by a 92% reduction in risk of HIV-1 transmission to their partner - (05/28/10)
     
  3069. HIV drugs for treatment, and for prevention Editorial - (05/28/10)
     
  3070. Tesamorelin & IGF-1 Levels - (05/28/10)
     
  3071. Tesamorelin Reduces VAT: FDA Hearing - (05/28/10)
     
  3072. VOTE: 16-0 to recommend approval for tesamorelin - 'benefit outweighs risk' - (05/28/10)
     
  3073. FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors - (05/26/10)
     
  3074. New CVD Anti-Inflammation Drug: Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome - pdf full text attached - (05/26/10)
     
  3075. People with AIDS more likely to develop cancers, research says - (05/26/10)
     
  3076. Tesamorelin FDA Briefing Document pdf attached - (05/26/10)
     
  3077. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation - pdf attached - (05/25/10)
     
  3078. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals - (05/25/10)
     
  3079. Cholesterol Crystals Incite Inflammation in Coronary Arteries, Research Finds - (05/25/10)
     
  3080. Cholesterol crystals incite inflammation in coronary arteries - (05/25/10)
     
  3081. 11th Wrkshp Adverse Drug Reactions Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy - (05/24/10)
     
  3082. 11th Wrkshp Adverse Drug Reactions Vitamin D and Efavirenz - (05/24/10)
     
  3083. 11th Wrkshp Adverse Drug ReactionsAssociation between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D - (05/24/10)
     
  3084. Study pinpoints how a normally defensive immune response can help HIV - journal commentary included - (05/24/10)
     
  3085. New Aging/HIV Study-blocking inflammation: Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease - (05/24/10)
     
  3086. Visceral fat is associated with lower brain volume in healthy middle-aged adults - (05/20/10)
     
  3087. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis - (05/18/10)
     
  3088. Low Vitamin D Levels Associated with Genotype 1, Fibrosis, Inflammation, with SVR, with waist circumference, Low HDL - (05/18/10)
     
  3089. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men - (05/17/10)
     
  3090. "A higher 25(OH)D (vit D) was associated with better dietary quality, lower %BF (body fat, central obesity), and lower number of MetD (metabolic disturbances including CRP, glucose)"...dairy in diet helped vit D levels - pdf attached - (05/13/10)
     
  3091. Denosumab Inhibits Bone Loss in RA - (05/13/10)
     
  3092. High Dose Vitamin D Increased Fall & Fracture Rate - (05/13/10)
     
  3093. High-Dose Vitamin D Supplementation, Too Much of a Good Thing? - (05/12/10)
     
  3094. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model - (05/12/10)
     
  3095. HPV, Genital wart virus may raise men's risk of HIV - link to free full text JID article - (05/12/10)
     
  3096. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection - (05/07/10)
     
  3097. Inflammation and Complications of HIV Disease - EDITORIAL COMMENTARY - (05/07/10)
     
  3098. Pre-HAART Immune Activation Associated with Developing Cancers & Death - (05/07/10)
     
  3099. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection (and HCV) - (05/07/10)
     
  3100. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy - (05/05/10)
     
  3101. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations - (05/05/10)
     
  3102. Experimental NYC HIV Anal Cancer Screening Clinic - (05/05/10)
     
  3103. An aged T cell phenotype: A prognostic indicator in liver transplant recipients? Editorial - (05/03/10)
     
  3104. Features of immune senescence in liver transplant recipients with established grafts - (05/03/10)
     
  3105. ACCORD Glycemia (intensive control <6% A1C) Results Continue to Puzzle Editorial - (05/03/10)
     
  3106. Intensive Sugar Control HbA1C <6% Is Beneficial; Unsuccessful intensive therapy the culprit in ACCORD - (05/03/10)
     
  3107. (Low A1C <6% Reduces Death) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial - (05/03/10)
     
  3108. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients - (04/29/10)
     
  3109. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis - (04/29/10)
     
  3110. PK Workshop: 11th International Workshop on Clinical Pharmacology of HIV Therapy (April 2010) Report - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (04/27/10)
     
  3111. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial - (04/26/10)
     
  3112. Statins for Primary Prevention in Older Adults: Who Is High Risk, Who Is Old, and What Denotes Primary Prevention? Editorial - (04/26/10)
     
  3113. PK Workshop: Evaluation of Ritonavir-boosted Elvitegravir PK upon Co-administration with a Second Potent CYP3A inhibitor, Ketoconazole - (04/23/10)
     
  3114. PK Workshop: Metabolism and Excretion in Humans of the Pharmacoenhancer GS-9350 - (04/22/10)
     
  3115. Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody - (04/22/10)
     
  3116. PK Workshop: Relative Bioavailability and Pharmacokinetics of Darunavir when boosted with the Pharmacoenhancer GS-9350 versus Ritonavir - (04/21/10)
     
  3117. Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study. - (04/13/10)
     
  3118. HAART Reduces HPV - Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women - (04/13/10)
     
  3119. The role of secondary lymphatic tissue in immune deficiency of HIV infection, and aging - (04/13/10)
     
  3120. HIV Drug Resistance over the Long Haul - EDITORIAL COMMENTARY - (04/13/10)
     
  3121. PK Workshop: GRACE PK Study: Median (range) AUC12h and C0h were similar between women and men, and across black, Hispanic and white patients; Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status - (04/13/10)
     
  3122. PK Workshop: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (04/13/10)
     
  3123. PK Workshop: Higher Darunavir and Raltegravir Levels in Small Study of People With Liver Disease - written by Mark Mascolini - (04/13/10)
     
  3124. PK Workshop: Limited Risk of Serious Interaction Between TMC278 and Methadone - written by Mark Mascolini - (04/13/10)
     
  3125. PK Workshop: More Than Half in Barcelona HIV Clinic Use Alternative Therapies - written by Mark Mascolini - (04/13/10)
     
  3126. PK Workshop: Cell Levels of Once-Daily Raltegravir Adequate in Pilot Study - written by Mark Mascolini - (04/13/10)
     
  3127. PK Workshop: Older Age Impairs Kidney Function During Tenofovir Therapy - written by Mark Mascolini - (04/13/10)
     
  3128. PK Workshop: Etravirine Lowers Levels of S/GSK Integrase Inhibitor, But PIs Counter Effect - written by Mark Mascolini - (04/13/10)
     
  3129. PK Workshop: Darunavir Boosting with GS-9350 (Cobicistat) or Ritonavir in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  3130. PK Workshop: Extra CYP3A Inhibitor Has Modest Impact on Already-Boosted Elvitegravir - written by Mark Mascolini - (04/13/10)
     
  3131. PK Workshop: What Will It Take To Replace Ritonavir as the Prime PK Booster? ...Debate Ritonavir v GS9350 - written by Mark Mascolini - (04/13/10)
     
  3132. PK Workshop: Higher Atazanavir Levels Sync With Higher Raltegravir Levels in Dual Combo - written by Mark Mascolini - (04/13/10)
     
  3133. PK Workshop: The Effect of Food Intake on Reyataz Blood Levels - written by Mark Mascolini - (04/13/10)
     
  3134. PK Workshop: Darunavir Levels Not Tied to Detectable HIV RNA in MONET Monotherapy Trial - written by Mark Mascolini - (04/13/10)
     
  3135. PK Workshop: Darunavir Levels Not Affected by Gender, Race, or Age in GRACE Trial - written by Mark Mascolini - (04/13/10)
     
  3136. PK Workshop: Impact of Pravastatin on Raltegravir Levels in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  3137. PK Workshop: Efavirenz Troughs Higher in People Over 50 Years Old - written by Mark Mascolini - (04/13/10)
     
  3138. PK Workshop: Women With Tight HIV Control Have Higher Antiretroviral Troughs Than General Population - written by Mark Mascolini - (04/13/10)
     
  3139. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials - (04/06/10)
     
  3140. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management - (04/06/10)
     
  3141. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients - (04/06/10)
     
  3142. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy - (04/06/10)
     
  3143. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience - (04/06/10)
     
  3144. CROI: HAART Reduces New Infections - Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco (CROI) - (04/05/10)
     
  3145. Conspiracy Beliefs About HIV Are Related to Antiretroviral Treatment Nonadherence Among African American Men With HIV - (04/05/10)
     
  3146. 45% of Eligible Patients Receive HIV Drug Resistance Testing - (04/05/10)
     
  3147. The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) - (04/05/10)
     
  3148. Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States - (04/05/10)
     
  3149. CROI: Prolonged Control of Viremia After Transfer of Autologous CD4 T Cells Genetically Modified with a Lentiviral Vector Expressing Long Antisense to HIV env (VRX496) - (04/04/10)
     
  3150. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function - (04/03/10)
     
  3151. Inflammation, CRP & new test (DTI, difussion tensor imaging) - Are white matter signal abnormalities clinically relevant? Editorial - (04/03/10)
     
  3152. Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome - (04/03/10)
     
  3153. Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis - (03/28/10)
     
  3154. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss - (03/28/10)
     
  3155. Evolving Data about Subtrochanteric Fractures and Bisphosphonates-EDITORIAL - (03/25/10)
     
  3156. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur - (03/25/10)
     
  3157. NYS Guidelines recommendations on anal pap smears - (03/25/10)
     
  3158. CROI: HIV Persistence, Raltegravir/Maravoric Intensification, Immunology: Some Impressions from San Francisco: CROI 2010 - written by David Margolis MD University of North Carolina - (03/24/10)
     
  3159. MRSA Risk 6-Fold Higher in HIV+: Community-Associated Methicillin-Resistant Staphylococcus aureus and HIV: Intersecting Epidemics - (03/24/10)
     
  3160. CROI: Management of Treatment-Experienced Patients: darunavir, raltegravir, raltegravir intensification, maraviroc, vicriviroc - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (03/23/10)
     
  3161. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects - pdf attached - (03/22//10)
     
  3162. Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy - (03/22/10)
     
  3163. Benefit or Toxicity from Neurologically Targeted Antiretroviral Therapy? EDITORIAL COMMENTARY - (03/22/10)
     
  3164. Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1-Infected Individuals Commencing cART? A Randomized, Controlled Study - (03/22/10)
     
  3165. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  3166. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  3167. CROI: No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial - (03/22/10)
     
  3168. CROI: Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - (03/22/10)
     
  3169. CROI: No Decrease in Intrathecal Immunoactivation or Residual CSF Viremiaduring Treatment Intensification in Patients on Stable ART - (03/22/10)
     
  3170. CROI: Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience in a Raltegravir Intensification Study - (03/22/10)
     
  3171. CROI: Differences in HIV Burden throughout the Gut of Patients on Suppressive ART: Implications for HIV Persistence - (03/21/10)
     
  3172. CROI: HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of HAART-suppressed Patients - (03/21/10)
     
  3173. CROI: Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response - (03/21/10)
     
  3174. Test & Treat-what is the impact? Can antiretroviral therapy eliminate HIV transmission? The lancet 2009 - (03/20//10)
     
  3175. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection - (03/19//10)
     
  3176. CROI: Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Macaques and Relationship to Systemic and Mucosal Drug Levels - (03/19/10)
     
  3177. CROI: Protection of Rhesus Macaques from Vaginal Infection by Maraviroc (solution), an Inhibitor of HIV-1 Entry via the CCR5 Co-receptor - (03/19/10)
     
  3178. CROI: Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Penetration, and Adverse Reactions - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center- (03/14/10)
     
  3179. CROI: CROI: Inflammation/activation linked to diseases of organ systems (heart, kidney, liver) & death in USA and now reported as well in Africa - HIV accelerated aging will be bigger problem in undeveloped countries - (03/18/10)
     
  3180. CROI: INFLAMMATORY MARKERS DURING TREATMENT OF OIs ARE PREDICTIVE OF LATE VIROLOGIC AND IMMUNOLOGIC RESPONSES: Sub-study of A5164 - (03/16/10)
     
  3181. CROI:Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort - (03/15/10)
     
  3182. CROI: Bone/Osteoporosis/Vitamin D CROI 2010 Update - written by Michael Yin, MD MS Assistant Professor of Clinical Medicine Columbia University Medical Center New York, NY- (03/14/10)
     
  3183. Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study - (03/11/10)
     
  3184. CROI: Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)
     
  3185. CROI: Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)
     
  3186. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate - (03/09/10)
     
  3187. Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy - (03/09/10)
     
  3188. CROI: Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban Sub-Saharan African Setting: 'high non-AIDS events rate in Africa' - (03/09/10)
     
  3189. CROI: Low CD4 Cell Count and Impaired Renal Function (eGFR) Are Independent Risk Factors for ARF (acute renal failure) in HIV-infected Patients - (03/09/10)
     
  3190. CROI: Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program - (03/09/10)
     
  3191. CROI: Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality - (03/09/10)
     
  3192. CROI: Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals - (03/09/10)
     
  3193. CROI: Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients - (03/09/10)
     
  3194. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV - (03/09/10)
     
  3195. CROI: HIV Prevention at CROI 2010 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/07/10)
     
  3196. CROI: 5-Year Tenofovir Therapy Is Associated with Maintained HBV Response and Renal Toxicity in HIV/HBV Co-infected Patients - (03/06/10)
     
  3197. CROI: Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care - (03/06/10)
     
  3198. CROI: Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study - (03/06/10)
     
  3199. CROI: Improved Correlation of Coronary Atherosclerosis with Estimated Glomerular Filtration Rate Assessed with Chronic Kidney Disease Epidemiology Collaboration Equation than with MDRD and Cockcroft-Gault in HIV-infected Patients - (03/06/10)
     
  3200. CROI: HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function - (03/06/10)
     
  3201. CROI: Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France) - (03/06/10)
     
  3202. CROI: Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients (503) - (03/06/10)
     
  3203. HbA1C Predicts Diabetes & CVD: Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults - (03/05/10)
     
  3204. CROI: DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells - (03/05/10)
     
  3205. CROI: Ritonavir and Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and Premature Senescence in Cultured Human Coronary Artery Endothelial Cells - (03/05/10)
     
  3206. CROI: In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells - (03/05/10)
     
  3207. CROI: Vicriviroc Phase 3 at CROI 2010 - (03/05/10)
     
  3208. CROI: Plasma Levels of Soluble CD14 (activation marker) Predict Mortality in HIV Infection - (03/05/10)
     
  3209. CROI: Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples From Protocol 004 - (03/05/10)
     
  3210. CROI:Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth - (03/05/10)
     
  3211. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patient - (03/04/10)
     
  3212. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  3213. CROI: A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults - (03/04/10)
     
  3214. CROI: Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)
     
  3215. CROI: Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes - (03/04/10)
     
  3216. CROI: Determining HIV-1 Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic Blood Samples, for Patients with Undetectable Viral Load - (03/04/10)
     
  3217. CROI: The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK - (03/04/10)
     
  3218. CROI: Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/04/10)
     
  3219. CROI: Effect of the Intensification with a CCR5 Antagonist Maraviroc on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - reduced activation - (03/04/10)
     
  3220. CROI:Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study - (03/04/10)
     
  3221. CROI: Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy - (03/03/10)
     
  3222. CROI:Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in Predicting Virologic Response to Maraviroc of Treatment-naïve Patients in the MERIT Trial - (03/03/10)
     
  3223. CROI:Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks - (03/03/10)
     
  3224. CROI:Large-Scale Application of "Deep" Sequencing Using 454 Technology to HIV Tropism Screening - (03/03/10)
     
  3225. CROI:HIV Did Not Worsen H1N1 Severity in Spanish Case-Control Study - written by Mark Mascolini - (03/03/10)
     
  3226. CROI:Failure to Respond to HBV Vaccine Linked to Higher Cancer Risk With HIV - written by Mark Mascolini - (03/03/10)
     
  3227. CROI:Prediction of X4-tropic Human Immunodeficiency Virus from Proviral Envelope Sequence in Patients with Suppressed Viral Load on Antiretroviral Therapy (ART). - (03/03/10)
     
  3228. CROI: Four Non-AIDS Cancers on the Rise With HIV in Big North American Cohort - written by Mark Mascolini - (03/03/10)
     
  3229. CROI:Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in Antiretroviral-naïve HIV-1 Infected Patients - (03/03/10)
     
  3230. CROI:Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America: high cancer rates in HIV+ - (03/03/10)
     
  3231. CROI: Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients - (03/03/10)
     
  3232. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)
     
  3233. CROI: The Kidney at CROI - written by Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/03/10)
     
  3234. CROI: Chronic Inflammation in HIV: CROI 2010 - written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (03/03/10)
     
  3235. CROI: Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial - written by Mark Mascolini - - (03/02/10)
     
  3236. CROI: CDC Finds 1 in 6 Newly Diagnosed With HIV Had Resistant Virus in 2007 - written by Mark Mascolini - - (03/02/10)
     
  3237. CROI: Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study - abstract 107LB - (03/02/10)
     
  3238. CROI: Higher Levels of Heart Cell Peptide Tied to Cardiovascular Disease in SMART Study Patients - written by Mark Mascolini - (03/01/10)
     
  3239. CROI: D-Dimer But Not hsCRP Predicts Impending Cardiovascular Disease in Case-Control Study - written by Mark Mascolini - (03/01/10)
     
  3240. CROI:Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  3241. CROI:Risk of Non-AIDS Death in HIV/HCV-Coinfected People in SMART - written by Mark Mascolini - (03/01/10)
     
  3242. CROI: T cell Senescence and Proliferation Defects Persist in Treated HIV-infected Individuals Maintaining Viral Suppression and Are Associated with Poor CD4+ T Cell Recovery - (03/01/10)
     
  3243. CROI: Impact of CD8+ T Cell Activation on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating Antiretroviral Therapy - (03/01/10)
     
  3244. CROI: Valganciclovir Reduces CD8+ T Cell Activation among HIV-infected Patients with Suboptimal CD4+ T cell Recovery During Antiretroviral Therapy - (03/01/10)
     
  3245. CROI:CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS) - (03/01/10)
     
  3246. CROI: Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype - (03/01/10)
     
  3247. CROI:Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients: a Substudy of the ANRS 139 TRIO Trial - (03/01/10)
     
  3248. CROI: Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  3249. CROI: Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen. - (03/01/10)
     
  3250. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/01/10)
     
  3251. CROI: Effect of Raltegravir-containing Intensification on HIV burden and T cell Activation in the Gut of HIV+ Adults on Suppressive Antiretroviral Therapy (ART) - reduced activation - (03/01/10)
     
  3252. CROI:Nadir CD4 Count Under 350 Predicts Arterial Stiffness in Case-Control Study - written by Mark Mascolini - (02/28/10)
     
  3253. CROI: Sociobehavioral Factors Affect Clinical Outcomes Apart From HIV Factors in Swiss Cohort - written by Mark Mascolini - (02/28/10)
     
  3254. CROI:Darunavir Penetrates Semen Well With High Levels Through 24 Hours - written by Mark Mascolini - (02/28/10)
     
  3255. CROI: Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy - (02/28/10)
     
  3256. CROI: Darunavir Monotherapy Increased Limb Fat - Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks - (02/28/10)
     
  3257. CROI: Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from HIV-Infected Patients - (02/28/10)
     
  3258. CROI: Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort: CPE Score predicts CSF suppression (02/27/10)
     
  3259. CROI: Neuropsychological Performance is Better in HIV-Infected Subjects Treated with Neuroactive HAART (02/27/10)
     
  3260. CROI: Plasma HIV Load Strongest Predictor of CSF Load in CHARTER Cohort - written by Mark Mascolini - (02/26/10)
     
  3261. CROI: Early Initiation of Antiretroviral Therapy in HIV-Infected Individuals Is Associated with Reduced Arterial Stiffness: a low nadir CD4+ T-cell counts are associated with arterial stiffness as assessed by Aix and PWV - (02/26/10)
     
  3262. CROI:Inflammation Is Associated with Endothelial Dysfunction Among Individuals with Treated and Suppressed HIV Infection - (02/26/10)
     
  3263. CROI:High Prevalence of Severe Vitamin D Deficiency in cART Naïve and Successfully Treated Swiss HIV Patients - (02/26/10)
     
  3264. CROI: Vitamin D Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected Women in the United States - (02/26/10)
     
  3265. CROI:Assessment of Vitamin D Levels Among HIV-infected Persons in the Study To Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) - (02/26/10)
     
  3266. CROI: The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile - (02/25/10)
     
  3267. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  3268. CROI: Cell Studies Point to Antiinflammatory Activity of Maraviroc - written by Mark Mascolini - (02/25/10)
     
  3269. CROI: Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below - written by Mark Mascolini - (02/25/10)
     
  3270. CROI:Early Antiretrovirals in People Diagnosed With AIDS May Quell Inflammation Faster - written by Mark Mascolini - (02/25/10)
     
  3271. CROI: The US Epidemic - Disparities in HIV Disease for African-Americans (02/25/10)
     
  3272. CROI:Maraviroc (MVC) Intensification for Suboptimal CD4+ Response Despite Sustained Virologic Suppression: ACTG 5256 (02/25/10)
     
  3273. CROI:CNS Toxicity of Antiretroviral Drugs (02/25/10)
     
  3274. CROI:Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort (02/25/10)
     
  3275. CROI:Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibitor, S/GSK1349572 (02/25/10)
     
  3276. CROI:S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones (02/23/10)
     
  3277. CROI:Worse Neuropsych Scores Tied to Viral Rebounds in CSF and Plasma; CPE Score Tied to CSF Rebound - written by Mark Mascolini - (02/23/10)
     
  3278. CROI:Low CD4 Nadir Predicts Neurocognitive Problems Despite Good CD4 Gains - written by Mark Mascolini - (02/23/10)
     
  3279. CROI: Metabolic complications of HIV infection at CROI 2010 (Feb 16-19) -Pablo Tebas, University of Pennsylvania. Philadelphia.- (02/23/10)
     
  3280. CROI:Standard First Regimens Less Effective in US Blacks Than Others - written by Mark Mascolini - (02/23/10)
     
  3281. Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus - (02/24/10)
     
  3282. Can the further clinical development of bevirimat be justified? editorial - (02/24/10)
     
  3283. CROI:ART Improves Cerebral Blood Flow--But Not to Levels in HIV-Negatives - written by Mark Mascolini - (02/23/10)
     
  3284. CROI: Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)
     
  3285. CROI:Bone Fractures at CROI 2010 - see slides below - (02/23/10)
     
  3286. CROI:Elevated Cancer Risks Remains in HAART Era: increasing mortality risk due to non-AIDS cancers- increased risk for these no-AIDS cancers - anal, liver, Hodgkin lymphoma, lung - (02/23/10)
     
  3287. CROI:Recent CD4 Predicts Risk for Cancers; Increased Risk for Anal/liver/Hodgkin Lymphoma/oral cavity pharynx cancers in HIV+ - (02/23/10)
     
  3288. CROI: Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores - written by Mark Mascolini - (02/22/10)
     
  3289. CROI: Bone Disease: Risk Factors - (02/22/10)
     
  3290. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  3291. CROI: Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients - (02/22/10)
     
  3292. CROI: Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients - "These data strongly suggest that inflammation contributes to the higher risk of atherosclerosis noted in HIV-infected persons." - (02/22/10)
     
  3293. CROI: CROI (2010 Feb 16-19) Selected Neurocognitive Abstracts - (02/22/10)
     
  3294. CROI: Vitamin D Deficiency Prevalence and Associations - (02/22/10)
     
  3295. CROI: A 48 week randomized study of uridine supplementation versus switch to tenofovir on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy - (02/22/10)
     
  3296. CROI: Uridine supplementation in the management of HIV lipoatrophy: Results of ACTG 5229 - (02/22/10)
     
  3297. CROI: Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients - (02/22/10)
     
  3298. CROI: Discovery of Potent HIV-1 Capsid Assembly Inhibitors - (02/22/10)
     
  3299. CROI: T-cell Senescence and T-cell Activation Predict Carotid Atherosclerosis in HIV-infected Women - (02/22/10)
     
  3300. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  3301. CROI: Heart Risk Factors Tied to Neurocognitive Skills in SMART Substudy - written by Mark Mascolini - (02/21/10)
     
  3302. CROI:Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)
     
  3303. CROI:Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years - (02/20/10)
     
  3304. CROI:High Triglycerides Independently Raise MI Risk in DAD Study - written by Mark Mascolini - (02/20/10)
     
  3305. CROI: Three Years With More Than 500 CD4s Normalizes Mortality in HIV+ Men - written by Mark Mascolini - (02/20/10)
     
  3306. CROI:Life Expectancy Approaches Normal in Dutch Without HIV Symptoms - written by Mark Mascolini - (02/20/10)
     
  3307. CROI: Chronic HIV and HCV Swell Stroke Risk in Veterans Aging Cohort - written by Mark Mascolini - (02/20/10)
     
  3308. CROI: Fast ART in Late Disease Means Slower Progression in Europe and Canada - written by Mark Mascolini - (02/20/10)
     
  3309. CROI:Heart Risk Falls With Time Since Quitting Smoking in DAD - written by Mark Mascolini - (02/20/10)
     
  3310. CROI: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - (02/20/10)
     
  3311. CROI:Chronic kidney disease and exposure to ARTs in a large cohrt with long-term follow-up: EuroSida - (02/20/10)
     
  3312. CROI: Bone & Limb Fat Outcomes in ACTG5202 Substudy: abacavir/3TC, tenofivir/FTC, efavirenz, atazanavir/r - (02/20/10)
     
  3313. CROI: Inflammation and Fibrosis Markers Tied to AIDS or Death After Good Virologic Response - written by Mark Mascolini - (02/19/10)
     
  3314. CROI:Inflammation Tied to Endothelial Dysfunction Despite Tight HIV Control - written by Mark Mascolini - (02/19/10)
     
  3315. CROI:Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone - written by Mark Mascolini - (02/19/10)
     
  3316. CROI:Most Non-AIDS Cancers Not Diagnosed at Earlier Age in People With AIDS - written by Mark Mascolini - (02/19/10)
     
  3317. CROI:HIV Load Tied to Fibrosis Signal in Women Without Hepatitis or Alcohol Abuse - written by Mark Mascolini - (02/19/10)
     
  3318. CROI: QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises - written by Mark Mascolini - (02/18/10)
     
  3319. CROI: Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People - written by Mark Mascolini - (02/18/10)
     
  3320. CROI: Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials - written by Mark Mascolini - (02/18/10)
     
  3321. CROI: Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA - written by Mark Mascolini - (02/18/10)
     
  3322. CROI: High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC - written by Mark Mascolini - (02/18/10)
     
  3323. CROI: Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study - written by Mark Mascolini - (02/18/10)
     
  3324. CROI: Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks - written by Mark Mascolini - (02/18/10)
     
  3325. CROI: RNA Spikes Predict Heart Disease, CD4s Predict Liver and Kidney Disease - written by Mark Mascolini - (02/18/10)
     
  3326. CROI: ODIN: efficacy and safety at 48 weeks of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients with no darunavir resistance-associated mutations - (02/18/10)
     
  3327. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  3328. CROI: ACTG5202 - (02/11/10)
     
  3329. CROI: New Data on ISENTRESS (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) - Merck announcement - (02/18/10)
     
  3330. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  3331. CROI: The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster - (02/18/10)
     
  3332. Aciclovir reduced risk of HIV-1 disease progression by 16% - (02/15/10)
     
  3333. Treating HIV infection with drugs for HSV-2 infection? Commentary - (02/15/10)
     
  3334. Early Immune Senescence in HIV Disease - (02/15/10)
     
  3335. Barriers To Retention in Care in HIV and HCV - (02/10/10)
     
  3336. FDA approves expanded rosuvastatin label, Includes CRP - (02/10/10)
     
  3337. Neurologic Disease Despite Undetectable Viral Load & The Use of Drugs That Penetrate Well the CSF - pdf of full article attached - (02/08/10)
     
  3338. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension - pdf attached - (02/08/10)
     
  3339. HIV Brain Impairment - (02/08/10)
     
  3340. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis - (02/08/10)
     
  3341. C-reactive protein and cardiovascular risk: more fuel to the fire - Comment - (02/08/10)
     
  3342. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero - (02/08/10)
     
  3343. Immunosupportive therapies in aging - pdf attached - (02/05/10)
     
  3344. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  3345. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  3346. Protein in Urine Presages More Severe Problems - free full text link below - (02/04/10)
     
  3347. Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV: "veterans coinfected with HCV have significantly higher rates of CKD and mortality" - (02/04/10)
     
  3348. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/10)
     
  3349. NYS AIDS Institute guidelines on Acute HIV Seroconversion Updated Jan 2010 - (01/28/09)
     
  3350. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report - (01/28/10)
     
  3351. Life Expectancy & Comorbidities in HIV: - (01/27/09)
     
  3352. Diagnosis and management of vitamin D deficiency - (01/27/09)
     
  3353. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study - (01/27/09)
     
  3354. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings - (01/27/09)
     
  3355. The anal Pap test as a screening tool- EDITORIAL - (01/27/09)
     
  3356. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (01/27/09)
     
  3357. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor and HIV protease inhibitors - (01/27/09)
     
  3358. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users - (01/27/09)
     
  3359. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/27/09)
     
  3360. Vicriviroc Effective in Treatment-Experienced Patients in Phase 2 Study VICTOR-E1 - (01/26/09)
     
  3361. Proinflammatory IL-18 Increased in HIV+ Despite HAART - (01/26/09)
     
  3362. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/26/09)
     
  3363. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters in SMART - (01/25/09)
     
  3364. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction - (01/25/09)
     
  3365. HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging - BRIEF REPORT - (01/25/09)
     
  3366. Estimating the proportion of patients infected with HIV who will die of comorbid diseases - pdf attached - (01/20/09)
     
  3367. Fish Oil Slows Telomere Aging - (01/20/09)
     
  3368. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  3369. HIV Life Expectancy Study Published - pdf attached - (01/19/09)
     
  3370. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies - (01/19/09)
     
  3371. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  3372. Aerobic Exercise Improved Cognitive Function in Older Adults with Mild Cognitive Impairment - (01/17/09)
     
  3373. Moderate Mid-Life Exercise Prevents Mild Cognitive Impairment - (01/17/09)
     
  3374. Will HIV Drug Resistance Rates Increase? Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection - (01/17/09)
     
  3375. Treatment of HIV-Related Inflammatory Cerebral Cryptococcoma with Adalimumab - brief report - (01/17/09)
     
  3376. Quality-Of-Life Predicts Survival in HIV: HIV & aging - (01/17/09)
     
  3377. The MONET trial: darunavir/ritonavir (monotherapy) with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml - (01/16/09)
     
  3378. Visceral Fat Causes Inflammation and Cytokines Leading To Bone Loss - (01/16/09)
     
  3379. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men - (01/15/09)
     
  3380. Antihypertensive agents and prevention of dementia - Editorial - (01/14/09)
     
  3381. Hypertension Medications Use To Prevent Dementia & Alzheimer's - (01/14/09)
     
  3382. Study: Certain hypertension drugs may reduce Alzheimer's risk - (01/14/09)
     
  3383. Raltegravir SWITCHMRK Study Published in The Lancet jan 13 2010 - publication pdf attached - (01/14/09)
     
  3384. Association of C-Reactive Protein With Cognitive Impairment - (01/13/09)
     
  3385. GS-9148 Nucleotide Active Against Resistance - (01/13/09)
     
  3386. Chloroquine To Block Immune Activation - pdf attached - (01/13/09)
     
  3387. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study - BMJ Jan 2010 - (01/12/09)
     
  3388. Update on HIV Eradication.... Report from the 4th HIV Persistence Intl Wksp (Dec 8-11 2009, David Margolis, MD - written by David Margolis MD, University of North Carolina at Chapel Hill - (01/12/09)
     
  3389. Investigational HIV agents for salvage - (01/11/09)
     
  3390. HIV-Infected Postmenopausal Women at High Risk for Bone Fractures - pdf publication attached - (01/11/09)
     
  3391. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/10/09)
     
  3392. Cardiac Risk: Not So Simple - EDITORIAL COMMENTARY D.A.D Study - (01/10/09)
     
  3393. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus - (01/10/09)
     
  3394. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes - publication pdf attached - (01/10/09)
     
  3395. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients - (01/10/09)
     
  3396. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/07/09)
     
  3397. Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy - (01/07/09)
     
  3398. hsCRP/inflammation & CVD in Patients with with low Framingham risk score & median CD4 of 500 & <50 HIV RNA - (01/07/09)
     
  3399. (EPO) Erythropoiesis-Stimulating Agents - Time for a Reevaluation - (01/07/09)
     
  3400. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/05/09)
     
  3401. Many Americans Have Pre-Diabetes and Should Be Considered for Metformin Therapy - (01/05/09)
     
  3402. Delay in Diagnosis of Diabetes Is Not the Patient's Fault - (01/05/09)
     
  3403. Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults - (01/05/09)
     
  3404. CD4 Recovery Severely Blunted After HAART Treatment Interruption - (01/05/09)
     
  3405. CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission - (12/29/09)
     
  3406. Double-Edged Genetic Swords and Immunity: Lesson from CCR5 and Beyond EDITORIAL COMMENTARY - (12/29/09)
     
  3407. Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients - (12/29/09)
     
  3408. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (12/29/09)
     
  3409. Bypass Anemia Drugs in Chronic Kidney Disease, Expert Says - (12/29/09)
     
  3410. Treatment of Anemia in Chronic Kidney Disease - Strategies Based on Evidence EDITORIAL - (12/29/09)
     
  3411. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  3412. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  3413. Enhanced Reyataz & Efavirenz Co-Pay Benefit Program - (12/21/09)
     
  3414. Testosterone: More Is Not Always Better - EDITORIAL - (12/21/09)
     
  3415. Thyroid Function and Longevity: New Insights into an Old Dilemma - EDITORIAL - (12/21/09)
     
  3416. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals - (12/17/09)
     
  3417. White House Community Discussions in 14 Cities Videos - (12/17/09)
     
  3418. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne (2) - (11/20/09)
     
  3419. Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality - EDITORIAL COMMENTARY - (12/15/09)
     
  3420. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy - (12/15/09)
     
  3421. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men (AIDS Dec 7 2009)-- pdf full text attached for you to download - (12/14/09)
     
  3422. EACS: The Impact of Maraviroc on Insulin Sensitivity, Lipids and Adipokines after 2 weeks in HIV Negative Male Volunteers - (12/10/09)
     
  3423. EACS: Pros and Cons of Boosted PI Monotherapy - (12/10/09)
     
  3424. Mediterranean Diet and Late-Life Cognitive Impairment -Editorial - (12/09/09)
     
  3425. Physical Activity, Diet, and Risk of Alzheimer Disease: In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. - (12/09/09)
     
  3426. New Changes in DHHS Guidelines- HAART Recommended Earlier in HIV; new What To Start; DHHS Reasons for Changes - (12/04/09)
     
  3427. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial - (12/04/09)
     
  3428. Updated European (EACS) & USA Treatment Guidelines (DHHS) - (12/04/09)
     
  3429. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (12/03/09)
     
  3430. Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall - (12/01/09)
     
  3431. When and how to use maraviroc in HIV-infected patients - (12/01/09)
     
  3432. New WHO HIV recommendations on HIV ART treatment, prevention & infant feeding to improve health, reduce infections and save lives - (12/01/09)
     
  3433. Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE - BRIEF REPORT - (11/30/09)
     
  3434. Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study - (11/30/09)
     
  3435. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  3436. IAS: HIV-1 INFECTION IN SUBJECTS OLDER THAN 70: A MULTICENTER CROSS-SECTIONAL ASSESSMENT IN CATALONIA, SPAIN - (11/29/09)
     
  3437. EACS: The ARTEN study: 48 week efficacy data stratified by screening viral load and CD4+ cell count - (11/30/09)
     
  3438. EACS: Pharmacokinetic interaction study between TMC278,an NNRTI, and the contraceptives norethindrone plus ethinylestradiol - (11/30/09)
     
  3439. EACS: Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers - (11/30/09)
     
  3440. EACS: Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278 - (11/24/09)
     
  3441. EACS: TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers - (11/24/09)
     
  3442. EACS: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (11/30/09)
     
  3443. EACS: A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects - (11/30/09)
     
  3444. EACS: Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment out-come in advanced naive subjects initiating cART - (11/30/09)
     
  3445. EACS: Association of effectiveness and adherence of antiretroviral treatment - (11/30/09)
     
  3446. EACS: Impact of different types of adherence behaviours and of cART characteristics on plasma HIV-1 RNA detection under lower limit of quantification at real-time assay - (11/30/09)
     
  3447. EACS: Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention: CVD algorithms underestimate risk in HIV+ - (11/30/09)
     
  3448. Oral Gonorrhea for Men & Women: pharynx a reservoir for gonorrhea - (11/24/09)
     
  3449. Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men Who Have Sex with Men - (11/24/09)
     
  3450. FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time - (11/24/09)
     
  3451. EACS: Adherence to and quality of life of a one-pill once-a-day HAART (Atripla). Results of the ADONE study - (11/24/09)
     
  3452. EACS: The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1 - (11/24/09)
     
  3453. EACS: Safety Profile of HIV-1 Patients Co-Infected With Hepatitis B or C in the Maraviroc Expanded Access Program - (11/24/09)
     
  3454. EACS: ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS - THE ERVIR STUDY - (11/24/09)
     
  3455. EACS: Gender-Based Differences in Antiretroviral-Naïve Patients Treated With Ritonavir-Boosted Protease Inhibitors: Results From the CASTLE Study Through 96 Weeks - (11/24/09)
     
  3456. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)
     
  3457. EACS: Viral Load Over 50 and Low CD4/CD8 Ratio Hoist MI Risk in French Cohort - Written Mark Mascolini - (11/20/09)
     
  3458. EACS: Risk of Cardiovascular Disease in ART-Naive People Without Heart Symptoms, Carotid Artery Ultrasonography May Be Useful - Written Mark Mascolini - (11/20/09)
     
  3459. EACS: Abdominal Adiposity Not Waning With Newer Antiretrovirals in France - Written Mark Mascolini - (11/20/09)
     
  3460. EACS: Metabolic Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV-infected Patients with Excess Abdominal Fat over a Period of 52 Weeks. A Pooled Analysis of 2 Multicenter, Double- blind, Placebo-controlled Phase 3 Trials with 816 Randomized Patients - (11/20/09)
     
  3461. EACS: "Deep" Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC) - (11/20/09)
     
  3462. EACS: Optimization of Clinically Relevant Cutpoints for the Determination of HIV Co-Receptor Usage to Predict Maraviroc Responses in Treatment Experienced (TE) Patients Using Population V3 Genotyping - (11/20/09)
     
  3463. EACS: Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects - (11/20/09)
     
  3464. EACS: Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in Treatment-Experienced, HIV-1-Infected Subjects - (11/20/09)
     
  3465. EACS: Diagnosis and management of cognitive disorders during successful HIV treatment - (11/20/09)
     
  3466. EACS: Simplified Antiretroviral Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age, Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802) - (11/18/09)
     
  3467. EACS: Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)
     
  3468. EACS: Kaletra QD Resistance Report: Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects - (11/18/09)
     
  3469. EACS: Etravirine demonstrates a favourable safety and tolerability profile: pooled 96-week results from the Phase III DUET trials - (11/18/09)
     
  3470. EACS: Safety and pharmacokinetics of etravirine in pregnant HIV-infected women - (11/18/09)
     
  3471. EACS: Tesamorelin Health-Related Quality of Life in HIV+ regarding belly and weight image - (11/18/09)
     
  3472. EACS: MIs, Cocaine/IVDUs French Database - (11/17/09)
     
  3473. EACS: S/GSK1349572 Integrase Inhibitor Resistance Profile - (11/17/09)
     
  3474. EACS: Potent Antiviral Activity of GSK Integrase S/GSK1349572 - (11/17/09)
     
  3475. EACS: A Phase II, open-label trial in treatment-naive, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/17/09)
     
  3476. EACS: Twice Daily Darunavir to Replace Dual Boosted Protease Inhibitors in Virologically Suppressed Patients - (11/17/09)
     
  3477. EACS: Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL - (11/17/09)
     
  3478. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  3479. EACS: A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/15/09)
     
  3480. EACS: Darunavir Maintenance Monotherapy - (11/15/09)
     
  3481. EACS: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (11/15/09)
     
  3482. EACS: Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results From the CASTLE Study Through 96 Weeks - (11/15/09)
     
  3483. EACS: Assessment of Safety and Efficacy of Abacavir/Lamivudine and Tenofovir/Emtricitabine in Treatment-Naïve HIV-1 Infected Subjects ASSERT: 48-Week Result - (11/15/09)
     
  3484. EACS: Once-Daily Dosing Ups Risk of Stopping Antiretrovirals in Single-Clinic Study - written by Mark Mascolini - (11/15/09)
     
  3485. EACS: Lower Intracellular Carbovir (Abacavir) Levels With Darunavir/Ritonavir - written by Mark Mascolini - (11/15/09)
     
  3486. EACS: Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study - written by Mark Mascolini - (11/15/09)
     
  3487. EACS: More Evidence of Low Vitamin D in People Taking Antiretrovirals - written by Mark Mascolini - (11/15/09)
     
  3488. EACS: Study of Once-Daily Boosted Darunavir Monotherapy as First-Line Therapy Had Difficulty - written by Mark Mascolini - (11/15/09)
     
  3489. EACS: Multicohort Study Confirms Continuing Hodgkin Lymphoma Risk With HAART - written by Mark Mascolini - (11/15/09)
     
  3490. EACS: Good 4-Year HIV Response in People Over 60, But High Cancer and Heart Disease Rates - written by Mark Mascolini - (11/15/09)
     
  3491. EACS: Later Year and Age Over 50 Tied to Better Response After Triple-Class Failure - written by Mark Mascolini - (11/15/09)
     
  3492. EACS: Hodgkin Lymphoma, Liver Cancer, Anal Cancer More Common With HIV - written by Mark Mascolini - (11/13/09)
     
  3493. EACS: Mortality High With Non-AIDS Cancers in EuroSIDA Despite HAART - written by Mark Mascolini - (11/13/09)
     
  3494. EACS: More Than Half in HIV Patient Series Carry High-Risk Human Papillomavirus - written by Mark Mascolini - (11/13/09)
     
  3495. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - written by Mark Mascolini - (11/13/09)
     
  3496. EACS: MONET Paints Noninferiority Picture With Darunavir/Ritonavir Monotherapy - written by Mark Mascolini - (11/13/09)
     
  3497. EACS: Twice-Daily Darunavir/Ritonavir to Replace Double-Boosted PIs - written by Mark Mascolini - (11/13/09)
     
  3498. Aging is a significant risk factor for cognitive impairment. As the HIV cohort ages, further investigation is needed into the effects of aging on HIV cognitive impairment. - (11/10/09)
     
  3499. ViiV Healthcare Launches: GSK/Pfizer New HIV Company - (11/10/09)
     
  3500. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  3501. IDSA: 144Week Efficacy & Safety of Raltegravir in TreatmentExperienced Patients, TripleClass Resistant - (11/01/09)
     
  3502. IDSA: (IDSA) TMC278 25mg qd has no effect on corrected QT interval in HIV-negative volunteers - (11/01/09)
     
  3503. IDSA: (IDSA) Predictors of Response in GRACE (Gender, Race And Clinical Experience) - (11/01/09)
     
  3504. IDSA: (IDSA) Darunavir, Ritonavir, and Etravirine Steady-state Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-infected Women Enrolled in the GRACE Study - (11/01/09)
     
  3505. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study - (11/01/09)
     
  3506. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials - (11/01/09)
     
  3507. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials - (11/01/09)
     
  3508. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication - (11/01/09)
     
  3509. Role of metabolic syndrome components in HIV-associated sensory neuropathy - (11/01/09)
     
  3510. HIV infection and the risk of cancers with and without a known infectious cause - (11/01/09)
     
  3511. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial - (10/28/09)
     
  3512. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1 infected patients: ARTEN Study Week 48 results - (10/28/09)
     
  3513. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening - (10/27/09)
     
  3514. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial - (10/27/09)
     
  3515. 11th Wrkshp Adverse Drug Reactions Co-morbidities: 48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening - (10/27/09)
     
  3516. Cardiovascular Diseases and Risk of Hip Fracture - (10/27/09)
     
  3517. ACG: ACE Inhibitor Use Linked to Liver Toxicity - (10/27/09)
     
  3518. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America - (10/27/09)
     
  3519. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe - BRIEF REPORT - (10/27/09)
     
  3520. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy - (10/25/09)
     
  3521. CDC Updated Oct 21 Interim Recommendations for H1N1 Influenza for HIV-Infected Adults and Adolescents - (10/25/09)
     
  3522. Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection - (10/25/09)
     
  3523. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection - (10/25/09)
     
  3524. Increased Peripheral Proinflammatory Cytokines in HIV-1-Infected Patients With Prolonged Viral Suppression Suffering From High Psychological Stress - (10/25/09)
     
  3525. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand - (10/20/09)
     
  3526. HIV Vaccine Trial Results - An Opening for Further Research EDITORIAL - (10/20/09)
     
  3527. Adverse health effects of non-medical cannabis use - (10/17/09)
     
  3528. High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial - (10/16/09)
     
  3529. IL-2 in HIV: associated with vascular events, inflammation, and no clinical benefit despite CD4 increase - (10/16/09)
     
  3530. New Approach To Targeting The Hidden Reservoir Of HIV: Siliciano Can Screen Compounds with new system - (10/16/09)
     
  3531. Bone Loss in HCV/HIV Coinfection - (10/16/09)
     
  3532. ICAAC:TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS - (10/13/09)
     
  3533. ICAAC: IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS - (10/13/09)
     
  3534. Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim - (10/12/09)
     
  3535. Clumsy FDA Antiviral Advisory Committee (Maraviroc hearing) for both HIV & HCV in the future - (10/12/09)
     
  3536. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects: more colon lesions in HIV+ - (10/09/09)
     
  3537. FDA Antivirals Advisory Panel Recommends Maraviroc for Naives Approval 10-4 - (10/09/09)
     
  3538. "Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer" - - (10/09/09)
     
  3539. Diabetes Can Impair Exercise Capacity: Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus - (10/07/09)
     
  3540. Subcutaneous (lipoatrophy) Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men - (10/07/09)
     
  3541. Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study - (10/07/09)
     
  3542. Frontostriatal fiber bundle compromise in HIV infection without dementia - (10/06/09)
     
  3543. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels - (10/06/09)
     
  3544. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy - (10/06/09)
     
  3545. New Approach To Targeting The Hidden Reservoir Of HIV - (10/05/09)
     
  3546. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  3547. Fall Prevention: how much vitamin D do you need? - (10/04/09)
     
  3548. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  3549. Doctors Prescribe Caution With Insulin's Cancer Ties - (10/04/09)
     
  3550. ICAAC: HIV-Associated Neurocognitive Disorders in the Era of Potent Antiretroviral Therapy: risk factors/prevalence, CSF HIV-RNA, HCV, ART PK/penetration, assessment tools - (10/04/09)
     
  3551. Lipoatrophy & Mortality, CVD - (09/30/09)
     
  3552. A1C Underestimates Glycemia in HIV Infection - (09/30/09)
     
  3553. Diabetes 2 Caused Brain Atrophy in Older Individuals - (09/30/09)
     
  3554. Vitamin D Improves Muscle Function - (09/29/09)
     
  3555. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells (HIV eradication) - (09/29/09)
     
  3556. Renal function with use of a tenofovir-containing initial antiretroviral regimen - (09/29/09)
     
  3557. CCR5 antagonism in HIV infection: ways, effects, and side effects - (09/29/09)
     
  3558. Evaluation of Adherence and Factors Affecting Adherence to Combination Antiretroviral Therapy Among White, Hispanic, and Black Men in the MACS Cohort - (09/29/09)
     
  3559. Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations - (09/29/09)
     
  3560. Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers - (09/29/09)
     
  3561. Incidence of Non-AIDS-Defining Malignancies Higher in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression - (09/26/09)
     
  3562. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  3563. Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+ T Cells - (09/25/09)
     
  3564. ICAAC: Differential Effects of Maraviroc (MVC) and Efavirenz (EFV) on Markers of Immune Activation (IA) and Inflammation and Their Association with CD4 Cell Rises: A Sub-analysis of the MERIT (09/21/09)
     
  3565. ICAAC: MERIT: Week 96 Virologic Response and Tropism at Virologic Failure by Baseline CD4+ Cell Count (09/21/09)
     
  3566. ICAAC: Maraviroc (MVC) is Similar to Efavirenz (EFV) for Virologic Response (VR) Across Subgroups: MERIT 96-Week (09/21/09)
     
  3567. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  3568. ICAAC:Renal Disease in Diabetics with HIV: "higher rate of microalbuminuria than either HIV-positive patients without diabetes or diabetics without HIV infection" - (09/21/09)
     
  3569. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  3570. ICAAC: Safety and Effectiveness of Raltegravir-based HAART in HIV-Subjects after Solid Organ Transplantation (09/20/09)
     
  3571. ICAAC: 24 Week Safety and Efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth (09/20/09)
     
  3572. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  3573. ICAAC: Phenotypic Screening for HIV Tropism versus both Population-based and "Deep" Sequencing (09/20/09)
     
  3574. ICAAC: Direct comparison with 454 pyrosequencing validates V3-loop based genotyping in patients eligible for Maraviroc initiation (09/20/09)
     
  3575. ICAAC: Prediction of HIV Disease Progression Using a Modification of the Enhanced Sensitivity (ES) Trofile Assay (09/20/09)
     
  3576. ICAAC:Prevalence of HIV-1 CCR5 Co-Receptor Tropism Differs by Env (gp41) Subtype in a Large Commercial Dataset (09/20/09)
     
  3577. ICAAC: The composition of dual-mixed HIV-1 populations can be discerned from the level of CXCR4-mediated infectivity (09/20/09)
     
  3578. ICAAC: Incorporation of Optimized Primers into the Trofile Assay Substantially Improves Determination of Viral Tropism in Genetically Diverse HIV Subtypes (09/20/09)
     
  3579. ICAAC: "Deep" Sequencing to Quantify in vivo Viral Fitness after Transmission of Resistant HIV (09/20/09)
     
  3580. ICAAC:Raltegravir in CSF: "Raltegravir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  3581. ICAAC: Darunavir in the CSF: "Darunavir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  3582. ICAAC: ART Helps Bring Lungs Up to Par in Nonsmokers, But Not Smokers - written by Mark Mascolini - (09/19/09)
     
  3583. ICAAC: Pharmacokinetics and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV-1 Infection (09/19/09)
     
  3584. ICAAC: The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects (09/19/09)
     
  3585. ICAAC: Lack of Interaction between the HIV Integrase Inhibitor, S/GSK1349572, and Tenofovir Disoproxil Fumarate (TDF) in Healthy Subjects (09/19/09)
     
  3586. ICAAC: Meta-Analysis of Safety for Short-term Dosing of an HIV Integrase Inhibitor, S/GSK1349572, from Seven Clinical Studies (09/19/09)
     
  3587. ICAAC: In Vitro Passage of Drug Resistant HIV-1 against a Next Generation Integrase Inhibitor (INI), S/GSK1349572 (09/19/09)
     
  3588. ICAAC: Evaluation of Antacid and Multivitamin (MVI) Effects on S/GSK1349572 Pharmacokinetics (PK) in Healthy Subjects (09/19/09)
     
  3589. ICAAC: Endothelial Function Drops in First Month of Antiretroviral Therapy - written by Mark Mascolini - (09/18/09)
     
  3590. ICAAC: Peripheral Endothelial Function is Reduced after Initiation of Antiretroviral Therapy in Treatment Naïve HIV Patients: A Prospective Longitudinal Study (09/18/09)
     
  3591. ICAAC: Steady State Evaluation of Two Extended Release (XR) Nevirapine (NVP) Tablets 400 mg QD Compared with Immediate Release (IR) NVP Tablets 200 mg BID in HIV-1 Infected Patients (09/18/09)
     
  3592. ICAAC: Pharmacokinetic interaction between etravirine and lopinavir/ritonavir (09/18/09)
     
  3593. ICAAC: Bevirimat Antiviral Activity & Safety, 14-Day Monotherapy Study (09/18/09)
     
  3594. ICAAC: GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48 (09/17/09)
     
  3595. Eradication Drug Research: Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors - (09/17/09)
     
  3596. ICAAC: Sharp Drop in ICU Mortality After Introduction of HAART in Netherlands - written by Mark Mascolini - (09/17/09)
     
  3597. ICAAC: Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the Extension of VICTOR-E1 Stud - (09/17/09)
     
  3598. ICAAC: INSPIRE Study: Effects of r-hIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients Receiving c-ART - Interim Analysis of a Phase I/IIa Multicenter Study - (09/17/09)
     
  3599. ICAAC: Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir - (09/17/09)
     
  3600. ICAAC: Effect of Food on Pharmacokinetics of Elvitegravir, Emtricitabine, Tenofovir DF and the Pharmacoenhancer GS-9350 as a Fixed- Dose Combination Tablet - (09/17/09)
     
  3601. ICAAC: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz, both with Zidovudine and Lamivudine, to Treatment-Naive HIV-Infected Patients: 96-Week Results from MERIT - (09/17/09)
     
  3602. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects GSK press release - (09/17/09)
     
  3603. ICAAC: Improvement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients - (09/17/09)
     
  3604. ICAAC: Phase 2a Study of PRO 140 in HIV-Infected Adults - (09/17/09)
     
  3605. ICAAC: Can IL-7 Succeed Where IL-2 Failed in People With HIV? - written by Mark Mascolini - (09/17/09)
     
  3606. ICAAC: Once-Daily Replacement Raltegravir as Good as Twice-Daily in Pilot Trial - written by Mark Mascolini - (09/17/09)
     
  3607. ICAAC: Another Small Study Suggests Viability of Unboosted Atazanavir/Raltegravir Maintenance - written by Mark Mascolini - (09/17/09)
     
  3608. ICAAC: Faster Viral Decay With Nevirapine Than Atazanavir/Ritonavir in ARTEN Trial - written by Mark Mascolini - (09/17/09)
     
  3609. ICAAC: Gut-Shielding Mix Slows CD4 Drop in People Not Taking Antiretrovirals - written by Mark Mascolini - (09/17/09)
     
  3610. ICAAC: Gilead GS-9350 Protease Inhibitor Booster - written by Mark Mascolini - (09/17/09)
     
  3611. ICAAC: Raltegravir Reaches Good Nervous System Levels 4.3 Fold x EC50 - written by Mark Mascolini - (09/17/09)
     
  3612. ICAAC: GSK "Backup" Integrase Inhibitor Looks Strong in People With HIV: 10-day monotherapy study - written by Mark Mascolini - (09/17/09)
     
  3613. ICAAC: Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis - (09/17/09)
     
  3614. ICAAC: A Pilot Study assessing Raltegravir QD versus BID in HIV patients included in a Simplification Trial - (09/17/09)
     
  3615. ICAAC: Dual Maintenance Therapy with Raltegravir 400 mg BID with Atazanavir 400 mg qD in Patients with no Prior PI Resistance and Intolerance to Other ARV Regimens: Preliminary Report - (09/17/09)
     
  3616. ICAAC: SCHERING-PLOUGH REPORTS LONG-TERM VICRIVIROC DATA FROM PHASE II OPEN-LABEL EXTENSION STUDY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS - Schering-Plough press releaser - (09/17/09)
     
  3617. ICAAC: Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity - (09/17/09)
     
  3618. ICAAC: Pharmacokinetics (PK) and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor - (09/17/09)
     
  3619. ICAAC: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data - (09/17/09)
     
  3620. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects - (09/14/09)
     
  3621. Gardasil HPV vaccine for boys - FDA Hearing Oct 21 - (09/11/09)
     
  3622. ICAAC: Weighted Antiretroviral Sensitivity Score May Be Better Predictor of Short-Term Response - written by Mark Mascolini - (09/14/09)
     
  3623. ICAAC: Seven Short Studies Suggest Good Safety Profile of New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  3624. ICAAC: Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients - Merck press release - (09/14/09)
     
  3625. ICAAC: Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs. Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients - (09/14/09)
     
  3626. ICAAC: Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics - (09/14/09)
     
  3627. ICAAC: Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals - (09/14/09)
     
  3628. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and buprenorphine/naloxone - (09/14/09)
     
  3629. ICAAC: Early Changes in HCV Viral Load During the First 24 Hours of Treatment Exhibit a Very High Negative Predictive Value of Sustained Virological Response in HCV/HIV Coinfected Patients - (09/14/09)
     
  3630. ICAAC:Role for Short-Term Enfuvirtide to Boost CD4s After Late Diagnosis? - written by Mark Mascolini - (09/14/09)
     
  3631. ICAAC: Lab Study Suggests High Barrier to Resistance With New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  3632. ICAAC: Smoking and Drinking Alcohol Linked to Lower Efavirenz Levels - written by Mark Mascolini - (09/14/09)
     
  3633. ICAAC: Tobacco and Marijuana Tied to Lower Atazanavir Concentrations - written by Mark Mascolini - (09/14/09)
     
  3634. ICAAC: DC Emergency Patients Who Decline HIV Test Have Twice Higher HIV Rate - written by Mark Mascolini - (09/14/09)
     
  3635. ICAAC: Impact of One-Time or Annual HIV Screening on Life Expectancy in France - written by Mark Mascolini - (09/14/09)
     
  3636. ICAAC: HCV Load Decay in First Day of PegIFN Treatment Predicts Long-Term Failure - written by Mark Mascolini - (09/14/09)
     
  3637. HIV and Aging: The Long-term Consequences of Successful Antiretroviral Therapy - (09/11/09)
     
  3638. HIV, HAART & Brain Damage & Repair - (09/11/09)
     
  3639. Effect of HAART on Risk of Sexual Transmission of HIV & Superinfection - CDC Report - (09/11/09)
     
  3640. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  3641. Sex Steroids & Fracture Risk in Men - (09/06/09)
     
  3642. Lipodystrophy & Bone Loss - (09/06/09)
     
  3643. Vitamin D, Diabetes & Bone in African-Americans - (09/06/09)
     
  3644. Inflammation & Diabetes, Interventions - (09/06/09)
     
  3645. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  3646. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  3647. A Potential Role for Vitamin D on HIV Infection? - (09/03/09)
     
  3648. Vitamin D Immunomodulator EDITORIAL - (09/03/09)
     
  3649. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (09/03/09)
     
  3650. Resting cerebral blood flow A potential biomarker of the effects of HIV in the brain - (09/03/09)
     
  3651. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients in TITAN - (09/03/09)
     
  3652. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (08/29/09)
     
  3653. Neurological Impairment Persists Despite HAART: "adjunctive therapies needed" - (08/29/09)
     
  3654. Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients: The Hawaii Aging With HIV Cohort - (08/29/09)
     
  3655. HCV Coinfection & Neurologic Impairment - (08/29/09)
     
  3656. 5th IAS: Association between activation of inflammatory and coagulation pathways and mortality during long-term follow up in SMART - (08/29/09)
     
  3657. 5th IAS: HAART Interruption Increased Inflammation - IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY - (08/29/09)
     
  3658. 5th IAS: HAART Did Not Control Immune Activation - (08/29/09)
     
  3659. 5th IAS: HAART Interruption Increases Immune Activation - (08/29/09)
     
  3660. 5th IAS: Kaletra Protects Mitochondria - (08/29/09)
     
  3661. Untreated HIV Infection and Large and Small Artery Elasticity - "Untreated HIV infection is associated with impaired arterial elasticity" - (08/28/09)
     
  3662. Higher CPE Score Improved Cognition, Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders - (08/28/09)
     
  3663. 5th IAS: Prevalence of HIV-1-Associated Neurocognitive Disorders in Argentina - (08/28/09)
     
  3664. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached - (08/27/09)
     
  3665. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  3666. The clot thickens-oxidized lipids and thrombosis - (08/26/09)
     
  3667. Oxidized lipids: a key to heart disease? - (08/26/09)
     
  3668. Aging/HIV Clinical Care & Research - New IDSA Guidelines - (08/26/09)
     
  3669. Thyroid Dysfunction, Hypogonadism, Testosterone, Bone, Prostate Cancer, HIV & HAART - (08/26/09)
     
  3670. Aging & HIV Recognized as a Serious Concern But No Real Discussion, Still Ignored. 2007 NIH Workshop recommendations - (08/26/09)
     
  3671. Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA) - (08/21/09)
     
  3672. Vitamin D Deficiency/Muscle Function/Frailty - (08/21/09)
     
  3673. GSK says latest Avandia findings are flawed: new pio vs rosiglitazone study - (08/20/09)
     
  3674. Diagnosis and management of neuropathic pain - Clinical Review - (08/20/09)
     
  3675. NIH Workshop on HIV in Older Adults Oct 20 2007 - (08/18/09)
     
  3676. A serum 25-hydroxyvitamin D level below 50 nmol/l has been associated with increased body sway and a level below 30 nmol/l with decreased muscle strength. - (08/18/09)
     
  3677. Vitamin D deficiency, muscle function, and falls in elderly people1,2 Review Article - (08/18/09)
     
  3678. 5th IAS: IAS: darunavir & etravirine studies - (08/16/09)
     
  3679. New IDSA HIV Guidelines Push 'Adherence to Care' - (08/17/09)
     
  3680. FDA Approves Generic Fixed Dose Efavirenz/FTC/Tenofovir - (08/14/09)
     
  3681. 5th IAS: Kaletra Once-Daily Dosing, IAS Summary - (08/14/09)
     
  3682. 5th IAS: Reyataz Studies at IAS - (08/14/09)
     
  3683. 5th IAS: Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE) - (08/14/09)
     
  3684. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  3685. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  3686. 5th IAS: Abacavir & MIs - IAS Summary - (08/12/09)
     
  3687. 5th IAS: Cancers & HIV at IAS Summary Report - (08/12/09)
     
  3688. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  3689. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  3690. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  3691. Lipoatrophy and lipohypertrophy are independently associated with hypertension - (08/12/09)
     
  3692. Physical Activity, Diet, and Risk of Alzheimer Disease (65% reduction in risk) - (08/12/09)
     
  3693. Mediterranean Diet and Late-Life Cognitive Impairment EDITORIAL - (08/12/09)
     
  3694. tenofovir & abacavir - Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients  - (08/12/09)
     
  3695. Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster than Previously Thought - NIH BULLETIN - (08/12/09)
     
  3696. Midlife Serum Cholesterol and Increased Risk of Alzheimer's and Vascular Dementia Three Decades Later- pdf attached - (08/12/09)
     
  3697. Structural biology: Aerial view of the HIV genome - (08/12/09)
     
  3698. Oral Cancer In Men Associated With HPV - (08/12/09)
     
  3699. Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir - New UK CHIC Study BRIEF REPORT - (08/12/09)
     
  3700. Thiazolidinediones and Fractures in Men and Women - (08/12/09)
     
  3701. Bone Guidelines Excerpted From New IDSA Guidelines- pdf of full paper attached  - (08/12/09)
     
  3702. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004 - pdf of published report attached - (08/12/09)
     
  3703. 5th IAS: New Drugs, New strategies - written by Joe Eron MD - (08/12/09)
     
  3704. WHO May Recommend HAART for PMTCT: IAS - (08/07/09)
     
  3705. Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission - (08/07/09)
     
  3706. WHO may change ARV guidelines for pregnant mothers: HAART reduces HIV transmission while breastfeeding - (08/07/09)
     
  3707. New review endorses CV benefits of fish oil - (08/06/09)
     
  3708. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases - (08/06/09)
     
  3709. HIV-associated brain dysfunction in the era of HAART - Editorials, Reasons for hope, but continued concern - (08/06/09)
     
  3710. The Pathogenetic Role of Cortisol in the Metabolic Syndrome (and lipodystrophy): A Hypothesis - (08/06/09)
     
  3711. Continuous antiretroviral therapy decreases bone mineral density in SMART - (08/06/09)
     
  3712. 5th IAS: Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057) - (08/04/09)
     
  3713. 5th IAS: Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09)
     
  3714. 5th IAS: 91% Have Low Vitamin D Levels in UK Cohort, 34% Severely Deficient; Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse, urban UK HIV cohort - (08/04/09)
     
  3715. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  3716. Bone mineral density and disorders of mineral metabolism in chronic liver disease: Cirrhotics Have Low Bone Density & Low Vitamin D Levels - (08/04/09)
     
  3717. -2.5% Bone Loss Over 96 Weeks on PI or NNRTI in study reported - (08/04/09)
     
  3718. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  3719. Scientists learn why even treated genital herpes sores boost the risk of HIV infection - (08/04/09)
     
  3720. 5th IAS: Earlier HAART at 350 CD4 Instead of Current 200 in Developing World Recommended - (08/01/09)
     
  3721. 5th IAS: Preliminary analyses suggest a higher rate of HIV seroconversion among men who were HPV positive at baseline - (08/01/09)
     
  3722. 5th IAS: Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)
     
  3723. 5th IAS: Duration of Viral Suppression Strongly Modifies the Adherence-Viral Rebound Relationship - (08/01/09)
     
  3724. Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure - (07/31/09)
     
  3725. 5th IAS: Neurocognitive Disorders Despite Undetectable HIV RNA - (07/31/09)
     
  3726. 5th IAS: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida (07/31/09)
     
  3727. 5th IAS: 48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)
     
  3728. 5th IAS: HIV Infection Modulates Cellular Proteins Associated With Cardiovascular Disorders - (07/31/09)
     
  3729. 5th IAS: Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). - (07/31/09)
     
  3730. CROI: Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study - (06/02/09)
     
  3731. 5th IAS: HIV Prevention at IAS 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (07/30/09)
     
  3732. 5th IAS: Genital HIV-1 RNA Concentrations and Heterosexual HIV-1 Transmission Risk: 'higher genital HIV levels increase HIV sex transmission risk' - (07/30/09)
     
  3733. 5th IAS: MIs & ARTs: Nested Control Study in Quebec Cohort - (07/30/09)
     
  3734. 5th IAS: Predictive factors of serious vascular events in HIV patients in LATINA (LATInamerican Network on AIDS) - (07/30/09)
     
  3735. 5th IAS: Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care - (07/30/09)
     
  3736. 5th IAS: Metabolic Complications of HIV infection Update form the 5th IAS Conference in Cape Town - Pablo Tebas MD, University of Pennsylvania - (07/30/09)
     
  3737. 5th IAS: Persistence and Progression of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study - (07/30/09)
     
  3738. Bioavailability of Efavirenz Capsule Contents (Sprinkles) Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults - (07/29/09)
     
  3739. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  3740. 5th IAS: Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial - (07/30/09)
     
  3741. 5th IAS: Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring - press release - (07/30/09)
     
  3742. 5th IAS: DART Study Slide Presentation at IAS - (07/30/09)
     
  3743. 5th IAS: Omega-3 polyunsaturated fatty acids inhibit the release of matrix metalloproteinases: therapeutic implications for HIV-associated immune activation - (07/30/09)
     
  3744. CHMP Recommends Expanded Use of ISENTRESS® (raltegravir), from MSD, in Treatment-Naïve Adult Patients with HIV-1 Infection - (07/29/09)
     
  3745. 5th IAS: Efavirenz Linked to Severe Vitamin D Deficit in Diverse London Clinic - written by Mark Mascolini - (07/29/09)
     
  3746. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz - (07/29/09)
     
  3747. HIV Can Kill Chimps; Infectious diseases: An ill wind for wild chimps? - (07/29/09)
     
  3748. 5th IAS: What CD4 Cell Count Levels are Associated With a Reduced Risk of Cancer? 'When To Begin HAART' - (07/29/09)
     
  3749. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  3750. 5th IAS: Varying Risk of AIDS and Non-AIDS Cancers in Diverse CD4 Brackets - written by Mark Mascolini - (07/29/09)
     
  3751. 5th IAS: Half in US HIV Group Have Neurocognitive Impairment, Which Improves With NNRTIs - written by Mark Mascolini - (07/29/09)
     
  3752. 5th IAS: Two Triple PEP Regimens With Truvada Look Safer Than Older PEPs - written by Mark Mascolini - (07/29/09)
     
  3753. 5th IAS: TB Rate in South African Township Plummets After Antiretrovirals Arrive - written by Mark Mascolini - (07/29/09)
     
  3754. 5th IAS: Anal Cancer Rates Keep Climbing in US HIV Group Despite HAART - written by Mark Mascolini - (07/29/09)
     
  3755. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  3756. 5th IAS: Adding Raltegravir to Suppressive Regimen Does Not Cut Low-Level Viremia - written by Mark Mascolini - (07/29/09)
     
  3757. 5th IAS: More Time With Low CD4 Count Boosts Non-AIDS Cancer Risk - written by Mark Mascolini - (07/29/09)
     
  3758. 5th IAS: THE FOTOSTUDY 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients - (07/29/09)
     
  3759. 5th IAS: ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)
     
  3760. 5th IAS: Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)
     
  3761. 5th IAS: Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  3762. 5th IAS: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)
     
  3763. 5th IAS: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  3764. 5th IAS: Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)
     
  3765. 5th IAS: Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730 - (07/28/09)
     
  3766. 5th IAS: Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)
     
  3767. 5th IAS: ARTs Cause Bone Loss - (07/28/09)
     
  3768. 5th IAS: Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - (07/28/09)
     
  3769. 5th IAS: Cumulative & Current Viral Replication & Low CD4 Increases NHL Risk: Immune deficiency, uncontrolled HIV replication and non-Hodgkin's lymphoma, ANRS CO3 Aquitaine Cohort, 1998-2006. - (07/28/09)
     
  3770. 5th IAS: ISENTRESS (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy - (07/23/09)
     
  3771. Tight Glucose Control Raises Mortality Risk in Heart Failure in a New Study - (07/23/09)
     
  3772. HIV & Kidney Disease: African-Americans with HIV are more susceptible to type of kidney disease known as HIVAN - (07/23/09)
     
  3773. 5th IAS: Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)
     
  3774. 5th IAS: Abacavir Not Associated with MIs, 2 Studies Report at IAS - (07/23/09)
     
  3775. 5th IAS: Swiss Suicide Risk Still High With HIV, But HAART Made a Difference - written by Mark Mascolini - (07/22/09)
     
  3776. 5th IAS: Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)
     
  3777. 5th IAS: Kaletra Once vs Twice Daily - (07/22/09)
     
  3778. 5th IAS: Once- and Twice-Daily Lopinavir/Ritonavir Equivalent in Antiretroviral Experienced - written by Mark Mascolini - (07/22/09)
     
  3779. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study - written by Mark Mascolini - (07/22/09)
     
  3780. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study; HCV Therapy Quadrupled Chance For Fibrosis Regression - written by Mark Mascolini - (07/22/09)
     
  3781. 5th IAS: Second Trial of Darunavir Monotherapy Seems Less Convincing - written by Mark Mascolini - (07/22/09)
     
  3782. 5th IAS: Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96 - (07/22/09)
     
  3783. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/22/09)
     
  3784. 5th IAS: Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)
     
  3785. 5th IAS: Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients - press release - (07/22/09)
     
  3786. 5th IAS: EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)
     
  3787. 5th IAS:Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)
     
  3788. 5th IAS: A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression: MONOI ANRS 136 - (07/22/09)
     
  3789. 5th IAS: Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)
     
  3790. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  3791. 5th IAS: Raltegravir Rescue Regimens Do Well With or Without a PI - written by Mark Mascolini - (07/21/09)
     
  3792. 5th IAS: Nevirapine Combo May Work for Some Kids Exposed to Single-Dose Nevirapine - written by Mark Mascolini - (07/21/09)
     
  3793. 5th IAS: Adding More NRTIs to Salvage May Lower Chance of Response - written by Mark Mascolini - (07/21/09)
     
  3794. 5th IAS: Once-Daily Darunavir Monotherapy Effective for 48 Weeks After Viral Control - written by Mark Mascolini - (07/21/09)
     
  3795. 5th IAS: New Once-Daily Integrase Inhibitor Looks Strong in Early Trial - written by Mark Mascolini - (07/21/09)
     
  3796. 5th IAS: Attacking LDL Cholesterol in People on ARVs Has Mixed Results - written by Mark Mascolini - (07/21/09)
     
  3797. 5th IAS: Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy - (07/21/09)
     
  3798. 5th IAS: The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline - (07/21/09)
     
  3799. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/21/09)
     
  3800. 5th IAS: The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)
     
  3801. 5th IAS: 96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)
     
  3802. 5th IAS: Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol - (07/21/09)
     
  3803. 5th IAS: Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 144-week data - (07/21/09)
     
  3804. 5th IAS: Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients - (07/21/09)
     
  3805. 5th IAS: Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI) - (07/21/09)
     
  3806. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  3807. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  3808. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  3809. Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals - (07/20/09)
     
  3810. 5th IAS: One Third With Undetectable HIV RNA Have Asymptomatic Neurocognitive Impairment - written by Mark Mascolini - (07/20/09)
     
  3811. 5th IAS: Raltegravir and Unboosted Atazanavir as Simple Maintenance Regimen - written by Mark Mascolini - (07/20/09)
     
  3812. 5th IAS: Abacavir Heart Attack Controversy: Kidney Disease Appears to Matter - written by Mark Mascolini - (07/20/09)
     
  3813. 5th IAS: New results from ARTEN study of nevirapine plus tenofovir and emtricitabine (TDF/FTC) versus boosted protease inhibitor regimen of atazanavir/ritonavir plus TDF/FTC revealed - BI Press Release For U.S. Media Only - (07/20/09)
     
  3814. 5th IAS: S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy - (07/20/09)
     
  3815. 5th IAS: 96-WEEK SAFETY AND EFFICACY FINDINGS PRESENTED FOR INTELENCETM (ETRAVIRINE) AS PART OF HIV COMBINATION THERAPY - Tibotec press release - (07/20/09)
     
  3816. 5th IAS: S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor - (07/20/09)
     
  3817. 5th IAS: Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-naive HIV-1 infected patients: ARTEN Study week 48 results - (07/20/09)
     
  3818. 5th IAS: NEW HIV STUDY SHOWS THAT LARGE NUMBERS OF WOMEN AND PEOPLE OF COLOR CAN BE SUCCESSFULLY ENROLLED IN U.S. HIV CLINICAL STUDIES - Tibtec press release - (07/20/09)
     
  3819. 5th IAS: IAS Opening Session - Recession Impact - (07/20/09)
     
  3820. 5th IAS: Thinking Through the CNS: The Importance of Considering the Blood-Brain Barrier. Slide talk by Scott Letende, GSK satellite meeting at IAS 2009 - (07/19/09)
     
  3821. 5th IAS: European Researchers Issuing Guidelines on Bone Disease - (07/19/09)
     
  3822. HIV-1 Infection Is Associated With an Earlier Occurrence of Frailty....in MACS - (07/18/09)
     
  3823. Male Circumcision Didn't Reduce HIV Transmission To Women in African Study - (07/18/09)
     
  3824. Male circumcision and HIV risks and benefits for women - EDITORIAL - (07/18/09)
     
  3825. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  3826. HIV Viral Replication Causes Non-AIDS Events - (07/17/09)
     
  3827. TMC278+Truvada Coformulation Announced by Gilead & Tibotec - (07/17/09)
     
  3828. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  3829. Vicriviroc/Reyataz Nuke-Sparing HAART: Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV - (07/16/09)
     
  3830. Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study - (07/16/09)
     
  3831. Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men - (07/16/09)
     
  3832. MRI Findings May Track Risk of Cognitive Impairment in Healthy Seniors - (07/16/09)
     
  3833. Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men - (07/16/09)
     
  3834. Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men - (07/16/09)
     
  3835. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  3836. DDI Associated with NonCirrhotic Portal Hypertension - (07/14/09)
     
  3837. Grinding to a Halt: The Effects of the Increasing Regulatory Burden on Research and Quality Improvement Efforts - IDSA POLICY PRINCIPLES - (07/10/09)
     
  3838. FDA: Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients - (07/10/09)
     
  3839. Glutamic Acid (Vegetables) May Lower Blood Pressure - (07/10/09)
     
  3840. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  3841. New HIV Research Finds Early Disabled Immune Response - (07/09/09)
     
  3842. Independent effects of physical activity in patients with nonalcoholic fatty liver disease: exercise improves fatty liver & metabolics - (07/08/09)
     
  3843. Nitrates May Be Environmental Trigger For Alzheimer's, Diabetes And Parkinson's Disease - (07/08/09)
     
  3844. Global Consequences of the Future of Aging with HIV - (07/08/09)
     
  3845. Stepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events A Randomized Trial - (07/08/09)
     
  3846. Study finds no increased progression of retinopathy with sanofi-aventis' Lantus - (07/08/09)
     
  3847. Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis - (07/08/09)
     
  3848. A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection - full text pdf attached - (07/07/09)
     
  3849. IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  3850. IL-21 Is Required to Control Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  3851. Immunology Controlling Chronic Viral Infections, EDITORS' CHOICE - (07/07/09)
     
  3852. A Chronic Need for IL-21 EDITORIAL - (07/07/09)
     
  3853. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy - (07/04/09)
     
  3854. Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL - (07/04/09)
     
  3855. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy - (07/04/09)
     
  3856. Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? - (07/03/09)
     
  3857. IL-7 Increased T-Cells CD4/CD8/Naive/Memory: In HIV, Cytokine Boosts Immune System  - (07/03/09)
     
  3858. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study - (07/03/09)
     
  3859. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance - (07/03/09)
     
  3860. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy EDITORIAL - (07/03/09)
     
  3861. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients - (07/03/09)
     
  3862. Metabolic bone disease in HIV infection: HIV, ART Implicated EDITORIAL - (07/02/09)
     
  3863. First line AZT/3TC/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir - (07/02/09)
     
  3864. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (07/02/09)
     
  3865. Inflammation Marker hsCRP & CVD- Cause or Effect: Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease - (07/02/09)
     
  3866. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community: "Minimal Benefit In Predicting CVD Compared To Traditional Risk Factors" - (07/02/09)
     
  3867. Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment - Editorial - (07/02/09)
     
  3868. CRP, other biomarkers, not clinically useful to predict CVD risk - (07/02/09)
     
  3869. New meta-analysis: Statins of benefit in primary prevention: improved survival & CVD risk in patients with only risk factors - (07/02/09)
     
  3870. HIV Resistance Wksp: Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure (06/26/09)
     
  3871. HIV Resistance Wksp: Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI- Malawi Study - (06/28/09)
     
  3872. HIV Resistance Wksp: Resistance mutations detected by OLA of HIV-1 DNA at the initiation of nevirapine containing ART are associated with virologic failure - (06/28/09)
     
  3873. HIV Resistance Wksp: Pre-Existing Low-Levels of the K103N HIV-1 RT Mutation Above a Threshold is Associated with Virological Failure in Treatment-Naïve Patients Undergoing EFV-Containing Antiretroviral Treatment (06/16/09)
     
  3874. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  3875. Monitoring bone mineral density during antiresorptive treatment for osteoporosis - Editorial - (06/27/09)
     
  3876. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (06/27/09)
     
  3877. The Value of Bone Density Testing - (06/27/09)
     
  3878. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study - (06/27/09)
     
  3879. Head-to-head 96-week study shows EPZICOM® was comparable to Truvada® -- in efficacy and safety measures -- for HIV treatment-naïve patients - (06/27/09)
     
  3880. HIV Resistance Wksp: Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  3881. HIV Resistance Wksp: CCR5 Tropism Genotype vs Trofile - (06/27/09)
     
  3882. HIV Resistance Wksp: Virco: Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools - (06/27/09)
     
  3883. HIV Resistance Wksp:Quest Tropism Assay: Performance of an HIV-1 Co-receptor Tropism Assay Utilizing Replicate V3 Loop Sequencing and Heteroduplex Analysis with Capillary Electrophoresis - (06/27/09)
     
  3884. HIV Resistance Wksp: Virco: Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays - (06/27/09)
     
  3885. HIV infection and the risk of diabetes mellitus in Vets - (06/26/09)
     
  3886. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction - (06/26/09)
     
  3887. Analysis of HIV-1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy - (06/26/09)
     
  3888. New HIV Eradication Theory: 2nd reservoir identified, HAART + IL-7 Inhibition - (06/26/09)
     
  3889. HIV Resistance Wksp: HIV Reservoirs and Potential Eradication - Written by Mark A. Wainberg, Ph.D. Professor and Director, McGill University AIDS Centre - (06/26/09)
     
  3890. HIV Resistance Wksp: PERSISTENCE, RESERVOIRS AND ELIMINATION STRATEGIES - Reported by David Margolis, University of North Carolina (06/26/09)
     
  3891. New Anti-Inflammation Modulator Improves Kidney/Diabetes Functions; for CNS disease too - (06/21/09)
     
  3892. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys - (06/19/09)
     
  3893. HIV Resistance Wksp: Phenotypic Resistance and Response to Tipranavir, evidence for Hypersusceptibility (06/19/09)
     
  3894. HIV Resistance Wksp: Emergence of mutations and phenotypic resistance with tipranavir treatment in protease inhibitor experienced patients (06/19/09)
     
  3895. HIV Resistance Wksp: Tipranavir & Darunavir, Prevalences of mutations in patients with discordant phenotypic resistance from Monogram Biosciences database of routine clinical samples from 2006 - 2008 (06/19/09)
     
  3896. HIV Resistance Wksp: Tipranavir - Phenotypic protease inhibitor resistance in the clinic from 2006 to 2008: available treatment options (06/19/09)
     
  3897. Interleukin-2: Trials and Tribulations; IL-2 Fails Again, EDITORIAL COMMENTARY - (06/17/09)
     
  3898. HIV Resistance Wksp: Genotypic, Phenotypic and Virtual Phenotypic Resistance Patterns for Darunavir and Tipranavir: An Independent Analysis of a Quebec HIV-1 Cohort Highly Resistant to all Other Protease Inhibitors (06/17/09)
     
  3899. HIV Resistance Wksp: Amino Acid Changes in gp41 of HIV-1 Associated with Coreceptor Tropism (06/17/09)
     
  3900. HIV Resistance Wksp: Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways: Monogram Report, Vs loop changes vary (06/17/09)
     
  3901. HIV Resistance Wksp: PI-Resistant Virus Seems More Prone to Emergence of Bevirimat Mutations - written by Mark Mascolini (06/16/09)
     
  3902. HIV Resistance Wksp: Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2 (06/16/09)
     
  3903. HIV Resistance Wksp: 48-Week Results From the Phase 3 Study A4001026 (MERIT) -"Time to Loss of Virologic Response" Virology Analysis of Failures in the Enhanced Trofile®-Censored Subpopulation (06/16/09)
     
  3904. 7th Euro HIV Drug Resis Wrkshp: Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc - (06/16/09)
     
  3905. HIV Resistance Wksp: High -Prevalence of bevirimat resistance mutations in non-B subtypes and in PI resistant HIV isolates (06/16/09)
     
  3906. HIV Resistance Wksp: Resistance Mutations in the Viral Protease Alter Bevirimat Resistance Patterns in vitro (06/16/09)
     
  3907. HIV Resistance Wksp: Prevalence and Clinical Significance of Transmitted Drug Resistant HIV Mutations by Ultra-Deep Sequencing in HIV-Infected ARV-Naïve Subjects in the CASTLE Study (06/16/09)
     
  3908. HIV Resistance Wksp: Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir (06/16/09)
     
  3909. HIV Resistance Wksp: Swiss Cohort Analysis Reveals Clusters of Transmitted Resistant HIV: "make sure patient names remain unlinked to transmission analyses" - written by Mark Mascolini - (06/16/09)
     
  3910. HIV Resistance Wksp: Low-Level K103N in Primary Infection Can Reappear After Suppressive Therapy - written by Mark Mascolini - (06/16/09)
     
  3911. HIV Resistance Wksp: CCR5 and CCR5 Screening Assays Comparisons: genotype, 454 Ultra-Deep Sequencing and Trofile (06/15/09)
     
  3912. HIV Resistance Wksp: Screening for HIV Tropism Using Population-Based V3 Genotypic Analysis: A Retrospective Virological Outcome Analysis Using Stored Plasma Screening Samples From MOTIVATE 1 (06/15/09)
     
  3913. HIV Resistance Wksp: In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09)
     
  3914. HIV Resistance Wksp: Weighted Genotype and Phenotypic Scores Predict Response to Maraviroc - written by Mark Mascolini - (06/15/09)
     
  3915. HIV Resistance Wksp: Key Etravirine Mutations Also Render HIV Resistant to Rilpivirine - written by Mark Mascolini - (06/15/09)
     
  3916. HIV Resistance Wksp: STD History Tied to Infection With Resistant HIV in San Francisco - written by Mark Mascolini - (06/15/09)
     
  3917. HIV Resistance Wksp: Low-Level Etravirine Mutations With K103N After NNRTI Failure - written by Mark Mascolini - (06/15/09)
     
  3918. HIV Resistance Wksp: Low-Level Q148R in People Without Integrase Inhibitor Experience - written by Mark Mascolini - (06/15/09)
     
  3919. HIV Resistance Wksp: Evolving Mutation Patterns Traced During Elvitegravir Failure - written by Mark Mascolini - (06/15/09)
     
  3920. HIV Resistance Wksp: Rising Rates of 3-Class Exposure But Falling Failure Rate in US Cities - written by Mark Mascolini - (06/15/09)
     
  3921. HIV Resistance Wksp: Transmitted Multidrug-Resistant HIV Persists in PBMC DNA for Years - written by Mark Mascolini - (06/15/09)
     
  3922. HIV Resistance Wksp: The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09)
     
  3923. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  3924. HIV Resistance Wksp: Early Response to Maraviroc Equivalent With Coreceptor Genotyping and Trofile Phenotyping - written by Mark Mascolini - (06/15/09)
     
  3925. HIV Resistance Wksp: Most Low-Level Pretreatment Mutations Did Not Affect Outcome in PI Trial - written by Mark Mascolini - (06/15/09)
     
  3926. HIV Resistance Wksp: Cutoffs Suggested for Predicting Efavirenz Failure With Low-Level K103N - written by Mark Mascolini - (06/15/09)
     
  3927. HIV Resistance Wksp: Regimens Lacking CCR5 Antagonists Have Minimal Impact on Coreceptor Use - written by Mark Mascolini - (06/12/09)
     
  3928. HIV Resistance Wksp: Lower M184V Rates With FTC/TDF Than With 3TC/TDF - written by Mark Mascolini - (06/12/09)
     
  3929. HIV Resistance Wksp: Raltegravir Did Not Lower HIV DNA Levels in Cell Reservoirs in Salvage Patients in 24 Weeks - written by Mark Mascolini - (06/12/09)
     
  3930. HIV Resistance Wksp: Intensification of Already Suppressive Therapy with Raltegravir Had No Impact on Low-Level (sub-50-copy) Viremia - written by Mark Mascolini - (06/12/09)
     
  3931. HIV Resistance Wksp: HIV Genetic Diversity Does Not Change Much After Complete Viral Control - written by Mark Mascolini - (06/12/09)
     
  3932. HIV Resistance Wksp: NNRTI/PI Regimen More Prone to Resistance Than Standard Triple Combos - written by Mark Mascolini - (06/12/09)
     
  3933. HIV Resistance Wksp: Success Rate With Genotype-Guided First Regimen Near 90% in California - written by Mark Mascolini - (06/12/09)
     
  3934. Thiazolidinediones and clinical outcomes in type 2 diabetes Comment - (06/09/09)
     
  3935. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial - (06/09/09)
     
  3936. PPI Use & Risk For Hip Fracture (Tagamet & Zantac to) - (06/09/09)
     
  3937. Drug Interactions with New and Investigational Antiretrovirals: darunavir, etravirine, rilpivirine (TMC278), maraviroc, vicriviroc, raltegravir, elvitegravir, INCB 9471 (CCR5), bevirimat [Review Articles] - (06/09/09)
     
  3938. Can HIV Be Eradicated? - (06/08/09)
     
  3939. Study in Neurology journal (Aug 2008) Reports Alzheimers Appears to Precede Frailty and Study in Jnl of Geronotology (2007) in the MACS Cohort Reports Risk of Frailty Higher in HIV+ vs HIV-; is early onset of Alzheimers or some other brain or cognitive dysfunction related to early onset and higher rates of frailty among HIV+? - (06/08/09)
     
  3940. DATA ON INVESTIGATIONAL DRUG TMC207 FOR TREATMENT OF MDR-TUBERCULOSIS, PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE - Tibotec announcement - (06/05/09)
     
  3941. TMC207, New Drug for TB MultiDrug Resistant (MDR) & XDR (extensively drug resistant) - (06/05/09)
     
  3942. Aspirin in CVD primary prevention: sex and baseline risk matter - (06/04/09)
     
  3943. Gardasil in Older Women Aged 24-45 Years - (06/04/09)
     
  3944. FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing, Once Every 2 Years - (06/03/09)
     
  3945. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy - (06/03/09)
     
  3946. Maraviroc Safety/CD4 - A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1 - (06/03/09)
     
  3947. HIV Viremia and the Development of AIDS-Related Lymphoma in Patients Treated with Highly Active Antiretroviral Therapy - EDITORIAL COMMENTARY - (06/03/09)
     
  3948. Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma - (06/03/09)
     
  3949. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (06/02/09)
     
  3950. Antiaging Therapy with TAT2: Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T Lymphocytes - (06/02/09)
     
  3951. Modulation of T Lymphocyte Replicative Senescence via TNF-{alpha} Inhibition: Role of Caspase-31 - (06/01/09)
     
  3952. Duration of antihypertensive drug use and risk of dementia: "Antihypertensive drug use was associated with 8% risk reduction of dementia per year of use for persons <75 years." - (05/29/09)
     
  3953. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons - (05/29/09)
     
  3954. Hypertension and late-life dementia - Editorial - (05/29/09)
     
  3955. Routine Use of Antihypertensive Medications Recommended For All Older People Even Those Who Do Not Have High Blood Pressure - (05/29/09)
     
  3956. Give blood pressure drugs to all - Criticism/Commentary - (05/29/09)
     
  3957. Editorials Management of blood pressure in primary care - (05/29/09)
     
  3958. In NFL, Higher Rates of Hypertension/Prehypertension & BMI (large size) Associated with Increased Cardiovascular Risk - (05/28/09)
     
  3959. Review of Prostate Cancer Treatment A 64-Year-Old Man With Low-Risk Prostate Cancer - (05/28/09)
     
  3960. Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients - (05/28/09)
     
  3961. Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir - (05/28/09)
     
  3962. Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis - (05/28/09)
     
  3963. Lipoatrophy Influenced by Genetics - (05/28/09)
     
  3964. Lipoatrophy and lipohypertrophy (belly fat not associated after BMI factored in) are independently associated with hypertension - (05/27/09)
     
  3965. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? - (05/27/09)
     
  3966. Hyperglycaemia and coronary heart disease: the meta picture - EDITORIAL - (05/27/09)
     
  3967. It is "premature to conclude that glucose control has no part to play." - (05/27/09)
     
  3968. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials - (05/27/09)
     
  3969. The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals - (05/27/09)
     
  3970. Sustained release of microbicides by newly engineered vaginal rings - TMC120/tenofovir/AZT - (05/26/09)
     
  3971. Interaction of Ginkgo biloba with efavirenz - (05/26/09)
     
  3972. Efavirenz and bone health - (05/22/09)
     
  3973. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  3974. Efavirenz and bone health - (05/22/09)
     
  3975. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  3976. Does HIV Increase Prostate Cancer Risk? - (05/21/09)
     
  3977. Effects of Oxidation and Inflammation, Cancer, Prostate Cancer - (05/21/09)
     
  3978. ACTG 5142 Published: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment - (05/21/09)
     
  3979. HIV viremia and changes in kidney function - (05/21/09)
     
  3980. ACTG 5164 Published: Early HAART Reduces AIDS/Death in Individuals with Acute OIs - (05/21/09)
     
  3981. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men - (05/21/09)
     
  3982. Immune Exhaustion in Aging and AIDS: Parallel Mechanisms and Possible Solutions - (05/21/09)
     
  3983. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis - (05/20/09)
     
  3984. Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  3985. Kidney Damage in Metabolic Syndrome: Nip It in the Bud - EDITORIAL - (05/18/09)
     
  3986. Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study - (05/18/09)
     
  3987. C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us? - (05/18/09)
     
  3988. 10th Int PK Wrkshp: 10th International Workshop on Clinical Pharmacology of HIV Therapy Written by Courtney V. Fletcher, Pharm.D. - (05/18/09)
     
  3989. Predicting risk of dementia in older adults. The late-life dementia risk index - Aging !!!! - (05/15/09)
     
  3990. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence - REVIEW ARTICLE - (05/15/09)
     
  3991. Ejaculation Frequency and Subsequent Risk of Prostate Cancer - "high ejaculation frequency was related to decreased risk of total prostate cancer." - (05/15/09)
     
  3992. Data on the Use of GARDASIL in Men Presented at the 25th Annual International Papillomavirus Conference - (05/15/09)
     
  3993. THE EFFFICACY OF QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE AGAINST HPV-RELATED GENITAL DISEASE AND INFECTION IN YOUNG MEN - (05/15/09)
     
  3994. Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects - (05/14/09)
     
  3995. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States; Increased Hypothyroidism Reported un HIV+ - (05/14/09)
     
  3996. Elevated A1C in Adults Without a History of Diabetes in the U.S. - (05/14/09)
     
  3997. Tenative approval of lamivudine/zidovudine fixed dose combination tablets plus nevirapine tablets - (05/14/09)
     
  3998. Raltegravir+Etravirine - Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort - (05/14/09)
     
  3999. Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay - (05/14/09)
     
  4000. Implementation of HIV Testing at 2 New York City Bathhouses: From Pilot to Clinical Service (4% HIV+) - (05/14/09)
     
  4001. Availability of HIV Postexposure Prophylaxis Services in Los Angeles County - (05/14/09)
     
  4002. RNA Testing for HIV Instead of Antibody Testing Could Detect Early Stage of HIV Infection And Would Likely Improve Prevention AND Allow for Early HAART' Could it Prevent Accelerated Aging? - (05/13/09)
     
  4003. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS (case study) - (05/13/09)
     
  4004. Cancers in HIV Review in AIDS May 15 2009 - (05/13/09)
     
  4005. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial - (05/13/09)
     
  4006. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival (NA-ACCORD): deferring HAART til <500 CD4s increased risk of death 94% - (05/11/09)
     
  4007. WHO Guidance for HIV Patient Care & Swine Flu - (05/11/09)
     
  4008. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials - (05/11/09)
     
  4009. Hypoglycemia Increased Risk for Death in Diabetics with Chronic Kidney Disease: - (05/11/09)
     
  4010. 10th Int PK Wrkshp: First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women - (04/30/09)
     
  4011. Interim Results of Abbott's PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra® (lopinavir/ritonavir) and Raltegravir - Abbott press release - (04/30/09)
     
  4012. Sunlight and Vitamin D Both Good for Cardiovascular Health - (04/22/09)
     
  4013. Tight Glycemic Control NOT Recommended for Diabetics in Annals Review - (04/22/09)
     
  4014. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease - (04/22/09)
     
  4015. 10th Int PK Wrkshp: Raltegravir Levels in Cervicovaginal Fluid May Prompt PEP and PrEP Studies - written by Mark Mascolini - (04/21/09)
     
  4016. 10th Int PK Wrkshp: Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor - written by Mark Mascolini - (04/20/09)
     
  4017. 10th Int PK Wrkshp: Differing Darunavir Troughs With Once- and Twice-Daily Dosing in Practice - written by Mark Mascolini - (04/20/09)
     
  4018. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial - (04/20/09)
     
  4019. Glucocorticoid-induced osteoporosis: hope on the HORIZON-COMMENT once yearly infusion therapy better than once weekly - (04/20/09)
     
  4020. Reversing HIV T-Cell Aging - (04/20/09)
     
  4021. HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty: HIV+ men in MACS 10-Times More Likely to Exhibit Frailty than HIV-negative Men. - (04/20/09)
     
  4022. MACS Frailty/HIV/CD4 Study Misses The Point - (04/20/09)
     
  4023. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  4024. PrEP, Microbicides and IL-2 - (04/20/09)
     
  4025. 15th Annual British HIV Conference April 1-3 2009 Abstracts/Presentations - (04/20/09)
     
  4026. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up - (04/20/09)
     
  4027. Lopinavir/Ritonavir (LPV/r) Combined With Raltegravir (RAL) Provides More Rapid Viral Decline Than LPV/r Combined With Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-naïve HIV-1 Infected Subjects - (04/20/09)
     
  4028. Ignoring Addiction in Prison/Jails Increases HIV & HCV Infections - (04/20/09)
     
  4029. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus - (04/20/09)
     
  4030. the REYATAZ and SUSTIVA Co-pay Benefit Program - (04/20/09)
     
  4031. Treatment Interruption Revisited with LOTTI Study: authors reported interruptions were not inferior to continuous HAART in this study - (04/20/09)
     
  4032. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases - (04/20/09)
     
  4033. 10th Int PK Wrkshp: Unboosted Atazanavir Plus Raltegravir Analyzed as Two-Drug Replacement Regimen - written by Mark Mascolini - (04/20/09)
     
  4034. 10th Int PK Wrkshp: Etravirine Levels Higher When Added After Darunavir vs With Darunavir - written by Mark Mascolini - (04/20/09)
     
  4035. 10th Int PK Wrkshp: Enfuvirtide-to-Raltegravir Switch Lowers Levels of Darunavir and Tipranavir - written by Mark Mascolini - (04/20/09)
     
  4036. CROI: Prevention of Rectal Simian HIV Transmission in Macaques by Intermittent Pre-exposure Prophylaxis with Oral Truvada - (04/17/09)
     
  4037. 10th Int PK Wrkshp: Efavirenz Lowers Levels of Darunavir Given as 900/100 mg Once Daily With Ritonavir - (04/16/09)
     
  4038. 10th Int PK Wrkshp: Early Look at Once-Daily Darunavir/Ritonavir for Treatment-Experienced Patients - written by Mark Mascolini - (04/16/09)
     
  4039. 10th Int PK Wrkshp: How Much (or How Little) Ritonavir Do You Need to Boost Another PI? - written by Mark Mascolini - (04/16/09)
     
  4040. 10th Int PK Wrkshp: Lopinavir/Ritonavir Monotherapy as an Antiretroviral Stopping Strategy - written by Mark Mascolini - (04/16/09)
     
  4041. 10th Int PK Wrkshp: Genetic Markers Tied to Early Discontinuation of Three Antiretrovirals - (04/16/09)
     
  4042. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  4043. Screening for Albuminuria Identifies Individuals at Increased Renal Risk - (04/10/09)
     
  4044. Should the CD4 threshold for starting ART be raised? Commentary - (04/10/09)
     
  4045. Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints - (04/10/09)
     
  4046. Vitamin D Deficiency in Older Men - (04/09/09)
     
  4047. Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons - (04/09/09)
     
  4048. The Relationship Between Prolonged Antiretroviral Therapy and Cryptogenic Liver Disease - (04/09/09)
     
  4049. Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? EDITORIAL - (04/09/09)
     
  4050. Leptin Improved Belly Fat/Dyslipidemia - The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia - Pilot Study - (04/09/09)
     
  4051. Belly Fat & Women. Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study - (04/09/09)
     
  4052. Broccoli sprouts appear to reduce risk for stomach cancer, reduced inflammation in stomach. - (04/08/09)
     
  4053. End-Stage Liver Disease in HIV+ in France A Leading Cause of Death - (04/03/09)
     
  4054. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study - (04/03/09)
     
  4055. 'When to Start HAART' Experts Disagree-NEJM Study - (04/03/09)
     
  4056. Does Inflammation Fuel the Fire in CKD? - (04/03/09)
     
  4057. HPV Test vs Cytologic Testing or Visual Inspection: HPV Screening for Cervical Cancer in Rural India - (04/03/09)
     
  4058. When to Start Antiretroviral Therapy - Ready When You Are? EDITORIAL (NA-ACCORD) - (04/03/09)
     
  4059. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes - (04/02/09)
     
  4060. Aspirin, salicylates, and cancer - (03/31/09)
     
  4061. JUPITER Study Reports Reducing hsCRP & LDL to Low Levels with Statin rosuvastatin Further Reduced Cardiovascular Risk - (03/31/09)
     
  4062. JUPITER: Rosuvastatin reduces risk of VTE in healthy subjects - (03/31/09)
     
  4063. EHDRW: Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data (03/31/09)
     
  4064. EHDRW: No Darunavir & Kaletra Major PI Mutations in ARTEMIS 96 Weeks (03/31/09)
     
  4065. EHDRW: Low-Level Transmitted K103N Mutation Predicts Virologic Failure - Written by Mark Mascolini (03/31/09)
     
  4066. EHDRW: No Resistance to Darunavir or Lopinavir After 96 Weeks in ARTEMIS - Written by Mark Mascolini (03/31/09)
     
  4067. EHDRW: Weighted Genotyping Scores Work Equally Well in Predicting Response to Etravirine - Written by Mark Mascolini (03/31/09)
     
  4068. EHDRW: Weighted Genotypic Score Predicts Response to Maraviroc in MOTIVATE Trials - Written by Mark Mascolini (03/30/09)
     
  4069. ART Interruption in Pregnancy Increases MTCT - (03/30/09)
     
  4070. Tight glucose control may increase mortality in critically ill patients - (03/30/09)
     
  4071. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators - (03/30/09)
     
  4072. Glucose Control in the ICU - How Tight Is Too Tight? EDITORIAL - (03/30/09)
     
  4073. Transfer of HIV between T Cells Captured on Video - (03/30/09)
     
  4074. Application of Lower Sodium Intake Recommendations to Adults --- United States, 1999--2006 - (03/30/09)
     
  4075. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study - (03/30/09)
     
  4076. Prevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral Therapy - (03/30/09)
     
  4077. EHDRW: Genotyping for Coreceptor Use Concordant With Trofile in PBMCs and Plasma: from Jules- genotyping this falls short - Written by Mark Mascolini - (03/27/09)
     
  4078. EHDRW: HIV-Induced CD4 Declines Affect Immune Response to HBV in Untreated People - Written by Mark Mascolini - (03/27/09)
     
  4079. Prevention of Viral Sexually Transmitted Infections - Foreskin at the Forefront (male circumcision) EDITORIAL - (03/27/09)
     
  4080. Midlife Patients With HIV or AIDS Require Care for Chronic Conditions: "HIV simulates aging" - (03/27/09)
     
  4081. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (03/27/09)
     
  4082. Avexa Reaches First Critical Evaluation Point for new NRTI ATC's Phase III Trial - (03/27/09)
     
  4083. Tight glucose control may increase mortality in critically ill patients - (03/27/09)
     
  4084. Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis: circumcision prevents HSV-2 and HPV - (03/27/09)
     
  4085. EHDRW: Viral Loads--But Not Transmission of Resistant Virus--Falling in Italian Cohort - Written by Mark Mascolini - (03/27/09)
     
  4086. EHDRW: Resistance Testing Is Not Standard-of-Care After Antiretroviral Failure in Europe - Written by Mark Mascolini - (03/27/09)
     
  4087. EHDRW: Cumulative Resistance Score Gives Broader View of Potential Antiretroviral Activity - Written by Mark Mascolini - (03/27/09)
     
  4088. CROI: Non-HIV Markers Add to HIV Signals in Predicting VA Cohort Deaths - written by Mark Mascolini - (03/25/09)
     
  4089. CROI: US and Canadian Studies Trace Impact of Resistance Results on Mortality - written by Mark Mascolini - (03/25/09)
     
  4090. CROI: Higher Rate of Non-AIDS Infection-Related Cancers With HIV May Be Waning in HAART Era - written by Mark Mascolini - (03/25/09)
     
  4091. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  4092. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  4093. ISHLVD: Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (U.S.) by Country/Region of Origin - (03/23/09)
     
  4094. ISHLVD: Federal Government's Response to Viral Hepatitis - (03/23/09)
     
  4095. ISHLVD: Key Health Care Provisions in Stimulus Legislation - (03/23/09)
     
  4096. ISHLVD: HCV Burden of Disease and Associated Costs: An Overview - (03/23/09)
     
  4097. ISHLVD: Barriers to HCV Care - (03/23/09)
     
  4098. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection - (03/24/09)
     
  4099. Is HIV Eradication Feasible? - (03/20/09)
     
  4100. CROI: Neurologic Complications of HIV Disease and Their Treatment - written by Scott L. Letendre, M.D. et al - (03/19/09)
     
  4101. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  4102. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  4103. Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor - (03/19/09)
     
  4104. Vicriviroc Does Not Increase Epstein-Barr Virus Replication: CCR5 and lymphoma - (03/19/09)
     
  4105. Changes in Cancer Mortality among HIV-infected Patients: The Mortalite 2005 Survey - (03/19/09)
     
  4106. Malignancy-Related Deaths among HIV-Infected Patients: increasing problems with cancers & non-AIDS events - EDITORIAL COMMENTARY - (03/19/09)
     
  4107. New Apricitabine 96 Week Data, Phase 3 Data Expected - (03/19/09)
     
  4108. Depletion of CD4+ T Cells in Semen During HIV Infection and Their Restoration Following Antiretroviral Therapy - (03/19/09)
     
  4109. Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection: naives with D/m progress more quickly, early ART? - (03/19/09)
     
  4110. CROI: Mitochondrial DNA Levels in Pregnancy Are Not Decreased in ARV-treated Women Compared to HIV- Controls - (03/18/09)
     
  4111. CROI: Raltegravir In Children and Adolescents: The French Expanded Access Program - (03/18/09)
     
  4112. CROI: Prognosis of Non-Hodgkin's Lymphoma in HIV-infected Patients - (03/18/09)
     
  4113. CROI: Influence of ART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin's Lymphoma: European Multi-Cohort Study, CD4 Predicts Non-Hodgkin's Lymphoma - (03/18/09)
     
  4114. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  4115. CROI: Liver Transplantation in 88 HIV-infected Patients - (03/17/09)
     
  4116. CROI: HCV Causes Neurcognitive Impairment in HIV+ - (03/17/09)
     
  4117. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  4118. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  4119. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  4120. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  4121. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  4122. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  4123. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  4124. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  4125. CROI: Association of Non-cirrhotic Portal Hypertension in HIV-infected Persons and ART with Didanosine - (03/17/09)
     
  4126. CROI: Prolonged ART and Risk for Chronic Elevation of Alanine Aminotransferase in HIV-infected Persons without HBV or HCV Co-infections - (03/17/09)
     
  4127. CROI: Incidence and Predictors of Acute Renal Failure in an Urban Cohort of Patients with HIV and Hepatitis C Co-infection - (03/17/09)
     
  4128. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART - (03/17/09)
     
  4129. CROI: Progression of Liver Fibrosis in a Large Cohort of HIV Patients Over 4 Years: Emerging Contribution of Antiretrovirals and Metabolic Abnormalities - (03/17/09)
     
  4130. Human Immunodeficiency Virus in Semen and Plasma: Investigation of Sexual Transmission Risk Behavioral Correlates - (03/16/09)
     
  4131. CROI: Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens - (03/16/09)
     
  4132. CROI: Platelet Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART - (03/16/09)
     
  4133. CROI: Association of Abacavir and HIV Disease Factors with Endothelial Function in Patients on Long-Term Suppressive Antiretroviral Therapy - (03/16/09)
     
  4134. CROI: HIV in Semen Despite Undetectable in Blood: "residual risk of transmission is still possible during unprotected intercourse" - (03/16/09)
     
  4135. HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy - (03/12/09)
     
  4136. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults - (03/12/09)
     
  4137. CROI: Inflammatory Markers among Abacavir and non-Abacavir Recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study - (03/13/09)
     
  4138. CROI: High-density Lipoprotein Particles but Not Low-density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study - (03/13/09)
     
  4139. How Inflammatory Disease Causes Fatigue: chronic inflammation infiltrates the brain but can be blocked - (03/10/09)
     
  4140. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction - (03/10/09)
     
  4141. New Microbcide Discovery in Monkeys from Ashley Haase - (03/10/09)
     
  4142. CROI: Microbicide gel PRO 2000 may help against HIV -Commentary - (03/10/09)
     
  4143. Response (safety, efficacy) to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection - (03/10/09)
     
  4144. National Women and Girls HIV/AIDS Awareness Day March 10, 2009 - - (03/10/09)
     
  4145. Use of Cognitive Enhancement Drugs - (03/10/09)
     
  4146. CROI: Antiretroviral agents that inhibit CCR5-utilizing HIV-1 - written by Eric S. Daar, M.D. (03/10/09)
     
  4147. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (03/10/09)
     
  4148. CROI: Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study -DAD Study - (03/09/09)
     
  4149. CROI: Activation (Inflammation) and Coagulation Biomarkers are Independent Predictors for the Development of Opportunistic Disease in Patients with HIV Infection - (03/09/09)
     
  4150. CROI: Biological Determinants of Immune Reconstitution following Long-term HAART: host factors & persistent gut microbial translocation drive chronic immune activation - (03/09/09)
     
  4151. The Challenge of Finding a Cure for HIV Infection - (03/09/09)
     
  4152. CROI: HIV+ Die More Quickly in FRAM & Low CD4 Predicts Death - (03/09/09)
     
  4153. CROI: Inflammation, Cancers and Other Life Threats for People Living with HIV - written by David Alain Wohl, MD - (03/06/09)
     
  4154. WHO | The unexplored story of HIV and ageing - (03/05/09)
     
  4155. CROI: Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD8+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09)
     
  4156. CROI: Evidence of persistent low-level viremia in long-term HAART-suppressed individuals - (03/05/09)
     
  4157. CROI: Brain Damage, Comorbidities and Early Death Threaten HIV+ - (03/05/09)
     
  4158. CROI: Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study: boosted PI+TDF associated with renal function - (03/05/09)
     
  4159. CROI: Viral Hepatitis is Associated with Reduced Bone Mineral Density in HIV-Infected Women but Not Men - (03/04/09)
     
  4160. CROI: First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplements - (03/04/09)
     
  4161. CROI: Effects of Aging on HIV-1 Pathogenesis: HIV causes inflammation & T-cell activation, reported here to be more in postmenopausal women - (03/04/09)
     
  4162. CROI: Raltegravir Intensification, Viral Replication, HIV Reservoirs & HAART - (03/04/09)
     
  4163. CROI: Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09)
     
  4164. CROI: Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy in the Era of Combination ART: Correlates in the CHARTER Study - (03/04/09)
     
  4165. CROI: Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome and Mortality during a Randomized Trial of Early versus Deferred ART in the Setting of Acute Opportunistic Infections (ACTG A5164) - (03/04/09)
     
  4166. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  4167. CROI: Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Caused by Acute HIV Infection are not Reverted by Early Initiation of HAART - (03/04/09)
     
  4168. CROI: Ongoing Viral Replication in the Gut Despite HAART Suppressive Viral Control: Lack of Compartmentalization of HIV HIV-1 Quasispecies and Circulation of CXCR4 using HIV-1 between Gut Associated Lymphoid Tissue (GALT) and the Peripheral Blood (PB) - (03/04/09)
     
  4169. CROI: HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09)
     
  4170. CROI: GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09)
     
  4171. CROI: Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09)
     
  4172. CROI: Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09)
     
  4173. CROI: Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09)
     
  4174. CROI: Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09)
     
  4175. CROI: HIV Drug Pipeline at CROI - (03/03/09)
     
  4176. CROI: Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09)
     
  4177. CROI: Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09)
     
  4178. CROI: Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09)
     
  4179. CROI: Short term bone loss in HIV infected premenopausal women - (03/03/09)
     
  4180. CROI: Back to Basics: the science at CROI focuses the tough questions that remain in HIV pathogenesis, Part 2 (focal points for new therapies.) - written by David Margolis MD, University of North Carolina - (03/03/09)
     
  4181. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  4182. CROI: HIV-Associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Protocol A5001 - (03/02/09)
     
  4183. Kaletra + Raltegravir PROGRESS Study - (03/02/09)
     
  4184. Kidney Disease in Patients with HIV Infection and AIDS - (03/02/09)
     
  4185. CROI: Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy - (03/02/09)
     
  4186. CROI: HIGH FREQUENCY (50%) OF NEUROCOGNITIVE DISORDERS IN OLDER (>60 yrs) HIV-INFECTED PATIENTS DESPITE A SUSTAINED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE ON CART: THE SIGMA STUDY - (03/02/09)
     
  4187. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
     
  4188. CROI: Summary of Antiretroviral Treatment Naïve Studies from CROI: Still Looking for a Consensus on When to Start - written by Susan J. Little, M.D. Associate Professor of Medicine University of California San Diego, USA - (02/27/09)
     
    -
  4189. Dairy Food, Calcium, and Risk of Cancer in the NIH-AARP Diet and Health Study - (02/27/09)
     
  4190. Telbivudine has activity against HIV-1 - (02/27/09)
     
  4191. HAART Does Not Reverse Premature T-Cell Aging Caused by HIV - (02/27/09)
     
  4192. Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment - (02/27/09)
     
  4193. EDITORIAL COMMENTARY The Paradox of Incomplete CD4+ Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early - (02/27/09)
     
  4194. CROI: HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09)
     
  4195. CROI: Aging with HIV - Lessons from CROI 2009 - Victor Valcour MD - (02/27/09)
     
  4196. CROI: Cognitive Impairment & Neuropathy Persist Despite HAART and Are Associated With Metabolic Syndrome - (02/27/09)
     
  4197. CROI: Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of MPC-9055 a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects - (02/27/09)
     
  4198. CROI: Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 - (02/27/09)
     
  4199. CROI: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses - (02/27/09)
     
  4200. CROI: In Vitro Resistance Selection Study and Favorable Human Pharmacokinetic Properties of RDEA427, a New HIV NNRTI - (02/27/09)
     
  4201. CROI: Clinical Pharmacology at CROI 2009: Pharmacoenhancement, Pharmacogenetics, Drug Interactions and the Pharmacotherapy of HIV Infection - written by Courtney V. Fletcher, Pharm.D. - (02/26/09)
     
  4202. CROI: Pharmacology at the 2009 Conference on Retroviruses and Opportunistic Infections - written by Stephen Becker MD - (02/26/09)
     
  4203. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
     
  4204. CROI: Forty-Fold Elevated Risk for Lymphoepithelial Carcinoma of Salivary Gland Among People with AIDS in the United States written by Kishor Bhatia, F Shebl, and E Engels NCI, NIH, Bethesda, MD, - (02/26/09)
     
  4205. CROI: Update on Kidney Disease in HIV Infection: CROI 2009 - written by Christina M. Wyatt and Paul E. Klotman, Mt Sinai Hospital, New York City - (02/26/09)
     
  4206. CROI: Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels - (02/26/09)
     
  4207. CROI: HIV & HAART Interruption Increase Inflammation and Disease - (02/26/09)
     
  4208. CROI: Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity: 2-week study - (02/26/09)
     
  4209. CROI: Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 ("OCTANE") - (02/25/09)
     
  4210. CROI: No Association of Abacavir (ABC) Use with Risk of Myocardial Infarction (MI) or Severe Cardiovascular Disease Events (SCVD): Results from ACTG A5001/ALLRT - (02/25/09)
     
  4211. CROI: Progression of High-grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+ Men Who Have Sex with Men - (02/25/09)
     
  4212. CROI: Prevalence of Cervical Cancer Screening Among HIV-Infected Women in the United States: 23% Did Not Receive Pap tests within last year - (02/25/09)
     
  4213. CROI: Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe: most common no-AIDS events malignancies/CVD/liver in EuroSida - (02/25/09)
     
  4214. CROI: Causes of Death in Patients Treated with ART (IDUs vs non-IDUs), 1996 to 2006: Collaborative Analysis of 13 Cohort Studies - (02/25/09)
     
  4215. CROI: Relationship between Current Level of Immunodeficiency and Non-AIDS-defining Malignancies, EuroSida: "Immunosuppression ...current CD4 count....was associated with an excess risk of NADM" - (02/25/09)
     
  4216. CROI: Infection-related Non-AIDS-defining Cancer Risk in HIV-infected and -uninfected Persons: Increased Rates in HIV+ vs HIV-negatives in Kaiser - (02/25/09)
     
  4217. CROI: New HIV Agents - written by Joe Eron, MD, University of North Carolina - (02/25/09)
     
  4218. CROI: Resistance Report - written by Mark A. Wainberg McGill University AIDS Centre, Montreal - (02/25/09)
     
  4219. CROI: New HIV Drug Candidates in Pre-Clinical Development - (02/24/09)
     
  4220. CROI: A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601, a Novel NRTI, in Healthy Subjects - (02/24/09)
     
  4221. CROI: CMX157 Conjugate of tenofovir, prodrug: Hexadecyloxypropyl Tenofovir Associates Directly with HIV and Subsequently Inhibits Viral Replication in Untreated Cells - (02/24/09)
     
  4222. CROI: Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents: Merck program - (02/24/09)
     
  4223. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve outcome of Hepatitis coinfection in HIV-Infected Patients? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (02/24/09)
     
  4224. CROI: High HCV Viral Load Is Associated with an Increased Risk for Mortality in HIV/HCV-co-infected Individuals - (02/24/09)
     
  4225. CROI: A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable ART in HIV-infected Subjects: Results from A5206 Study Team v - (02/24/09)
     
  4226. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
     
  4227. CROI: Cardiovascular complications 16th CROI - written by Pablo Tebas, MD University of Pennsylvania - (02/24/09)
     
  4228. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  4229. CROI: HIV Infection May Make the Brain 15 to 20 Years Older: HIV slows cerebral blood flow and stimulus response in MRI study - written by Mark Mascolini - (02/23/09)
     
  4230. CROI: Framingham Risk Score Linked to Other Heart Risk Factors in HIV Cohort - written by Mark Mascolini - (02/23/09)
     
  4231. CROI: No Residual Raltegravir Activity After Resistance Emerges - written by Mark Mascolini - (02/23/09)
     
  4232. CROI: Effects of Aging on HIV Pathogenesis: aging is associated with higher t-cell activation in women than men, effects of menopause on inflammation and immune activation...." (02/23/09)
     
  4233. CROI: Bone Loss at Baseline and Week 144 in Study 903 TDF vs d4T + EFV (02/23/09)
     
  4234. CROI: Safety and Efficacy of Raltegravir (RAL) in Pediatric HIV Infection. Preliminary Analysis From IMPAACT P1066 (02/23/09)
     
  4235. CROI: Telbivudine Has Activity against HIV (02/23/09)
     
  4236. CROI: Abacavir Use is Not Associated with Lack of Virologic Response in ARV-treated HIV/HCV-Coinfected Patients Receiving PEG-IFN and Ribavirin (02/23/09)
     
  4237. CROI: Telbivudine Has No In Vitro Activity Against Laboratory and Clinical HIV-1, Including 5 Clades and Drug Resistant Clinical Isolates (02/23/09)
     
  4238. CROI: Heart Disease Marker Rises in Women During 96 Weeks of Suppressive Efavirenz - written by Mark Mascolini - (02/20/09)
     
  4239. CROI: Liver Fibrosis Marker Rises in SMART Interrupters and Predicts Non-AIDS Deaths - written by Mark Mascolini - (02/20/09)
     
  4240. CROI: Diverse Disease Markers Up in SMART Patients Regardless of Antiretroviral Therapy: inflammation markers linked to death, ART interruption, HIV, aging, & ART - written by Mark Mascolini - (02/20/09)
     
  4241. CROI: Immune Activators Stay High Despite Long-Term HIV Suppression With Antiretrovirals: affects CD4 recovery - written by Mark Mascolini - (02/20/09)
     
  4242. CROI: Pharmacokinetics and Safety of Twice Daily Atazanavir 300 mg and Raltegravir 400 mg in Healthy Subjects - (02/20/09)
     
  4243. CROI: Epidemic of Acute HCV Among MSM in Europe and New York City - (02/20/09)
     
  4244. CROI: Neurocognitive Disorders Threaten HIV+ - (02/20/09)
     
  4245. CROI: Immune Senescence, Activation, and Abnormal T Cell Homeostasis despite Effective HAART, a Hallmark of Early Aging in HIV Disease: "HIV-infected subjects (median 56 years) with good immune reconstitution and viral suppression had immune changes comparable to older (median 88 years) HIV-negative subjects" - (02/20/09)
     
  4246. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART: 35% without HCV or HBV had significant liver disease - (02/20/09)
     
  4247. CROI: CCR5-tropic Resistance to Maraviroc is Uncommon Even Among Patients on Functional MVC Monotherapy or with Ongoing Low-level Replication - (02/20/09)
     
  4248. CROI: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD University of Miami, Jackson Memorial Hospital (02/20/09)
     
  4249. CROI: HIV Prevention at CROI 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (02/20/09)
     
  4250. CROI: New HIV Drugs: NNRTI, PRO140, Maturation (02/19/09)
     
  4251. CROI: Markers of Inflammation, Coagulation and Renal Function in HIV-infected Adults in SMART and in two Large Population-Based Studies, CARDIA and MESA: HIV+ have higher levels of inflammatory markers on and off HAART, "markers appear to predict mortality & disease progression in HIV" (02/19/09)
     
  4252. CROI: No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001 (02/19/09)
     
  4253. CROI: Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naive HIV-Infected Patients (02/19/09)
     
  4254. CROI: Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive HIV-1-infected patients in ARTEMIS at 96 weeks (02/19/09)
     
  4255. CROI: Characterization of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment-naive patients (Week 96 analysis) (02/19/09)
     
  4256. CROI: Emerging Patterns of Resistance to Integrase Inhibitors (02/19/09)
     
  4257. CROI: Assessment of Renal Findings of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study (02/19/09)
     
  4258. CROI: Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study (02/19/09)
     
  4259. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study (02/19/09)
     
  4260. CROI: HIV-1 INFECTION IS ASSOCIATED WITH ACCELERATED VASCULAR AGING (02/18/09)
     
  4261. CROI: SIMPLIFICATION WITH FIXED-DOSE TENOFOVIR-EMTRICITABINE OR ABACAVIRLAMIVUDINE IN ADULTS WITH SUPPRESSED HIV REPLICATION (THE STEAL STUDY): A RANDOMIZED, OPEN-LABEL, 96-WEEK, NON-INFERIORITY TRIAL (02/18/09)
     
  4262. CROI: Neurocognitive (and neuropathy) Impairment Rate Remains High in Diverse US Cohort - written by Mark Mascolini - (02/18/09)
     
  4263. CROI: Antiretrovirals Have Not Banished Brain Injury in 7-Center US Imaging Study: brain damage persists despite HAART- inflammation and neuronal damage - written by Mark Mascolini - (02/18/09)
     
  4264. CROI: HCV Independently Adds to Hospital, Emergency Room, and Disability Days With HIV: days in hospital doubled - written by Mark Mascolini - (02/18/09)
     
  4265. CROI: Suspending Antiretrovirals Has Fast Negative Impact on HDL Particle Concentrations: interruptions reduce HDL and this predicts risk for cardiovascular disease in SMART - written by Mark Mascolini - (02/18/09)
     
  4266. CROI: First Double-Blind HIV+ Trial of Ezetimibe Plus Statin Finds Falling LDL Cholesterol - written by Mark Mascolini - (02/18/09)
     
  4267. CROI: Endothelial Function, Inflammatory Markers Do Not Change 24 Weeks After Switch to Atazanavir - written by Mark Mascolini - (02/18/09)
     
  4268. CROI: Two Inflammation Markers (hsCRP & IL-6) Predict Higher Risk of Opportunistic Disease in SMART - written by Mark Mascolini - (02/18/09)
     
  4269. CROI: Platelet Function & Heart Attacks in HIV+ & ART (02/17/09)
     
  4270. CROI: Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive (02/17/09)
     
  4271. CROI: HIV Progression Not Affected by Hormonal Contraception in Africa Study (02/17/09)
     
  4272. CROI: The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-naive Patients Through Seven Years (02/17/09)
     
  4273. CROI: HIV, Cancer and Immunity (02/17/09)
     
  4274. CROI: HIV Sometimes Detectable in Semen When Undetectable in Blood - written by Mark Mascolini - (02/13/09)
     
  4275. CROI: Low-Level HIV in CSF When HIV-RNA is < 50 Tied to Type of ART and Worse Cognitive Function - written by Mark Mascolini - (02/13/09)
     
  4276. CROI: Multicohort D:A:D Study Pinpoints Non-HIV Death Risk Factors People Can Change - written by Mark Mascolini - (02/13/09)
     
  4277. CROI: Helping HIV Patients Stop Smoking--Worthy Goal But Tough Work - written by Mark Mascolini - (02/13/09)
     
  4278. CROI: HIV Has as Much Impact on Heart Health as Traditional Risk Factors - written by Mark Mascolini - (02/13/09)
     
  4279. CROI: K103N and Efavirenz vs Nevirapine Tied to Better Response to Etravirine - written by Mark Mascolini - (02/13/09)
     
  4280. CROI: Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PKE) - (02/12/09)
     
  4281. CROI: Review of Cancer Incidence in Raltegravir (RAL) Clinical Trials - (02/12/09)
     
  4282. CROI: 96-Week Results from BENCHMRK 1&2, Phase III Studies of Raltegravir (RAL) in Patients (pts) Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV - (02/12/09)
     
  4283. CROI: Abacavir - (02/12/09)
     
  4284. CROI: 3 Studies on Abacavir & MI Risk: French Cohort, D.A.D. (slides), ALLRT with 2 Different Results - (02/12/09)
     
  4285. CROI: Switch to Raltegravir From Lopinavir in Highly Treatment-Experienced Patient Group: SWITCHMRK 1 & 2 Studies - written by Mark Mascolini - (02/12/09)
     
  4286. CROI: Replacing Enfuvirtide With Raltegravir in France - written by Mark Mascolini - (02/12/09)
     
  4287. CROI: Lower CD4 Count Linked to Non-AIDS Cancers in EuroSIDA Study - written by Mark Mascolini - (02/12/09)
     
  4288. CROI: Risk of non-Hodgkin Lymphoma Death Still Higher With HIV Infection - written by Mark Mascolini - (02/12/09)
     
  4289. CROI: Extra CD4s With IL-2 Confer No Clinical Benefit in Two Randomized Trials - written by Mark Mascolini - (02/12/09)
     
  4290. CROI: High HCV Load Doubles the Death Risk in People Coinfected With HIV - written by Mark Mascolini - (02/12/09)
     
  4291. CROI: Peginterferon (Pegasys) and Weight-Based Ribavirin for 72 Weeks in HIV+ Early Responders - written by Mark Mascolini - (02/12/09)
     
  4292. CROI: MI Rates Converge in California Health System Groups With and Without HIV: trend down in HIV+ - written by Mark Mascolini - (02/12/09)
     
  4293. CROI: Non-AIDS Illness More Common Than AIDS--and More Deadly--in EuroSIDA - written by Mark Mascolini - (02/12/09)
     
  4294. CROI: French Hospital Study and Further D:A:D Analyses Suggest MI Risk With Abacavir - written by Mark Mascolini - (02/12/09)
     
  4295. BMS Co-Payment Assistance Program - (02/11/09)
     
  4296. CROI: GS-9350: A Pharmacoenhancer Without anti-HIV Activity - (02/11/09)
     
  4297. CROI: Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350 - (02/11/09)
     
  4298. CROI: Complete Protection against Repeated Vaginal Simian HIV Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine - (02/11/09)
     
  4299. CROI: Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK) - (02/11/09)
     
  4300. CROI: Smoking Emerges as Top Death Risk Factor in FRAM Participants With HIV - written by Mark Mascolini - (02/11/09)
     
  4301. CROI: HIV and Diabetes/Hyperlipidemia Cause Kidney Decline - written by Mark Mascolini - (02/11/09)
     
  4302. Causes of Accelerated Aging in HIV: HIV Induces Aging of T-Cells - (02/10/09)
     
  4303. CROI: World Health Organization CD4 Criteria Fall Far Short in Predicting Antiretroviral Failure written by Mark Mascolini - (02/10/09)
     
  4304. Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients? [Letters to the Editor] - (02/07/09)
     
  4305. Vitamin D's Expanding Role EDITORIAL - (02/07/09)
     
  4306. Vitamin D Status and Muscle Function in Post-Menarchal Adolescent Girls - (02/07/09)
     
  4307. GSK Acquires New HIV NNRTI IDX899 From Idenix - (02/07/09)
     
  4308. Is Dual Therapy With Raltegravir and Protease Inhibitors a Feasible Option in Rescue Strategy in HIV-1 Infection? [Letters to the Editor] - (02/07/09)
     
  4309. Use of Saliva as a Lubricant in Anal Sexual Practices Among Homosexual Men - (02/07/09)
     
  4310. FDA grants traditional approval of Isentress (raltegravir) - (02/06/09)
     
  4311. Patient Information Page from The Hormone Foundation: Vitamin D, Calcium, and Bone Health - (02/06/09)
     
  4312. Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine) - (02/06/09)
     
  4313. Once-Daily Prezista® (darunavir) for Treatment-Naive Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy - (02/06/09)
     
  4314. Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women - (02/05/09)
     
  4315. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients - (02/05/09)
     
  4316. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men - (02/05/09)
     
  4317. Oral Cancer In Men Associated With HPV - (02/05/09)
     
  4318. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study - (02/05/09)
     
  4319. New Gene Therapy Disrupts CCR5/HIV Entry: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases - (02/04/09)
     
  4320. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS - (02/04/09)
     
  4321. High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients - (02/03/09)
     
  4322. Vitamin D Deficiency in Older Men - (01/30/09)
     
  4323. New Norvir Tablet Application Submitted to FDA by Abbott - (01/29/09)
     
  4324. Ultrasensitive Assessment of Residual HIV Viraemia in HAART-Treated Patients With Persistently Undetectable Plasma HIV-RNA: A Cross-Sectional Evaluation - (01/29/09)
     
  4325. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity: review by Steve Deeks and Andrew Phillips - (01/28/09)
     
  4326. Aerobic + Strength Exercise is Optimal for Insulin Resistance and Improved Health & Frailty in Study of Obese and Older, Average Age 67 Yrs - (01/28/09)
     
  4327. Methicillin-Resistant Staphylococcus aureus (MRSA) Strain ST398 Is Present in Midwestern U.S. Swine and Swine Workers - (01/28/09)
     
  4328. Heart Association Recommends Daily Intake of Omega-6 Fatty Acids - (01/28/09)
     
  4329. TNX-355 survives Tanox: new Phase 2 Dose-Finding StudyStudy - (01/28/09)
     
  4330. VRX496 Update, Novel HIV Gene Therapy - (01/27/09)
     
  4331. FRONTLINE: the age of aids: interviews: martin delaney | PBS - (01/27/09)
     
  4332. Fauci Statement - Martin Delaney - (01/27/09)
     
  4333. Martin Delaney, HIV treatment activist, dies at 63 - (01/27/09)
     
  4334. AIDS Activist Martin Delaney Honoured By NIAID - (01/27/09)
     
  4335. AGING AND INFECTIOUS DISEASES: effects of aging; Immunosenescence and Vaccination in Nursing Home Residents - (01/22/09)
     
  4336. Once-Daily HAART Modestly Beats Twice-Daily on Adherence & Viral Suppression: meta-analysis - (01/22/09)
     
  4337. Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptase - (01/22/09)
     
  4338. HIV Prematurely Accelerates Aging - (01/22/09)
     
  4339. HIV Super-Infection Not Found Among MSM Couples: Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus - (01/21/09)
     
  4340. Effects of Omeprazole on Plasma Levels of Raltegravir - (01/21/09)
     
  4341. New Article Criticizes Term "on the Down low": Moving beyond "the Down Low": A critical analysis of terminology guiding HIV prevention efforts for African American men who have secretive sex with men - (01/21/09)
     
  4342. Persistent Minority K103N Mutations among Women Exposed to Single-dose Nevirapine and Virologic Response to Nonnucleoside reverse-Transcriptase Inhibitor-Based Therapy - (01/21/09)
     
  4343. Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV Type 1: Balancing the Benefits and Risks EDITORIAL COMMENTARY - (01/21/09)
     
  4344. YouTube - Anthony Fauci Tribute to Martin Delaney - (01/20/09)
     
  4345. NIAID Honors AIDS Activist Martin Delaney - (01/20/09)
     
  4346. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  4347. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
     
  4348. ICAAC: The New Antitubercular Drugs SQ109 and TMC207 Act Synergistically In Vitro to Kill M. tuberculosis - (01/17/09)
     
  4349. ICAAC: Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis: effective and safe - (01/17/09)
     
  4350. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  4351. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study - (01/14/09)
     
  4352. Researchers Identify IL-7 New Regulatory Circuit Controlling Immune Cell Production in Mice - (01/13/09)
     
  4353. Prolonged Nevirapine Use In Breast-Fed Babies Prevents HIV, Increased Resistance Risk - (01/13/09)
     
  4354. Factors Associated with Acquisition and Clearance of Human Papillomavirus Infection in a Cohort of US Men: A Prospective Study - (01/13/09)
     
  4355. Our results suggest that HIV-1 infection induces an accelerated aging of T lymphocytes, which is associated with the clinical progression to AIDS and death - (01/13/09)
     
  4356. Insulin Resistance (25%) Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients [Letters to the Editor] - (01/12/09)
     
  4357. Cardiovascular Complications in HIV Management: Past, Present, and Future [Critical Review: Clinical Science] - (01/12/09)
     
  4358. Predictive Factors for Long-Term Non-Progressors - (01/12/09)
     
  4359. Racial Disparities in HIV Virologic Failure: Do Missed Visits Matter? - (01/12/09)
     
  4360. The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options - (01/12/09)
     
  4361. Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384 - (01/12/09)
     
  4362. CD4+ T Cell Recovery with Antiretroviral Therapy: More Than the Sum of the Parts, EDITORIAL COMMENTARY - (01/12/09)
     
  4363. Increased Melanoma Rates in USA Are Real and Aging/HIV - (01/09/09)
     
  4364. Public Citizen issues list of 56 drugs to be avoided with Erectyle Dysfunction therapies - (01/07/09)
     
  4365. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women - (01/07/09)
     
  4366. ICAAC: New CCR5 Drug PRO 140 Reduced Viral Load by 2 Logs With Single 10 mg Intravenous Dose; 5/5 patients with single 10 mg dose had >2 log reduction in viral load - (01/06/09)
     
  4367. Osteonecrosis of the Jaw & Bisphohosphonates for Osteoporosis Treatment - (01/06/09)
     
  4368. Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy - (01/06/09)
     
  4369. Childhood Trauma and Neurological Development and Stress, and Chronic Fatigue Syndrome - (01/06/09)
     
  4370. AIDS Denialism by South African Govt Leader Pres Mbeki Loses 330,000 Lives & 35,000 HIV+ Babies Born - (01/05/09)
     
  4371. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era - (01/05/09)
     
  4372. Long-term consequences of the delay between virologic failure of HAART and regimen modification - (01/05/09)
     
  4373. Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and -Adherent Patients - (01/05/09)